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UNIVERSITY OF SOUTHAMPTON 
 
ABSTRACT 
 
FACULTY OF NATURAL AND ENVIRONMENTAL SCIENCES 
 
SCHOOL OF CHEMISTRY 
Doctor of Philosophy 
 
Synthesis of dimeric pyridylguanidinium based supramolecular structures 
stable in polar and aqueous solvent systems 
 
by Biniam Fessehaye Tesfatsion 
 
This thesis describes the synthesis of a series of pyridyl guanidinium-carboxylates. 
Dilution and spectroscopic studies are made thus affording information concerning 
the molecular forces controlling their dimerisation. Chapter I provides an introduction 
to the thesis and discusses, in the main part, the thermodynamics of self-assembly 
with  particular  focus  given  to  guanidinium-carboxylates.  Chapter  II  describes  the 
syntheses  and  dimerisation  studies  undertaken  and  Chapter  III  contains  the 
experimental  procedures  and  results.  The  dimerisation  of  the  pyridylguanidinium-
carboxylates was investigated in DMSO and H2O/DMSO mixtures using isothermal 
calorimetric and NMR dilution techniques and the relative importance of H-bonding, 
π- π stacking,  electrostatic and hydrophobic interactions  in  constructing  a dimeric 
self-assembled system in polar and aqueous environment has been investigated.While 
most of the guanidinium-carboxylates show excellent dimerisation in DMSO (~ Kdim 
= 7692±1124  M
-1) and 10% H2O/DMSO (~ Kdim= 2695±151  M
-1), some of them 
exhibit entropy driven dimerisation in an aqueous environment containing up to 50% 
(~Kdim= 55±8 M
-1) and 75% (~Kdim= 27±7 M
-1) H2O in DMSO.     
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1. Introduction 
 
Supramolecular chemistry has significantly advanced in recent years both in terms of 
prospective applications and in its relevance to biological systems. The formation and 
function of supramolecular complexes is orchestrated through non-covalent binding 
forces that usually occur in multiplicity in a given system.
1 The study of non-covalent 
interactions  is  crucial  to  understanding  many  biological  processes  that  depend  on 
these  forces  for  structure  and  function.  Weak,  non-covalent,  intermolecular 
interactions  responsible  for  the  binding  and  self-assembly  of  supramolecular 
structures  include  hydrogen  bonds,  coordination  bonds  in  ligands  and  complexes, 
ionic  interactions,  dipolar  interactions,  van  der  Waals  forces  and  hydrophobic 
interactions.  Hydrogen  bonding  is  the  favourite  intermolecular  force  in  self-
assembling systems by virtue of its directionality, specificity, and its abundance in 
biological systems.
2 Many protein structures in water are held together by hydrogen 
bonding.
3 Monomeric structures can self assemble with the help of hydrogen bonding 
since  the  energy  stored  in  an  intermolecular  hydrogen  bond  is  large  enough  to 
overcome the intermolecular thermal energy (30 kJ mol 
-1 vs  4 kJ mol 
-1). 
1.1 The biological significance of non-covalent bond interactions 
 
All  physiological  processes  in  biological  systems  involve  non-covalent  bond 
interactions of one or more types and alterations or disruptions of the nature of the 
non-covalent binding forces in a given system are likely to be followed by a change in 
the  physiological  processes.  Cell  division,  enzyme  substrate  binding,  hormonal 
regulations, antigen-antibody binding, transportation of macromolecules in the blood, 
intercellular  communications,  neurotransmitter  activities  and  intracellular  signal 
transduction processes are only a few of the  activities in our body which are crucially 
dependent on non-covalent binding forces operating among macromolecules involved 
in the particular process. With this in mind, it is not unexpected that physiological and 
anatomical  malfunctions  resulting  in  alteration  of  features  important  in  the  non-
covalent binding processes of a given biological system will result in pathological 
conditions. In most of the circumstances the underlying causes for the alteration are 
unknown but are believed to be of genetic origin. Understanding the disease processes 
and hence coming up with a therapeutic intervention strategy requires a profound and    
deep knowledge of the binding phenomena occurring among biomolecules involved 
in the given system. 
 1.1.1 Diseases of protein aggregation 
Protein  aggregation  is  a  very  common  phenomenon  in  biological  systems  and 
significantly involved in numerous physiological and pathological processes. Partial 
folding of protein intermediates which may arise as a result of genetic alterations is 
believed to be the cause of the formation of protein aggregates. These intermediates 
are susceptible to aggregation due to the exposure of the hydrophobic core which 
usually lies in the inside core of a tertiary and secondary protein structure. In vitro 
studies  done  by  exposing  proteins  to  solvent  environments  similar  to  those  of 
biological  systems  have  established  this  generic  property  of  proteins.
4  A  detailed 
analysis of amino acid-amino acid interactions in protein structures especially those of 
the side chains of non-polar residues is very important if we wish to have a better 
understanding of disease processes which are the direct result of abnormal protein 
aggregations.  
In human  etiology, more than 20 different  devastating human diseases have been 
reported to be associated with protein aggregation. It is increasingly being established 
that neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease 
(PD),  Huntington's  disease  (HD),  amyotrophic  lateral  sclerosis  (ALS)  and  prion 
diseases  are  characterized  by  molecular  mechanisms  resulting  in  the  formation  of 
protein aggregates. The aggregates are made up of fibres containing misfolded protein 
with a ß-sheet conformation, termed an amyloid. Accumulation of these abnormal 
proteins in tissues is believed to play the crucial part in the disease process by causing 
cell degeneration. These visible protein aggregates are the end result of a molecular 
cascade  of  several  steps  and  are  directly  associated  with  the  pathogenesis  of  the 
particular  neurodegenerative  disease.  Protein  aggregation  diseases  have  been  the 
centre  of intense research and a lot of research activities are being undertaken to 
understand  the  pathways  and  the  mechanisms  involved  in  protein  aggregation. 
Understanding protein aggregation at molecular level will pave the way to rational 
therapeutic strategies for neurodegenerative diseases which are now collectively one 
of the leading causes of mortality in the developed world.
 5    
1.1.2 Non-covalent bond interactions and drug design 
 
Apart from their importance in explaining enzyme kinetics and various physiological 
and  pathological  phenomena,  non-covalent  interactions  are  widely  recognized  for 
their paramount importance in the processes of molecular recognition.
 Various kinds 
of  supramolecular  structures  have  been  designed  and  exploited  for  their  usage  as 
molecular recognition entities by virtue of their ability to make selective binding with 
the desired target substances.
 6 This concept is hugely important in drug design as 
drugs  should  have  the  optimum  bioavailability  only  at  the  desired  site  of  action 
thereby minimizing undesired effects of the drug resulting mainly from interaction 
with  non-target  receptors  in  other  tissues.
7  Pharmacokinetics  and  tissue  drug 
distribution are also hugely affected by the reversible non-covalent bond interactions 
occurring between the drug molecule and the transporter macromolecule inside our 
body.
8 The huge potential of supramolecular chemistry in revolutionizing therapeutics 
is being exploited and can be exemplified by the developments of supramolecular 
capsules, nanoparticles and liposomes which are opening the door for the concept of 
targeted drug delivery.
9 Commercial preparations of liposomes are now available to 
fight  life-threatening  diseases.
10  Liposomes  are  formed  spontaneously  through  the 
self-assembly  of  phospholipids  when  placed  in  an  aqueous  medium.  The  vesicles 
consist of simple lipid bilayers that resemble biological membranes, in the form of a 
spherical shell. It is their particle entrapping ability that makes liposomes drug carrier 
structures.
11  They  are  potential  drug  carriers  for  small  molecular  weight  drugs, 
therapeutic proteins, and diagnostic agents. 
1.1.3 Supramolecular chemistry and biological processes 
 
One very common feature of supramolecular and biological systems is the fact that 
the function of both is crucially dependent on non-covalent interactions operating in 
the systems. Some attempts have been made to simulate biological processes through 
synthetic supramolecular structures.
12 However, this is severely restricted to nonpolar 
solvent  systems  because  of  the  very  limited  usage  of  synthetic  supramolecular 
systems in solvents of high polarity. This research project will attempt to throw a light 
on this by synthesizing supramolcular structures that can maintain stability in polar 
environment.  These  pyridoguanidinium  based  supramolecular  structures  to  be    
considered in this project would permit investigation of some biologically pertinent 
amino acid amino acid interactions.  
1.2 Binding mechanisms in supramolecular systems 
1.2.1 Non-covalent bond interactions 
 
As mentioned previously, at the heart of most  biological processes and molecular 
recognition  events  is  the  concept  of  non-covalent  interactions.  A  non-covalent 
interaction can simply be described as an interaction between two species that does 
not  involve  the  sharing  of  pairs  of  electrons,  but  rather  involves  more  dispersed 
electromagnetic interactions.  Associations  of this  nature cover  a variable range of 
energies (2 kJmol
-1 in London dispersion forces to 350 kJmol
-1 in ionic-interactions) 
and depend explicitly on the structure and functionality of the species involved in the 
non-covalent  bonding  and  also  on  the  local  environment  in  which  the  bonding  is 
happening.
13 Though the magnitude of individual non-covalent bonds is much less 
than covalent bonds,  additive interactions involving a multitude of binding centres in 
reversibly  formed  supramolecular  complexes  can  lead  to  binding  strengths 
approaching those of covalent bonds. This is due to what is referred as the ‘chelate 
effect’  or  ‘multivalency’.
14 The  table  below  lists  the  major  types  of  non-covalent 
interactions important in biological systems.
15 
 
Interaction type   Properties  
 
Charge-charge 
 
Attractive or repulsive, distance 
dependent, ranges 100-350 kJ.mol
-1 
 
Charge-dipole  
Attractive, distance dependent, ranges 50-
200 kJ.mol
-1 
 
Dipole-dipole  
Attractive or repulsive, distance 
dependent, short range interactions, ranges 
5-50 kJ.mol
-1  
 
Nonpolar – nonpolar (London 
dispersion energy) 
Attractive, distance dependent 
 
Hydrogen bond 
Directed interaction,  responsible for the 
special properties of water and biological 
macromolecules, ranges 5-30 kJ.mol
-1   
 
Hydrophobic 
Does not arise as a result of a direct 
interaction between the non-polar 
molecules, comparable in energy to 
hydrogen bonds  
                            
                       Table 1 Types of non-covalent bond interactions    
As  seen  from  table  1,  most  of  the  interactions  are  attractive  in  nature.  There  are 
circumstances  when  charge-charge  and  dipole-dipole  might  be  repulsive.  This 
depends on the signs of the charges and the relative angular orientation of the dipoles. 
Permanent and induced dipoles cause an attractive interaction by accommodating the 
forces acting upon them. Species with no charge or dipole associated with them can 
still attract each other due to Van der Waals forces (non polar-non polar interactions) 
caused by the polarizability of the group. All types of non-covalent bond interacting 
forces are distance-dependent.  The dielectric constant of the medium through which 
the interaction is happening greatly influences the strength of the non-covalent bond 
interaction.  A solvent with a high dielectric constant, such as water and DMSO, will 
greatly reduce interaction energies. The dielectric constant also explains the difference 
between the magnitudes of these forces in solution versus the gas phase, where the 
dielectric effect of the solvent is not present. It is also established that energies of 
interactions based on charge-non polar, dipole- non polar and non polar- non polar 
events are expected to increase as the effect of solvation is removed. This is due to the 
decrease of the polarizability of the interacting  species in  the presence  of solvent 
molecules.  An exception to this is a hydrophobic interaction between two non polar 
units, where the presence of water increases the attraction between these moieties. 
Hydrogen bonding interactions, hydrophobic interactions and ion pair interactions, 
which are the dominant binding forces in supramolecular complexes and which will 
be exploited in this PhD research project are further explained below.  
1.2.2 Hydrogen bonds 
 
A hydrogen bond is an attractive force of interaction between hydrogen attached to an 
electronegative  atom  of  one  molecule  and  an  electronegative  atom  of  a  different 
molecule. Hydrogen bonds have been traditionally defined by the formalism D-H…A, 
where donor D and acceptor A are both electronegative atoms, such as N, O, or F.
16  
Currently, even weaker donor atoms, such as carbon, are also found to contribute to 
the formation of hydrogen bonding in many binding systems. It has to be noted that a 
hydrogen  bond  is  largely  electrostatic  in  nature;  but  it  does  not  involve  actual 
ionization. Electrostatic and exchange-repulsion terms are considered to account for 
more than 80% of the hydrogen-bond interaction, with the other 20% made up of 
dispersive and polarization energies.
17  It is also observed that hydrogen bonds show a    
tendency  toward  more  cooperative  effects  through  mutual  polarization  of  the 
interacting groups participating in the hydrogen bonding.
18 The nature of the solvent 
molecules greatly influences the extent of these interactions, since they may have 
hydrogen-donor  and  -acceptor  character  as  well  and  hence  create  a  competitive 
environment. The contribution of the hydrogen bond can be reduced dramatically in 
solution due to entropic effects, solvation, or dielectric conditions.
19  
 
One very important feature of hydrogen bonding is that the degree of interaction is 
critically dependent not only on the distance, but also on the orientation or alignment 
of the hydrogen bonding groups.
20 The directionality of hydrogen bonds is a very 
important  characteristic for the process  of selective molecular recognition.  Classic 
examples include synthetic receptors such as 1 used for the selective complexation of 
carboxylates. In DMSO, carboxylates are bound by 1 with K >10
3 M
-1, but sulfates or 
halides with only K< 50 M
-1.
21  
 
 
 
Though individual H-bonds are weak, a strong, positive cooperative effect has been 
observed when there are a multitude of hydrogen bonds in a given supramolecular 
complex. This property of hydrogen bonds can be exploited in the development of 
receptors  for  drug  molecules.  Hamilton  et  al.  have  designed  receptors  2  for 
barbiturates  and  studied  the  effect  of  multiple  hydrogen  bonding  on  the  binding 
affinity of the receptor. 
22  
    
 
 
The  selectivity  of  receptor  2  for  various  derivatives  of  barbiturates  (3-7)  was 
investigated and marked  selectivity (Kass~10
5 M
-1 in DCM) was observed for barbital 
3 which contains additional hydrogen accepter sites as compared with barbitals 4, 5 
and 7 (Fig1).  
 
 
 
 
Steric  factors  also  contributed  for  the  less  efficient  binding  of  barbitals  5  and  7.  
Though all the six H-bonding sites are present in 6, the binding is 350-fold weaker. 
This  is  consistent  with  the  weaker  H-bond  accepting  characteristics  of  sulfur 
(compared to oxygen) as well as its larger size, inhibiting binding into the cavity.  
    
 
 
                     Fig 1 Binding of barbital 3 with the macrocyclic receptor 2  
 
Hydrogen bonding is seen to be one of the dominant forms of non-covalent binding 
forces being exploited by supramolecular chemists in developing synthetic receptors 
and self-assembled systems.  The self-assembled systems  designed in  this  research 
project will be crucially dependent on the intermolecular bidentate hydrogen bonding 
between the guanidinium moiety and the carboxylate anion.  
1.2.3 Hydrophobic interactions 
 
 Solvophobicity is a phenomenon that explains the interaction between polar solvent 
molecules  and  non-polar  solutes.  Hydrophobicity  is  the  most  commonly  observed 
solvophobic phenomenon owing to the ubiquitous nature of water.
13 The hydrophobic 
effect originates from the disruption of the highly structured  hydrogen bond network 
among water molecules upon mixing with non-polar solutes. Water exhibits a much 
stronger solvophobic effect than other solvents. This is due to the fact that a large 
number  of  solvent  molecules  are  required  to  solvate  a  given  substrate  and  water, 
owing to its small size, does the job more efficiently than other common solvents. In 
addition, the heavily structured nature of water molecules through hydrogen bonding 
plays a crucial role in creating favourable theromodynamics for the solvation process.  
 
The classical Frank–Evans model illustrates the hydrophobic effect as  an entropic 
advantage  upon  the  association  of  lipophilic  substrates,  which  arises  through  the 
release of water molecules surrounding the lipophilic molecules. When a lipophilic 
molecule is  put  in  water it results  in increased ordering of the surrounding water    
molecules  forming  the  solvation  sphere.  This  leads  to  significant  losses  in 
translational  and  rotational  entropy  of  water  molecules  and  makes  the  process 
unfavorable in terms of the free energy of the system. Upon coalescence of two or 
more  substrate  molecules,  less  water  molecules  are  required  to  form  the  solvent 
sphere surrounding the resulting aggregate than were previously necessary. This is 
simply due to  the decrease in  surface area. This  new system  will experience less 
significant loss in entropy as compared to the previous one and hence a favourable 
free energy of formation.
 23 
.  
Hydrophobic  interactions  play  a  major  role  not  only  in  biologically  important 
interactions,  but  also  in  many  biomimetic  synthetic  complexes.  The  hydrophobic 
effect  plays  an  important  role  in  protein  aggregation,  lipid  bilayer  formation, 
membrane protein structuring and protein-small molecule interactions.
 24  
1.2.4 Electrostatic or ion pair interactions 
 
Ion pairs and electrostatic interactions play a very significant role in the formation of 
both biological and supramolecular complexes. It is one of the most dominant forces 
that  operate  in  enzyme-substrate  interactions  and  is  largely  responsible  for  the 
selective and specific binding of a substrate with an active site of an enzyme.The 
contribution of these types of interactions for the stabilization of the secondary and 
tertiary structure of peptides and proteins is also of paramount importance in nature. 
25  
 
The free  energy  of interaction accompanying two charged  groups in  a vacuum  is 
purely enthalpy driven. But this is not the case when there are solvent molecules 
accompanying the charged species. The free energy of interaction between charged 
groups in water is often dominated by entropy. This is due to reconfiguration of water 
molecules surrounding the charges in response to the association or interaction of the 
charged species. And the effect of the solvent is correlated with the dielectric constant 
and is expected to be high in solvents like water and DMSO.
25  
 
The free energy of interaction (ΔG) between two charged species in solution is given 
by the following relation:  
. 
    
ΔG =  e
2z1z2/4πEoEr, where z1, z2 = The number of charges, Eo = The dielectric 
permittivity in vacuum, E = The relative permittivity of the solvent 
 
It is evident from the equations above that the dielectric constant (E) of the solvent 
through  which  the  interaction  between  the  charged  species  is  happening  directly 
affects the free energy of the binding process. The interaction between two charged 
species in organic solvents of low dielectric constant is enthalpy driven as opposed to 
the  entropy  driven  interaction  of  the  same  charged  species  in  solvents  of  high 
dielectric constant like water.  
 
In  this  PhD  research  work,  we  will  attempt  to  use  a  combination  of  the  above 
mentioned  non-covalent  interactions  in  order  to  access  dimeric  supramolecular 
structures in solvents of high polarity and dielectric constant (DMSO and DMSO-H2O 
mixture). Analysis of the thermodynamic behaviour of these supramolecular systems 
might enable us to better understand these interactions in polar and aqueous solvent 
systems  and  enrich  our  knowledge  of  numerous  biologically  important  processes 
which depend on non-covalent bond interactions for their function.  
1.3 Solvent effect on the binding phenomena 
 
Solvent effect on the binding process is very crucial and should never be understated.  
If binding between two complimentary interacting molecules is to occur, first and 
foremost  solvation  of  the  chemical  groups  should  happen.  This  is  a  must  if  the 
molecules are to  be dissolved by the solvent  in which the binding study is  to  be 
undertaken. Once dissolved, the molecules should diffuse through the medium and 
approach  each  other.  The  solvent  will  help  in  moderating  the  temperature  of  the 
binding process either by absorbing heat as in the case of exothermic processes or 
releasing heat if it is an endothermic one.  
 
One of the main challenges of supramolecular chemistry is to design a host guest 
system that can function in a solvent medium which mimics a biological environment, 
i.e very high polarity and dielectric constant. Binding is greatly hampered in such kind 
of competitive solvent systems due to the solvent molecule’s ability to form hydrogen 
bonding  with  the  interacting  sites  which  makes  the  binding  event  enthalpically 
unfavourable. If binding occurs in such media, it is often entropy driven which arises    
from the liberation of the solvent molecules upon association of the molecules. The 
enthalpic loss should be well compensated by entropy if the binding is to be feasible 
thermodynamically.  It  is  the  overall  balance  of  enthalpy  and  entropy  that  will 
eventually decide the thermodynamic feasibility of the binding process. 
26  This is 
what is referred to as the enthalpy-entropy compensation.
27  
1.4 Free Energy of Binding   
 
The free energy of binding in a given physico-chemical process is given by the Gibbs-
Helmholtz equation: ΔG = ΔH - TΔS, where ΔG is the Gibbs free energy, ΔH is 
enthalpy, T is temperature in Kelvin, and ΔS is entropy. For a binding process to 
proceed spontaneously ΔG should be less than zero. The more negative the value of 
ΔG, the more favourable is the binding process, and this is associated with either a 
negative value of   ΔH or a positive value of ΔS, or both. 
 
The thermodynamic feasibility of a given binding process depends on the balance of 
contributions made by each species upon complexation. These contributions can be 
negative or positive and arise due to the modification of the solvation of the host 
and/or guest, the modification of the degrees of freedom of the host and/or guest, the 
electrostatic interactions, the hydrophobic interactions, the hydrogen bonding, the π– 
π interactions, etc.
28 It is impossible to dissect the enthalpic and entropic contribution 
of all the components in a given supramolecular complex. However, some general 
trends can be anticipated in a given binding process. In water for example, ion pairing 
is  entropically  driven  while  long-range  coulombic  bonds  or  hydrogen  bonds  are 
generally enthalpically driven. It was also noted that π– π interactions give a negative 
(favorable)  contribution  to  ΔH  where  as  hydrophobic  interactions  give  a  positive 
contribution to TΔS.  However, a clear elucidation of the overall interplay of all the 
factors to give either a positive or negative ΔG value is a daunting task awaiting a 
very formidable research endeavour. 
 
 
 
 
    
1.5 Quantification of non-covalent interactions in synthetic systems 
 
Quantification  of  a  specific  non  covalent  bond  interaction  from  an  array  of 
interactions in a given system is a very difficult task and is a current challenge for 
supramolecular chemists.
 30 Some degree of success has been registered in developing 
supramolecular  models  which  could  be  used  to  study  specific  non-covalent 
interactions among a multitude of interactions operating in a given supramolecular 
structure. The double-mutant cycle (DMC) method, which is now a standard practice 
for the quantification of non-covalent interactions in proteins 
29, is also valuable to 
study individual functional group interactions present in other synthetic systems. 
30, 31 
A simplified schematic representation of the DMC cycle was proposed by Fersht in 
1994 (Fig 2).
32 If the change in free energy upon making a single X mutation (ΔG 
XY→X’Y) differs from the free energy change when the same mutation is made to a 
single Y mutant protein (ΔG XY’→X’Y’), then there must be an interaction between the 
mutated residues X and Y. The extent of any direct and indirect interaction of X and 
Y is given by: 
 
                                 ΔΔG = ΔGXY→X′Y – ΔGXY′→X′Y′ = ΔGXY→XY′ – ΔGX′Y→X′Y 
 
 
                    
                      Fig 2  Schematic representation of the double mutant cycle 
30 
 
However, the following criteria should be met for the validity of the DMC approach 
to be accurate for such a purpose. 
 
  The mutant substitutions should be non-interacting    
  There should be no differences in the conformation of each member of the 
cycle 
  The molecular framework should remain intact as it might be an essential part  
of the molecular recognition event 
Synthetic  systems  which  fulfilled  the  above  mentioned  requirements  have  been 
synthesized and exploited using the concept of DMC approach to quantify a number 
of  non-covalent  bond  interactions.
33  Edge-to-face  aromatic  interactions  (Fig.3), 
aromatic–cation  interactions,  aromatic–halogen  interactions,  aromatic–carbohydrate 
interactions and aromatic stacking interactions have been successfully investigated by 
this approach. 
 
 
Fig 3  A double-mutant cycle for determining the magnitude of the two terminal edge-
to-face aromatic interactions 
30 
  
Based on this approach the magnitude of one of the edge-to-face aromatic interactions 
in CDCl3 was found to be -1.3 kJmol
-1.  
 
The principle of quantification of non-covalent interactions however has been limited 
mostly to non-polar solvent systems. 
17, 34, 35 In contrast to covalent bonding, non-
covalent bond interactions are highly dependent upon external parameters  such as 
solvent composition, polarity and temperature.
36 In this context water as a solvent is 
the most challenging one. Electrostatic interactions (H-bonding and ion pair), which 
Synthetic supramolecular systems in quantification of non-covalent 
interactions
• Supramolecular chemistry has been extremely successful in developing synthetic systems which 
allow specific interactions to quantified. 
ΔΔG = ΔGXY→X′Y – ΔGXY′→X′Y′ = 
ΔGXY→XY′ – ΔGX′Y→X′Y 
Limitations of this approach
Secondary perturbations must be 
additive functions of the mutations. 
The mutant substitutions should be non-
interacting
There should be no differences in the 
conformation of each member of the cycle 
The molecular framework might be  an 
essential part of a molecular recognition 
event
DMC has been used successfully for quantification 
of:
Edge-to-face aromatic interactions, aromatic-cation
interactions , aromatic-halogen interactions, 
aromatic-carbohydrate interactions, aromatic 
stacking interactions
Scott L. Cockroft and Christopher A. Hunter Chem. Soc. 
Rev., 2007, 36, 172-188    
are  well-exploited  in  artificial  supramolecular  systems,  are  very  weak  in  aqueous 
solvent systems.
 37 
 
 Hydrophobic  and  aromatic  stacking  interactions,  which  can  be  rather  strong  in 
aqueous solvents, are much more difficult to deliberately design and use in synthetic 
receptors. 
38, 39 However, it is very desirable to design systems that will be useful to 
quantify non-covalent bond interactions in aqueous and polar solvents like water and 
DMSO by employing supramolecular systems stable under these conditions. This is 
important to simulate the working environment of the natural biological system.
40 This 
is one of the current challenges facing the field of supramolecular chemistry. In this 
PhD  research  work,  we  will  try  to  develop  synthetic  pyridoguanidinium  based 
supramolecular structures which are stable in polar solvent systems. Achieving this 
might  pave  the  way  to  use  the  DMC  approach  in  quantifying  non-covalent 
interactions in polar and aqueous solvent systems.    
1.6 Analytical methods for quantification of non-covalent bond 
interactions 
 
Several techniques have been forwarded by chemists to measure the strength of non-
covalent  bond  interactions  in  supramolecular  complexes.  NMR  dilution/titration, 
isothermal  calorimetric  dilution/titration,  ionization  mass  spectrometry 
41  and  UV 
dilution/titration techniques 
42 are some of the methods which have been successfully 
used  to  study  non-covalent  bond  interactions  in  biological  and  supramolecular 
systems. NMR and ITC techniques are discussed below as they are the most widely 
exploited techniques in studying supramolecular complexes and are the ones to be 
used in this research project.  
1.6.1 NMR dilution experiments 
 
NMR is the most widely reported technique in the literature to study non-covalent 
interactions  in  supramolecular  complexes.  NMR  experiments  are  used  to  follow 
binding  events  by  observing  the  change  in  the  resonance  signals  of  magnetically 
active  nuclei,  such  as 
1H, 
13C,  and 
15N,  in  a  host  or  guest  molecule.
43  The 
concentration-dependent change in the chemical shift value of the protons involved in 
the hydrogen bonding between the host and guest molecules is correlated with the    
stability/binding  constant  of  the  host-guest  (self-assembled)  complex.  This 
information can also be used to study the thermodynamic properties associated with 
the  complex  formation.  NMR  techniques  have  been  previously  used  to  study  the 
structures of nucleic acids. The base pairing between guanosine and cytidine was first 
studied  by  Katz  and  Penman  using  an  NMR  titration  technique.
44  Though  the 
accuracy of the method is debatable 
45, NMR studies can be used to figure out the 
thermodynamic  profile  of  binding  phenomena.  Thermodynamic  determinations  of 
ΔGass, ΔHass, and ΔSass can be done using NMR experiments through the construction 
of  a  van’t  Hoff  plot.  Performing  NMR  studies  of  a  binding  process  at  different 
temperatures and plotting the natural logarithm of the equilibrium constant versus the 
reciprocal temperature gives the van’t Hoff plot. This curve can then be analysed to 
deduce  the  enthalpy  and  entropy  of  binding  involved  in  complex  formation.
46  In 
addition to getting direct information about the association or dissociation constant of 
a supramolecular complex,  NMR techniques (NOEs and DOSY) are also useful for 
gathering precise knowledge of solution-phase binding phenomena. 
47  
1.6.2 Isothermal titration calorimetry 
 
Isothermal  titration  calorimetry  (ITC)  is  becoming  the  method  of  choice  for  the 
determination  of  the  thermodynamic  parameters  associated  with  the  non-covalent 
interaction of two (or more) molecules. ITC is the only technique available to date 
that  can  directly  measure  both  the  stability  constant  (K)  and  enthalpy  (ΔH)  of  a 
binding process. 
48 The experiment involves titration of one of the binding partners 
into the other binding partner contained in a calorimetric sample cell at a constant 
temperature. After each addition of a small aliquot of titrant, the heat released or 
absorbed in the sample cell is measured with respect to a reference cell filled with a 
buffer solution. The heat change (ΔH) is expressed as the electrical power required to 
maintain a constant temperature difference between the sample cell and the reference 
cell, which are both placed in an adiabatic jacket.
49 The amount of complex formed 
(extent of dissociation) at each injection is directly proportional to the heat given out 
and this heat of interaction is used as a probe of the course of the binding process as 
one component is titrated into the other. This will allow for the amount of free and 
bound ligand to be determined at any point in the titration process. From this the 
observed  equilibrium  binding  (association)  constant,  KB  (KB  =  1/dissociation    
constant,  1/KD)  can  be  determined.  Once  these  parameters  are  at  hand  a  full 
thermodynamic  characterization  of  the  binding  event  can  be  determined  from  the 
relationships below.
50, 51, 52, 53. 
 
The change in free energy, ΔG is related to the KB by: 
 
KB =  e 
-ΔG/RT 
 
where R is the gas constant and T is the experimental temperature.  
 
The change in entropy, ΔS is related to the ΔH by: 
 
ΔH = ΔG + TΔS 
 
ITC is becoming the method of choice in binding studies ranging from drug design to 
polymer chemistry and from cellular biology to nanotechnology.
54 The ITC binding 
study technique offers numerous advantages over NMR and other techniques. The 
method is more sensitive and accurate and it allows the dissection of association free 
energies  into  the  enthalpic  and  entropic  components.  As  previously  mentioned, 
determination of the enthalpic and entropic component  of the binding phenomena 
using NMR technique is very laborious and error prone.  
1.6.3 ITC investigation of dimeric suprmaolecular systems 
 
The principles of the ITC technique in a binding study can be extended to investigate 
the  dimerisation  process  of  a  supramolecular  system.
55,  56  The  dimerisation 
characteristics of all the pyridoguanidinium carboxylates considered in this project 
were primarily investigated using the isothermal titration calorimetry (ITC) technique. 
A reasonably concentrated solution of the guanidinium carboxylate which is believed 
to contain a higher proportion of the dimeric form of the compound is sequentially 
injected from a syringe into a blank solvent contained in the calorimeter cell.
 This 
results in dissociation of the dimer which is usually accompanied by a heat uptake 
from the surrounding environment.
 57 This results in endothermic heat signals. The 
magnitude  of  the  endothermic  heat  signals  decreases  non-linearly  with  successive 
injections and this is due the build up of concentration of the compound in the cell 
thereby shifting the equilibrium of dimer dissociation to the left (Fig 4). 
    
 
 
                                     Fig 4  Monomer-dimer equilibrium  
 
The  series  of  the  endothermic  heat  pulse  data  is  then  fitted  to  a  monomer-dimer 
equilibrium model used for estimating Kdiss and ∆Hdiss directly. The inverse of these 
parameters will give the Kdim and ∆Hdim and the other thermodynamic parameters 
∆Gdim and T∆Sdim can be calculated using the Gibbs-Helmholtz equation.  
1.7 Carboxylate binding by guanidinium derivatives 
1.7.1 Significance of the guanidinium group  
 
The guanidinium group has served as an excellent ‘work horse’ for supramolecular 
chemists because of its important role in nature.
58 It is widely found in nature and 
mediates a variety of specific non-covalent interactions in biological systems.
59 The 
guanidine  moiety  of  the  arginine  amino  acid  mediates  the  interaction  of  many 
negatively charged anionic species (phosph[on]ates, sulf[on]ates, and carboxylates) or 
electron  rich  aromatic  moieties  found  in  substrates  with  enzymes  or  receptors.
60 
Nature often uses simple alkyl guanidinium cations in the form of the amino acid 
arginine for the binding of oxyanions.
61 A large number of natural products and drugs 
contain a guanidinium moiety and this is believed to be responsible for the bioactivity 
of  many  drug  molecules.
 The  guanidinium-carboxylate  binding  has  been  found  to 
form the basis for the biological activity of quite a number of alkaloids and toxins 
such as ptilomycalin A (Fig 5) and related guanidinium natural products.
62, 63  
 
                                      
 
 
Fig 5  Ptilomycalin A which has anti tumour, antifungal and antimicrobial activity 
 
The  guanidinium  functionality  has  exceptionally  high  stability  in  an  aqueous 
environment due to resonance stabilization.
64 All the resonance structures have six 
potential hydrogen bond donors and the positive charge is distributed equally to the 
three nitrogen atoms (Fig 6).  
 
                                
                  
                   Fig 6 Resonance stabilization of a guanidinium functionality 
 
Guanidine has a pKa value of ~ 13.5 in water. This makes it protonated over a wide 
pH range. Substitution of one or two of the hydrogens by an alkyl group decreases the 
pKa as is observed in arginine which has a pKa value of 12.5. The extent of lowering 
of the pKa value by mono substitution depends on the nature of the neighbouring 
group  (substituent).  In  general,  it  was  observed  that  the  pKa  lowering  effect  was 
acyl > phenyl > alkyl in mono substituted guanidines. An X-ray crystal structure has 
revealed that  the C-N single bond length  in  an alkylguanidine is  shorter than  the 
normal C-N bonds. In guanidine, all three bond lengths and bond angles are nearly 
equal with an average of 1.33 Å and 120°, respectively. 
    
The  reason  for  the  strong  binding  of  guanidiniums  with  oxoanions  is  due  to  the 
binding  pattern  featuring  two  parallel  hydrogen  bonds  augmented  by  electrostatic 
attraction (Fig 7), a structural motif that can be found in many crystal structures of 
enzyme complexes with oxoanionic substrates.
65, 66 
 
 
  
  Fig 7 Binding modes of the guanidinium group of arginine with carboxylates 
67   
 
In  biological  systems,  this  binding  usually  occurs  in  the  hydrophobic  pockets  of 
enzymes, thereby avoiding solvation effects of the water molecules. Exploiting the 
guanidinium  functionality  for  carboxylate  binding  in  artificial  receptor  systems 
however is hampered by the very effective solvation of the guanidinium functionality 
in water leading to weaker electrostatic interactions. In spite of these setbacks, the 
guanidinium  group  has  served  as  a  basis  for  the  development  of  an  appreciable 
number of artificial guanidinium-based receptors for anions.
68 
1.7.2 Synthetic guanidinium receptors 
 
Inspired by nature’s use of arginine, a variety of host systems based on guanidinium 
cations have been designed.
69 However, most of the receptors developed so far are 
functional only in non-polar solvents. The current challenge of designing guanidinium 
receptors  focuses  on  issues  like  utility  of  the  receptor  in  aqueous  media  and 
enhancement of enantioselectivity of the receptor. 
 
Designing a guanidinium based receptor that can function in an aqueous environment 
is  a  very  difficult  task.  This  however  is  circumvented  in  nature  by  the  overall 
hydrophobic  character  of  the  binding  pockets  in  the  enzymes.  This  enhances  the 
strength  of  the  enzyme  substrate  interaction.
70  Supramolecular  chemistry  has 
employed this concept and some guanidinium based receptors showing appreciable    
binding  strength  in  aqueous  environments  have  been  reported  in  the  literature.  A 
bisguanidinium-based receptor 8 developed in 1992 by Hamilton et al is one of the 
pioneering works  in  developing  guanidinium based receptors for anion binding in 
aqueous solvent systems. Receptor 8 was developed with the idea of mimicking the 
active  site  of  staphylococcal  nuclease  which  is  important  in  accelerating 
phosphodiester  cleavage  in  RNA.  Another  related  work  by  Hamilton  et  al  has 
reported  a  well  characterized  bisguanidinium  receptor  9  with  an  intramolecular 
distance of 4-5 A
o for recognition of the aspartate group. 
71 
 
                                    
 
Hamilton et al made an in depth analysis of the thermodynamic behaviour of the 
binding  phenomena  of  guanidinium  groups  and  carboxylate  anions  in  competitive 
solvent systems such as water. They have clearly established the fact that decreased 
stability  of  the  guanidinium-carboxylate  complex  is  attributed  to  solvation  of  the 
hydrogen bond forming sites by the water molecules. The modest binding observed in 
water was entropy driven as opposed to the enthalpy driven binding in DMSO.  
 
Other notable works in the development of guanidinium based anion receptors include; 
the  bicyclic  guanidinium  receptor  10  for  enantioselective  recognition  of  anions 
developed by De Mendoza et al 
72, the ditopic receptor 11 which is  able to bind 
tetrahedral  anions  such  as  phosphate  in  chloroform  and  in  water  developed  by 
Schmidtchen et al 
73, pyrrole guanidinium-based receptors  12 with a high binding 
affinity  for  carboxylates  in  water  developed  by  Schmuck  et  al 
61,  and  pyrido-
guanidinium  based  receptors  and  tweezers  (13)  which  showed  enantioselective 
recognition for carboxylates in DMSO/water systems developed by Kilburn et al.
74  
 
                                  
    
 
                      
 
 
 
    
 
                                          
 
 
 
A relevant work by Schmidtchen et al has focused on the design of guanidinium-
based  receptors  capable  of  overcoming  the  enthalpic  penalty  for  association  in 
competitive  media.
75  This  approach  is  similar  to  nature’s  strategy  of  enhancing 
enzyme substrate binding through creating an overall hydrophobic environment in the 
form of binding pockets in the enzymes. With this concept, Schmidtchen et al have 
developed receptors of the type 14 wherein the receptor site is lined with aromatic 
residues to reduce the solvation in the vicinity of the binding site.  
 
 
 
Pyrrole and pyridine based guanidinium receptors have been extensively studied by 
Schmuck and Kilburn respectively and these systems are discussed below as they are 
pertinent to this research project.  
 
    
1.7.3 Pyrrole acyl guanidiniums as carboxylate receptors  
 
Schmuck’s approach of developing receptors for carboxylates is based on substituted 
2-(guanidiniocarbonyl)-1H-pyrroles (Fig 8). Important features have been installed in 
this scaffold to enhance the complexation of carboxylates in aqueous solvents.
76 The 
pKa values of acyl guanidiniums (7–8) are lower than those of simple guanidiniums 
(~13).  This  enhances  the  acidity  of  the  guanidinium  protons  which  consequently 
increases its binding affinity for the formation of hydrogen bonded ion pairs with 
carboxylate guests.
76 In addition to the ion pairing with the guanidinium, the hydrogen 
bonding from the pyrrole NH is also believed to be crucial in enhancing the binding 
strength. Another advantage of this carboxylate receptor motif is the fact that the 
binding  cleft  is  planar  and  rather  rigid  and  therefore  ideally  preorganised  for  the 
binding of planar anions such as carboxylates. 
76 
 
 
   
                    Fig 8  Carboxylate binding by 2-(guanidiniocarbonyl)-1H-pyrroles 
 
These properties of 2-(guanidiniocarbonyl)-1H-pyrroles have made them superior to 
simple guanidinium cations in binding carboxylates effectively even in polar solvent 
systems.  Variation  of  the  amide  side  chain  R  allows  fine  tuning  of  the  binding 
selectivity of the receptor for different substrates. Incorporating chiral amino acids in 
the  side  chain  has  been  utilized  for  chiral  substrate  recognition  processes. 
Sterioselective recognition has been achieved through this approach.
77 Making use of 
the  above  concept,  Schmuck  et  al  synthesized  many  potent  carboxylate  receptors 
derived  from  the  2-(guanidiniocarbonyl)-1H-pyrrole  scaffold.  The  ethylamide 
receptor 15 and the L-valine derived receptor 16 have been found to bind N-acetyl    
alanyl carboxylates with binding constants of 770 M
-1 and 1610 M
-1 respectively in 
40% H2O/DMSO.
76  
 
                                 
 
The chiral, L-valine derived receptor 16 shows not only side chain selectivity but also 
moderate stereoselectivity. 
76 The superiority of receptor 16 compared to receptor 15 
is  owing  to  the  additional  hydrogen  bond  from  the  terminal  carbonyl  group.  The 
ability of receptor 16 to discriminate between D-alanine (K = 730 M
-1) and L-alanine 
(K = 1610 M
-1) lies in the fact that there is an unfavorable steric repulsion between the 
methyl group of the D-amino acid and the isopropyl side chain of the receptor which 
is not present in the complex with the L-enantiomer where the methyl group points 
away from the isopropyl group (Fig 9).  
 
                                    
 
              Fig 9 Proposed binding mode of L and D-alanine by receptor 16  
 
 
One important feature of Schmuck’s guanidiniocarbonyl pyrrole receptors is that the 
improved  binding  properties  in  aqueous  solvents  are  solely  based  on  electrostatic 
interactions  without  the  need  of  creating  hydrophobic  cavities.  A  remarkable 
improvement of the receptor’s ability to bind Ala in an aqueous environment was 
achieved  by  the  introduction  of  a  third  positive  charge  in  the  form  of  a  primary 
ammonium group in receptor 17. This was designed with the expectation of enhancing 
the electrostatic interactions which is proved to be crucial for the binding efficiency in 
water.
78  Receptor  17  showed  appreciable  binding  affinity  (K  =  2100  M
-1)  for 
carboxylates in nearly pure water (10% DMSO).     
 
                                       
 
Schmuck  et  al  have  further  exploited  the  guanidiniocarbonyl  pyrrole  scaffold  to 
design  receptors  for  larger  substrates  such  as  peptides  and  oligopeptides.  Using 
molecular mechanics approach dipeptide receptor 18 was designed which is expected 
to  form  a  hydrogen  bonded  ion  pair  with  the  carboxylate,  and  show  additional 
hydrogen bonding with the dipeptide backbone. As seen by NMR- and UV-titration 
experiments, this receptor indeed binds anionic dipeptides very efficiently in buffered 
water (K ≈ 5×10
4 M
−1) Table.   
 
            
                                                                                  
 
The increase in stability for the dipeptides as compared with simple amino acids must 
be due to the additional binding sites within the complex (the H-bonds between the 
backbone amides and interactions with the imidazole group). 
1.7.4 Pyridoguanidiniums as carboxylate receptors 
 
Kilburn  et  al  have  extensively  utilized  the  guanidinium  motif  for  the  purpose  of 
carboxylate  recognition.  Similar  to  the  principle  of  peptide  recognition  used  by 
Schmuck, Kilburn has earlier synthesized a guanidinium based tweezer receptor 19 
which  showed  95%  selectivity  for  binding  with  tripeptides  having  valine  at  the 
carboxy terminus and 40% selectivity for binding with tripeptides having Glu(OtBu) 
at the amino terminus. An ITC aided binding study has shown that receptor 19 binds 
with Cbz-Glu(OtBu)-Ser(OtBu)-Val-OH with a binding constant of Kass = 4 × 10
5 M
-1 
in 17% DMSO/H2O buffered at  pH = 9.2.
38  
Carboxylate   K [M
-1] 
Gly-Gly  15900 
Ala-Ala  30600 
Val-Ala  43800 
Val-Val  54300 
Ala  7400 
Gly  5200 
    
 
                   
 
This tweezer receptor has the potential to form both hydrophobic and β-sheet like 
hydrogen bonding interactions with the backbone of the incoming peptide substrate. 
Ion pairs and hydrogen bonding are primarily responsible for the binding energy. In 
addition  to  contributing  to  the  binding  process,  hydrophobic  interactions  play  an 
important role in imparting selectivity to the receptor.
79 
 
Kilburn et al have recently synthesized a chiral bisguanidinium macrocycle 20 which 
binds strongly with biscarboxylates in a highly competitive aqueous solvent system. 
80 
This  macrocycle  has  shown  enantioselectivity  in  binding  with  N-Boc-  glutamate 
amino acids. It shows preference in binding with N-Boc-L-glutamate (K = 3.8 x 10
4 
M
-1)  over  N-Boc-D-glutamate  (2.9  x  10
3  M
-1)  in  50%  H2O–DMSO  (using  a  tris 
buffer).  There is a precise and tight fit within the macrocyclic cavity for the preferred 
guest,  N-Boc-L-glutamate,  with  strong  hydrogen  bonding  interactions  to  both 
carboxylate groups of the glutamate. 
                                                
Following  this,  Kilburn  et  al  have  introduced  pyridylguanidinium  motifs  for  the 
purpose  of  carboxylate  binding.  Using  the  pyridine  scaffold  has  the  potential 
advantage of preorganizing the binding cavity into the desired conformation by the 
weak intramolecular H-bonding between the pyridine N-lone pair electrons and the 
amide NH and/or guanidine NH. This property of the pyridine carboxyamide motif 
has  been  exploited  to  preorganize  macrocyclic  and  acyclic  receptors.  However, 
possible  electrostatic  repulsions  between  the  pyridyl  nitrogen  and  the  incoming 
anionic guest might create a setback in the binding process (Fig 10). Whether the 
favourable preorganization effect outweighs the unfavourable electrostatic repulsion 
or not might depend on the size and electronic structure of the incoming carboxylate 
guest. 
 
 
 Fig 10  Possible electrostatic repulsions between the pyridyl nitrogen of tetralactam 
macrocycles and the incoming carbonyl oxygen of guest 
 
The deleterious effect of the electrostatic repulsion between the electron density at the 
pyridine  nitrogen  and  the  negative  charge  of  the  incoming  anionic  guest  can  be 
minimized by introducing electron withdrawing groups (NO2, Cl) into the pyridine 
ring.
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A number of efficient pyrido guanidinium based receptors which showed excellent 
binding with carboxylates have been developed by Kilburn et al.
59 The most recent of 
these is the carboxylate receptor 21 which was found to efficiently bind acetate (Kass= 
22000 M
-1) in a highly polar solvent system, DMSO. The thermodynamic data of the 
binding shows that the binding is entropy driven (ΔG = -24.8 kJ mol
-1, ΔH = - 8.0 kJ 
mol
-1, TΔS = 16.8 kJ mol
-1) and this confirms that the preorganisation effect of the 
pyridine N is indeed very important in creating the binding cleft. The preorganisation 
is as a result of two intramolecular hydrogen bonds between the pyridine lone pair and 
adjacent  guanidinium/amide  protons.  The  receptor  has  maintained  some  of  its    
carboxylate binding property even in more aqueous solvent systems. It binds acetate 
with K = 480 M
-1 in 30% H2O/DMSO with the entropic component still the driving 
force (ΔG = -15.3 kJ mol
-1, ΔH = - 2.0 kJ mol
-1, TΔS = 13.3 kJ mol
-1).This dramatic 
decline from 22,000 M 
-1  to 480 M
-1 upon changing the solvent system from pure 
DMSO to 30% water/DMSO is as a result of the competitive solvation of hydrogen 
and electrostatic bond donor and acceptor sites by the water molecules. This is not 
unexpected  and  is  one  of  the  current  challenges  of  supramolecular  chemistry. 
However, it has to be noted that the 480 M
-1 binding constant is highly encouraging 
for future development of efficient carboxylate binding receptors in water using the 
pyridine scaffold.  
                                                         
To further substantiate the importance of preorganization by the pyridine nitrogen, 
compound 22 in which the pyridine moiety was replaced with a benzene ring was 
synthesized  and  its  acetate  binding  properties  were  investigated  under  the  same 
conditions as compound 21. It was found that the binding constant falls dramatically 
to 5300 M 
-1 and the thermodynamic parameters of the binding (ΔG = -21.2 kJ mol
-1, 
ΔH = - 19.4 kJ mol
-1, TΔS = 1.8 kJ mol
-1) showing the binding process is enthalpy 
driven.  
                                                    
    
1.7.5 Importance of guanidinium functionality in self-assembly 
 
As previously mentioned guanidiniums are very versatile functionalities in biological 
systems and found abundantly in many protein structures and enzymes. Numerous 
biological processes are mediated through them.  This makes guanidiniums very good 
candidates  to  be  exploited  for  the  purpose  of  developing  self  assembled 
supramolecular systems which can mimic biological functions. This research project 
will try to make use of this concept and aim to develop self-assembled systems built 
on guanidinium motifs.   
1.8 Self-assembly and molecular recognition 
1.8.1 Principles of self-assembly 
 
Over  the  past  few  years,  intense  research  has  been  directed  towards  gaining  an 
understanding  of  the  concepts  and  principles  that  govern  the  processes  of  self-
assembly.
82  The  self-assembly  of  molecules  can  lead  to  the  formation  of  highly 
complex  and  fascinating  structures  from  simple  monomeric  building  blocks.  Self-
assembly can offer ways of making very complex structures which otherwise would 
have been very difficult and/or uneconomical to synthesize using covalent synthesis. 
The core principle of self-assembly lies in the fact that the spontaneous assembly is 
dictated by the supramolecular information  encoded in  the interacting sites of the 
simple building block.
 83 This principle is very widely used in nature, as exemplified 
by the molecular architecture of the tobacco virus, the formation of protein plaques in 
Alzheimer’s disease, the formation of the DNA double helix 
84 and the association of 
microtubuli  during  mitosis.
85,  86  The  units  forming  these  super  structures 
spontaneously  self-assemble  in  aqueous  media  by  ingeniously  employing  multiple 
non-covalent interactions such as electrostatic interactions, hydrogen bonding, dipole-
dipole interactions, and hydrophobic association.
87 
 
Supramolecular  chemistry  has  recently  been  successful  in  using  the  principle  of 
programmed  self-assembly  of  simple  synthetic  molecules  to  get  a  detailed 
understanding  of  the  formation  of  complex  supramolecular  structures.  Structurally 
diversified and exciting self-assembled systems have been reported in the literature.    
These include dimers 
88, capsules 
89, oligomers 
90, polymers, and nanostructures 
91 
such as micelles, vesicles and nanotubes.  
 
One  important  feature  of  self-assembly  is  the  reversibility  of  the  process.  As  the 
process  is  entirely  governed by non-covalent interactions,  external  factors  such as 
polarity of the solvent, pH and temperature should be closely monitored to fine tune 
the  formation  of  the  desired  system.  This  control  over  the  formation  of  the  self-
assembled system offers some advantage over the kinetically controlled synthesis of 
complex covalent structures such as polymers in which defects in the final structure 
cannot  be  rectified.  The  responsiveness  of  the  self-assembled  systems  to  the 
surrounding environment and their ability to communicate with thier surroundings is 
another advantage over covalent structures.
92  
1.8.2 Self-assembly in polar solvents based on specific interactions 
 
Most self-assembled systems described to date show stability only in the solid state or 
in  organic  solvents  such  as  chloroform.  H-bonds  are  the  main  non-covalent 
interactions used due to their directionality and complementarity in non-polar solvent 
systems.
93  The  disadvantage  of  these  H-bond  based  assemblies  is  that  they  work 
beautifully only in solvents of low polarity but not in aqueous solvents due to the 
competitive solvation of  donor and acceptor sites by the solvent molecules.
94 
 
However,  it  is  very  desirable  to  have  access  to  self-assembling  systems  that  also 
function in more polar solvents such as DMSO or water.  This requires a strategy to 
circumvent  the  problem  of  solvation  by  seeking  ways  to  enhance  covalent  bond 
interactions  in  such  kind  of  solvents.  Metal-ligand  complexes  have  been  used  to 
achieve  strong  complexation  in  aqueous  solvent  systems.  But  this  approach  is  of 
limited  use  for  biological  purpose  owing  to  bio-incompatability  of  metals  and/or 
unfavorable complexation kinetics. 
95  
 
Another  plausible  approach  to  design  a  self  assembled-system  is  to  exploit  the 
enhanced  strength  of  hydrophobic-hydrophobic  or  aromatic-aromatic  stacking 
interactions  in  aqueous  solvent  systems.  However,  to  deliberately  encode 
supramolecular information in monomeric structures using these types of interactions 
is very difficult because they are not as directional and specific as H-bonding. Hence,    
the  sole  use  of  these  kinds  of  solvophobic  interactions  in  constructing  a  self-
assembled system is improbable. Self-assembly in polar solvent systems requires a 
combination of several non-covalent interactions in the system.  A combination of H-
bonds and hydrophobic/aromatic stacking interactions has been previously employed 
for  such  a  purpose  but  only  with  limited  degree  of  success.  It  has  recently  been 
revealed that H-bonded ion pairs like guanidinium-carboxylate complexes have been 
proven  useful  in  maintaining  the  systems  in  polar  and  aqueous  environments.
  61 
Another  factor  that  should  be  taken  into  account  when  designing  a  monomeric 
structure for the purpose of self-assembly is careful analysis of the propensity of the 
molecule to make intra versus intermolecular interactions. Intramolecular interactions 
might hamper the self-assembly process. In line with this is molecular rigidity of the 
monomer as it is very crucial in maintaining the self-assembled system.
92 Using the 
concepts  above,  some  developments  are  being  made  in  designing  synthetic  self-
assembled systems in polar solvents like DMSO, MeOH or even water.
96  
1.8.3 Self-assembling systems based on guanidine derivatives  
 
Schmuck et al have synthesized pyrrole based guanidinium compounds which are 
excellent supramolecular architectures from the point of view of both binding strongly 
with carboxylate anions and forming well elaborated dimers in polar solvent systems.  
The  zwitterionic  compound  5-(guanidiniocarbonyl)-1H-  pyrrole-2-carboxylate  (23) 
self assembles to form dimers (Kass =10
12 mol
-1) (Fig 11), which are stable in DMSO 
at 170 
oC and at concentrations of 0.001 mM. 
97 This system has also been found to 
show some degree of stability even in pure water (Kass = 170 M
-1).  
 
 
 
       Fig 11 Dimerisation of 5-(guanidiniocarbonyl)-1H- pyrrole-2-carboxylate 
 
 
Schmuck has predicted that the surprisingly high stability of the zwitterionic dimer is 
most likely due to a combination of both ion pairing and the formation of a directed    
H-bond pattern. To probe the importance of the electrostatic interaction, an analogue 
of  5-(guanidiniocarbonyl)-1H-  pyrrole-2-carboxylate  with  an  amidopyridine  group 
replacing the guanidinium cation was synthesized with the intention of switching off 
the  electrostatic  interaction  in  the  dimeric  structure.  ESI-MS  and  NMR  dilution 
studies confirmed that compound 24 dimerizes in solution (Fig 12) 
 
       
 
Fig 12 Dimerisation of compound 24 
 
The X-ray crystal structure reveals that in the solid state the structure of this dimer is 
identical  to  the  zwitterionic  5-(guanidiniocarbonyl)-1H-pyrrole-2-carboxylate. 
Comparing the stability of the two dimers shows that the neutral dimer is only stable 
in chloroform (Kass>10
4 M
-1). It shows no dimerisation at all in pure DMSO thereby 
underlining the fact that the charge interaction in 23 is absolutely necessary for stable 
self-assembly in polar, protic solutions.
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Another  important  factor  which  needs  proper  attention  in  the  design  of  a  self-
assembling  system  is  rigidity  of  the  monomeric  unit.  Schmuck  has  synthesized 
derivatives of the 5-(guanidiniocarbonyl)-1H- pyrrole-2-carboxylate (25) in which the 
carboxylate  is  not  directly  attached  to  the  guanidiniocarbonyl  pyrrole  but  with  a 
spacer.
137  
                                              
 
It was observed that the degree of self-assembly was found to decrease as the number 
of carbons in the spacer increases. For n = 1, large aggregates were observed even at a 
very low concentration. Whereas a very large concentration of the monomeric unit    
was required for n = 3-5, for any detectable self-assembling system to be formed. The 
differences  between  the  five  zwitterions  can  be  explained  based  on  the  extent  of 
intramolecular  charge  interaction  within  the  monomers.  Any  intramolecular 
interaction between the binding sites within the monomer weakens the intermolecular 
self-assembly. In addition, increased intermolecular motion might also be responsible 
for the weakening of the self assembly.
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Following  this  Schmuck  has  reported  one  of  the  most  efficient  self-assembling 
systems in water reported so far. In water compound 26 was found to dimerise with an 
association  constant  of  170  M
-1.
97 The  binding  is  again  attributed  to  the  ion-pair 
formation between the complementary guanidinium and carboxylate groups. 
 
                                       
 
 
Kilburn  has  recently  synthesized  self-assembled  dimeric  structures  based  on  the 
previous pyridoguanidinium motif used for the purpose of carboxylate binding. A 
carboxylic  functionality  was  incorporated  into  the  pyridoguanidinium  receptor  22 
with  the  idea  of  inducing  head-to-tail  self  association  primarily  based  on  the 
complimentary carboxylate-guanidinium intermolecular interaction (Fig 13).
88     
 
      
 
         Fig 13 Proposed dimerisation mode of a pyridoguanidium-carobxylate  
 
 
The  bidentate  hydrogen  bonding  and  electrostatic  interactions  between  the 
carboxylate  and  the  guanidinium  functionalities  are  believed  to  be  crucial  in 
maintaining the dimeric structure in polar and aqueous solvent system. Additional 
non-covalent  interaction  furnishing  sites  (X)  are  encoded/installed  in  the  building 
block to impart further stability into the dimeric structure. In addition, the monomeric 
zwitter ion is designed in such a way that it is easily amenable/tunable for structural 
manipulation  and  hence  potentially  makes  this  supramolecular  system  serve  as  a 
platform to investigate any chosen covalent interaction like hydrophobic-hydrophobic 
interactions in peptides and aromatic aromatic stacking interactions. 
 
Kilburn et  al have exploited this  approach to  investigate the strength  of aromatic 
stacking  interactions  and  the  biologically  important  Val-Val  and  Leu-Leu 
hydrophobic interactions. ITC aided dimerization study of compound 27 shows that it 
forms a stable dimer in DMSO solution (Kdim = 11876 M
-1, ΔGdim = -23.2 kJmol 
-1, 
ΔHdim = -10.0 kJmol 
-1, TΔSdim = 13.2 kJmol 
-1). Upon changing the solvent system to 
10% H2O/DMSO, the dimerisation constant has declined dramatically (Kdim = 532 M
-   
1, ΔGdim = -15.6 kJmol 
-1, ΔHdim = -11.5 kJmol 
-1, TΔSdim = 4.1 kJmol 
-1) due to the 
expected solvation effect by the water molecules. It was unexpected that the enthalpic 
contribution in the dimerisation process was more in 10% H2O/DMSO than in pure 
DMSO.  An  entropy  driven  binding  of  the  receptor  with  acetate  was  observed 
previously in DMSO/water systems. 
                                                  
 
In the solid state, the dimer was found to be a well-defined structure with closely 
stacked aromatic rings and a water molecule bridging a hydrogen bonding between 
the amide hydrogen and the carboxylate (Fig 14). Though a solid state structure might 
not  be  extrapolated  to  the  solution  phase  structure  of  the  dimeric  molecule,  the 
constructive  role  of  the  water  molecule  in  the  solid  state  dimeric  structure  in 
mediating the hydrogen bonding might explain the unexpected increase in enthalpy in 
10% water/DMSO system.   
 
 
 
            Fig 14 Schematic  representation of  the dimeric structure of compound 27     
1.8.4 Functional supramolecular structures using guanidinium derived 
receptors 
 
In one of his recent works, Schmuck has taken a great stride towards the application 
of the guanidiniocarbonyl pyrrole carboxylate receptors in the field of medicine. The 
focus of the research was to design biosensors, targeting specific cellular processes in 
Alzheimer’s  disease.  It  is  known  that  the  self-aggregation  of  small  peptides  is 
responsible both in animals and humans for a variety of neuro degenerative diseases 
like  Alzheimer’s  disease  (AD).  The  senile  plaques  found  within  the  brain  of  AD 
patients consist of an insoluble aggregate of a 39–42 residue peptide, called amyloid 
β-peptide  (Aβ).
99  One  possible  therapeutic  intervention  in  the  pathogenesis  of 
Alzheimer’s  disease  (AD)  is  to  prevent  the  Aβ  self-aggregation.
100  Recently 
rifampcine  and  oligopeptides  which  contain  fragments  of  the  Aβ  itself  have  been 
tested in vitro and showed encouraging results for the inhibition of Aβ aggregation.
101 
However, nothing is known regarding the molecular basis of their interaction with Aβ 
and it is not even certain in some cases that a specific complexation between Aβ and 
the  inhibitor  actually  occurs.
102  This  lack  of  understanding  of  quantitative 
experimental binding data is a major setback in the design of more specific amyloid 
inhibitors for future therapeutic use. Having this in mind Schmuck et al have designed 
a supramolecular approach that helps to identify the structural and thermodynamic 
parameters that control the self-association and hence also possible interactions with 
aggregation  inhibitors.  Schmuck  has  synthesized  a  combinatorial  receptor  library 
based on the observation that the C-terminal sequence of Aβ (-Val39-Val40-Ile41-
Ala42)  is  one  of  two  domains  mainly  responsible  for  its  self-aggregation.
103  This 
domain  promotes  the  formation  of  aggregated  β-sheets  stabilized  through  a 
combination  of  H-bonds  and  hydrophobic  interactions.    Schmuck  has  chosen  a 
tripeptide receptor library with the the idea of making an antiparallel β-sheet with the 
backbone of this Aβ tetrapeptide substrate. H-Bonding and hydrophobic interactions 
are believed to be the main dominant non-covalent bond forces to stabilise the β-sheet 
structure.  
 
 
 
    
 
 
 
Fig 15 A tripeptide-based library of cationic guanidiniocarbonyl pyrrole receptors of 
the general structure Amino-TentaGel-AA1-AA2-AA3-Gua (AA = amino acid, Gua = 
guanidiniocarbonyl pyrrole cation) designed for the binding of L-Val-L-Val-L-Ile-L-
Ala, a tetrapeptide representing the C-terminus of Aβ. 
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The  functional  application  of  a  guanidiniocarbonyl  pyrrole  carboxylate  receptor 
comes  into  picture  here  as  the  complexation  process  in  polar  solvents  must  be 
augmented  by  electrostatic  interactions.  H-bonding  and  hydrophobic  interactions 
alone will not suffice to maintain the anticipated β-sheet structure in aqueous solvent 
system.Using  the  combinatorial  synthesis  approach,  Schmuck  has  prepared  125 
members of receptors which can bind with high affinity to a tetrapeptide representing 
the  C-terminal  end  of  the  Alzheimer  amyloid  peptide  Aβ.  Analysis  of  selected 
receptors shows that the binding of the C-terminal Aβ fragment with the receptor is 
controlled  by  interplay  between  electrostatic  and  hydrophobic  interactions.
104  This 
preliminary  result  is  a  way  forward  for  the  development  of  biosensors,  targeting 
specific cellular processes (e.g., cancer, Alzheimer’s disease, and bacterial infections), 
and the design of new therapeutics. 
 
Functional  self-assembled  supramolecular  structures  have  been  synthesized  using 
guanidiniocarbonyl  pyrrole  carboxylate  zwitterions  as  building  blocks.  A  possible 
vesicle  membrane  has  been  synthesized  using  a  pyrroleguanidinium  monomeric 
structure. The carboxylate group is separated from the guanidinium group by a chiral 
linker based on L-alanine leading to a rigid rod-like molecule with two oppositely 
charged ends and a less polar middle section (Fig 16). 
105 
 
    
 
 
 
               Fig 16 Suggested membrane formation via the self-assembly 
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1.8.5 Membrane transport using acyclic guanidinium receptors 
 
Lehn et al have previously demonstrated that receptors based on lipophilic quaternary 
ammonium compounds were used to transport amino acids and dipeptides from one 
aqueous phase through a chloroform layer into another aqueous phase. 
106 By a similar 
approach,  Schmuck  has  recently  reported  efficient  amino  acid  transporter  using  a 
guanidiniocarbonyl–pyrrole receptor. Amino acid transportation across membranes is 
the most widely happening phenomenon in biological processes.  Movement of amino 
acids from one aqueous phase across a lipid bilayer membrane to another aqueous 
phase requires a host molecule (receptor) capable of efficiently binding the substrate 
under aqueous conditions. A guanidiniocarbonyl pyrrole motif, which has previously 
proved  to  be  an  efficient  carboxylate  receptor,  was  derivatised  by  introducing  a 
lipophilic tris(dodecylbenzyl) group synthesized (28). The long alkyl chain imparts 
the desired solubility of the receptor in organic solvent systems (lipid bilayers). Where 
as the guanidinium groups will align themselves at the interface of the aqueous phase 
and ready to bind to carboxylates.  
    
 
 
The pH gradient between the source and the receiving phase is the driving force for 
the symport of the amino acid carboxylate and the proton. (Fig 17) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 17 Transport of acetylated amino acid carboxylates (S) by receptor 29 (R).Only 
the protonated form RH+ of the receptor can bind the anionic substrate S and 
transport it across the bulk liquid membrane. 
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Transportation of N-acylated amino acids of alanine, valine, tyrosine, phenylalanine, 
and tryptophan was conducted in this experiment and it was observed that the receptor 
is capable of efficiently transporting the amino acids studied across the chloroform 
phase with the transportation efficiency in the order of Val > Phe >Ala >Trp >Tyr. 
The  rate-determining  step  in  the  transportation  process  is  not  the  binding  of  the 
substrate  but  its  release  upon  contact  with  the  receiving  phase.  The  stronger  a 
substrate binds, the higher is the energy barrier  for its release from the receptor–
substrate complex, in accord with the Bell–Evans–Polanyi principle.  
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R-H+
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R
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2. Aim of the research project 
 
Supramolecular chemistry has been successful in developing synthetic systems which 
could allow investigation of specific noncovalent bond interactions. However, most of 
the systems designed so far work reasonably well only in solvents of low polarity. The 
design  of  models  that  can  function  in  polar  and  aqueous  environments  is  a  very 
difficult  task  for supramolecular  chemists, owing to  the  weak nature  of hydrogen 
bonding and ion pair interactions in such competitive solvent systems.  
 
Kilburn et al have investigated several pyridylguanidinium based receptors for their 
carboxylate  binding  properties  in  polar  and  aqueous  solvent  systems.  As  a 
continuation  of  this  well  established  research  work,  we  have  considered  that 
incorporating  carboxylate  functionality  into  the  pyridylguanidinium  receptor  will 
induce a complementary head-to-tail dimerisation process (Fig 18). This is based on 
the  fact  that  self-assembly  in  polar  solvents  requires  efficient  self-complementary 
binding motifs. 
 
           Fig 18 Proposed dimerisation mode of pyridoguanidinium-carboxylates 
 
The  main  driving  force  of  the  dimerisation  process  will  be  the  combination  of 
multiple non-covalent bond interactions  (H-bonding, hydrophobic and  electrostatic 
interactions) installed in the system. As seen from fig 18, at the heart of the proposed Aims of the research project 
   
dimeric structure will be the bidentate intermolecular hydrogen bonding-electrostatic 
interaction between the guanidinium and carboxylate functionalities. This interaction 
will  be  augmented  by  the  preorganisation  of  the  pyridine  scaffold  through 
intramolecular hydrogen bonding between the pyridine N and the adjacent amide and 
guanidine protons. Additional non-covalent bond interactions (π- π stacking and/or 
hydrophobic interactions) will be furnished into the system through the R group. 
 
This  PhD  research  project  will  primarily  focus  on  the  design  and  synthesis  of 
pyridylguanidinium  supramolecular  structures  stable  in  polar  and  aqueous 
environments. Synthesis of various pyridylguanidinium derivatives will be undertaken 
and  this  will  be  followed  by  investigation  of  their  dimerisation  properties  using 
isothermal calorimetric (ITC) and NMR dilution techniques. This will allow direct 
determination of the thermodynamic parameters associated with the formation of the 
dimeric supramolecular structures.The magnitude of these parameters (Kdim, ∆Gdim, 
T∆Sdim and ∆Hdim) will allow a direct measure and quantification of the strength of 
interactions between structural elements which lead to the formation of the dimeric 
supramolecular system. Crystal structure determination (when possible) will also be 
considered with the above mentioned binding study techniques and this will enable us 
to make a detailed structural analysis of dimerisation and self assembly. 
 
The  first  part  of  our  work  will  focus  on  structural  optimisation  with  the  aim  of 
accessing the dimeric structure in polar solvent systems. The first approach will be 
through  systematic  replacement  of  the  ‘R’  side  chain  with  non-polar  amino  acid 
residues  that  can  deliver  hydrophobic-hydrophobic  interactions  into  the  dimeric 
supramolecular system. For this purpose, a series of pyridylguanidinium carboxylates 
containing  β-Ala,  Leu  and  Val  amino  acid  residues  in  the  side  chain  will  be 
synthesized and their dimerisation properties will be investigated. This investigation 
will be vital to:  
 
  Understand  the  importance  of  hydrophobic  interactions  in  stabilizing  the 
dimeric structures in aqueous environments. 
  Investigate  amino  acid-amino  acid  interactions  which  are  of  biological 
significance. Aims of the research project 
   
Determination of Val-Val and Leu-Leu interactions will be attempted at the initial 
phase of this project since the two interactions are abundantly present in secondary 
and tertiary protein structures.  
 
Once we optimize the conditions and have a better control of the dimerisation process, 
a  series  of  peptide-pyridyl  guanidinium  derivatives  will  be  prepared  and  their 
dimerization properties will be investigated (Fig 19).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig  19  Proposed  dimerisation  mode  of  peptide  containing  pyridoguanidinium-
carboxylates 
 
It is expected that once the desired degree of stability is achieved in polar solvent 
systems, our dimeric supramolecular structures can serve as a platform to investigate a 
chosen non-covalent bond interaction via tailoring of the structure of ‘R’.  
 
We  have  designed  the  dimeric  supramolecular  systems  in  this  research  project  in 
order that they will meet the following criteria:  
 
   Stable in polar environment 
   Amenable to structural changes Aims of the research project 
   
   Designed in such a way that it will enable to mimic functions of biological 
systems 
   Reasonably easy to synthesize  
 
The outcome and the in-depth assessment of the dimerisation study results of the 
proposed guanidinium-carboxylates will help us to have a better understanding of the 
principles of self-assembly in polar and aqueous solvent systems. This in turn will 
enhance our understanding of the molecular recognition events and allow the future 
design of efficient carboxylate receptors which can function in aqueous systems.   
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3. Results and Discussion 
3.1 Introduction 
 
Several  pyridylguanidinium  based  anion  receptors  have  been  investigated  in  our 
group for their amino acid binding properties in polar and aqueous solvent systems. A 
recent study showed that the pyridylguanidinium receptor 21 binds acetate strongly in 
30% H2O/DMSO making it an effective synthetic carboxylate receptor.
59 
  
 
 
                               
In subsequent studies by Kilburn et al, 
88 a derivative of 21 incorporating carboxylate 
functionality (27) was designed to form dimers via an intermolecular head-to-tail self-
assembly  orchestrated  by  electrostatic  and  H-bonding  interaction  between  the 
carboxylate with the guanidine moieties. Schmuck has used similar strategy to induce 
self-assembly of pyrroleguanidinium carboxylates.
 97  
 
Compound 27 is found to dimerise strongly in polar solvent systems (DMSO and 10% 
H2O/DMSO) with aromatic stacking interactions which are believed to contribute to 
the high binding energy of the dimeric structure as established by ITC dilution studies. 
This mode of dimer formation was also substantiated by evidence from the solid state 
X-ray structure (see page 81).  
 Results and Discussion 
   
 
Fig 20 Dimerisation of compound 27 in DMSO 
 
 
With this in mind, optimisation of the dimerisation process was commenced with 
designing pyridylguanidinium derivatives 29 and 30 where the benzyl side chain is 
replaced with ß-Ala and l-valine amino acid residues respectively. This will help not 
only  to  understand  the  contribution  of  the  possible  aromatic-aromatic  stacking 
interaction for the stability of the aforementioned dimer, but also to probe a Val-Val 
aminoacid interaction which is important in secondary and tertiary protein structure. 
Val and Leu are important in this regard and will be investigated in this research 
work.
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3.2 Synthesis of guanidine-carboxylates 29 and 30 
 
The syntheses of all the pyridoguanidine systems considered in this project involve 
syntheses of the basic pyridine scaffolds 35 and 36. Syntheses of these scaffolds were Results and Discussion 
   
achieved by building upon the commercially available pyridine-2, 6-dicarboxylic acid 
(31). The scaffold was then functionalized appropriately to give the desired system.  
 
Scheme1 describes the synthesis of the basic pyridine scaffold. Esterification of 31 
was  followed  by  reduction  with  sodium  borohydride  to  give  the  alcohol  32.  The 
approach used to synthesize 34 is via activation of the hydroxyl group by converting it 
first into a good leaving group, mesylate or chloride. Subsequent SN2 reactions with 
the nucleophile, HNBoc2, gave compound 34 in a good yield.  
 
Scheme 1 
 
 
 
 
A Mitsunobu reaction was initially attempted to convert the primary OH group of 32 
directly into the Boc protected product 34. But it was accomplished in only 35 % 
yield.
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Ester hydrolysis of 34 was initially undertaken with Me3SiOK but it did not proceed 
with a good yield. The problem has been circumvented by using lithium salts for the 
hydrolysis  procedure,  a  procedure  which  is  recommended  specially  for  ester 
functionalities  containing  a  β-heteroatom.
110  Coordination  of  lithium  to  the  ester 
carbonyl group and to the heteroatom at the β position makes the ester carbonyl centre 
more reactive to nucleophilic attack (Fig 21).   
 
                                             
   Fig 21  A proposed reaction mechanism of lithium mediated ester hydroysis 
 Results and Discussion 
   
Functionalization of the pyridine scaffold was undertaken by coupling reactions with 
β-alanine  methyl  ester  and  valine  methyl  ester  to  give  compounds  37  and  38 
respectively (Scheme 2).  
 
 
 
Scheme 3 depicts the synthesis of the Cbz activated thiourea compound 42 which will 
be used at a later stage to establish the guanidine functionality into the system. This 
synthetic route was previously used in our group 
59 and exploited to synthesise various 
pyridyl  guanidinium  salts  for  the  purpose  of  carboxylate  binding  in  polar  solvent 
systems. All the transformations in Scheme 3 were accomplished in reasonably good 
yields.  
 
 
 
Scheme 4 shows coupling of compounds 37 with the thiourea compound 42 to give 
the  corresponding  Cbz  protected  compounds  43.  This  procedure  was  followed  by 
ester hydrolysis and hydrogenolysis steps leading to the synthesis of the carboxylate-
guanidinium compound 29.  Results and Discussion 
   
 
 
Scheme 5 shows the similar approach used in scheme 4 that leads to the synthesis of 
the carboxylate-guanidinium compound 30. The structures of these novel carboxylate-
guanidinium compounds were fully characterized using spectroscopic (NMR, MS and 
IR) analysis.  
 
 
 
 
 
 
 
 
 Results and Discussion 
   
3.3 Dimerisation studies of guanidnium-carboxylates 29 and 30  
3.3.1 Isothermal calorimetric dilution study of 29 and 30 
 
The initial dimerisation studies of 29 and 30 were performed in DMSO. DMSO was 
the solvent of choice to start the investigation owing to its similarity with water in 
terms of solvent properties, dipole moment and dielectric constant. Both water and 
DMSO  can  form  hydrogen  bonds  owing  to  the  strongly  polarized  O-H  and  S-O 
groups respectively. While water can accept and donate H-bonding, DMSO is capable 
of accepting hydrogen bonds. The initial dilution studies with these compounds have 
resulted in endothermic heat pulses as expected from dimer dissociation (Fig 22). 
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Fig 22 Calorimetric data obtained for ITC dilution studies of 29 (left) and 30 (right) 
in DMSO at 298K. a) c) Raw ITC data of 27 & 31 respectively  in DMSO (29 x 10 µL 
injections); b) d) Non-linear curve fittings of the reference corrected data into the 
dimer-dissociation model  
 
 
 
 
 Results and Discussion 
   
The full thermodynamic profile of the dimerisation phenomena is tabulated below.  
 
Compound   Kdim [M 
-1]  ∆Gdim
  [kJ mol
-1]  ∆Hdim
  [kJ mol
-1]  T∆Sdim
 [kJ mol
-1] 
29  79 ±14  -9.0  -6 ±0.3  3.0  
30  400 ±22  -14.8  -11±0.1  3.7 
 
Table 2 Energetics of dimerisations of compounds 29 and 30 (concentrations of 20 
mM and 10 mM respectively) at 298 K in DMSO.  
 
The negative ∆Gdim
 values
 indicate the spontaneous and thermodynamically favoured 
formation of the dimeric complexes (Table 2).
57 Dissection of the free energy into its 
enthalpic and entropic components reveals that the dimerisation is driven by enthalpy 
although  it  can  be  seen  that  there  is  a  modest  positive  entropic  contribution. 
Compound 30 was found to form a more stable dimer in DMSO than compound 29 
with  an  extra  stabilization  energy  of  -5.8  kJ  mol
-1.  This  extra  stability  might  be 
attributed  to  the  van  der  Waals  contact  via  Val-Val  side  chain  interaction  in  the 
dimeric structure. But it should not be ruled out that the decreased stability of the 
dimeric  structure  from  compound  29  might  be  due  to  possible  deleterious 
intramolecular interactions leading to conformational changes resulting in decreased 
dimer formation. The more flexibility imparted to the monomer by the ß-Ala side 
chain could lead to this intramolecular interaction.  
 
Investigation of the dimerisation in 10% H2O/DMSO shows that there was complete 
disruption of the dimers. No endothermic heat pulse was observed. This is due to the 
competitive solvation of the hydrogen bond forming sites by the water molecules.
111 It 
was envisaged that a hydrophobic Val-Val side chain interaction might stabilise the 
dimer in 10% H2O/DMSO, however either its effect was not detectable by the ITC or 
it did not materialise at all. Further dilution studies were made on compound 30 in 30, 
40 and 50% H2O/DMSO. Some degree of dimerisation was anticipated for compound 
30 in the above solvent systems, considering the fact that hydrophobic interactions get 
stronger in a more aqueous environment. Nevertheless, no dimerisation was observed 
in these solvent systems.  
 Results and Discussion 
   
Encouraging results have been registered for the initial structural optimisations made 
on compound 27. It can be suggested that the possible Val-Val side chain interaction 
might be responsible for the improved dimerisation of compound  30  as compared 
with 29. In addition, the results above are also important in highlighting the possible 
role of an aromatic-aromatic stacking interaction in dimer 27.  
3.4 Synthesis of guanidinium-carboxylates 45 and 46 
 
In  order  to  undertake  further  structural  optimization,  compounds  45  and  46  were 
designed in which the phenylpropyl amide side chain in compounds 29 and 30 is 
replaced with a simple benzyl group. As guanidinium carboxylates 45  and 46  are 
more rigid, it is expected that they might dimerise more strongly.
 92  
 
In addition, the dimerisation studies on these compounds will help to establish if the 
extra  amide  groups  in  the  previous  guandinium-carboxylates  were  important  in 
stablising the dimeric structure. 
                                                        
Scheme 6 outlines the synthesis of the thiourea compound which was used to install 
the  benzyl-guanidine  functionality  into  the  system.  Benzylchloroformate  was 
converted into the corresponding thiocyanate derivative via a simple replacement of 
chloride with SCN
-. 
112 This was followed by a coupling reaction with benzylamine to 
give the Cbz activated thiourea compound 49. Compound 48 was found to be highly 
unstable with a propensity to decompose completely in a few hours if kept at room 
temperature.  
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Scheme 6 
 
Scheme 7 shows coupling of compound 37 with the thiourea compound 49 to give 
Cbz and ester protected form of the final carboxylate-guanidinium 45. Final ester 
hydrolysis and Cbz deprotection steps then concluded the synthesis of guanidinium-
carboxylate 45. 
 
 
Scheme 8 shows similar procedures leading to the synthesis of 46. A lower yield was 
recorded for the valine functionalized derivative which might be due to a steric factor 
associated with the isopropyl side chain of valine during the methyl ester hydrolysis 
by Me3SiOK. 
  
 
 Results and Discussion 
   
  
The  final  compounds  45  and  46  were  purified  by  repeated  precipitation  from 
methanol using diethyl ether. The high degree of polarity of the compounds precludes 
the use of normal phase chromatography as a means of purification. 
3.4.1 Isothermal calorimetric dilution study of 45 and 46 
 
ITC  dilution  studies  of  compounds  45  and  46  were  designed  to  look  into  the 
contribution of the propanamide side chain in the dimerisation process of compounds 
29 and 30, and were initially performed in DMSO (Fig 23). The studies also help to 
verify the importance of the Val-Val side chain interaction for the stability of the 
dimeric structure.  
 Results and Discussion 
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Fig 23 Calorimetric data obtained for ITC dilution studies of 45 (left) and 46 (right) 
in DMSO at 298 K. a & c) Raw ITC data (29 x 10 µL injections); b & d) Non-linear 
curve fitting of the reference corrected  data into the  dimer dissociation model  
 
The  Val-functionalized  compound  46  was  found  to  form  a  very  stable  dimer  in 
DMSO  with  a  Kdim  of  4608±1954  M
-1.  Dissection  of  the  free  energy  of  the 
dimerisation indicates that the process is primarily enthalpy driven (Table 3). 
 
Compound   Kdim [M 
-1]  ∆Gdim
  [kJ mol
-1]  ∆Hdim
  [kJ mol
-1]  T∆Sdim
 [kJ mol
-1] 
45  180±30  -12.9  -24.4 ±0.4  -11.4 
46  4608±1954  -20.9  -21.8±1.1  -0.9 
 
Table 3 Energetics of dimerisations of compounds 45 and 46 (concentrations of 10 
mM and 4 mM respectively) at 298 K in DMSO 
 
The possible contribution of a Val-Val non-polar interaction in the dimeric structure 
again comes into the picture. Compared to compound 45, an extra stabilization energy 
of -5.1 kJ mol
-1 was observed for the dimer of compound 46 and this is similar to the Results and Discussion 
   
extra stabilization observed in the dimer of compound 30 compared with compound 
29  which was  -5.8  kJ  mol
-1 (Fig  24). This  consolidates the possibility of the role 
played by the Val side chain in enhancing the dimer stability.  
 
                          
     
  Fig 24 Comparison of the dimerisation energies of compounds 29, 30, 45 and 46  
 
In both ß-Ala (compounds 45 and 29) and Val (compounds 46 and 30) functionalized 
systems, the replacement of the phenyl propanamide side chain with a simple benzyl 
chain has resulted in an increase in ∆Gdim = -6.1 kJmol
-1. Both systems indicate the 
possible deleterious effect of the propanamide side chain in the dimerisation process. 
However, in another set of compounds which contain aromatic side chains, it was the 
benzylpropane amide analogue rather than the simple benzyl one which was found to 
form  a  more  stable  dimer.
88  Compound  52  is  an  analogue  of  27  in  which  the 
benzylpropane amide side chain was replaced with a benzyl group.
 
 Results and Discussion 
   
                      
The dimers of both compounds are believed to be stabilized by aromatic-aromatic 
stacking  interactions.  However,  it  was  noted  that  the  dimer  stability  of  52  (Kdim 
(DMSO) = 6622±2105 M
-1, Kdim (10% H2O/DMSO) = 148±31 M
-1) was found to be 
lower than that of  27  (Kdim(DMSO) = 11876±1692  M
-1 Kdim(10% H2O/DMSO) = 
532±23 M
-1). The constructive role of the benzyl propane amide moeity has also been 
observed in the binding of carboxylates by pyridoguandinium receptors incorporating 
this side chain.
59 The superiority of compound 27 is due to the possible involvement 
of the amide hydrogen in the dimerisation process. This is substantiated by the crystal 
structure  evidences  of  27  and  52.
113  The  dimer  architecture  of  the  guanidinium 
carboxylates with aliphatic side chains, however, might not allow the participation of 
the amide hydrogen in intermolecular hydrogen bonding as in the case of compound 
27.  
  
Another plausible explanation for the weaker dimer stability of compound 45 vs 46 
and compound 29 vs 30 is a possible non-covalent intramolecular interaction which 
can  bring  conformational  changes  affecting  the  intermolecular  non-covalent 
interactions  which  are  vital  for  dimer  stability.  A  solid  state  X-ray  structure  of 
compound 45 substantiates this point (Fig 25).  Results and Discussion 
   
 
                             Fig 25  Solid state X-ray structure of compound 45  
The crystal structure analysis of 45 shows that there are four important inter and intra 
molecular  hydrogen  bonding  interactions.  Intramolecular  H-bonding  was  observed 
between the amide NH and one of the carboxylate oxygens (N1H...O2, 2.813 Å).  
Three  important  intermolecular  hydrogen  bonds  between  the  guanidinium  and 
carboxylate group were found in the X-ray structure. These guanidinium carboxylate 
interactions  involve  N3H...O1  (2.772  Å),  N5H...O2  (2.749  Å)  and  O1H...N4 
(2.776  Å).  The  intermolecular  H-bonding  between  the  carboxylate  and  the 
guanidinium functionalities observed in the solid state are believed to be the driving 
force for the solution phase dimerisation of the compound (Fig 26). The flexibility of 
the  β-Ala  side  chain  in  45  allows  intramolecular  H-bonding  between  one  of  the 
carboxylate  oxygens  and  the  amide  hydrogen.  This  may  lead  to  conformational 
constraints which impede proper alignment for effective dimerisation in solution. The 
dimerisation  process  also  requires  breaking  of  the  intramolecular  H-bonds  thus 
subtracting from the overall dimerisation energy. It is likely that the intramolecular 
hydrogen  bonding  will  also  be  in  the  solution  phase  structure  as  intramolecular 
interactions are more likely to be preserved in solution compared to intermolecular 
ones.
114  However,  it  is  has  also  to  be  in  mind  that  solid  state  structures  do  not 
necessarily represent solution phase structures.
115  
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Fig 26 Self-association of compound 45 in the solid state 
 
The  dimerisation  of  compounds  45  and  46  was  further  investigated  in  10% 
H2O/DMSO system (Fig 27). 
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Fig 27 Calorimetric data obtained for ITC dilution studies of 45 (left) and 46 (right) 
in 10% H2O/DMSO at 298 K. a & c) Raw ITC data (29 x 10 µL injections); b & d) 
Non-linear curve fitting of the reference corrected  data into the dimer dissociation 
model  
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The dimerisation of both compounds was found to be reduced significantly in 10% 
H2O/DMSO. The marked difference in stability observed between the dimers from 
compounds 45 and 46 in DMSO was not apparent in 10% H2O/DMSO (Table 4). This 
is unexpected as it was anticipated that the hydrophobic Val-Val interaction might 
help  in  preserving  the  dimerisation  in  an  aqueous  environment  and  hence  bring 
considerable differences in terms of dimer stabilities between the two compounds. 
  
Compound   Kdim [M 
-1]  ∆Gdim
  [kJ mol
-1]  ∆Hdim
  [kJ mol
-1]  T∆Sdim
 [kJ mol
-1] 
45  54±8  -9.9  -6.2±0.1  3.6 
46  54±4  -9.8  -5.6±0.1  4.2 
 
Table 4 Energetics of dimerisation of compounds 45 and 46 (concentrations of 20 
mM each) at 298 K in 10% H2O/DMSO  
 
It was also noted that the contribution of the entropic component of the free energy 
has  significantly  increased  in  10%  H2O/DMSO.  This  is  expected  as  hydrophobic 
interactions in aqueous environments are entropy driven. The ordered water molecules 
surrounding the monomeric structure are released into the bulk system during the 
dimerisation process and this directly results in increase of the entropy of the system. 
As expected, the entropic contribution is greater in compound 46 which might be due 
to  the  Val-Val  hydrophobic  interaction.  It  has  to  be  noted  however  that  ITC 
determination of enthalpy amd entropy is not reliable for processes with small binding 
constants.  
 
In summary, by synthesizing compounds 45 and 46 and studying their dimerisation, 
we  were  able  to  undergo  further  analysis  of  dimer  stability  in  DMSO  and  10% 
H2O/DMSO. In these two compounds, the negative role of the propane amide side 
chain  and  the  positive  role  of  the  Val  side  chain  in  the  stability  of  the  dimeric 
structures were noted.  
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3.4.2 NMR dilution study of 29, 30, 45 and 46 
 
Having  established  the  dimerisation  of  the  above  compounds  using  ITC,  NMR 
dilution study was carried out to verify the self assembly process. This might not only 
confirm the stability constants of the dimer obtained from the ITC experiment but also 
give  structural  information  regarding  the  dimerisation  process  in  solution.  The 
feasibility of undertaking an NMR dilution study was first assessed by calculating the 
concentration  of  any  given  monomer  needed  to  prepare  solutions  which  should 
contain a significant amount of dimer (9:1, dimer:monomer ratio) and a significant 
amount  of  the  monomer  (1:9,  dimer:monomer  ratio)  in  the  given  solvent  system. 
These calculations were made using the Kdim values obtained from the ITC studies. 
Out of the four compounds  it was  only  compound  45 which could  practically be 
studied by an NMR dilution experiment. In cases of the other compounds either the 
concentration required is beyond the solubility limits or is too dilute to be studied 
practically by NMR (Table 5).  
 
Compound  90%[D*]  85%[D*]  50%[D*]  20%[D*]  15%[D*] 
29  487.80  204.70  10.8  1.69  1.12 
30  102.15  42.90  2.30  0.35  0.23 
45  54.60  22.90  1.20  0.19  0.13 
46  7.50  3.10  0.17  0.02  0.01 
 
[D*]= the concentration of the compound in mg/mL which contains the specified 
percentage of dimer in DMSO solution, calculated based on the Kdim   obtained from 
ITC dilution studies. [D*] = ([dimer]/Kdim* [monomer]
2)*MW.  
 
Table 5  Concentration needed to prepare solutions of compounds 29, 30, 45 and 46 
in  DMSO  that  is  supposed  to  contain  90%,  85%,  50%,  20%  and  15%  dimeric 
structure  
 
A preliminary NMR dilution study was made by preparing a concentrated (10 mg/mL) 
and a dilute (1 mg/mL) solution of compound 45 in DMSO. The NMR spectra of 
these solutions show that there is a concentration dependent change in the chemical 
shift value of the NH protons (Fig 28). These concentration dependent changes of the 
chemical shift values are believed to be a direct result of the dimerisation process.  Results and Discussion 
   
 
 
Fig 28 
1H  NMR spectra of compound 45 a) 1 mg/mL in DMSO b) 10 mg/mL in 
DMSO 
 
It can be seen from the NMR spectra above that two NH signals that resonate at the 
same chemical shift in the concentrated solution spectrum of compound 45 separated 
in the dilute solution spectrum. As we go from the dilute solution spectrum into the 
concentrated one, one of the NH signals shifts upfield and the other shifts downfield. 
The downfield shift is due to complexation of the guanidinium NH with carboxylate 
in the dimeric structure. However, the upfield shift could not justify the constructive 
involvement of the NH proton in the dimerisation process. This can be attributed to 
the fact that the amide NH might be involved in intramolecular H-bonding in the 
monomer, most probably with the carboxylate oxygen as observed from the X-ray 
structure  (Fig  26),  resulting  in  an  upfield  shift  when  the  solution  gets  more 
concentrated. In dimer form, the carboxylate oxygen will be hydrogen bonded not 
only  intramolecularly  with  the  amide  NH  but  also  intermolecularly  with  the 
guanidinium NH. With  increasing  substrate concentration and  as  formation  of the 
dimer begins, the strength of the intramolecular H-bonding decreases. This results in 
successive  upfield  shift  of  the  amide  proton  signal  as  the  concentration  of  the 
substrate increases.   
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This preliminary study was followed by a full NMR dilution study that would permit 
to make a full quantitative determination of the dimerisation constant in DMSO. 
102 
Diverging (one upfield and another downfield) shifts of the two NH proton signals 
were successively observed as the solution is increasingly diluted (Fig 29).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig  29  Part  of 
1H  NMR  signals  of  compound  45  in  DMSO  along  with  the 
concentration of the sample  at 298 K 
 
Plots  of  the  observed  chemical  shifts  versus  concentration  give  two  isothermic 
binding curves (Figure 30) and these concentration dependent changes of the two NH 
signals is correlated with the shift in the monomer-dimer equilibrium.  
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                                  a                                                                         b 
Fig  30  a   &  b, Concentration  versus chemical  shift  plots  of  the two NH protons 
signals which show concentration dependent chemical shift change  in DMSO at 298 
K    
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The two NMR dilution data sets were analysed using nonlinear curve fitting to a 
dimerisation isotherm (NMRDil_Dimer)
 30 and were found to have a Kdim = 57.5 M
-1 
using  the dilution data obtained from the guanidine NH and Kdim = 31.8 M
-1 using  
the dilution data obtained from the amide  NH. These results are lower than the Kdim 
(180  M
-1)  obtained  from  the  ITC  study  but  are  of  the  same  order  of  magnitude. 
Results obtained with other dimers (vide infra) generally gave a consistent picture i.e 
dimerisation constants from NMR and ITC with the same order of magnitude.  
 
Inaddition  to  verifying  the  ITC  dimerisation  figures,  the  NMR  dilution  study  has 
helped us to observe the involvement of the guanidine and the amide protons in the 
dimerisation process in solution.   
3.5 Synthesis of guanidinium-carboxylate 53 
 
Most of the compounds considered so far have shown good dimerisation in DMSO 
and  10%  H2O/DMSO  systems.  This  has  been  well  established  by  ITC  dilution 
experiments. However, verification of the dimerisation process could not be made for 
most  of  the  compounds  using  NMR  dilution  studies  due  to  the  fact  that  the 
concentration needed to span a 10%–90% range of dimer formation is not suitable for 
the NMR dilution experiment. However, it is desirable to verify the dimerisation by 
an NMR study and get more structural information on the dimer architecture and the 
binding event in solution.  
 
Guanidine-carboxylate  53  is  a compound  previously synthesised in our  lab which 
showed a Kdim = 877±100 M
-1 in DMSO (Fig 31) as determined by ITC dilution study. Results and Discussion 
   
Fig 31 Schematic representation of the proposed dimerisation of compound 53 
 
Compound 53 is an analogue of compound 30 in which the Val amino acid side chain 
is  replaced  with  Leu.  Calculations  based  on  ITC  dimerisation  data  show  that 
compound 53 is amenable to NMR dilution studies. The working concentration range 
of the proposed NMR dilution experiment was established based on the Kdim value 
obtained from the ITC study result (Table 6).  
 
Compound  85% [D*]  80% [D*]  50% [D*]  15% [D*]  10% [D*] 
122  20.20  10.7  1.10  0.11  0.07 
 
[D*]= the concentration of the compound in mg/mL which contains the specified 
percentage of dimer in DMSO solution, calculated based on the Kdim   obtained from 
ITC dilution studies. [D*] = ([dimer]/Kdim* [monomer]
2)*MW.  
 
Table 6  Concentration needed to prepare solutions of compounds 53  in DMSO that 
are  supposed to contain 85%, 80%, 50%, 15% and 10% dimeric structure 
  
 
As seen from table 6, a concentration range that spans solutions containing 85:15 
dimer:monomer ratio up to 15:85 dimer:monomer ratio can suitably be prepared thus 
making compound 53 a very good candidate for NMR dilution studies.  
 
With this in mind, compound 53 was resynthesised and its dimerisation properties 
were fully investigated by ITC and NMR dilution experiments. Scheme 9 shows the 
synthesis of compound 53. The pyridine scaffold 35 was coupled with the methyl 
ester of L-Leu amino acid to yield compound 54. Boc deprotection of 54 followed by 
coupling with the Cbz activated thiourea compound 42 has then afforded compound Results and Discussion 
   
55 which is the Cbz and methyl ester protected version of the final compound. In the 
previous synthesis procedure 
88, a reverse order of coupling procedure was used to 
access compound 55. Boc deprotected methyl ester of the pyridine scaffold 35 was 
coupled with the Cbz activated thiourea compound 42. This was followed by methyl 
ester hydrolysis and coupling with Leu methyl ester to access compound 55. The last 
two procedures, methyl ester hydrolysis and Cbz deprotection of 55, are the same in 
both synthetic schemes and similar yields were recorded.   
 
  
Compound 53 was fully characterized and its purity established using spectroscopic 
analyses.  
 
 
 
 Results and Discussion 
   
3.5.1 Isothermal calorimetric dilution study of 53 
 
Prior  to  performing  NMR  dilution  experiments,  an  ITC  dimerisation  study  of 
compound 53 was performed to verify the results from the previous ITC experiments 
and also to further investigate the dimerisation process in different solvent systems 
(Fig 32) 
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Fig 32 Calorimetric data obtained for ITC dilution studies of 53 in DMSO (left), 10% 
H2O/DMSO (middle) and 50% H2O/DMSO  (right)  at 298K. a, c & e) Raw ITC data 
(29 x 10µL injections); b, d & f) Non-linear curve fitting of the reference corrected  
data into the dimer dissociation model  
 
The full thermodynamic profile associated with the dimerisation of compound 53 is 
given below.  
 
Solvent  Kdim [M 
-1]  ∆Gdim
  [kJ mol
-1]  ∆Hdim
  [kJ mol
-1]  T∆Sdim
 [kJ mol
-1] 
DMSO  952±64  -17.0  -16.7±0.2  0.3 
10% H2O/DMSO  73±5  -10.6  -8.6±0.1  2.0 
50% H2O/DMSO  55±8  -6.4  -1.8±0.2  4.6 
 
Table 7 Energetics of dimerisation of compound 53 at 298 K in DMSO (3 mM), 10% 
H2O/DMSO (10 mM) and 50% (20 mM) 
 
An enthalpy driven dimerisation was observed in DMSO (Kdim [M 
-1] = 952±64) and 
10%  H2O/DMSO  (Kdim  [M 
-1]  =  73±5).  This  is  consistent  with  the  previous  ITC Results and Discussion 
   
dilution result (Kdim = 877±100 M
-1 in DMSO). Compared with the Val analogue (Kdim 
[M 
-1] = 400±22 in DMSO), compound 53 produced a more stable dimer which might 
be attributed to the Leu-Leu side chain interactions in the dimeric system. Comparing 
with  dimeric systems from compounds 29 and 30 (Fig 33), it is observed that the 
dimer stability enhances as the hydrophobicity of the side chain increases and this 
might explain the importance of hydrophobic-hydrophobic interaction in stabilizing 
the dimers from compounds 29 and 53. It has been reported in the literature that non-
polar pairings between amino acids (Ile-Ile, Val-Val, Leu-Leu) occurring in parallel β-
sheets  are  of  the  dominant  types  of  pairings  occurring  between  adjacent  peptide 
strands. The rationale behind this is the good van der Waals contacts obtained by 
nested arrangement.
116 
 
 
Fig 33 The order of stabilities of the dimeric structures of compounds 29, 30 and 53 
in DMSO 
 
The superiority of the dimerisation of compound 53 over compounds 29 and 30 is 
once  again  demonstrated  when  the  dimerisation  studies  were  undertaken  in  10% 
H2O/DMSO system. The dimer of compound 30 was completely disrupted at 10% 
H2O/DMSO while compound 53 maintains an enthalpy driven dimerisation of Kdim  = 
73 ± 4.6 M 
-1.  It is also interesting to see that there was some dimerisation, which is 
essentially  entropy  driven,  observed  at  50%  H2O/DMSO  level  signifying  the 
importance of the Leu-Leu hydrophobic interaction in enhancing dimer stability in 
aqueous environments. Encouraged by these results further studies were undertaken at 
75%  H2O/DMSO  system.  Some  qualitative  evidence  of  dimerisation  has  been 
obtained  in  this  system.  As  seen  in  fig  34  successive  injections  produced  an 
endothermic heat  pulse  which is  characteristic  of dissociation  of a dimer into the Results and Discussion 
   
monomeric structure. However, the error associated with the curve fitting is too large 
to make the estimated Kdim a quantitatively valid result.  
 
 
 
 
 
 
 
 
 
 
 
Fig 34 Calorimetric data obtained for ITC dilution studies of 53 in 75% H2O/DMSO 
at 298 K. a) Raw ITC data (29 x 10µL injections); b) Attempted non-linear curve 
fitting of the reference corrected data into the dimer dissociation model 
3.5.2 NMR dilution study of 53  
 
A  preliminary  NMR  dilution  experiment  using  a  concentrated  (10  mg/mL)  and  a 
dilute (1 mg/mL) solution of compound  53  indicated that there is a concentration 
dependent change in the observed chemical shift value of the NH proton signals. A 
very noticeable change was observed for two of the NH protons (Fig 35). There is an 
upfield chemical shift of 0.64 ppm observed for the NH proton signal at A (9.45 ppm 
to 8.81 ppm) when the concentration of compound 53 was increased from 1 mg/mL to 
10 mg/mL. The NH proton signal at B (8.28 ppm) was significantly shifted downfield 
where it moved from 7.61 ppm in the dilute solution spectrum and overlapped with 
the aromatic CH proton signals (7.81-7.90 ppm) in the concentrated solution spectrum. 
Spectral analysis of compound 53 has shown that the NH signal at A corresponds to 
the  benzyl-amide  NH  proton  whereas  the  signal  at  B  corresponds  to  one  of  the 
guandine protons.  
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The H
1 NMR spectra of the concentrated and the dilute solution are shown below for 
comparison.  
 
 
 
 
 
 
 
 
 
 
 
 
 
     
Fig 35 Part of 
1H NMR spectrum of compound 53 in DMSO.  The spectrum above 
belongs to the concentrated solution (10 mg/mL) and below to the dilute solution (1 
mg/mL) of compound 53 
 
Following this, the optimum concentration range of the samples needed for a full 
NMR dilution experiment were calculated based on the Kdim value obtained from the 
ITC study result (Table 7).  
 
Considering the solubility of the compound and the sensitivity of the NMR instrument, 
concentrations  that  contain  85:15  dimer:monomer  ratio  (19.01  mg/mL)  and  10:90 
dimer:monomer  ratio  (0.062  mg/mL)  were  chosen  as  the  highest  and  the  lowest 
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concentration limits respectively. Accordingly 15 dilutions (40.60 mM - 0.13 mM) 
were prepared from a stock solution of 19.01 mg/mL and their 
1H NMR spectra were 
recorded (Fig 36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 36  Parts of the 
1H NMR spectra (400 MHz, 298 K) of 122  in DMSO showing the 
dimerization induced shift changes (Concentrations from bottom to top: 0.13, 0.23, 
0.35,0.51, 0.72, 0.99, 1.35, 1.85, 2.55, 3.58 5.14, 7.70, 12.10, 20.60, 40.60 mM)  
 
The full NMR dilution experiment has demonstrated that there are indeed successive 
concentration dependent changes in the chemical shift value of the two NH proton 
signals  mentioned  above  (Fig  36).  As  expected,  the  guanidine  NH  signal  is 
downshifted as the concentration was sequentially increasing. This is expected to be 
the direct result of the head-to-tail complimentary complexation of the NH proton via 
hydrogen bonding with the carboxylate oxygen in the dimeric structure. However, the 
upfield shift of the amide proton signal with successive increments of concentration 
does not reflect the constructive intermolecular bond engagement of this proton. A 
plausible  explanation  for  this  is  that  the  amide  proton  might  be  intramolecularly 
bonded with one of the carboxylate oxygens and the upfield shift of the amide proton 
with  concentration  increments  would  be  due  to  weakening  of  this  intramolecular 
hydrogen bond as a result of the dimerisation process.  
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Fig 37 Plots of concentration versus observed chemical shift value of the amide and 
one of the guanidine NH   protons of compound 53 in DMSO  
 
The two NMR dilution data sets were analysed using nonlinear curve fitting to a 
dimerisation isotherm (NMRDil_Dimer) (Fig 38) and gave Kdim values of 647 M
-1 
and 1110 M
-1. This is in good agreement with the dimerization constant obtained from 
the ITC study, which is 931 M
-1. 
       
     
 Fig  38  Nonlinear  curve  fitting  of  the  NMR  data  to  a  dimerisation  isotherm 
(NMRDil_Dimer) model  
 
In this  experiment,  we  have demonstrated the  good  agreement of the  Kdim values 
determined by NMR and ITC dilution experiments. This can also be considered as a 
validation and verification of ITC determined Kdim figures of compounds 46, 29 and 
30. Furthermore the NMR dilution studies have revealed structural components of 
compound 53 which are involved in the solution phase intermolecular interaction.  
 
 
 
 
 Results and Discussion 
   
3.6 Synthesis of guanidinium-carboxylate 57  
 
So far, we have uncovered some important structural features which play important 
roles in the dimerisation process. The main driving force of the dimeric architectures 
accessed so far in DMSO is the intermolecular complimentary H-bonding between the 
carboxylate and the guanidinium moieties. The effect of this H-bonding however was 
found to dramatically decline upon addition of even 10% H2O into the system. Fine 
tuning of the dimerisation process has been undertaken by introducing stabilizing non-
covalent  bond  forming  features  into  the  system  and  significant  progress  has  been 
made in this regard. It has been proved in our previous systems that π- π stacking 
interaction, Val-Val side chain interaction and Leu-Leu side chain interaction may 
contribute to additional stability in the dimeric system. However, none of the above 
interactions  by  themselves  could  effectively  compensate  for  the  loss  of  the 
guanidinium-carboxylate hydrogen bonding energy and maintain the dimeric structure 
in a more aqueous environment (>20% H2O/DMSO), although it is noteworthy that 
compound  53,  which  has  a  Leu  amino  acid  side  chain  showed  a  quantitatively 
measurable dimerisation (Kdim = 13±4.8 M
-1) in 50% H2O/DMSO. 
 
Based on the above encouraging result, it was envisaged that a pyridoguanidinium 
dimeric  supramolecular  system  that  encompasses  a  combination  of  the  above 
mentioned features might show improved stability in an aqueous environment. With 
this in mind, compound 57, which has a side chain containing a bis-aromatic moiety 
sandwiching a leucine amino acid residue, was designed.  
 
 
 Results and Discussion 
   
Considering the fact that Leu-Leu and aromatic-aromatic stacking interactions have 
been  proved  to  be  important  features  for  dimer  stability,  it  was  thought  that  a 
compound such as  57 which simultaneously can furnish a bis aromatic-aromatic and 
a  Leu-Leu  hydrophobic  intermolecular  interaction  will  enhance  the  energetics  of 
dimerisation  in  more  aqueous  environments  (Fig  39).  It  was  also  expected  that 
cooperativity  among  the  non-covalent  bonds  would  further  strengthen  the  dimer 
stability.  
Hydrophobic-hydrophobic 
interactions
Aromatic-aromatic interactions
 
 
Fig  39  Expected  dimer  of  compound  57  showing  the  possible  intermolecular 
interactions contributing to the dimer stability.  
 
It was anticipated that the NOESY spectrum analysis of such compounds in solution 
might give us further structural information on the dimer structure as it is envisaged 
that a through space intermolecular interaction should occur between the aromatic 
protons which are expected to be in close proximity in the dimeric system.
117, 118  
  
The  synthetic  work  undertaken  initially  was  the  large  scale  synthesis  of  the  Cbz 
protected pyridoguanidine compound 59 (Scheme 10). This synthetic procedure was 
previously optimized in our group and has been used in creating versatile building 
block to make various pyridoguanidinium carboxylates.  
 Results and Discussion 
   
 
 
The next  synthetic scheme (Scheme  11) describes  the synthesis of  compound  64, 
which is a peptide side chain containing the  bis aromatic moieties sandwiching a 
leucine amino acid.  
 
 
 
Compound 64 was then coupled to compound 59 using the standard peptide coupling 
procedure (Scheme 15). This results in the precursor 65 of the final compound which 
requires  methyl  ester  hydrolysis  and  hydrogenolysis  of  to  give  guanidinium 
carboxylate 53.  Results and Discussion 
   
 
The last part of the synthetic procedure is identical to the synthesis of the previous 
guanidinium-carboxylates. However, the enhanced polarity of the system necessitates 
a tedious purification procedure by column chromatography. The final product from 
hydrogenolysis  was  further  purified  by  precipitation  from  methanol  using  diethyl 
ether. Characterization of this novel compound was established with spectroscopic 
techniques, 1 D and 2 D NMR, MS and IR.  
 
   
 
 
 
 
 
 Results and Discussion 
   
3.6.1 ITC dilution study of guanidinium carboxylate 57 
 
Following  the  successful  synthesis  of  guanidinium  carboxylate  57,  extensive  ITC 
dimerisation studies were undertaken in solvent systems containing as much as 50% 
H2O/DMSO  (Table  8).  The  very  poor  solubility  of  the  compound  has  precluded 
dimerisation studies in a more aqueous environment.   
 
Solvent  Kdim [M 
-1]  ∆Gdim
 [kJ mol
-1]  ∆Hdim
  [kJ mol
-1]  T∆Sdim
 [kJ mol
-1] 
DMSO  4032±1789  -20.6  -13.8±0.9  6.8 
10% H2O/DMSO  336±58  -14.4  -3.7±0.1  10.8 
40% H2O/DMSO  0  0  0  0 
50% H2O/DMSO  345±535*  -14.5  -0.6±0.16  13.9 
 *Error is too big to make the dimerisation figure statistically significant.  
 
Table 8 Energetics of dimerisations of compound 57  at 298 K in DMSO (3 mM),10% 
H2O/DMSO (10 mM), 40% Η2Ο/ DMSO (10 mM) and 50% Η2Ο/ DMSO (10 mM)  
 
Dimer  formation  was  observed  for  compound  57  in  DMSO  (Kdim  =  4032±1789). 
However,  compared  with  compound  27  (Kdim  =  11876±1692)  the  stability  of  the 
dimer has decreased. This is the opposite of what we have initially envisaged. This 
difference, however, was not observed at 10% H2O/DMSO where compound 57 has a 
Kdim = 336±58 and compound 27 has Kdim = 533±23 and this might suggest that the 
effect of the hydrophobic-hydrophobic interaction is stronger in the 10% H2O/DMSO 
system. Nevertheless, the anticipated increase in dimer stability by introducing extra 
aromatic stacking and hydrophobic interaction was not achieved in DMSO and 10% 
H2O/DMSO systems. Two possible reasons can be  forwarded for this. One is the 
possibility  of  intramolecular  interactions  in  flexible  compounds  like  57  thereby 
disrupting  the  conformational  requirement  required  for  effective  dimerisation.  In 
addition to or another explanation which might be responsible for the decrease of the 
Kdim in DMSO is the possibility of increased intermolecular motion of the extended 
dimeric structure.
27 As the complex becomes loose, the enthalpy contribution of each 
individual  interaction  becomes  less  favourable  and  this  might  hinder  effective 
enthalpy-entropy compensations required for maintaining the free energy of binding. 
It has been previously mentioned that rigidity of the monomeric compound is one of Results and Discussion 
   
the key structural features needed for effective self-assembly.
92 Schmuck et al have 
observed the deleterious effect of increased flexibility on dimerisation by synthesizing 
derivatives of the 5-(guanidiniocarbonyl)-1H- pyrrole-2-carboxylate (25) in which the 
carboxylate  is  not  directly  attached  to  the  guanidiniocarbonyl  pyrrole  but  with  a 
spacer.
105  He  noted  that  as  the  length  of  the  spacer  increases  the  degree  of 
dimerisation decreases.   
 
The ITC study was pursued in more aqueous environments (40% H2O and 50% H2O). 
It was found that in 40% H2O/DMSO there was no dimerisation observed. However, 
recovery  of  dimerisation  which  is  entirely  entropy  driven  was  observed  at  50% 
H2O/DMSO  suggesting  the  bis-aromatic-aromatic  and  the  hydrophobic  Leu-Leu 
interactions  might  have  started  to  get  stronger  and  hence  stabilize  the  dimeric 
structure  to  a  greater  extent  at  50%  H2O/DMSO  than  they  do  at  lower  water 
concentrations (Fig 40). 
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Fig 40 Calorimetric data obtained for ITC dilution studies of compound 57 in DMSO 
(left), 10% H2O/DMSO (middle) and 50% H2O/DMSO  (right)  at 298 K. a, c & e) 
Raw  ITC  data  (29  x  10µL  injections);  b,  d  &  f)  Non-linear  curve  fitting  of  the 
reference corrected  data into the dimer dissociation model  
 
Due to poor solubility of compound 57 in 50% H2O/DMSO, the concentration of the 
solution prepared was not high enough to observe a good quality curve fitting and the 
error  associated  with  Kdim  (345±535)  determination  was  too  big  to  make  the 
dimerisation figure statistically valid. However, it shows that there is some qualitative Results and Discussion 
   
evidence of dimerisation occurring at 50% H2O/DMSO. No dimerisation study could 
be undertaken in more aqueous systems due to solubility problems.  
 
In summary, although the anticipated increase in dimer stability was not obsreved in 
DMSO and 10% H2O/DMSO, it is encouraging that some evidence of dimerisation 
was observed in 50% H2O/DMSO.  
3.7 Synthesis of guanidinium-carboxylate 67 
 
One of the problems that preclude making ITC studies in more aqueous environments 
was  the  poor  aqueous  solubility  of  the  guanidinium  carboxylate  compounds 
synthesized so far. Solubility was found to dramatically decline upon addition of 10% 
water  in  DMSO  and  as  a  result  doing  ITC  dilution  experiments  in  an  increased 
percentage of water was very difficult.  
 
Compound 67 incorporating a tetraethyleneglycol side chain was designed with the 
intention of imparting water solubility in order to undertake dimerisation studies in 
aqueous environments. Compound 67 is the water soluble analogue of compound 27,
 
which showed excellent dimerisation in DMSO (Kdim = 11876 ± 1692M
-1). ITC study 
of compound 27 could not be made in an aqueous environment (> 20% H2O/DMSO) 
with  accuracy  due  to  its  poor  solubility  in  an  aqueous  environment.  The  benzyl 
propanamide side chain was replaced with a tetraethyleneglycol side chain to enhance 
aqueous solubility. 
                       
                           
.  
 
Amine 72 was synthesised (scheme 13) using a standard literature procedure 
119 and 
coupled  with  the  thiocyanate  compound  18  to  give  the  Cbz  activated  thiourea 
compound  which  is  required  to  furnish  the  guanidine  functionality  into  the  final 
product. Tetraethylene glycol was asymmetrically mesylated to give compound  69 Results and Discussion 
   
with a 50% yield. A considerable amount of bis-mesylated side product was formed 
and this has contributed to the very low yield obtained. The purification of this step 
was found to be very tedious and time consuming due to the very similar polarity of 
the bis-mesylated side product, the mono-mesylated product and the unreacted tetra-
ethylene glycol compounds. The next two steps, azide formation and  reduction to 
amine, were accomplished in reasonably good yields.  
         
  
 
Coupling of amine 72 with phthalidoimidyl propanoyl chloride gave compound 73 
(Scheme 14). The phthalidoimide group was removed with hydrazine hydrate and the 
resulting crude amine was coupled with CbzSCN to give the Cbz activated thiourea 
74 incorporating a PEG chain.  
 
 
The next synthesis procedure shows transformations leading to the target compound 
67. Similar strategies were used as before (Scheme 4) but employed the benzyl ester 
instead of the methyl ester of the 4-methylamino benzoic acid for the synthesis of 
compound 75. This synthetic modification was vital as the final two steps of benzyl 
ester  hydrolysis  and  Cbz  deprotection  could  be  undertaken  simultaneously  by 
hydrogenolysis. The penultimate methyl ester hydrolysis procedure in the previous Results and Discussion 
   
synthetic  strategies  was  problematic  as  it  involved  a  tedious  and  time  consuming 
purification  process  and  usually  a  very  low  yield  was  obtained.  The  final  Cbz 
deprotected and benzyl ester hydrolysed product was purified by precipitation from 
methanol using diethyl ether.  
 
 
3.7.1 Isothermal calorimetric dilution study of 67 
 
The  objective  of  imparting  aqeous  solubility  was  successfully  achieved  and 
dimerisation studies could be undertaken even in essentially aqueous environments 
(DMSO, 10% H2O/DMSO, 20% H2O/DMSO, 50% H2O/DMSO and H2O) (Fig 41). 
 
 
 
 
 
 
 
 
 
  
 Results and Discussion 
   
 
 
  
 
 
 
 
  
 
 
 
 
Fig 41 Calorimetric data obtained for ITC dilution studies of 67 in DMSO (left), 10% 
H2O/DMSO (middle) and 20% H2O/DMSO  (right)  at 298 K. a, c & e) Raw ITC data 
(29 x 10µL injections); b ,d & f) Non-linear curve fitting of the reference corrected  
data into the dimer dissociation model  
 
The full thermodynamic profile of the dimerisation study result of compound 67 is 
summarized in table 9. 
 
Solvent  Kdim [M 
-1]  ∆Gdim
  [kJ mol
-1]  ∆Hdim
  [kJ mol
-1]  T∆Sdim
 [kJ mol
-1] 
DMSO  7692±1124  -22.2  -4.7±1.6  17.5 
10% H2O/DMSO  495±44  -15.4  -9.8±0.2  5.6 
20% H2O/DMSO  57±9  -10.0  -4.6±0.2  5.4 
50% H2O/DMSO  0  0  0  0 
H2O  0  0  0  0 
 
Table 9 Energetics of dimerisations of compound  67 at 298 K in DMSO (3 mM),10% 
H2O/DMSO (20 mM), 20% Η2Ο/ DMSO (20 mM), 50% Η2Ο/DMSO (20 mM) and  
Η2Ο (20 mM) 
 
Stable  dimeric  complexes  of  compound  67  were  observed  in  DMSO,  10% 
H2O/DMSO  and  20%  H2O/DMSO  (Fig  39).  In  DMSO,  the  dimer  stability  of 
compound 67 (Kdim(67) = 7692 ±1124) was slightly lower than that of compound 27 
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(Kdim(2)  =11876±1692  M
-1.  It  is  believed  that  the  aromatic-aromatic  stacking 
interaction may still contribute to the dimer stability of compound 67.
120 There are 
favourable enthalpy and entropy contributions for the dimerisation of both compounds 
though the enthalpic contribution is relatively greater in compound 27 (∆Gdim
    = -
23.2 kJ mol
-1, ∆Hdim
   = -10±0.4 kJ mol
-1 and T∆Sdim
 = 13.2 kJ mol
-1), whereas the 
dimerisation of compound 67 is driven more by entropy (∆Gdim
  = -22.2 kJ mol
-1, 
∆Hdim
 = -4.7±1.6 kJ mol
-1 and T∆Sdim
 = 17.5 kJ mol
-1). The slight decrease of the 
dimer stability associated with compound 67 might be attributed to the loss of some 
favourable  intermolecular  bonding  that  can  potentially  be  mediated  through  the 
benzyl propanamide side chain as was observed in compound 27. The crystal structure 
for 27 indicates that the dimeric form of the compound involves a complimentary 
head-to-tail guanidinium-carboxylate interaction with one of the carboxylate oxygens 
intermolecularly  bonded  to  the  amide  hydrogen  of  the  propanamide  side  chain 
through a bridging water molecule (Fig 42).
113 This also explains the greater enthalpic 
stabilisation of dimer 27 compared to dimer 67 which might lack this interaction. We 
could  not  explain  the  observation  of  the  higher  entropic  contribution  in  the 
dimerisation of compound 67 in comparison with compound 27 and could not make 
any correlation between the introduction of the PEG chain and the increase in entropy.   
 
                                                
                                           Fig 42 X-ray structure of compound 27 
 
 Comparison  of  the  thermodynamic  parameters  associated  with  dimerisation  of 
compound 67 (Kdim(67) = 495±44) with compound 27 (Kdim(2)= 532±23M
-1) in 10% 
H2O/DMSO  shows  that  introducing  the  tetraethylene  glycol  side  chain  has  not 
resulted  in  any  significant  decrease  of  dimer  stability.  Hence,  the  objective  of 
enhancing solubility while maintaining dimerisation intact has been attained in 10% Results and Discussion 
   
H2O/DMSO.  No  dimerisation  studies  were  undertaken  on  compound  27  in  more 
aqueous  medium  due  to  its  poor  solubility  and  hence  we  could  not  compare  its 
dimerisation profile with that of compound 67 in solvent systems containing more 
than 10% H2O in DMSO. A very dramatic fall of dimerisation (Kdim = 57±9) was 
observed for compound 67 when the percentage of water was increased to 20%, and  
there was no dimerization observed at 50% and 100% H2O/DMSO systems which 
suggests that the hydrogen bond forming entities are completely solvated by water 
leading to complete disruption of the dimeric system. It was anticipated that the π- π 
stacking interaction could get stronger in more aqueous media and might impart some 
stability  to  the  dimeric  system.  The  possibility  of  conformational  changes  of 
compound 67 in more aqueous systems should also not be ruled out. This might not 
allow efficient π- π stacking interaction and may lead to dimer disruption.
118  
3.8 Synthesis of guanidinium-carboxylate 78 
 
After  the  aqueous  solubility  of  compound  67  was  successfully  enhanced  without 
compromising its dimer stability, we decided to synthesise an analogue of compound 
57 in which the benzyl propanamide side chain is replaced with a tetraethylene glycol 
moiety. At 50% H2O/DMSO system, the ITC dilution data of compound 57 showed 
some dimerisation but the error associated with the curve fitting of the dilution data 
into the dimer dissociation model was too big to make a valid quantitative estimation 
of the thermodynamic parameters. The very poor solubility of compound 57 in 50% 
H2O/DMSO makes it difficult to prepare a homogenous solution of compound 57.  
 
 
 
As  with  guanidinium-carboxylate  57,  it  was  hypothesised  that  78  might  use  bis 
aromatic-aromatic  interaction  and  hydrophobic  Leu-Leu  interaction  in  the  dimeric Results and Discussion 
   
structure.  It  was  envisaged  that  these  combined  non-covalent  interactions  in  the 
system might get stronger in more aqueous environments and lead to a stable dimeric 
structure.Undertaking dimerisation studies of compound 78 in more aqueous systems 
will help to probe this hypothesis (Fig 43).    
       
π- π stacking interactions
Hydrophobic-hydrophobic
interactions
Enhanced
aqueous solubility
Enhanced
aqueous solubility
 
 
Fig 43 Expected dimerisation mode of compound 78 where X represents a Leu amino 
acid residue  
 
Scheme 16 shows the synthetic route undertaken to access guanidinium-carboxylate 
78. Unlike the case with the syntheses of the previous compounds, a relatively poor 
yield was observed in the coupling reaction of the Boc deprotected form of compound 
72 with the thiourea compound 74. The possible complexation of the PEG chain with 
ammonium ion might be responsible for the low yield.The ester hydrolysis reaction 
with compound 80 went to completion fairly quickly. However, repeated purification 
via column chromatography was needed to get acid 81. The purification process at 
this stage must be done with maximum care as the final guanidinium–carboxylate 
compounds are too polar to be purified by normal phase column chromatography.   
 Results and Discussion 
   
 
3.8.1 Isothermal calorimetric dilution study of 78 
 
The aqueous solubility of compound 78 was greatly improved compared to compound 
53 and this has enabled dimerisation studies in 50% H2O/DMSO and H2O (Fig 44).         
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Fig 44 Calorimetric data obtained for ITC dilution studies of 78 in DMSO (I), 5% 
H2O/DMSO (II), 10% H2O/DMSO (III) & 50% H2O/DMSO (IV) at 298 K. a, c, e & g) 
Raw ITC data (29 x 10 µL injections); b, d, f & g) Non-linear curve fitting of the 
reference corrected  data into the dimer dissociation model  
 Results and Discussion 
   
It  was  observed  that  compound  78  exhibits  a  similar  trend  of  dimerisation  to 
compound  53.  There  is  a  positive  contribution  of  both  the  enthalpy  and  entropy 
parameters to the free energy of dimerisations in DMSO and 10% H2O/DMSO. Upon 
increasing the aqueous level to 40%, the dimeric structure was completely disrupted 
and no measurable enthalpy change was detected. The full thermodynamic profile of 
the dimerisation process is given below.  
 
Solvent  Kdim [M 
-1]  ∆Gdim
  [kJ mol
-1]  ∆Hdim
  [kJ mol
-1]  T∆Sdim[kJ mol
-1] 
DMSO  5076±876  -21.4  -11.7±0.4  9.4 
5% H2O/DMSO  862±104  -16.8  -10.3±0.2  6.5 
10% H2O/DMSO  156±6  -12.5  -7.4±0.1  5.1 
40% H2O/DMSO  0  0  0  0 
50% H2O/DMSO *  -  -  -  - 
H2O  0  0  0  0 
*Error is too big to make the dimerisation figure statistically significant. 
 
Table 10  Energetics of dimerisations of compound 85 at 298 K in DMSO (3 mM), 
5% H2O/DMSO (10 mM), 10% Η2Ο/ DMSO (20 mM), 40% Η2Ο/DMSO (20 mM), 
50% Η2Ο/ DMSO (20 mM) and  Η2Ο (20 mM).  
 
The dilution study of 78 at 50% H2O/DMSO shows similar results with compound 53. 
Still the error associated with the curve fitting of the dilution data is too big to make 
the estimation of the thermodynamic parameters valid. It might be the case that the 
Kdim is too small to be measured accurately. It has been reported in the literature that 
complexes should be reasonably stable  for accurate and reliable ITC measurements.
27 
The complete lack of dimerisation at 40% H2O/DMSO and the recovery of some of 
the dimerisation energy at 50% H2O/DMSO, has suggested that the hydrophobic and 
the  aromatic-aromatic  stacking  interactions  might  get  stronger  in  more  aqueous 
environments. With this in mind, a dilution study was undertaken in pure water. But 
no noticeable dimerisation was observed. It is believed that the bis aromatic-aromatic 
stacking  and  the  Leu-Leu  hydrophobic  interactions  are  still  not  strong  enough  to 
maintain the dimeric structure in aqueous environments. But again we should not rule 
out the possibility of conformational alterations which preclude the formation of the 
dimeric structure in more aqeous systems. Another possible disadvantage of extending Results and Discussion 
   
the  side  chain  is  that  it  may  impart  lack  of  rigidity  to  the  system  which  will  be 
obstructive in maintaining the supramolecular dimeric structure. 
3.8.2 NMR dilution experiment of guanidinium carboxylate 78  
 
Considering the solubility of the compound and the sensitivity of the NMR instrument, 
5%  H2O/DMSO  was  found  to  be  the  best  solvent  system  to  carry  out  the  NMR 
dilution experiment (Table 11).  
 
Solvent  90%[D*] 
 
80%[D*] 
 
30%[D*] 
 
20%[D*] 
 
10%[D*] 
 
DMSO  14.8  3.3  0.1  0.05  0.02 
5%H2O  83.5  19.5  0.6  0.3  0.12 
10%H2O  551  123  3.8  1.9  0.76 
                
[D*]= the concentration of the compound in mg/mL which contains the specified 
percentage  of  dimer  in  DMSO,  5%  H2O/DMSO  and  10%  H2O/DMSO  solution, 
calculated  based  on  the  Kdim      obtained  from  ITC  dilution  studies.  [D*]  = 
([dimer]/Kdim* [monomer]
2)*MW.  
 
Table 11 Concentration needed to prepare solutions of compounds 78  in DMSO, 5% 
H2O/DMSO & 10% H2O/DMSO that is supposed to contain 90%, 85%, 50%, 20% 
and 15%  dimeric structure  
 
A preliminary NMR dilution study performed using concentrated (30 mM) and dilute 
(0.15 mM) solutions of compound 78 in 5% H2O/DMSO shows that there is indeed a 
concentration dependent chemical shift change of the NH protons. One of the NH 
protons (signal B) was shifted downfield from 9.36 ppm to 9.66 ppm and one of the 
other guanidine protons (signal C) has downshifted from 7.66 ppm and overlaps with 
the aromatic proton signals (7.83 ppm-8.01 ppm) upon changing the concentration 
from 0.15 mM to 30 mM.  Results and Discussion 
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Fig 45 Part of 
1H NMR spectrum of compound 78 in 5% H2O/DMSO at 298 K.  The 
spectrum  above  belongs  to  the  dilute  solution  (0.15  mM)  and  below  to  the 
concentrated solution (30 mM) of compound 78 
 
The  full  NMR  dilution  experiment  of  compound  78  shows  the  successive 
concentration dependent chemical shift changes of the NH proton signals noted above 
(Fig  45).  The  observed  chemical  shift  of  two of  the  NH  proton  signals  has  been 
successively downshifted as the concentration increases and this is believed to be the 
direct  result  of  H-bond  mediated  complexation  of  the  guanidine  protons  with 
carboxylate in the dimeric structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 Results and Discussion 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig  46  Parts  of  the 
1H NMR spectra  (400 MHz,  298K) of  78  in 5% H2O/DMSO 
showing the dimerisation induced shift changes 
 
Processing the NMR dilution data sets of the two guanidine proton signals using a 1:1 
dimer dissociation model has given dimerisation constants of 305 M
-1 and 255 M
-1. 
This is consistent with the ITC measured dimerisation constant of 78 (860 M
1).     
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Fig 47 Plots of concentration versus observed chemical shift of the two NH protons 
 
The NMR dilution experiment has again substantiated not only the ITC study result 
but  also  the  proposed  mode  of  dimerisation  orchestrated  through  complimentary 
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intermolecular  head-to-tail  complexation  between  the  guanidinum  protons  and  the 
carboxylates.    
3.9 Synthesis of guanidinium-carboxylate 82 
 
After the dimerisation results of the previous compounds have been properly assessed, 
it was envisaged that strengthening the hydrophobic interaction might be an option to 
access  the  dimeric  system  in  a  more  aqueous  environment.The  bis-aromatic 
compound 85 was not found to preserve the dimeric system in more aqueous systems 
(>50% H2O). It might be the case that the bis aromatic-aromatic interactions were not 
strong  enough  to  maintain  the  dimeric  architecture.  Hydrophobic-hydrophobic 
interactions might be more important than the aromatic-aromatic stacking interaction 
in  a  more  aqueous  solvent  system  and  this  can  be  illustrated  by  comparing  the 
dimerisation properties  of compounds 27 and 53. It was found that compound 27 
showed  excellent  dimerisation  in  DMSO  (Kdim  =  11876±1692  M
-1)  and  10% 
H2O/DMSO (Kdim = 532±23 M
-1). However, its water soluble analogue, compound 67, 
showed no sign of dimerisation in a 50% H2O/DMSO and in H2O which suggested 
that the aromatic-aromatic interaction was not strong enough to maintain the dimeric 
structure in  these solvent  systems.  In contrast  to  this, compound  53 in  which the 
aromatic  side  chain  is  replaced  with  Leu  showed  a  Kdim  of  55±8  M
-1  in  50% 
H2O/DMSO. However in DMSO the dimerisation of 53 (Kdim = 952±64) is much less 
than  that  of  compound  27.  Assuming  both  compounds  have  the  same  dimer 
architecture  in  solution,  it  can  be  sugested  that  aromatic-aromatic  interactions  are 
superior to the hydrophobic Leu-Leu interaction in DMSO and the reverse in 50% 
H2O/DMSO system. However, making this assumption might be erroneous as the two 
compounds might have different conformations in different solvent systems and hence 
dissimilar  modes  of  dimerisation.  But  the  positive  contribution  of  the  Leu-Leu 
interaction in aqueous dimer stability is well noticed and with this in mind it was 
predicted  that  guanidinium-carboxylates  that  contain  more  hydrophobic  moeties 
might lead to stable dimeric structures in aqueous environments. Compound 83 that 
features a Leu-Leu dipepetide side chain has previously been synthesised in a parallel 
PhD  project  within  our  research  group 
88  and  its  dimerisation  property  was 
investigated. Results and Discussion 
   
 
Guanidinium carboxylate 83 showed an entropy driven dimerisation (Kdim = 50±10 M
-
1, ∆Gdim  = -9.7 kJmol
-1, ∆Hdim = -1.0±0.1  kJmol
-1 , T∆Sdim = 8.7 kJmol
-1 ) in 50% 
H2O/DMSO. It was expected that there would be improved dimerisation of compound 
83  in  aqueous  environments  by  virtue  of  its  enhanced  hydrophobic  side  chain. 
However,  it  was  found  that  the  dimer  from  guanidinium  carboxylate  83  in  50% 
H2O/DMSO is slightly less stable than that from guanidinium carboxylate 53 (Kdim = 
55±8 M
-1, ∆Gdim  = -9.9 kJmol
-1, ∆Hdim = -1.5±0.1  kJmol
-1 , T∆Sdim = 8.4 kJmol
-1 ). 
Steric and electronic factors might have undermined the dimerisation process. Having 
this in mind, we designed compound 82 that contains a peptide sidearm with a Gly-
Ile-Ala amino acid sequence. While the Gly residue merely functions as a linker, it is 
believed that the Ile-Ala sequence might furnish the desired degree of hydrophobic 
interaction  by  minimizing  the  possible  steric  and  electronic  clash  in  the  dimeric 
structure.  This  peptide  sequence  has  also  some  biological  significance  as  it  is 
frequently observed in some enzyme molecules and β-amyloid proteins. Sequence of 
aminoacids  at  the  N-terminus  of  the  virus  protein  responsible  for  foot-and-mouth 
disease has been found to contain the Gly-Ile sequence very frequently. 
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 Results and Discussion 
   
Standard peptide coupling procedures were used for the synthesis of the peptide (Gly-
Ile-Ala) side arm that is to be tethered into the pyridine scaffold (Scheme 17).  
 
 
 
The peptide arm 88 was then coupled to the pyridine scaffold to give compound 89 
(Scheme 18). Boc deprotection of compound 89 was followed by a coupling reaction 
with the thiourea compound 74 to give 91. Ester hydrolysis and Cbz deprotection 
procedures then afforded guanidinium carboxylate 82.  
  
 Results and Discussion 
   
3.9.1 Isothermal calorimetric dilution study of 82 
 
ITC  dilution  studies  were  commenced  in  DMSO  and  then  continued  with  10% 
H2O/DMSO and 50% H2O/DMSO systems. In all the three systems endothermic heat 
pulses which characterize the dissociation of a dimer into a monomer were observed 
(Fig 48). 
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Fig 48 Calorimetric data obtained for ITC dilution studies of 82  in DMSO (left), 10% 
H2O/DMSO (middle) and 50% H2O/DMSO  (right)  at 298K. a, c & e) Raw ITC data 
(29 x 10µL injections); b, d & f) Non-linear curve fitting of the reference corrected  
data into the dimer dissociation model 
 
Compared with guanidinium carboxylate 78 (Kdim = 5076±876 M
-1, ∆Hdim
   = -11.7±0.4 
kJ mol
-1, T∆Sdim
  = 9.4 kJ mol
-1 ) and 57 (Kdim = 4032±1789, ∆Hdim
  = -13.8±0.9 kJ mol
-1, 
T∆Sdim
  = 6.8 kJ mol
-1 ) in DMSO, the dimer stability of  82 (Table 12) is weaker in 
DMSO and this again highlights the strong possibility of the  bis-aromatic-aromatic 
stacking interaction in the dimeric structure of  compounds 57 and 78 in DMSO. 
Upon dissection of the free energy of dimerisation  into its  enthalpic and entropic 
components, it was noted that the dimerisation of 82 in DMSO is more entropy driven 
compared to 78 and 57. The same is true in 10% H2O/DMSO system. 
  
 
 
 Results and Discussion 
   
 
Solvent  Kdim [M 
-1]  ∆Gdim
  [kJ mol
-1]  ∆Hdim
  [kJ mol
-1]  T∆Sdim
 [kJ mol
-1] 
DMSO  357±98  -14.6  -3.1±0.2  11.5 
10% H2O/DMSO  78±30  -10.8  -2.7±0.3  8.1 
50% H2O/DMSO  24±15  -7.8  -1.4±0.2  6.5 
 
Table 12 Energetics of dimerisations of compound 82 at 298 K in DMSO, 10% Η2Ο/ 
DMSO and 50% Η2Ο/ DMSO 
 
The ITC study at 50% H2O/DMSO has resulted in a statistically valid dimerisation 
figure (Kdim = 24±15 M
-1). This might be an indication that the possible hydrophobic-
hydrophobic interaction in 50% H2O/DMSO in dimer 82 is more significant than the 
possible bis-aromatic-aromatic interactions in dimers 78 and 57. But it has to be noted 
again that we are not making quantitative comparison of these interactions as they 
might have different conformations and modes of dimerisation in different solvent 
systems.
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3.9.2 NMR dilution experiment of compound 82 
 
ITC  dilution  study  showed  that  guanidinium  carboxylate  82  exhibits  a  moderate 
degree of dimerisation in DMSO. This was followed as before by an NMR dilution 
study.  Apart  from  verifying  the  ITC  result,  the  NMR  study  will  give  evidence 
regarding the structure of the dimer in solution thereby enabling us to infer the mode 
of dimerisation.     
    
                            Fig  49 Proposed dimerisation of compound 82   Results and Discussion 
   
The  suitability  of  compound  82  for  an  NMR  dilution  experiment  in  DMSO  was 
initially confirmed. It was calculated, based on ITC results, that 24 mg/mL solution of 
compound  95 will have a 4:1  dimer:monomer ratio and a 0.4 mg/mL  solution  of 
compound 95 will have a 1:4 dimer:monomer ratio. By using these concentrations, a 
preliminary NMR dilution experiment was performed and showed the concentration 
dependent  change  of  the  chemical  shift  of  some  of  the  NH  protons  (Fig  50).       
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Fig 50 Part of 
1H NMR spectrum of compound 82  in DMSO at 298 K.  The spectrum 
above belongs to the concentrated solution (20 mM) and below to the dilute solution 
(0.3 mM) of compound 82 
 
The most noticeable change was observed for the guanidinium NH proton B which 
was shifted downfield from 7.40 ppm to 7.54 ppm. Whereas an NH proton at A has 
been shifted upfield from 10.03 ppm to 9.76 ppm. This might be attributed to some 
intramolecular H-bonding involvement of the NH proton at A.  
 
A  full  NMR  dilution  experiment  of  compound  82  was  carried  out  in  which  10 
dilutions (33.8 mM - 0.35 mM) were prepared from a stock solution of 23.6 mg/mL 
and their 
1H NMR spectra were recorded (Fig 51). 
 
 
 Results and Discussion 
   
 
 
 
 
 
 
 
 
 
 
 
Fig 51 Parts of the 
1H NMR spectra (400 MHz, 298 K) of 82  in DMSO showing the 
dimerisation  induced  chemical  shift  changes  (Concentrations  from  bottom  to  top: 
0.35, 0.71, 1.2, 1.9, 0.72, 2.93, 4.47, 6.90, 11.0, 18.40 mM) 
 
A plot of the observed chemical shift versus concentration of the two NH protons 
gave  isothermic  binding  curves.  The  curves  indicate  a  concentration  dependent 
change of the two NH signals which is attributed to the shift in the monomer-dimer 
equilibrium. 
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       Fig 52 Plots of concentration versus chemical shift of the two NH protons  
 
The NMR dilution data were analysed to give a dimerisation constant of 287 M
-1. This 
is  again  in  very  good  agreement  with  the  ITC  determined  value  355  M
-1.  The 
reliability of the ITC dilution technique in determining the thermodynamic parameters 
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associated with a self assembly process is once again well established using NMR 
dilution experiment. 
3.10 Synthesis of guanidinium carboxylates 93 and 94 
 
It is clear from the dimerisation study results of the compounds synthesised so far that 
hydrophobic interactions can be very important in accessing the dimeric structures in 
more aqueous systems. In compounds 78 and 82, some degree of dimerisation was 
observed at 50% H2O/DMSO. It was considered that strengthening the hydrophobic 
interaction by introducing more non-polar amino acid residues into the system might 
enhance  the  stability  of  the  dimeric  structure  in  an  aqueous  environment.  One 
possibility would be to make analogues of compound 85 in which the single Leu 
amino acid residue sandwiched between the bis-aromatic systems is replaced with a 
di-peptide and a tri-peptide moiety. With this in mind compounds 93 and 94 were 
designed and their syntheses were undertaken.  
 
 
Scheme 19 depicts the synthesis of the peptide side chain 101 which contains a Leu-
Leu dipeptide flanked between the two aromatic moieties. Standard peptide coupling 
procedures were used in this synthetic procedure.  Results and Discussion 
   
 
 
 
The  peptide  side  chain  was  then  coupled  with  the  pyridine  scaffold  36  to  give 
compound  102  (Scheme  20).    Boc  deprotection  of  compound  102  followed  by 
coupling with thiourea 74 gave the precursor compound 104. Ester hydrolysis of 104 
and hydrogenolysis gave guanidinium-carboxylate 93.   
 Results and Discussion 
   
 
 
 
 
The same strategy was used to synthesise compound 94 with the tripeptide Leu-Leu-
Leu sandwiched between the two aromatic moieties, which was expected to further 
enhance the possible hydrophobic-hydrophobic interaction in the dimeric structure. 
Scheme 21 shows the synthesis of this peptide side arm.  
 
 
 
 
 Results and Discussion 
   
 
 
Transformations undertaken to access the final guanidinium-carboxylate compound 
94 are shown in scheme 22. Purification of the final compound was carried out by 
precipitaion from a methanol solution using diethyl ether.  
 
 
 
 
 
 
 
 
 
 
 Results and Discussion 
   
 
 
 
 
 
 
3.10.1 Isothermal calorimetric dilution study of 93 and 94 
 
Though  the  hydrophobicity  of  compounds  93  and  94  was  greatly  enhanced,  the 
aqueous solubility was maintained due to the PEG chain. ITC dilution studies were 
then undertaken in DMSO, 10% H2O/DMSO, 50% H2O/DMSO, 75% H2O/DMSO 
and  H2O.  Unfortunately,  neither  of  the  two  compounds  showed  any  measurable 
dimerisation in all of the solvent systems except in 75% H2O/DMSO. Presumably 
conformational  constraints  preclude  the  formation  of  the  anticipated  dimeric Results and Discussion 
   
architecture  in  solution  and  this  is  most  likely  due  to  intramolecular  interactions 
which are expected from very extended and flexible compounds like 93 and 94. The 
hydrophobicity  was  imparted  into  the  compounds  at  the  expense  of  increasing 
flexibility.  
 
In  75%  H2O/DMSO  system  some  degree  of  dimerisation  was  observed  for 
compounds  93  and  94  (Fig  53).  The  thermodynamic  figures  associated  with  the 
dimerisation of 93   (Kdim= 27±7 M
-1, ∆Gdim
  [kJ mol
-1] = -8.1, ∆Hdim
  [kJ mol
-1]= -
4.2±0.4, T∆Sdim
  [kJ mol
-1]= 3.9) suggested that the dimerisation is favourable both 
enthalpically and entropically. It could not be understood why particularly the 75% 
H2O/DMSO system is conducive for the dimerisation process. It might be explained 
in  simple  terms  by  saying  this  solvent  system  might  induce  the  right  degree  of 
hydrophobicity  for  the  dimerisation  processs  while  maintaining  some  degree  of 
hydrogen bonding. An aqueous content more than 75% H2O is expected to enhance 
the  hydrophobic  effect  more,  however  it  might  have  been  disruptive  for  dimer 
stability  due  to  the  increased  degree  of  solvation  of  the  hydrogen  bond  forming 
moieties.  
 
A more rigorous analysis is needed from a physical chemistry point of view as to how 
this particular solvent system is conducive for the dimerisation process. It has been 
reported in the literature that water and DMSO form a non-ideal solution. Solvent 
properties like viscosities, densities, refractive indices, and enthalpies of mixing have 
found to deviate from ideality for aqueous DMSO solutions and this is attributed to 
association interactions between the molecules of water and DMSO. The degree of 
these interactions depends on the water:DMSO ratio in the solution and is found to be 
at a maximum when the water-DMSO molar ratio is 2:l.
 123 In water-DMSO solutions, 
large amounts of water disrupts  DMSO structure while small amounts of DMSO 
rigidify rather than break the H-bonding network among water molecules. We do not 
have a clear picture as to what extent the degree of interaction between water and 
DMSO influences the dimerisation process. It might be erroneous to simply correlate 
increased water percentage with enhanced solvation of the hydrogen bond forming 
moieties and hence decreased dimerisation. A specific ratio of water:DMSO solvent 
mixture might have its own unique property that may affect the dimerisation process Results and Discussion 
   
either positively or negatively. In the dimerisation of guanidinium-carboxylate 93 and 
94, the 75% H2O/DMSO solvent mixture might have the proper balance of all the 
relevant solvent properties permissive for the dimerisation process. 
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Fig 53 Calorimetric data obtained for ITC dilution studies of 93 (left) and 94 (right) 
in  75%  H2O/DMSO  at  298K.  a)  Raw  ITC  data  in  75%H2O/DMSO  (29x10µL 
injections) b) Non-linear curve fitting of the reference corrected data into the dimer 
dissociation model  
 
Investigation of the dimerisation of compound 94 in 75% H2O/DMSO has also shown 
a positive result (Fig 51). The ITC data was fitted to the dimer dissociation model and 
gave a Kdim =127± 100. The thermodynamic data (∆Gdim
  [kJ mol
-1] = -12, ∆Hdim
  [kJ 
mol
-1]=  -33±7,  T∆Sdim
  [kJ  mol
-1]=  -21.4)  suggested  the  process  is  more  enthalpy 
driven. The relatively big error associated with the Kdim of 94 makes it difficult to 
make a comparison with the Kdim of compound 93.   
 
 
 
 
 Results and Discussion 
   
3.11 Synthesis of guanidine-carboxylate 116 
 
One further structural modification which was thought to be worthy of consideration 
was introduction of a carbonyl functionality on the carbon between the guanidine N 
and the pyridine ring.   
 
                          
 
The  acyl  pyridoguanidinium  derivatives  are  superior  to  simple  alkyl  and  benzyl 
guanidines in their affinity for carboxylate anions and consequently a better stability 
of the dimeric structures in polar solvent systems.
61 Acyl guanidiniums have pKa 
values between 7 and 8 as compared to 13 for simple alkylguanidines. This increased 
acidity  should  further  consolidate  the  strength  of  the  hydrogen  bonded  ion  pair 
complexes between the carboxylate and the guanidinium. An aromatic side chain was 
included in 116 to provide possible π- π interactions in the dimeric systems (Fig 54).  
The  rigidity  of  the  guanidine-carboxylate  116  is  also  an  important  criterion  for 
making a dimeric structure in solution. The extreme flexibility associated with the 
previous  systems  is  thought  to  be  partly  responsible  for  the  weak  dimerisation 
observed in more aqueous environments.  
                             
                                            
                        Fig 54 The proposed dimerisation mode of compound 116  Results and Discussion 
   
 
Scheme 23 illustrates the first route considered for the synthesis of compound 116. A 
literature procedure was used to synthesize compounds 117 through 120.
70 However 
in  the  final  step,  the  methyl  ester  hydrolysis  reaction  of  compound  121  did  not 
proceed as smoothly as expected. 
 
 
 
Many ester hydrolysis procedures
 were attempted to prepare compound 122 but none 
were  successeful  for  the  selective  hydrolysis  the  methyl  ester.  Instead  preferred 
nucleophilic  attack  took  place  on  the  carbonyl  carbon  adjacent  to  the  protected 
guanidine functionality resulting in cleavage of the Cbz guanidine from the pyridine 
scaffold.  
To circumvent this problem, the synthetic scheme was redesigned so that compound 
120 was coupled to the benzyl ester of 4–(aminomethyl) benzoic acid instead of the 
methyl ester (Scheme 24). Benzyl ester hydrolysis and Cbz deprotection procedures 
were carried out simultaneously giving the desired target compound 116.  
 Results and Discussion 
   
 
3.11.1 Isothermal calorimetric dilution study of 116 
 
The very poor aqueous solubility of compound 116 has restricted the dimerisation 
investigation only to DMSO and 10% water/DMSO. The study result indicates that 
compound 116 shows appreciable dimer formation in both solvent systems (Fig 55).  
 
0.0 0.5 1.0 1.5 2.0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
-0.5
0.0
0.5
1.0
1.5
-10 0 10 20 30 40 50 60 70 80 90 100110120130
Time (min)
µ
c
a
l
/
s
e
c
c
Molar Ratio
k
c
a
l
/
m
o
l
e
 
o
f
 
i
n
j
e
c
t
a
n
t d
0.0 0.5
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
1.3
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
-10 0 10 20 30 40 50 60 70 80 90 100110120130
Time (min)
µ
c
a
l
/
s
e
c
a
Molar Ratio
k
c
a
l
/
m
o
l
e
 
o
f
 
i
n
j
e
c
t
a
n
t
b
 
 
Fig 55 Calorimetric data obtained for ITC dilution studies of 58 in DMSO (left), and 
10% H2O/DMSO (right) at 298 K. a & c) Raw ITC data (29 x 10 µL injections); b & 
d) Non-linear curve fitting of the reference corrected  data into the dimer dissociation 
mode  
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The dimer stability of 116 is not as strong as the dimer of compound 27 (Kdim = 11876 
M
-1) in DMSO (Table 13).  An explanation may be that the dimer from compound 53 
(116) is too strained and hence some unfavourable electronic interactions might have 
been created. However, compound 58 has formed a strong dimer (Kdim = 2695±151) 
at 10% H2O/DMSO. Unlike the other systems investigated so far, the dimer stability 
in 10% H2O/DMSO is stronger than in pure DMSO. This is the largest Kdim value (at 
a 10% H2O/DMSO) of all the guanidinium carboxylates investigated in this research 
project.  
 
Solvent  Kdim [M 
-1]  ∆Gdim
  [kJ mol
-1]  ∆Hdim
  [kJ mol
-1]  T∆Sdim
 [kJ mol
-1] 
DMSO  1002±201  -17.1  -8.5±0.3  8.6 
10% H2O/DMSO  2695±151  -19.6  -6.7±0.3  12.9 
 
Table 13 Energetics of dimerisations of compound 116 at 298 K in DMSO and 10% 
Η2Ο/ DMSO 
 
We could  not  come up with  a clear  explanation as  to  how the 10%  water  added 
facilitated the dimerisation process. The presence of the carbonyl functionality might 
have enhanced the H-bond forming potential of the guanidinium protons. Schmuck 
has  exploited  this  for  the  purpose  of  carboxylate  binding  by  pyrrole  guanidinium 
receptors  in  aqueous  solvent  systems.
124  Schmuck  used  the  same  principle  to 
synthesize a dimeric structure based on pyrrole guanidinium carbonyl moiety which 
was stable in pure water (170 M
-1). This dimeric structure was stabilized solely by 
hydrogen bonding and an electrostatic interaction.
97 The enhanced ionic character of 
the guandinium moiety has formed a stronger ion-pair interaction with carboxylates. 
The possible contribution of a π- π stacking interaction for the high binding energy in 
10% H2O/DMSO should not be overlooked as well.  
 
 It  is  disappointing  that  the  solubility  of  this  compound  is  very  poor  and  its 
dimerisation could not be investigated in more aqueous systems. It might be worth 
designing a water soluble analogue of this compound to undertake the dimerisation 
study in more aqueous environments. The improved dimerisation registered in 10% 
H2O/DMSO compared to pure DMSO might be an indication that dimerisation could 
increase even in more aqueous environments.  Results and Discussion 
   
3.12 Synthesis of guanidine-carboxylate 124 
 
The dimerisation results of compound 116, especially in 10% H2O/DMSO encouraged 
us  to  design  the  guanidino-carbonyl  analogue  of  compound  27  which  had  shown 
excellent dimerisation in DMSO, but much weaker dimerisation in 10% H2O/DMSO 
system. It was envisaged that similar to compound 116 compound 124 might show 
excellent dimerisation in 10% H2O/DMSO and more aqueous environments.  
 
                      
 
 
First,  pyridine-2, 6-dicarboxylic acid was asymmetrically  coupled with the benzyl 
ester of 4-aminomethyl benzoic acid (Scheme 25). 
 
 
 
 
Phenylpropanamide guanidine 130 was coupled with compound 125 to give 131.
125, 
126 The guanylating agent 1H-pyrazole-1-carboxamidine hydrochloride was first bis-
Boc  protected  to  give  128.  This  reacted  with  N-benzyl  B-alanine,  a  compound 
previously synthesized, to give the bis-Boc protected guanidine 129. Boc deprotection 
with TFA afforded compound 130, and coupling with 60 was attempted to give the 
precursor 131 of the final guanidinium-carboxylate. However this coupling procedure 
did  not  work.  This  may  be  due  to  the  fact  that  the  bases  used  in  the  coupling 
procedures are too weak to deprotonate the guanidinium ion. Alkylguanidiniums have 
pKa values of around 14 and it might be needed to use a strong base like NaOH to 
fully  deprotonate  the  guanidinium  carbocation  and  hence  make  it  nucleophilic  to 
permit the coupling reaction. However, direct use of a strong base like NaOH is not 
advisable as previous experience showed that the acyl pyridoguanidinium compounds 
are susceptible to hydrolysis.  Results and Discussion 
   
 
 
 
The synthesis was redesigned so that a guanidine NH is protected with a Cbz group 
hence enhancing the basicity of the other NH2 allowing the coupling in the standard 
coupling procedure. However, forming the Cbz protected compound was not feasible 
from a practical point of view. All the literature procedures recommend the use of 
excess  (10  equivalent)  of  the  guanidinium  compound  and  this  was  found  to  be 
impractical.  An  attempt  made  to  form  the  product  by  using  2-3  equivalents  of 
compound 130 was not successful. Synthesis of compound 124 did not proceed from 
here.  
 
 
 
 
 Results and Discussion 
   
3.13 Synthesis of guanidine-carboxylate 133 
 
The  dimeric  structures  developed  so  far  are  based  on  a  pyridine  scaffold.  We 
pondered the idea of employing a pyrrole scaffold instead of a pyridine scaffold  so 
that  a comparison could be made between the preorganization effect of the pyridine 
nitrogen  and the hydrogen bond stabilization effect of the pyrrole NH proton with the 
incoming  carboxylate  oxygen  (Fig  56).  This  comparison  was  intended  to  help  in 
choosing  the  better  scaffold  for  the  future  development  of  stable  self  assembling 
systems based on carboxylate and guanidinium functionalities.  
 
 
 
Fig 56 The proposed dimerisation mode of compound 59 
 
With this in mind we designed compound 133 which is an analogue of compound 116 
incorporating a pyrrole scaffold instead of pyridine.  
 
                                     
 
Initially  scheme  28  was  considered,  and  all  the  transformations  were  successfully 
achieved  except  the  last  one.  Standard  literature  procedures  were  employed  to 
undertake all the transformations leading to the synthesis of compound 141.
61 141 was 
then coupled with the methyl ester 4-aminomethyl benzoic acid to afford 142. Methyl Results and Discussion 
   
ester hydrolysis of 142 gave the penultimate compound 143. However, compound 143 
was  proved  to  be  insoluble  in  any  of  the  conventional  solvents  used  for 
hydrogenolysis and hence the final Cbz deprotection step could not be undertaken.  
 
 
 
 
To circumvent the solubility problem of compound 143, the synthetic scheme was 
redesigned with the methyl ester replaced with a benzyl ester (Scheme 29). Synthesis 
of  the  benzyl  ester  coupled  product  144  was  undertaken  with  standard  peptide 
coupling  conditions.  Benzyl  ester  hydrolysis  and  Cbz  deprotection  were  then 
successfully  undertaken  simultaneously  via  hydrogenolysis  and  resulted  in  the 
guanidinocarbonyl carboxylate 133.  
 
 Results and Discussion 
   
 
3.13.1 Isothermal calorimetric dilution study of 133 
 
As  seen  from  table  14,  the  pyrrole  guanidocarbonyl  compound  exhibits  strong 
dimerisation in DMSO and 10%  H2O/DMSO. The negative ∆G
 values indicate the 
spontaneous and thermodynamically favoured formation of the dimeric complexes.  
 
Solvent  Kdim [M 
-1]  ∆Gdim
  [kJ mol
-1]  ∆Hdim
  [kJ mol
-1]  T∆Sdim
 [kJ mol
-1] 
DMSO  1767±364  -18.5  -19.5±1.5  -0.9 
10% H2O/DMSO  7634±3904  -22.2  -2.7±0.2  19.4 
 
Table 14 Energetics of dimerisations of compound 133 at 298 K in DMSO and 10% 
Η2Ο/ DMSO  
 
As with compound 116, there was more enhanced dimer stability in 10% H2O/DMSO 
than in pure DMSO. Comparison between the dimer stabilities of compound 133 with 
that of compound 116 shows that the two systems have more or less similar stability 
in DMSO and 10% H2O/DMSO systems.  
 
Schmuck has demonstrated that guanidiniocarbonylpyrrole moiety is one of the most 
efficient  carboxylate  binding  motifs  known  to  date  (Fig  8).  He  made  a  thorough 
investigation  to  indicate  which  of  the  multiple  binding  interactions  present  in 
complexes with carboxylates is responsible for its unique binding properties. The ion 
pair interaction has been proved to be crucial for the interaction. 
76 Apart from that the 
actual  impact  of  the  pyrrole  ring  itself  has  been  investigated  and  compared  with 
guanidiniocarbonylpyridine receptors. By doing so Schmuck et al has tried to prove if  Results and Discussion 
   
the pyrrole NH is actively involved in the binding or not, if the size and electronic 
structure of the aromatic ring are important or not  and if the angle between the two 
adjacent amides is crucial for the binding. NMR binding studies of receptors 15 and 
145  showed  that  the  binding  of  Ala  with  the  pyridine  system  (K  =  360  M
-1)  is 
generally less efficient than that with the pyrrole receptors (K = 1630 M
-1) in 40% 
H2O/DMSO.
70  
 
                                               
 
Calculations  showed  that  in  the  pyridine  system  the  complexation  brings  the 
carboxylate oxygen into close contact with the pyridine nitrogen (< 3Ǻ). The resulting 
dipole repulsion between the lone pairs on the two heteroatoms could be the reason 
for the decreased complex stability in the pyridine receptor. One would expect the 
nitrogen lone pair to help orientate the two neighbouring amide NHs inwards, thereby 
favouring the specific receptor conformation needed for substrate binding. However, 
in the above pyridine system it has been observed that the unfavourable electronic 
repulsion dominates and resulted in the less efficient binding with carboxylates.  
  
On  the  other  hand,  Kilburn  et  al 
38,  127  has  clearly  demonstrated  that  the 
preorganisation  effect  of  pyridine  N  is  crucial  in  pyridoguanidinium  receptors  for 
binding with carboxylates. This has been discussed in chapter one of the thesis and 
exemplified by the more efficient binding of acetate by receptor 21 (Kass = 22,000 M
-1 
in DMSO) compared with that of receptor 22 (Kass = 5300 M
-1 in DMSO) which lacks 
the preorganisation effect of the pyridine N. 
 Results and Discussion 
   
                                                                
   
 
Kilburn  et  al  has  further  investigated  the  importance  of  preorganisation  in  self 
assembely of dimeric systems developed based on pyridine (27) and benzene (146) 
scaffolds. Similar results were registered as 27 dimerises (Kdim = 11876±1692 M
-1) 
more  strongly  than  146  (Kdim  =  1600±160  M
-1).  This  again  shows  that  the 
preorganisation effect of the pyridine N is important in the formation of the dimeric 
structure.
136  
                                      
 
Considering their differences when the two scaffolds were used for the purpose of 
carboxylate binding, 
124 it was anticipated that there would be some differences of 
stabilities between dimers of pyrrole (133) and pyridine (116) based compounds. Both 
systems have their own merits to function as scaffolds for the purpose of building a 
dimeric self assembling system. However, the differences observed between the two 
scaffolds in their usage as carboxylate receptors is not reflected when compounds 133 
and  116  were  used  as  self  assembled  dimeric  systems.  At  this  stage,  we  cannot 
suggest  the  preferability  of  using  one  scaffold  over  the  other  for  the  purpose  of 
developing  dimeric  structures.  More  work  is  needed  to  investigate  these  systems 
thoroughly and suggest the preference of using one scaffold over the other.    
 Results and Discussion 
   
Another  observation  in  the  dimeric  system  of  compound  133  is  the  fact  the 
dimerisation is reversed from enthalpy driven in DMSO into entropy driven in 10% 
H2O/DMSO. That does not happen in compound 116.  It is indeed expected that the 
difference between these scaffolds will be more obvious when they are subjected to 
more  aqueous  environments.  This  is  due  to  the  fact  that  solvation  effect  by  the 
surrounding water molecules will affect the hydrogen bonding between the pyrrole 
NH and the carboxylate more than it does the preorganization phenomenon in the 
pyridine system.  
 
The poor solubilities of compounds 133 and 116 precluded dimerisation studies in 
more aqueous environments. Hence comparisons of these scaffolds in more aqueous 
solvent systems could not be made. At this juncture, we might not be able to suggest a 
pyridine scaffold is better than pyrrole in synthesising dimeric self assembled systems 
or vice versa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 General conclusions and future prospect 
   
4. General conclusions and future prospects 
 
In  this  PhD  project  various  pyridoguanidinium-carboxylate  compounds  were 
synthesized and investigated in terms of their ability to form dimeric self assembling 
systems  in  polar  solvents  (DMSO,  DMSO-water  mixtures  and  pure  water). 
Considering the fact that there was not much literature precedent on the synthesis of 
self assembling systems in polar solvent systems that do not employ a metal ligand 
template, we believe that good progress has been made towards understanding the 
principles governing the process of self assembly in polar solvent systems.  
 
In the first set of compounds 45, 46, 29 and 30, features that are believed to furnish a 
combination of H-bonding and hydrophobic interactions have been encoded into the 
monomeric structures and their dimerisation properties were thoroughly investigated. 
All the four compounds showed significant dimerisation in DMSO and through this 
the concept of employing a combination of H-bonding, electrostatic and hydrophobic 
interactions in stabilizing a self assembled system have been clearly demonstrated. 
This is illustrated by the excellent dimerisation property of compound 46 in DMSO 
(Kdim [M 
-1] = 4608±1954). The guanidinium-carboxylate H-bonding and electrostatic 
interaction  augmented  by  the  Val-Val  interaction  is  believed  to  be  responsible  in 
overcoming the high polarity and solvation properties associated with DMSO. The 
comparison of the dimerisation energies between the valine functionalized (45 and 29) 
and  the  β-Ala  functionalized  (46  and  30)  compounds  suggested  that  Val-Val 
interactions might be important in enhancing the stability of the dimeric structures in 
solution. The dramatic decrease of dimer stabilities in 10% H2O/DMSO underscores 
the challenges and difficulties associated with the task of designing supramolecular 
self assembled systems in aqueous environments.  
 
The superiority of guanidinium carboxylate 53  compared to compounds 29 and 30 in 
forming reasonably stable dimers in more aqueous environments demonstrates the 
possibility of utilizing hydrophobic interactions in creating self assembled systems in 
such competitive environments. The dimerisation of guanidinium carboxylate 53 in 
50% H2O/DMSO (Kdim [M 
-1] = 55±8) is a very good example in this regard and can 
be  a  stepping  stone  towards  developing  more  stable  systems  in  more  aqueous General conclusions and future prospect 
   
mediums. NMR dilution studies on 53 have not only verified the ITC dimerisation 
figures but also gave information regarding the structure of the dimer in solution.  
 
The synthesis of compound 57 was undertaken to exploit the strength of a combined 
aromatic-aromatic  stacking  and  hydrophobic-hydrophobic  interactions  in  more 
aqueous  environments.  Some  degree  of  dimerisation  was  observed  in  50% 
H2O/DMSO.  However,  the  poor  solubility  of  the  compound  has  precluded  a  full 
investigation of the dimerisation property in more aqueous systems. The anticipated 
through space interaction of the aromatic protons was not observed in the NOESY 
spectrum  analysis  of  this  compound.  This  might  not  rule  out  the  presence  of  the 
anticipated through space contact of the aromatic protons as a number of factors might 
interfere  with  getting  a  good  quality  NOESY  spectrum.  One  possibility  is  the 
increased  intermolecular  motion  in  the  dimeric  structure  which  is  typical  of  such 
extended monomeric systems. 
 
The objective of synthesizing compounds 67 and 78 was basically to impart water 
solubility  into  the  systems  so  that  dilution  studies  could  be  undertaken  in  more 
aqueous mediums. This objective has been achieved without compromising the dimer 
strength. Aromatic-aromatic stacking interactions were once again proved to be vital 
for dimer strength as compound 67 exhibits a much stronger dimerisation in DMSO 
and 10% H2O/DMSO than the previous aliphatic systems.  
 
Compound  82  was  designed  to  introduce  more  hydrophobic  interactions  into  the 
dimeric  system.  In  addition  to  the  dimerisations  observed  in  DMSO  and  10% 
H2O/DMSO, a reasonably stable dimeric structure was detected in 50% H2O/DMSO. 
This illustrated once again the potential in utilizing intermolecular forces based on 
hydrophobic interactions in more aqueous environments. The suitability of compound 
82  for  NMR  dilution  studies  has  also  helped  in  verifying  the  ITC  dilution  study 
results.  
 
Encouraged by the results of compound 82 we have looked into more hydrophobic 
systems 93 and 94 and these systems have yielded dimeric structures with stability 
constants of 27±7 M
-1and 127± 100 M
-1 respectively in a 75% H2O/DMSO system. It 
is  for the first time that we observed dimerisation in  this  solvent  system.  This  is 
important  not  only  in  terms  of  accessing  the  dimeric  structures  in  such  aqueous General conclusions and future prospect 
   
environment but also in understanding the properties of hydrophobic interactions in 
aqueous media.  
 
We  investigated  the  importance  of  Val-Val,  Leu-Leu,  aromatic-aromatic  stacking 
interactions in the dimerisation phenomena and recognized their pros and cons in the 
process  and we looked  into other structural  features  which might  be important  in 
improving  dimer  strength  in  aqueous  systems.  Introducing  a  carbonyl  group  in 
between  the  guanidine  and  the  pyridine  scaffold  was  observed  to  play  a  very 
constructive role in making compound 116 an excellent dimer in 10% H2O/DMSO 
(Kdim = 2695±151 M
-1).  
 
In this PhD project, we have been able to access dimeric supramolecular structures 
stable in polar solvent systems. Virtually all the guanidinium-carboxylate compounds 
considered,  exhibit  excellent  dimerisation  in  DMSO  and  10%  H2O/DMSO.  Some 
encouraging  dimerisation  results  have  also  been  registered  in  solvent  systems 
containing 50% and 75% water in DMSO. All the pieces of information we gathered 
from each of the guanidinium-carboxylates can help us design systems which contain 
all  the  optimum  structural  features  (hydrophobicity,  aqueous  solubility,  rigidity, 
introduction of a guanidinocarbonyl functionality and aromatic moities) can pave the 
way  for  the  design  of  a  more  efficient  supramolecular  system  based  pyrido 
guandinium-carboxylate for the future. 
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5. Experimental 
5.1 General Experimental 
 
Reactions requiring a dry atmosphere were carried out in oven dried glassware under 
a nitrogen atmosphere. Where degassed solvents were used, a stream of nitrogen was 
passed  through  them  immediately  prior  to  use.  Solvents  and  reagents  were  of 
commercial grade and were used without further purification and where necessary, 
distilled  prior  to  use.  THF  was  distilled  under  argon  from  benzophenonone  and 
sodium;  DCM,  Et3N,  PE  and  EtOAc  were  distilled  from  calcium  hydride.TLC 
analysis was carried out using foil-backed sheets coated with silica gel (0.25 mm) and 
containing  the  fluorescent  indicator  UV254.  Flash  column  chromatography  was 
performed on Sorbsil C60, 40-60 mesh silica.  
5.2 Instrumentation 
 
Proton NMR spectra were obtained at 300 MHz on a Bruker AC 300 and at 400 MHz 
on a Bruker DPX 400 spectrometer. Carbon NMR spectra were recorded at 75 MHz 
on a Bruker AC 300 and at 100 MHz on a Bruker DPX 400 spectrometer. Spectra 
were  referenced  to  the solvent  residual  peak  for  the  deuterated  solvent.  Chemical 
shifts are reported in ppm on the ʴ scale relative to the signal of the solvent used. 
Coupling constants (J) are given in Hz. Signal multiplicities were determined using 
the distortionless enhancement by a phase transfer (DEPT) spectral editing technique.  
 
Infra-red spectra were recorded on a BIORAD Golden Gate FTS 135. All samples 
were  run  either  as  neat  solids  or  oils.  Melting  points  were  determined  in  open 
capillary tubes using a Gallenkamp Electrothermal melting point apparatus and are 
uncorrected.  
 
Optical rotations were measured on a PolAr2001 polarimeter using the solvent stated, 
the  concentrations  given  are  in  g/100  mL.  Mass  spectra  were  obtained  on  a  VG 
analytical  70-250  SE  normal  geometry  double  focusing  mass  spectrometer.  All 
electron  ionisation  spectra  were  recorded  on  a  ThermoQuest  Trace  MS  single 
quadrupole GC-MS mass analyser with an electron ionisation ion source using DCM Experimental 
   
as  solvent.  All  electrospray  (ES)  spectra  were  recorded  on  a  Micromass  Platform 
quadrupole mass analyser with an electrospray ion source using acetonitrile as solvent. 
High resolution accurate mass measurements were carried out at 10,000 resolution on 
a  Bruker  Apex  III  FT-ICR  mass  spectrometer.  Microanalysis  wre  performed  by 
MEDAC  Ltd.,  Surrey.  Calorimetry  experiments  were  performed  on  an  Isothermal 
Titration Calorimeter from Microcal Inc., USA. 
5.3 Experimental for ITC dilution studies 
 
By directly measuring the heat evolved or absorbed as a function of time, ITC allows 
the determination of all the thermodynamic parameters associated with dissociation of 
self-assembled systems. In a single experiment the dissociation constant (Kdiss), the 
stoichiometry (n) and the enthalpy (∆Hdiss) of the dissociation process are determined. 
The association constant (Ka) of the self assembled system is simply the inverse of 
Kdiss and the relation between the enthalpy of the dissociation process (∆Hdiss) and the 
association process (∆Ha), is: 
          ∆Hdiss = -∆Ha         
From the association constant (Ka), it is possible to calculate the Gibbs free energy 
(∆Ga) according to: 
          ∆Ga = -RT. ln Ka         
With R = gas constant, T = temperature, Ka = association constant expressed in mole 
fraction units. 
The entropy of the process is obtained using the Gibbs-Helmholtz relation: 
          T.∆Sa = ∆Ha - ∆Ga       
A  typical  ITC  dilution  experiment  begins  with  a  degassed  solvent  in  cell  and 
controlled  aliquots  of  known  concentration  sample  solution  are  added  through  a 
syringe. As the dissociation begins, an endothermic or exothermic signal depending 
on the nature of dissociation is observed. As the concentration of dimer increases in 
the cell, we reach a plateau in terms of the amount of heat evolved or absorbed on 
further addition of dimer solution. 
5.4 Method for obtaining calorimetric data 
 
All dilution experiments were performed on an Isothermal Titration Calorimeter from 
Microcal  Inc.  (Northampton,  MA).  In  a  typical  experiment,  the  degassed  solvent Experimental 
   
system used for the experiment is placed inside a calorimetric cell and a solution of 
receptor with a known concentration is introduced sequentially in 29 injections from a 
computer controlled syringe in 10 μL portion. The solution is continuously stirred at 
310  rpm  to  ensure  rapid  mixing  and  the  system  is  kept  at  25
oC,  through  the 
combination of an external cooling bath and an internal heater. Dilution effects are 
determined by performing  a blank  experiment  by  adding  solvent  into  solvent  and 
subtracting  it  from  the  raw  titration  to  produce  the  final  dissociation  curve. 
Dissociation parameters are found by applying a 1:1 dimer dissociation model, using 
the Origin 7.0 software provided.  These methods rely on standard nonlinear least-
squares  regression  (Levenberg-Marquard  method)  to  fit  the  curves,  taking  into 
account the change in volume that occurs during the calorimetric dilution.  
5.5 Experimental for NMR dilution studies 
 
Obtaining  dimerisation  constants  by 
1H  NMR  dilution  experiments  involve 
preparation of a series of dilutions of the pyridoguanidinium compound which spans 
concentration ranges containing a predominantly dimeric form of the compound in 
one end and predominantly monomeric form of the compound in the other end. Upon 
complexation, protons in the pyridoguanidinium compounds may undergo a change in 
chemical  shifts.  In  particular,  protons  involved  in  hydrogen  bonding  undergo  a 
dramatic shift and therefore are used to determine association constants. After the data 
from  the dilution experiment have been  acquired, curve fitting software for a 1:1 
dimer  dissociation  model  (NMRDil_Dimer)  is  employed  to  determine  the 
dimerisation constant.
135   The monomer and the dimer are in equilibrium.  
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5.6 Synthesis 
 
Ethyl 6-(((methylsulfonyl) oxy) methyl) picolinate (33a) and ethyl 6-
(chloromethyl) picolinate (33b) 
 
Compound 32 (5.00 g, 27.62 mmol) was dissolved in DCM (30 mL) at 0 °C. Et3N (7 
mL,  50.34  mmol)  and  MsCl  (5  mL,  52.20  mmol)  were  added  and  the  resulting 
solution was stirred overnight at room temperature. In vacuo drying of the reaction 
mixture and purification of the resulting crude product by column chromatography 
(SiO2, 1:9 EA/PE) afforded 33a (334 mg, 5%) as a white solid and 33b (4.50 g, 82%) 
as a yellowish oily liquid. 
 
Ethyl 6-(((methylsulfonyl) oxy) methyl) picolinate  
(33a) 
 
 
 
MP = 50-53°C; 
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 8.03 (1 H, d, J = 7.9 Hz , CH), 
7.86  (1  H,  t,  J  =  8.5  Hz,  CH),  7.60  (1  H,  d,  J  =  8.5  Hz,  CH ),  5.37  (2  H,  s, 
CH2S(O)2CH3), 4.40 (2 H, q, J = 7.9 Hz, CH2CH3), 3.13 (s, 3 H, CH2S(O)2CH3), 1.36 
(3 H, t, J = 7.9 Hz, CH2CH3); 
13C NMR (75 MHz, CDCl3): ʴ (ppm) = 164.7 (Cq), 
154.4 (Cq), 148.1 (Cq), 138.2 (CH), 125.1 (CH), 124.8 (CH), 71.1 (CH2), 62.1 (CH2), 
38.2  (CH3),  14.3  (CH3);  ESMS:  m/z  =  321  [M+Na]
+;  HRMS  (ES):  Calcd.  for 
C10H13NNaO5S ([M+Na]
+) 282.0412, found 282.0408;  FT-IR  (solid):  ν  max cm
-1 = 
2982 (m), 1736 (s), 1716 (s), 1589 (s) , 1456 (m), 1369 (m), 1315 (s), 1257 (s), 1226 
(m), 1173 (s), 1131 (s), 747 (m), 696 (m). 
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Ethyl 6-(chloromethyl) picolinate  
(33b) 
 
 
  
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 8.02 (1 H, d, J = 8.53 Hz, CH), 7.89 (1 H, d, 
J = 8.53 Hz, CH), 7.68 (1 H, d, J = 8.73 Hz, CH), 4.74 ( 2 H, s, CH2Cl), 4.44 (2 H, q, 
J = 8.0 Hz, CH2CH3), 1.39 (3 H, t, J = 7.2 Hz, CH2CH3); 
13C NMR (75 MHz, CDCl3): 
ʴ (ppm) = 164.8 (Cq), 157.2 (Cq), 147.7 (Cq), 138.1 (CH), 126.0 (CH), 124.3 (CH), 
62.1 (CH2), 46.3 (CH2), 14.3 (CH3); ESMS: m/z = 222 [M+Na]
+; FT-IR (liquid): ν max 
cm
-1 = 2982 (m), 1736 (s), 1716 (s), 1589 (m), 1455 (m), 745 (s), 694 (s). 
 
N, N-Di-tert butyloxycarbonyl –N-[6-(ethoxy carbonyl) pyridn-2-yl] 
methaneamine  
(34) 
 
 
 
33b (4.25 g, 21.25 mmol) was dissolved in dry DMF (50 mL). K2CO3 (3.80 g, 27.00 
mmol) and NHBoc2 (5.90 g, 27.00 mmol) were added successively to the reaction 
mixture which was stirred for 24 hrs at 60 
°C. The solvent was removed in vacuo and 
the resulting residue was dissolved in DCM (50 mL). The organic layer was washed 
with water (50 mL), brine (50 mL) and dried over MgSO4. In vacuo removal of the 
organic solvent and purification of the resulting crude by column chromatography 
(SiO2, 1:20 EtOAc/PE) afforded 34 (6.6 g, 75%) as a pale yellowish oily liquid. 
1H 
NMR (300 MHz, CDCl3): ʴ (ppm) = 7.95 (1 H, d, J = 8.5 Hz, CH), 7.75 (1 H, dd, J = 
8.6 Hz, 8.5 Hz, CH), 7.31 (1 H, d, J = 8.7 Hz, CH), 4.99 (2 H, s, CH2NBoc2), 4.42 (2 
H, q, J = 7.93 Hz, CH2CH3), 1.30-1.45 (21 H, m , 2 x C(CH3)3 + CH2CH3);  
13C NMR 
(75 MHz, CDCl3): ʴ (ppm) = 165.2 (Cq), 159.1 (Cq), 152.3 (Cq), 147.8 (Cq), 137.4 
(CH), 123.3 (CH), 122.8 (CH), 82.9 (Cq), 61.8 (CH2), 51.4 (CH2), 30.0 (CH3), 14.3 
(CH3);  ESMS:  m/z  =  403  [M+Na]
+,  784  [2M+Na]
+;  HRMS  (ES):  Calcd.  for 
C19H28N2NaO6 ([M+Na]
+)  403.1845, found 403.1846; FT-IR (liquid): ν  max cm
-1 = 
2979 (m), 1717 (s), 1366 (m), 1141 (s), 1091 (s).  Experimental  
   
 
6-((Di-(tert-butoxycarbonyl) amino) methyl) picolinic acid (35) and 6-(((tert-
butoxycarbonyl) amino) methyl) picolinic acid  
(36) 
 
Compound 34 (1.8 g, 4.74 mmol) was dissolved in CH3CN (20 mL) containing 2 % 
(v/v) of water. Et3N (2.2 mL, 15.80 mmol) and LiBr (4.60 g, 53.49 mmol) were added 
successively to the reaction mixture which was stirred vigorously at room temperature 
for  24  hrs.  Water  (100  mL)  and  EA  (100  mL)  were  added  and  the  mixture  was 
directly acidified with 2M HCl until the pH of the reaction mixture was 2-3. The 
organic phase was washed with water (50 mL), dried over MgSO4 and concentrated in 
vacuo. Purification of the resulting crude product by column chromatography (SiO2, 
1:20 MeOH/DCM) afforded compound 35 (0.95 g, 57 %) and compound 36 (0.38 g, 
32 %) as white solids. 
 
6-((Di-(tert-butoxycarbonyl) amino) methyl) picolinic acid  
(35) 
 
 
 
MP = 63-66 °C; 
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 9.23 (1 H, s, COOH), 8.11 (1  
H, d, J = 8.6 Hz, CH), 7.92 (1  H, t, J = 8.5 Hz, CH), 7.48 (1 H, d, J = 8.5 Hz, CH), 
4.98 (2 H, s, CH2 NBoc2), 1.41 (18 H, s, 2 x C(CH3)3); 
13C NMR (75 MHz, CDCl3): ʴ 
(ppm) = 165.4 (Cq), 156.1 (Cq), 146.3 (Cq), 138.6 (CH), 125.6 (CH), 122.8 (CH), 
81.5 (Cq), 53.4 (CH2), 28.3 (CH3); ESMS: m/z = 375 ([M+Na]
+); HRMS (ES): Calcd 
for C17H24N2NaO6 ([M+Na]
+)  375.1532, found 375.1521; FT-IR (solid): ν max cm
-1 = 
3566 (b), 2364 (m), 1733 (s), 1558 (m), 1507 (m), 1364 (m), 1113 (m). 
 
6-(((tert-butoxycarbonyl) amino) methyl)picolinic acid  
(36) 
 
 Experimental  
   
 
MP =  89-90 °C; 
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 8.12 (1 H, d, J = 8.3 Hz, 
CH), 7.91 (1 H, t, J = 8.5 Hz, CH), 7.56 (1 H, d, J = 8.3 Hz, CH), 5.36 (1 H, s(b), 
NHBoc2) 4.51 (2 H, d, J = 6.5 Hz, NHCH2), 1.46 (9H, s, C(CH3)3 ); 
13C NMR (75 
MHz, CDCl3): ʴ (ppm) =165.4 (Cq), 157.3 (Cq), 152.6 (Cq), 139.1 (CH), 124.9 (CH), 
122.1 (CH), 83.3 (Cq), 50.1 (CH2), 28.0 (CH3); ESMS: m/z = 275 [M+Na]
+, HRMS 
(ES): Calcd for C12H16N2NaO4 ([M+Na]
+) 275.1008, found 275.1006; FT-IR (solid): 
ν max cm
-1 =   3566 (b), 2364 (m),1733 (s).  
 
Methyl 3-(6-(((tert-butoxycarbonyl)amino)methyl)picolinamido)propanoate  
(37a) 
 
 
 
Compound 36 (3.40 g, 13.49 mmol) was dissolved in dry DCM (50 mL). iPr2NEt 
(4.42 g, 34.20 mmol), EDC (4.40 g, 28.39 mmol), HOBt (3.90 g, 28.89 mmol) and 
alanin-β-methyl  ester  (2.60  g,  19.40  mmol)  dissolved  in  25  mL  DCM:DMF  (4:1 
mixture) were added successively to the reaction mixture which was stirred at room 
temperature for 72 hrs. In vacuo drying of the reaction mixture and purification of the 
resulting crude by column chromatography (SiO2, 1:20 MeOH/DCM) afforded 37a 
(2.30 g, 48%) as a white solid. MP = 60-62 °C; 
1H NMR (300 MHz, CDCl3): ʴ (ppm) 
= 8.30 (1 H, s, NH), 8.02 (1 H, dd, J = 8.5 Hz, 1.0 Hz, CH), 7.77 (1 H, t, J = 8.7 Hz, 
CH), 7.28 (1 H, dd, J = 8.5 Hz, 0.8 Hz, CH), 4.90 (2 H, s, CH2NHBoc), 3.71 (2 H, t, J 
=  7.3  Hz,  OCCH2CH2NH),  3.68  (3  H,  s,  OCH3),  2.62  (2  H,  t  ,  J  =  7.3  Hz, 
CH2CH2NH), 1.41 (18 H, s, C(CH3)3); 
13 C NMR (75 MHz, CDCl3): ʴ (ppm) = 172.3 
(Cq), 164.3 (Cq), 156.9 (Cq), 152.5 (Cq), 149.0 (Cq), 137.9 (CH), 122.7 (CH), 120.5 
(CH), 82.7 (Cq), 51.9 (CH3), 50.1 (CH2), 35.0 (CH2), 34.1 (CH2), 27.9 (CH3); ESMS: 
m/z = 460 [M+Na]
+, 898 [2M+Na]
+; HRMS (ES): Calcd for C16H23N3NaO5 ([M+Na]
+) 
460.2060, found 460.2051; FT-IR (solid): ν max cm
-1 = 3397 (m), 2974 (s), 1743 (m), 
1728 (s), 1680 (s). 
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(R)-Methyl 2-(6-(((tert-butoxycarbonyl)amino)methyl)picolinamido)-3- 
methylbutanoate   
(38a) 
 
 
 
Compound 36 (100 mg, 0.36 mmol) was dissolved in DCM (25 mL). iPr2NEt (0.2 mL, 
1.26 mmol), EDC.HCl (165 mg, 0.90 mmol), HOBt (146 mg, 1.08 mmol) and valine 
methyl ester (120 mg, 0.72 mmol) were added successively to the reaction mixture 
which was stirred at room temperature for 72 hrs. DCM (40 mL) and 1M KHSO4 (40 
mL) were added to the reaction mixture. The organic layer was separated, washed 
with sat Na2CO3 (30 mL) and brine (30 mL) successively, and dried over MgSO4. In 
vacuo  removal  of  the  solvent  and  purification  of  the  resulting  crude  product  by 
column chromatography (SiO2, 1:1 DCM/PE → 1:50 MeOH/DCM) afforded 38a (80 
mg, 50%) as yellowish oily liquid. 
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 8.43 (1 H, 
d, J = 10.2 Hz, CHNHBoc), 8.04 (1 H, d, J = 8.5 Hz, CH), 7.80  (1 H, t, J = 8.5 
Hz ,CH),  7.43 (1 H, d,  J = 8.93 Hz , CH), 5.32 (1 H, s, CH2NH), 4.70 (1 H, dd, J = 
10.2  Hz, 5.7 Hz, CHCH(COOMe)NH), 4.48 (2 H, d, J = 6.5 Hz, NHCH2), 3.79 (3 H, 
s, COOCH3), 2.29 (1 H, m, (CH3)2CHCH), 1.45 (9 H, s, NHCOO(CH3)3), 1.01( 3 H, d, 
J = 2.5 Hz, CH(CH3)2), 0.99 (3 H, d, J =  2.5 Hz , CH(CH3)2); 
13C NMR (75 MHz, 
CDCl3): ʴ(ppm) = 172.3 (Cq), 164.1 (Cq), 157.2 (Cq), 156.0 (Cq), 148.8 (Cq) , 138.1 
(CH), 124.2 (CH), 120.9 (CH), 79.8 (Cq), 57.3 (CH), 52.2 (CH), 45.7 (CH2), 31.5 
(CH3), 28.4 (CH3), 19.2 (CH3), 17.9 (CH3); ESMS: m/z = 388 [M+Na]
+; HRMS (ES): 
Calcd for C18H27N3NaO5 ([M+Na]
+) 388.1849, found 388.1841; FT-IR (liquid): ν max 
cm
-1 =  3018 (w), 1671 (m), 1518 (m), 1214 (s), 745 (s). 
 
 
(R)-Methyl 2-(6-(aminomethyl)picolinamido)-3-methylbutanoate   
(38) 
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Compound  38a  (56  mg,  0.15  mmol)  was  dissolved  in  DCM  (10  mL).  20%  (v/v) 
TFA/DCM (2 mL) was added to the reaction mixture which was stirred for 5 hrs at 
room  temperature.  In  vacuo  drying  of  the  reaction  mixture  after  the  addition  of 
toluene (3 x 2 mL) afforded 38 (30 mg, 72%) as a yellowish oily liquid. 
1H NMR (300 
MHz, CDCl3): ʴ (ppm) = 8.59 (broad, NΗ & NH2), 8.09 (1 Η, d, J = 8.5 Hz, CH), 
7.84 (1 H, t, J = 8.5 Hz , CH), 7.39 (1 Η, d, J = 8.5 Hz, CH),  4.61 (1 H, dd, J = 10.0 
Hz, 7.7 Hz, CHCH(COOMe)NH), 4.35 (2 H, s, CH2NH2), 3.70 (3 H, s, COOCH3), 
2.22 (1 H, m, (CH3)2CHCH), 0.95 (3 H, d, J = 3.0 Hz , CH(CH3)2), 0.93 (3 H, d, J =  
3.0 Hz , CH(CH3)2); 
13C NMR (75 MHz, CDCl3): ʴ (ppm) = 174.2 (Cq), 164.2 (Cq), 
150.9 (Cq), 149.1 (Cq), 138.9 (CH), 125.1 (CH), 122.8 (CH), 58.3 (CH), 52.4 (CH), 
43.2 (CH2), 31.0 (CH3), 19.0 (CH3), 18.2 (CH3); ESMS: m/z = 266 [M+H]
 +; HRMS 
(ES): Calcd for C13H20N3O3 ([M+H]
+) 266.1504, found 266.1495; FT-IR (liquid): ν 
max cm
-1 =  2961 (w), 1668 (m), 1594 (m),  903 (s), 728 (s). 
 
.                N-Benzyl-3-(1,3-dioxoisoindolin-2-yl)propanamide 
        (41) 
 
 
40 (0.30 g, 1.26 mmol) was dissolved in DCM (25 mL) and added dropwise to a 
solution of benzylamine (1.0 mL) and Et3N (1.5 mL) in DCM (20 mL) at 0 °C. After 
an overnight stirring at room temperature, the reaction mixture was poured into ice 
cold 2M HCl (20 mL) and extracted with DCM (3 x 50 mL). The organic phases were 
combined, washed with brine and dried over MgSO4. In vacuo removal of the organic 
solvent afforded 41 (0.30 g, 77%) as a white solid with no further purification. MP = 
146-148 °C;  
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 8.46 (1 Η, t, J = 6.0 Ηz, NΗ), 
7.88-7.80 (4 Η, m, CΗ ), 7.24-7.16 (5 Η, m, CΗ), 4.21 (2 Η, d, J = 6.5 Hz, CΗ2), 3.82 
(2 Η, t, J = 8.0 Hz, NCH2CΗ2), 2.52 (2 Η, t, J = 8.0 Hz, NCH2CΗ2); 
13C NMR (75 
MHz, CDCl3): ʴ (ppm) = 169.4 (Cq), 167.6 (Cq), 139.3 (Cq), 134.3 (Cq), 131.7 (CH), 
128.2 (CH), 127.1 (CH), 126.7 (CH), 123.0 (CH), 42.0 (CH2), 34.4 (CH2), 33.8 (CH2); 
ESMS:  m/z  =  331  [M+Na]
+;  HRMS  (ES):  Calcd  for  C18H16N2NaO3  ([M+Na]
+) 
331.1059, found 331.1054;  FT-IR (solid): ν max cm
-1 =   3290 (m), 1705 (s), 1631 (s), 
1540 (m).  Experimental  
   
 
[N-(N-Benzyl ethylamino carbonyl)-N-(benzyl formyl)]-thioguanidine  
(42)  
 
 
 
Compound 41 (0.30 g, 0.87 mmol) was suspended in EtOH (20 mL) and refluxed 
with hydrazine hydrate (76 μL) for 3 hrs and cooled to room temperature. Filtration of 
the reaction mixture and in vacuo drying of the resulting filtrate afforded compound 
41a (0.20 g, 100%) as a yellowish solid and was used for the next step with no further 
purification. Compound 41a (0.23 g, 1.00 mmol) was dissolved in DCM (20 mL) and 
cooled to 0 
oC. Et3N (50 μL) and 48 (0.76 g, 2.0 mmol) were added to the reaction 
mixture which was stirred for 30 mins at 0 °C and then overnight at room temprature. 
In vacuo drying of the reaction mixture and purification of the resulting crude by 
column chromatography (SiO2, 1:5 EA/PE) afforded 42 (0.31 g, 81%) as a white solid. 
MP = 137-139 °C; 
1H NMR (300 MHz, DMSO-d6): ʴ (ppm) = 10.16 (1 Η, s,  NΗ), 
8.04 (1 Η, s,  NΗ), 7.34-7.23 (10 Η, m, CΗ), 5.88 (1 Η, s,  NΗ), 5.19 (2 Η, s,  
COCΗ2Ar), 4.42 (2 Η, d, J = 6.5 Hz, NHCΗ2), 3.96 (2 Η, t, J = 7.0 Hz, CΗ2), 2.58 (2 
Η, t, J = 7.0 Hz, CΗ2); 
13C NMR (75 MHz, DMSO-d6): ʴ (ppm) = 179.0 (Cq), 170.6 
(Cq), 152.1 (Cq), 137.9 (Cq), 134.5 (Cq), 128.9 (CH), 128.8 (CH), 128.4 (CH), 127.9 
(CH), 127.6 (CH), 68.2 (CH2), 43.7 (CH2), 41.6 (CH2), 34.3 (CH2); ESMS: m/z = 
394.2 [M+Na]
+; HRMS (ES): Calcd for ([M+Na]
+) 394.1202, found 394.1197. FT-IR 
(solid): ν max cm
-1 = 3290 (w) (b), 1718 (m), 1653 (m), 1647 (m), 1541(s), 1522 (s). 
 
Methyl 3-(6-((3-(3-(benzylamino)-3-oxopropyl)-2- 
((benzyloxy)carbonyl)guanidino)methyl)picolinamido)propanoate  
(43) 
 
 
 
Compound  37a  (0.50  g,  1.48  mmol)  was  dissolved  in  DCM  (50  mL).  20%  (v/v) 
TFA/DCM (5 mL) was added to the reaction mixture which was stirred for 5 hrs at Experimental  
   
room  temperature.  In  vacuo  drying  of  the  reaction  mixture  after  the  addition  of 
toluene (3 x 2 mL) afforded the TFA salt as a white gummy solid (0.37 g, quantitative) 
which used for the next step with no further purification. (0.23 g, 1.04 mmol) of the 
TFA salt  was dissolved in DCM (40 mL). EDC.HCl (0.45 g, 2.13 mmol), Et3N (0.5 
mL, 3.10 mmol) and 42 were added successively to the reaction mixture which was 
stirred for 3 days at room temperature. The reaction mixture was washed with 1M aq. 
KHSO4 (50 mL) and brine, dried over MgSO4 and concentrated in vacuo. Purification 
of  the  resulting  crude  product  by  column  chromatography  (SiO2,  1:100  →  1:20 
MeOH/DCM) afforded 43 (0.50 g, 84%) as a white solid. MP = 118-120 °C;  
1H 
NMR (300 MHz, CDCl3): ʴ (ppm) = 10.27 (1 Η, s, NΗ), 9.30 (1 Η, s(b), NΗ), 8.64 (1 
Η, s, NΗ), 8.12 (1 Η, d, J = 5.4 Hz, CΗ), 7.86 (1 Η, s, J = CΗ), 7.42-7.32 (11 Η, m, 
CΗ), 5.31 (2 Η, s, CΗ2), 4.76 (2 Η, s, CΗ2), 4.39 (2 Η, d, J = 5.0 Ηz, CΗ2), 3.73 (4 Η, 
s, 2 x CΗ2), 3.60 (2 Η, s, CΗ3), 2.72 (4 Η, m, 2 x CΗ2); 
13C NMR (75 MHz, DMSO): 
ʴ (ppm) = 181.2 (Cq), 139.1 (Cq), 138.2 (Cq), 129.0 (CH), 128.3 (CH), 128.2 (CH), 
127.9 (CH), 124.9 (Cq), 122.1 (Cq), 52.1 (CH3), 46.4 (CH2), 44.3 (CH2), 38.5 (CH2), 
36.1 (CH2), 34.5 (CH2), 32.6 (CH2); ESMS: m/z = 575.5 [M+H]
+; HRMS (ES): Calcd 
for C30H35N6O6 ([M+H]
+) 575.2618, found 575.2612;  FT-IR (solid): ν  max cm
-1 = 
1735 (m), 1637 (s), 1672 (s), 1594 (s). 
 
3-(6-((3-(3-(Benzylamino)-3-oxopropyl)-2- 
((benzyloxy)carbonyl)guanidino)methyl)picolinamido)propanoic acid 
 (43a) 
 
 
 
Compound  43  (0.45 g, 0.78 mmol) was  dissolved in  THF (30 mL) and added to 
Me3SiOK (100 mg, 0.78 mmol) suspended in THF (10 mL) under N2. After overnight 
stirring at room temperature, DCM (50 mL) and H2O (50 mL) were added and the 
reaction mixture was cooled to 0 °C. Citric acid (0.1 M aqueous) was added dropwise 
until the pH was 6-7 and further stirred for 1 hr. In vacuo drying of the organic phase 
and purification of the resulting crude by column chromatography (SiO2, 1:50 → 1:20 
MeOH/DCM) afforded 43a (0.30 g, 69%) as a white solid. MP = 215-217 °C; 
1H 
NMR (300 MHz, DMSO-d6): ʴ (ppm) = 12.30 (1 H, s, COOH), 10.50 (1 H, s, NH) Experimental  
   
9.10 (1 H, s(b), NH), 8.78 (1 H, NH), 8.50 (1 H, s, NH), 7.92 (2 H, s, CH), 7.48 (1 H, 
d, J = 8.0 Hz , CH), 7.26-7.18 (10 H, m , CH), 4.96 (2 H, s, CH2), 4.55 ( 2 H, d, J = 
5.0 Hz, CH2), 4.26 (2 H, d, J = 5.5 Hz, CH2), 3.50 (4 H, s(b), 2 x CH2), 2.54 (4 H, m, 
2 x CH2); 
13C NMR (75 MHz, DMSO-d6): ʴ (ppm) = 180.1 (Cq), 171.0 (Cq), 138.3 
(Cq), 128.7 (CH), 128.1 (CH), 127.9 (CH), 127.7 (CH), 127.2 (CH), 66.0 (CH2), 42.5 
(CH2), 35.6 (CH2), 34.3 (CH2), 32.1 (CH2), 31.1 (CH2); ESMS: m/z = 561 [M+H]
+; 
HRMS  (ES):  Calcd  for  C29H33N6O6  ([M+H]
+)  561.2461,  found  561.2464.  FT-IR 
(solid): ν max cm
-1 = 3208 (m) (b), 2957 (m), 2927 (m), 2361 (m), 1728 (s), 1636 (s), 
1573 (s),1518 (s), 1452 (m),1380 (s), 1271 (s). 
 
 
3-(6-((3-(3-(Benzylamino)-3-
oxopropyl)guanidino)methyl)picolinamido)propanoic acid  
(29) 
 
 
 
Compound 43a (0.33 g, 0.58 mmol) was dissolved in MeOH (50 mL). Pd/C (60 mg, 
0.58 mmol) was added and the reaction mixture was stirred for 48 hrs under hydrogen 
(1 atm) at room temperature. The reaction mixture was filtered through celite and 
dried in vacuo. Purification of the resulting solid by precipitation from MeOH using 
Et2O afforded compound 27 (0.20 g, 81 %) as a white solid. MP = 218-220 °C; 
1H 
NMR (300 MHz, MeOD-d4): ʴ (ppm) =  7.95-7.89 (2 H, m, CH), 7.46 (1 H, d,  J = 
8.9 Hz , CH), 7.25-7.06 (5 H, m, CH), 4.49 (2 H, s, CH2), 4.28 (2 H, s, CH2), 3.52-
3.56 (4 H, m, 2 x CH2), 2.58 (2 H, t, J = 7.0 Hz, CH2), 2.43 (2 H, t, J = 7.0 Hz, CH2); 
13C NMR (75 MHz, MeOD-d4): ʴ(ppm) = 177.0 (Cq), 170.8 (Cq), 162.9 (Cq), 156.6 
(Cq), 152.0 (Cq),  149.5 (Cq), 139.9 (Cq), 139.3 (CH), 128.5 (CH), 127.5 (CH), 127.0 
(CH), 124.4 (CH), 120.4 (CH),  55.4 (CH2), 42.6 (CH2), 38.9 (CH2), 37.4 (CH2), 36.6 
(CH2), 35.1 (CH2); ESMS: m/z = 427 [M+H]
 +; HRMS (ES): Calcd for C21H27N6O4 
([M+H]
+) 427.2094, found 427.2077; FT-IR (solid): ν max cm
-1 =   3286 (w), 1644 (s), 
1567 (s), 1537 (s), 697 (m), 607 (m).  
 
 
 Experimental  
   
 
(R)-Methyl 2-(6-((3-(3-(Benzylamino)-3-oxopropyl)- 
2-((benzyloxy)carbonyl)guanidino)methyl)picolinamido)-3-methylbutanoate  
(44) 
 
                                 
 
Compound 38 (0.46 g, 1.75 mmol) was dissolved in DCM (30 mL). EDC.HCl (0.84 g, 
4.48 mmol), Et3N (0.74 mL, 5.25 mmol) and 42 (0.65 g, 1.75 mmol) were added 
successively and the resulting solution was stirred for 3 days at room temperature. 
The reaction mixture was washed with 1M aq. KHSO4 (50 mL) and brine (40 mL), 
dried over MgSO4 and concenterated in  vacuo. Purification of the resulting crude 
product by column chromatography (SiO2, 1:100 → 3:100 MeOH/DCM) afforded 44 
(0.58 g, 50%) as a white solid. MP = 102-104 °C;  
1H NMR (300 MHz, CDCl3): ʴ 
(ppm) = 10.13 (1 H, s, NH), 9.24 (1 H, s, NH), 8.76 (1 H, s, NH), 8.57 (1 H, s, NH), 
8.07 (1 Η, s, CΗ), 7.79 (1 Η, s , CΗ), 7.47-7.17 (11 Η, m, CΗ), 5.08 (2 Η, s, CΗ2), 
4.62 (3 Η, m,  CΗ2 + CH), 4.30 (2 Η, dt, J = 16.3 Hz, 7.0 Hz, NHCΗ2CΗ2), 3.29 (3 Η, 
s, CΗ3OOC), 2.48 (2 Η, s, CΗ2), 2.30 (1 Η, m, CH(CΗ3)2), 1.70 (2 Η, s, CΗ2), 0.95 (6 
Η, m, CH(CΗ3)2); 
13C NMR (75 MHz, CDCl3): ʴ (ppm) = 128.7 (CH), 128.3 (CH), 
127.9 (CH), 127.7 (CH), 127.5 (CH), 66.5 (CH2), 52.1 (CH), 50.8 (CH), 45.6 (CH3), 
38.9 (CH2), 36.6 (CH2), 35.1 (CH2), 19.2 (CH3), 19.2 (CH2), 18.4 (CH3); ESMS: m/z 
= 603.5 [M+H]
 +; FT-IR (solid): ν max cm
-1 = 3250 (m) (b), 1735 (m), 1637 (s), 1672 
(s), 1594 (s). 
 
 
(R)-2-(6-((3-(3-(benzylamino)-3-oxopropyl)-2- 
((benzyloxy)carbonyl)guanidino)methyl)picolinamido)-3-methylbutanoic acid 
(44a) 
 
 
 
Compound  44  (0.47 g, 0.78 mmol) was  dissolved in  THF (30 mL) and added to 
Me3SiOK (133 mg, 1.04 mmol) suspended in THF (10 mL) under N2. After overnight Experimental  
   
stirring, DCM (50 mL) and H2O (50 mL) were added and the reaction mixture was 
cooled to 0 °C. Citric acid (0.1 M) was added dropwise until the pH was 6-7 and 
further stirred for 1hr. In vacuo drying of the organic phase and purification of the 
resulting  crude  by  column  chromatography  (SiO2,  3:100  →  1:10  MeOH/DCM) 
afforded 44a (0.25 g, 54%) as a white solid. MP = 204-206 °C; [ʱ]D 
25 =-3.0 
o (c 0.1, 
MeOH); 
1H NMR (300 MHz, MeOD-d4): ʴ (ppm) = 8.01 (1 Η, d, J = 8.0 Hz, CΗ), 
7.93 (1 Η, t , J = 8.0 Hz, CΗ), 7.50 (1 Η, d , J = 8.5 Hz, CΗ), 7.37-7.13 (10 Η, m, CΗ), 
5.13 (2 Η, s, CΗ2), 4.64 (2 Η, s, CΗ2), 4.48 (1 Η, m, CΗCH(CH3)2), 4.32 (2 Η, s, 
CΗ2),  3.66  (2  Η,  t,  apparent  triplet,  NHCΗ2CΗ2),  2.58  (2  Η,  t,  apparent  triplet, 
NHCΗ2CΗ2), 2.35 (1 Η, m, CΗCH(CH3)2), 0.98 (6Η, m, CH(CH3)2); 
13C NMR (75 
MHz, MeOD-d4): ʴ (ppm) = 139.8 (Cq), 130.0 (CH), 129.9 (CH), 129.4 (CH), 129.0 
(CH), 128.6 (CH), 126.2 (CH), 68.9 (CH2), 47.0 (CH2), 44.6 (CH2), 39.6(CH2), 34.0 
(CH2), 20.4 (CH3) (2CH peaks overlapped with solvent peaks); ESMS: m/z = 589.4 
[M+H]
+; HRMS (ES): Calcd for C31H37N6O6 ([M+H]
+) 589.2774, found 589.2766; 
FT-IR (solid): ν max cm
-1 =  3357 (m)(b), 2502 (w), 2072 (m), 1641 (s), 1593 (m), 972 
(s).  
 
 
(R)-2-(6-((3-(3-(Benzylamino)-3-oxopropyl)guanidino)methyl)picolinamido)-3- 
methylbutanoic acid  
(30) 
 
 
 
Compound 44a (0.24 g, 0.41 mmol) was dissolved in MeOH (30 mL). Pd/C (43.4 mg, 
0.41 mmol) was added and the reaction mixture was stirred for 48 hrs under hydrogen 
(1 atm) at room temperature. The reaction mixture was filtered through celite and 
dried in vacuo. Purification by precipitation from MeOH using Et2O afforded 30 (0.12 
g, 55 %) as a white solid. MP = 242-244 °C; [ʱ]D 
25 =-18.0 
o (c 0.7, MeOH); 
1H NMR 
(300 MHz, MeOD-d4): ʴ (ppm) = 8.02-7.92 (2 Η, m, CΗ), 7.49 (1 Η, d , J = 7.5 Hz, 
CΗ),  7.27-7.18  (5  Η,  m,  CΗ),  4.48  (2  Η,  s,  CΗ2),  4.30  (1  Η,  d,    J  =  5.5  Hz, 
CHCΗ(CΗ3)2), 4.22 (2 Η, s, CΗ2), 3.45 (2 Η, dt, J = 6.5 Hz, 2.5 Hz, NHCH2CΗ2), 
2.48 (2 Η, t, J = 7.5 Hz, NHCH2CΗ2), 2.10-2.24 (1 Η, m, CHCΗ(CΗ3)2), 0.84-0.89 (6 
Η, m, CΗ(CΗ3)2). 
13C NMR (75 MHz, MeOD-d4): ʴ (ppm) = 173.4 (Cq), 165.6 (Cq), Experimental  
   
158.8 (Cq), 156.5 (Cq), 151.2 (Cq), 140.3 (Cq) ,140.3 (Cq), 129.9 (CH), 129.0 (CH), 
128.6 (CH), 126.1(CH), 122.6 (CH), 61.9 (CH), 47.0 (CH2), 44.6 (CH2), 39.6 (CH2), 
36.4 (CH2), 33.9 (CH), 20.6 (CH3), 19.0 (CH3). ESMS: m/z = 455.4 [M+H]
+; HRMS 
(ES): Calcd  for  ([M+H]
+) 455.2407, found 455.2389;  FT-IR (solid):  ν  max  cm
-1 = 
3208w (b), 2957 (s), 2927 (s), 2858 (w), 2361 (s), 2342 (m), 1728 (s).  
 
N-(Benzylamino carbothiol) benzyloxycarbonyl amide  
(49) 
    
                                                         
 
Compound 48 (0.80 g, 4.15 mmol) was dissolved in DCM (20 mL). Benzylamine (0.7 
mL) was added under N2 to the reaction mixture which was stirred overnight at room 
temperature. In vacuo drying of the reaction mixture and purification of the  resulting 
crude product by column chromatography (SiO2, DCM) afforded 49 (0.80 g, 64 %) as 
a white solid. MP = 56-58 °C;  
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 9.8 (1 H, s, 
NH), 8.05 (1 H, s, NH), 7.23 (10 H, m, CH), 5.05 ( 2 H, s, CH2), 4.74 (2 H, d, J = 5.5 
Hz, CH2); 
13C NMR (75 MHz, CDCl3): ʴ (ppm) = 179.1 (Cq), 152.4 (Cq), 136.2 (Cq) 
134.4 (Cq), 128.9 (CH), 128.8 (CH), 128.3 (CH), 128.0 (CH), 127.9 (CH), 68.3 (CH2), 
49.7  (CH2);  ESMS:  m/z  =  301  [M+H]
+;  HRMS  (ES):  Calcd  for  C16H16N2NaO2S 
([M+Na]
+) 323.0827, found 323.0827; FT-IR (solid): ν max cm
-1 =  3689 (s), 3648 (s), 
2563 (w), 1740 (s). 
 
Methyl 3-(6-((3-benzyl-2-((benzyloxy) 
carbonyl)guanidino)methyl)picolinamido)propanoate (50) 
 
 
 
            
Compound 37 (0.50 g, 1.90 mmol) was dissolved in DCM (50 mL). Et3N (520 μL, 
3.80 mmol) and EDC.HCl (0.73 g, 3.99 mmol) were added and the reaction mixture 
was  stirred  until  it  formed  a  clear  solution.  Compound  49  (N-(benzylamino 
carbothioyl)  benzyloxycarbonyl  amide)  (0.52  g,  1.91  mmol)  was  added  and  the Experimental  
   
reaction mixture was further stirred for 48 hrs at room temperature. In vacuo drying of 
the  reaction  mixture  and  purification  of  the  resulting  crude  material  by  column 
chromatography (SiO2, 3:100 MeOH/DCM) afforded 50 (0.43 g, 50%) as a white 
solid. MP = 74-76 °C; 
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 10.45 (1 H, s, NH), 
8.67 (1 H, s, NH),  7.76 (1 H, d, J = 8.1 Hz , CH), 7.52 (1 H, t, J = 8.1 Hz, CH), 7.09 
(11 H, m, CH), 6.05 (1 H, s, NH),  4.97 (2 H, s, CH2), 4.41 (4 H, m, 2 x CH2), 3.52 (2 
H, d, J = 6.5 Hz, CH2), 3.44 (3 H, s, CH3), 2.60 (2 H, t, J = 6.9 Hz, CH2);
 13C NMR 
(75 MHz, CDCl3): ʴ (ppm) = 172.3 (Cq), 164.1 (Cq), 160.0 (Cq), 153.2 (Cq), 148.5 
(Cq), 138.1 (Cq), 137.5 (CH), 128.6 (CH), 128.3 (CH), 128.1 (Cq), 127.7 (CH), 127.6 
(CH), 127.3 (CH), 124.1 (CH), 120.7 (CH), 66.6 (CH2), 51.7 (CH3), 45.2 (CH2), 44.9 
(CH2), 35.3 (CH2), 33.8 (CH2); ESMS: m/z =  526.3 [M+Na]
+, 1007.8 [M+2Na]
 +; 
HRMS  (ES):  Calcd  for  C27H30N5O5  ([M+H]
+)  504.2247,  found  504.2242;  FT-IR 
(liquid): ν max cm
-1 =  3355 (w), 3249 (w), 2359 (w),  2341 (w), 1733 (s), 1723 (s), 
1668 (m), 1668 (m).  
 
3-(6-((3-Benzyl-2-
((benzyloxy)carbonyl)guanidino)methyl)picolinamido)propanoic acid  
(50a) 
 
 
Compound 50 (0.40 g, 0.80 mmol) was dissolved in dry THF (25 mL) and added to a 
suspension of Me3SiOK (0.14 g, 1.04 mmol) in THF (25 mL) under N2 which was 
stirred overnight at room temperature. DCM (50 mL) and H2O (50 mL) were added 
and the reaction mixture was cooled to 0 
oC. Citric acid   (0.1 M aqeous) was added 
until the pH was 6-7 and further stirred for 1 hr. In vacuo removal of the organic 
solvent and purification of the resulting crude by column chromatography (SiO2, 1:50 
→ 1:20 MeOH/DCM) afforded 50a (0.3 g, 77%) as a white solid. MP = 156-158 
oC; 
 
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 9.00 (1 H, s, NH), 8.49 (1 H, s, NH), 7.91 (1 
H, d,  J = 8.5 Hz , CH), 7.5 (1H, t,  J = 7.7 Hz, CH), 7.27-7.22 (11 H, m, CH), 5.05 (2 
H, s, CH2), 4.46 (2 H, s, CH2), 3.58 (2 H, m, CH2CH2NH), 2.53 (2 H, t, J = 6.9 Hz, 
HOOCCH2), 1.38 (2 H, s, CH2);
13C NMR (75 MHz, CDCl3): ʴ(ppm) = 164.0 (Cq) , 
149.0 (Cq) ,137.0 (CH), 128.9 (CH), 128.4 (CH), 127.9 (CH), 127.8 (CH), 127.2 
(CH), 124.3 (CH),  67.0 (CH2), 45.7 (CH2), 45.3 (CH2), 35.3 (CH2), 34.3 (CH2); Experimental  
   
ESMS: m/z = 490 [M+H]
+; HRMS (ES): Calcd for C26H28N5O5 ([M+H]
+) 490.2090, 
found 490.2088; FT-IR (solid): ν max cm
-1 = 3566 (w), 1714 (s), 1734 (s), 1717 (m), 
1065 (m). 
 
3-(6-((3-benzylguanidino)methyl)picolinamido)propanoic acid   
(45) 
 
 
 
Compound 50a (90 mg, 0.2 mmol) was dissolved in MeOH (20 mL). Pd/C (20 mg) 
was added and the reaction mixture was stirred for 48 hrs under H2 (1 atm) at room 
temperature.  The  reaction  mixture  was  filtered  through  celite  and  dried  in  vacuo. 
Purification of the resulting solid by precipitation from MeOH using Et2O afforded 45 
(65 mg, 92%) as a white solid. MP = 276-278 °C;  
1H NMR (300 MHz, DMSO): ʴ 
(ppm) = 10.34 (1 Η, s, ΝΗ), 10.13 (1 Η, s, ΝΗ), 8.18 (1 Η, t,  J = 5 Ηz, CΗ), 8.11 (1 
Η, d,  J = 5.0 Hz, CΗ), 7.68  (1 Η, d,  J = 5.0 Hz , CΗ),  7.55-7.46 (5 Η, m, CΗ), 4.81 
(2 Η, s, CΗ2), 4.62 (2 Η, s, CΗ2), 3.70 (2 Η, t, J = 5.0 Ηz, COOHCΗ2), 2.50 (2 Η,  t,  
J = 5.0 Ηz, CH2CΗ2NH);  
13C NMR (75 MHz, DMSO): ʴ (ppm) = 181.2 (Cq), 176.6 
(Cq), 163.3 (Cq), 156.7 (Cq), 149.7 (Cq), 138.8 (CH), 138.2 (Cq), 128.5 (CH), 127.3 
(CH), 127.2 (CH), 124.0 (CH), 120.3 (CH), 45.5 (CH2), 44.1 (CH2), 38.5 (CH2), 37.1 
(CH2); ESMS: m/z = 356 [M+H]
+; HRMS (ES): Calcd for C18H22N5O3 ([M+H]
+) 
356.1723, found 356.1713;  FT-IR  (solid):  ν  max  cm
-1  =  3689  (s), 3675  (s), 3628 
(b),1739 (m) ,1734 (s).  
 
(R)-Methyl 2-(6-((3-benzyl-2-
((benzyloxy)carbonyl)guanidino)methyl)picolinamido)-3-Methylbutanoate  
(51) 
 
 
 
Compound 38 (0.90 g, 3.39 mol) was dissolved in DCM (15 mL). Et3N (0.1 mL), 
EDC.HCl (55 mg, 0.30 mmol) and 49 (67.5 mg, 0.2 mmol) were added successively Experimental  
   
to the reaction mixture which was stirred for 3 days at room temperature. In vacuo 
drying  of  the  reaction  mixture  and  purification  of  the  resulting  crude  by  column 
chromatography (SiO2, DCM → 3:100 MeOH/DCM) afforded 51 (1.35 g, 75% yield) 
as a white oily liquid. 
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 10.20 (1 H, s, NH),  
9.42 (1 H, s, NH),  8.35 (1 H, d, J = 9.8 Hz , CH), 7.98 (1 H, d, J = 8.1 Hz, CH), 7.72 
(1 H, t, J = 8.5 Hz, CH), 7.34-7.18 (10 H, m , CH), 5.75 (1 H, s, NH), 5.05 (2 H, s, 
CH2), 4.60 (3 H, m, CHCH(CH3)2 + CH2), 4.49 (2 H, s, CH2), 3.65 (3 H, s, COOCH3 ), 
2.20 (1 H, m, CHCH(CH3)2), 0.89 (3 H, d, J = 4.6 Hz, CH(CH3)2), 0.86 (3 H, d, J = 
4.6 Hz, CH(CH3)2); 
13C NMR (75 MHz, CDCl3): ʴ(ppm) = 172.4 (Cq), 164.2 (Cq), 
163.8 (Cq), 160.0 (Cq), 148.8 (Cq), 138.4 (CH), 137.5 (Cq), 128.9 (CH), 128.3 (CH), 
128.0 (CH), 127.7 (CH), 127.5 (CH), 124.6 (CH), 121.4 (CH), 66.6 (CH2), 57.4 (CH), 
52.2  (CH3),  45.4  (CH2),  31.6  (CH),  19.1  (CH3),  18.1  (CH3);  ESMS:  m/z  =  532 
[M+H]
+; HRMS (ES): Calcd for C29H34N5O5 ([M+H]
+) 532.2560, found 532.2548; 
FT-IR (liquid): ν max cm
-1 = 1713 (s), 1662 (m), 1523 (m). 
 
(Benzyl N-(3-benzylamino)-6-{[(2-hydroxycarbonyl)-isopropyl-1-amino] 
carbonyl}-[(2-pyridylmethyl) amino] methylenecarbamate)  
(51a) 
 
 
 
Compound 51 (0.35 g, 0.66 mmol) was dissolved in dry THF (25 mL) and added to a 
suspension  of  Me3SiOK (85 mg, 0.66 mmol) in THF  (25 mL)  which  was  stirred 
overnight at room temperature under N2. DCM (50 mL) and H2O (50 mL) were added  
and the reaction mixture was cooled to 0 °C. Citric acid (0.1 M aqeous) was added 
dropwise until the pH was 6-7 and further stirred for 1 hr. In vacuo removal of the 
organic solvent and purification the resulting crude by column chromatography (SiO2, 
1:50 → 1:20 MeOH/DCM) afforded 51a (0.15 g, 43%) as a white solid. MP =132-
134 °C; 
1H NMR (300 MHz, MeOD-d4): ʴ (ppm) = 8.35 (1 H, d, J = 8.0 Hz, CH), 
7.98 (1 H, d, J = 9.0 Hz, CH), 7.72 (1 H, t, J = 9.0 Hz, CH), 7.34-7.18 (10 H, m , CH), 
5.05 (2 H, s, CH2), 4.60 (2 H, s, CH2), 4.49 (2 H, s, CH2), 4.39 (1 H, d, J = 5.7 Hz, 
HOOCCHNH), 2.20 (1 H, m, CH(CH3)2), 0.91 (3 H, d, J = 2.5 Hz, CH(CH3)2), 0.89 
(3 H, d, J = 2.5 Hz, CH(CH3)2); 
13C NMR (75 MHz, MeOD-d4) ʴ(ppm): 165.6 (Cq), Experimental  
   
150.1 (Cq), 139.6 (CH) ,138.6 (Cq), 129.7 (CH), 129.4 (CH), 128.8 (CH), 128.4 (CH), 
125.6 (CH), 121.8 (CH), 68.3 (CH2), 60.4 (CH), 46.7 (CH2), 46.0 (CH2), 32.8 (CH), 
20.1 (CH3), 18.6 (CH3); ESMS: m/z = 518.3 [M+H]
+; FT-IR (solid): ν max cm
-1 = cm
-1 
3296 (w) (b), 1729 (m), 1599 (m), 733 (s). 
 
(R)-2-(6-((3-Benzylguanidino)methyl)picolinamido)-3-methylbutanoic acid  
(46) 
 
 
 
 
Compound 51a (0.30 g, 0.58 mmol) was dissolved in MeOH (30 mL). Pd/C (64 mg) 
was added and the reaction mixture was stirred for 48 hrs at room temperature under 
hydrogen (1 atm). The reaction mixture was filtered through celite and dried in vacuo. 
Purification of the resulting solid by precipitation from MeOH using Et2O afforded 46 
(110 mg, 50%) as a white solid. MP = 260-262 °C; [ʱ]D 
25 = -5.0 
o (c 0.43, MeOH); 
1H 
NMR (300 MHz, MeOD-d4): ʴ (ppm) = 7.95 (1 Η, t,  J = 5 Ηz, CΗ ), 7.90 (1 Η, t, J = 
6.0 Hz , CΗ), 7.43 (1 Η, d, J = 6.0 Hz, CΗ) 7.28-7.21 (5 Η, m, CΗ ), 4.60 (2 Η, s, 
CΗ2), 4.42 (2 Η, s, CΗ2), 4.34 (1 Η, d, J = 4.0 Hz, HOOCCΗNH), 2.19 (1 Η, m, 
CΗ(CH3)2), 0.92 (3 Η, d, J = 5.8 Ηz, CΗ(CH3)2), 0.90 (3 Η, d, J = 5.8 Ηz, CΗ(CH3)2); 
13C NMR (75 MHz, MeOD-d4): ʴ (ppm) =  177.0 (Cq), 164.2 (Cq), 157.4 (Cq), 155.3 
(Cq), 150.0 (Cq), 138.9 (CH), 136.7 (Cq), 128.9 (CH), 128.0 (CH), 127.3 (CH), 124.6 
(CH), 121.2 (CH), 60.5 (CH), 45.7 (CH), 45.2 (CH2), 32.5 (CH2), 19.2 (CH3), 17.6 
(CH3); ESMS: m/z = 384.4 [M+H]
 +; HRMS (ES): Calcd for C20H26N5O3 ([M+H]
+) 
384.2035, found 384.2036; FT-IR (solid): ν max cm
-1 = 3188 (w) (b), 1651 (s), 1393 
(m). 
 
(R)-Methyl 2-(6-(((tert-butoxycarbonyl)amino)methyl)picolinamido)-4-
methylpentanoate  
(54) 
 
 Experimental  
   
Compound 35 (1.20 g, 4.76 mmol) was dissolved in DCM (30 mL). iPr2EtN (2.9 mL, 
16.68 mmol), EDC.HCl (2.2 g, 12.02 mmol), HOBt (1.9 g, 14.07 mmol) and L-Leu-
methyl ester (1.10 g, 6.05 mmol) were added successively and the resulting solution 
was stirred at room temperature for 72 hrs. DCM (20 mL) and aq. 1M KHSO4 (20 mL) 
were added to the reaction mixture. The organic layer was separated, washed with sat. 
Na2CO3 (20 mL) and brine (20 mL) successively, and dried over MgSO4. In vacuo 
removal  of  solvents  and  purification  of  the  resulting  crude  product  by  column 
chromatography (SiO2, 1:50 MeOH/DCM) afforded 54 (1.30 g, 71%) as a white solid. 
MP = 68 
oC - 70 
oC; 
 1H NMR (400 MHz, CDCl3): ʴ (ppm) =  8.31 (1 H, d, J = 5.0 Hz, 
CHNH), 8.07( 1 H, d, J = 5.0 Hz, CH ), 7.82 (1 H, t, J = 5.0 Hz ,CH),  7.44 (1 H, d,  J 
= 5.0 Hz, CH), 5.32(1H, s, NHBoc), 4.82-4.86 (1 H, m, (CH3)2CHCH), 4.49 (2 H, d, J 
= 5.0 Hz, NHCH2 ), 3.77 (3 H, s, COOCH3 ), 1.70-1.80 (3 H, m, (CH3)2CHCH2CH + 
(CH3)2CHCH2CH), 1.46 (9 H, s, NHCOO(CH3 )3, 0.98 (3 H, d, J = 5.0 Hz, CH(CH3)2, 
0.96 (3 H, d, J = 5.0 Hz, CH(CH3)2; 
13C NMR (100 MHz, CDCl3): ʴ(ppm) = 173.6 
(Cq), 164.2 (Cq), 157.5 (Cq), 156.3 (Cq), 149.1 (Cq) , 138.4 (CH), 124.6(CH), 121.3 
(CH), 80.1 (Cq), 52.6  (CH), 51.1  (CH), 46.0 (CH2), 41.9 (CH2), 28.7 (CH3 ), 25.3 
(CH3 ), 23.2 (CH3 ), 22.2 (CH3); MSES: m/z = 402.2 [M+Na]
 +; HRMS (ES): Calcd 
for C19H29N3NaO5 402.2005 ([M+Na]
+), found 402.2004; FT-IR (solid): ν max cm
-1 = 
3018 (w), 1671(m), 1518 (m), 1214(s), 745(s). 
 
(R)-Methyl 2-(6-(aminomethyl)picolinamido)-4-methylpentanoate 
(54a) 
 
                                                 
Compound 54a (1.20 g, 3.16 mmol) was stirred in 20% v/v TFA/DCM (25 mL) at 
room temperature for 3h. In vacuo drying of the reaction mixture after the addition of 
toluene (3 x 3 mL) followed from precipitation by diethyl ether afforded the TFA salt 
of the target compound (1.20 g, quantitative yield) as a white solid compound. MP =  
102-104 
oC
 1H NMR (400 MHz, CDCl3): ʴ (ppm) = 8.96 (1 H, d, J = 5.0 Hz, CHNH), 
8.66 (1 H, s(b), NH2), 8.09( 1 H, d, J = 5.0 Hz, CH), 7.83 (1 H, t, J = 5.0 Hz, CH),  
7.35(1 H, d,  J = 5.0 Hz, CH), 4.83-4.88 (1 H, m, CHCH(COOMe)NH ), 3.76 (3 H, s, 
COOCH3), 3.49 (3 H, s, NHCH2), 1.90-1.94 (1 H, m, (CH3)2CHCH2CH ), 1.71-1.74 Experimental  
   
(2 H, m, CH3)2CHCH2CH), 0.91-0.96 (6 H, m, 2 x CH(CH3)2; 
13C NMR (100 MHz, 
CDCl3): ʴ(ppm) = 176.2 (Cq), 164.6 (Cq), 151.3 (Cq), 149.4 (Cq), 139.1 (CH), 125.4 
(CH), 123.0 (CH), 53.0 (CH), 51.6 (CH), 43.65 (CH2), 40.4 (CH2), 25.3 (CH3 ), 23.0 
(CH3 ), 21.6 (CH3).  
 
(R)-Methyl 2-(6-((3-(3-(benzylamino)-3-oxopropyl)-2-
((benzyloxy)carbonyl)guanidino)methyl)picolinamido)-4-methylpentanoate  
(55) 
 
 
Compound 54a (0.90 g, 3.20 mmol) was dissolved in DCM (50 mL). Et3N (1.40 mL, 
9.6 mmol) and EDC.HCl (1.5 g, 8.0 mmol) were added to the reaction mixture which 
was stirred until it formed a clear solution. Compound 42 (1.20 g, 3.20 mmol) was 
added and the reaction mixture was further stirred for 24 hrs at room temperature. In 
vacuo  removal  of  the  solvent  and  purification  of  the  resulting  crude  by  column 
chromatography (SiO2, 1:50 MeOH/DCM) afforded 55 (1.20 g, 61%) a white solid. 
MP = 60-62 ˚C; 
1H NMR (400 MHz, CDCl3): ʴ (ppm) = 10.29 (1 H, s, NH), 9.27 (1 H, 
s, NH), 9.12 (1 H, s, NH), 8.71 (1 H, s, NH), 8.12 (1 Η, s, CΗ), 7.83 (1 Η, s , CΗ), 
7.23-7.29 (11 Η, m, CΗ), 5.13 (2 Η, s, CΗ2), 4.86-4.88 (1 H, m, CH), 4.66 (2 Η, d, J = 
5.0 Hz, CΗ2), 4.36 (2 Η, s, CΗ2), 3.69 (5 Η, m, CΗ2 + CH3), 2.52 (2 Η, s, CΗ2), 1.73-
1.91 (3 H, m, (CH3)2CHCH2CH + (CH3)2CHCH2CH), 0.93-0.96 (6 H, m, CH(CH3)2; 
13C NMR (100 MHz, CDCl3): ʴ (ppm) = 173.5 (Cq), 172.1 (Cq), 164.0 (Cq), 148.8 
(Cq),138.4 (Cq), 137.9 (Cq), 129.1 (CH), 128.6 (CH), 127.9 (CH), 127.9 (CH), 127.6 
(CH), 127.5 (CH), 124.4 (Cq), 121.8 (Cq), 66.7 (CH2), 52.2 (CH3), 50.9 (CH), 45.6 
(CH2), 43.6 (CH2), 40.8 (CH2), 37.6 (CH2), 24.9 (CH), 23.0 (CH3), 21.7 (CH3); MSES: 
m/z = 617.4 [M+H]
+; HRMS (ES): Calcd for C33H40N6NaO6 617.3087, ([M+Na]
+), 
found 617.3076; FT-IR (solid): ν max cm
-1 = 3308 broad, 2955 (w), 2360 (m), 1745 
(m), 1635 (s), 1520 (s). 
 
 
 
 
 Experimental  
   
 
(R)-2-(6-((3-(3-(Benzylamino)-3-oxopropyl)-2-
((benzyloxy)carbonyl)guanidino)methyl)picolinamido)-4-methylpentanoic acid 
(56) 
 
 
Compound  55  (1.1  g,  1.8  mmol)  was  dissolved  in  THF  (40  mL)  and  added  to 
Me3SiOK  (0.35  g,  2.7  mmol)  suspended  in  THF  (30  mL)  under  nitrogen.  After 
overnight  stirring, DCM (30 mL)  and H2O (20 mL) were  added and the reaction 
mixture was cooled to 0 ˚C. Citric acid (0.1 M) was added dropwise until the pH was 
6-7. In vacuo drying of the organic phase and purification of the resulting crude by 
column chromatography (SiO2, 1:20 MeOH/DCM) afforded 56 (0.80 g, 74%) as a 
white solid. MP = 104-106 ˚C; 
1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 12.80 (1 H, 
s(b), COOH), 10.21 (1 H, s, NH), 9.04 (1 H, s(b), NH), 8.72 (1 Η, d, J = 5.0 Hz, CΗ), 
8.49 (1 H, s, NH), 7.96 (1 Η, s, NH), 7.55 (1 Η, d, J = 2.5 Hz, CΗ), 7.18-7.31 (11 Η, 
m, CΗ), 4.98 (2 Η, s, CΗ2), 4.61 (2 Η, d, J = 2.5 Hz, CΗ2), 4.53-4.55 (1 H, m, 
(CH3)2CHCH2CH), 4.27-4.28 (2 Η, d, J = 2.5 Hz, CΗ2), 3.53 (2 Η, d, J = 2.5 Hz, 
CΗ2), 2.46 (2 Η, s, CΗ2), 1.64-1.85 (3 H, m, (CH3)2CHCH2CH + (CH3)2CHCH2CH), 
0.85-0.98 (6 H, m, CH(CH3)2; 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 174.2 (Cq), 
171.0 (Cq), 163.9 (Cq), 160.1 (Cq), 139.9 (Cq), 138.2 (Cq), 128.7 (CH), 128.7 (CH), 
128.2 (CH), 128.0 (CH), 127.7 (CH), 127.2 (CH), 66.0 (CH2), 50.9 (CH), 45.5 (CH2), 
42.5 (CH2), 40.4 (CH2), 37.7 (CH2), 35.9 (CH2), 25.0 (CH), 23.3 (CH3), 21.8 (CH3); 
MSES:  m/z  =  603.3  [M+H]
  +;  HRMS  (ES):  Calcd  for  C32H38N6NaO6   603.2933,  
([M+Na]
+), found 603.2933; FT-IR (solid): ν max cm
-1 = 3246 (b), 1635 (m), 1593 (s), 
1386 (m). Experimental  
   
(R)-2-(6-((3-(3-(Benzylamino)-3-oxopropyl)guanidino)methyl)picolinamido)-4-
methylpentanoic acid  
(53) 
 
Compound 56 (0.2g, 0.33mmol) was dissolved in MeOH (30 mL). Pd/C (35 mg, 0.33 
mmol) was added and the reaction mixture was stirred for 5 hrs at room temperature 
under hydrogen (1 atm). The reaction mixture was filtered through celite and dried in 
vacou to give 53 (0.15 mg, 97%) as a white solid. MP = 204-206 ˚C; [ʱ]D 
25 =-2.4 
o (c 
0.2, MeOH); 
1H-NMR (400 MHz, MeOD-d4): ʴ(ppm): 7.99-7.91 (2 H, m, CH), 7.49 
(1 H, t, J = 7.52 Hz, CH), 7.26-7.17 (5 H, m, CH), 4.58 (2 H, s, PhCH2NHCO), 4.56 
(1 H, m, NHCHCOOH), 4.35 (2 H, s, CH2NHCNH), 3.56 (2 H, overlap with water 
peak, NHCH2CH2CO), 2.60 (2 H, t, J = 6.52 Hz, NHCH2CH2CO), 1.80-1.75 (1 H, m, 
(CH3)2CH), 1.74-1.66 (2 H, m, (CH3)2CHCH2), 0.96 (6 H, m, 6.0 Hz, CH(CH3)2).
13C-
NMR (100 MHz, MeOD-d4): ʴ(ppm) = 176.7 (Cq), 170.7 (Cq), 162.8 (Cq), 157.3 
(Cq), 156.2 (Cq), 150.1 (Cq),  139.8 (CH), 138.7 (Cq), 128.7 (CH), 127.6 (CH), 127.1 
(CH), 124.10 (CH),  120.6 (CH), 53.4 (CH), 45.7 (CH2), 43.2 (CH2), 42.8 (CH2), 38.3 
(CH2), 34.5 (CH2), 24.7 (CH), 22.8 (CH3), 22.7 (CH3); MSES: m/z = 469.4  [M + H]
+;  
HRMS (ES
+): Calcd for [M + H]
+ C24H33N6O4 469.2563; found: 469.2562. FT-IR 
(solid): ν max cm
-1 = 3232 (b), 1651 (s), 1538 (s), 1392 (s). 
 
(R)-Methyl 2-(4-(2-((tert-butoxycarbonyl)amino)-4-
methylpentanamido)phenyl)acetate  
(62) 
 
 
 
 Experimental  
   
Compound 61 (1.3 g, 7.88 mmol) was dissolved in DCM (50 mL). iPr2NEt (2.4 mL, 
13.80 mmol), EDC.HCl (1.88 g, 9.82 mmol), HOBt (1.60 g, 11.85 mmol) and Boc-
Leu-OH (0.90 g, 3.92 mmol) previously dissolved in DCM (25 mL) and DMF (1 mL), 
were added successively and the resulting solution was stirred at room temperature for 
72 hrs. DCM (40 mL) and aq. 1M KHSO4 (30 mL) were added to the reaction mixture. 
The organic layer was separated, washed with sat. Na2CO3 (30 mL) and brine (30 mL) 
successively, and dried over MgSO4. In vacuo drying and purification of the resulting 
crude by column chromatography (SiO2, 1:100 MeOH/DCM) afforded 62 (1.20 g, 
72%) as an orange solid. MP = 46-50 ˚C; 
1H NMR (300 MHz, DMSO-d6): ʴ (ppm) = 
9.91 (1 H, s, NH), 7.53 (2 Η, d, J = 9.6  Ηz, CH), 7.18 (2 Η, d, J = 9.6  Ηz, CH), 6.70 
(1 Η, d, J = 8.7 Hz, NH), 4.15 (1 H, m, CH(CH3)2), 3.59-3.61 (5 H, m, CH2 + CH3), 
1.69 (1 H, m, CH2CH), 1.37 (9 Η, s, C(CΗ3)3, 0.95-0.98 (6 Η, m, CH(CH3)2); 
13C 
NMR (100 MHz, DMSO-d6): ʴ (ppm) = 171.7 (Cq), 137.9 (Cq),  129.6 (Cq), 129.1 
(Cq), 119.3 (CH), 78.0 (Cq), 51.6 (CH), 40.6 (CH2), 39.5 (CH2), 28.2 (CH3), 28.1 
(CH3), 24.3 (CH3), 22.9 (CH3), 21.6 (CH); MSES: m/z = 401.20 [M+Na]
+, 779.5 
[2M+Na]
+;  HRMS  (ES):  Calcd  for  C20H30N2NaO5    401.2053  ([M+Na]
+),  found 
401.2046; FT-IR (solid): ν max cm
-1 =  3294 (w), 2956 (w), 1738 (s), 1662 (s), 1158 (s).  
 
Compound 63 
 
 
 
 
Compound  62  (1.6  g,  0.15  mmol)  was  dissolved  in  DCM  (10  mL).  20%  (v/v) 
TFA/DCM (5 mL) was added and the resulting solution was stirred for 5 hrs at room 
temperature. In vacuo drying of the reaction mixture after the addition of toluene (3 x 
2 mL) afforded 63 (1.6 g, 100%) as a yellowish oily compound which was used for 
the next step with no further purification. 
 
(R)-Methyl 2-(4-(2-(4-(((tert-butoxycarbonyl)amino)methyl)benzamido)-4-
methylpentanamido)phenyl)acetate  Experimental  
   
(64a) 
 
 
 
 
 
4-(tert-Butoxycarbonylamino-methyl)-benzoic  acid  (0.80  g,  3.19  mmol)  was 
dissolved in DCM (50 mL). iPr2NEt (1.6 mL, 9.61 mmol), EDC.HCl (1.48 g, 7.97 
mmol), HOBt (1.3 g, 9.6 mmol) and 63 (1.21 g, 3.22 mmol) were added successively 
and the resulting solution was stirred at room temperature for 48 hrs. DCM (40 mL) 
and aq 1M KHSO4 (20 mL) were added to the reaction mixture. The organic layer 
was separated, washed with sat. Na2CO3 (20 mL) and brine (20 mL) successively, and 
dried over MgSO4. In vacuo drying and purification of the resulting crude by column 
chromatography (SiO2, 0.5:100 MeOH/DCM) afforded 64a (1.60 g, 94%) as a white 
solid. MP = 68-70 
oC; 
1H NMR (300 MHz, DMSO-d6): ʴ (ppm) = 8.94 (1 H, s, NH), 
7.73 (2 Η, d, J = 5.0  Ηz, CH), 7.47 (2 Η, d, J = 5.0  Ηz, CH), 7.28 (2 Η, d, J = 5.0 Ηz, 
CH), 7.16 (2 Η, d, J = 5.0 Ηz, CH), 6.91 (1 Η, d, J = 5.0 Hz, NH), 5.06 (1 Η, s, NH), 
4.85-4.91 (1 H, m, CH2CHNH), 4.32 (2 H, d, J = 2.5 Ηz, CH2NHBoc), 3.65 (3 H, s, 
CΗ3COO),  3.54  (2  H,  s,  CH2COOMe),  1.70-1.88  (3  H,  m,  (CH3)2CHCH2CH  + 
(CH3)2CHCH2CH), 1.44 (9 Η, s, C(CH3)3), 0.98-1.01 (6 Η, m, (CH3)2CH);
 13C NMR 
(100 MHz, DMSO-d6): ʴ (ppm) = 173.30 (Cq), 171.8 (Cq), 169.0 (Cq), 157.2 (Cq), 
144.6 (Cq), 138.2 (Cq), 133.6 (Cq), 131.1 (Cq), 131.40 (CH), 128.8 (CH), 128.6 (CH), 
122.4 (CH), 81.03 (Cq),  54.4 (CH), 53.3 (CH3), 45.5 (CH2), 41.1 (CH2), 41.0 (CH2), 
28.8 (CH3), 25.4 (CH3), 23.3 (CH3), 22.7 (CH); MSES: m/z = 534.3 [M+Na]
+, 1045.8 
[2M+Na]
+; HRMS (ES): Calcd for C28H38N3O6 534.2580 ([M+H]
+), found 534.2570; 
FT-IR (solid): ν max cm
-1 = 3296(b), 1642 (s), 1522 (m), 1388 (s). 
 
(R)-(4-((1-((4-(2-Methoxy-2-oxoethyl)phenyl)amino)-4-methyl-1-oxopentan-2-
yl)carbamoyl)phenyl)methanaminium  
(64) 
 Experimental  
   
 
 
 
 
64a (1.60 g, 3.13 mmol) was dissolved in DCM (10 mL). 20% (v/v) TFA/DCM (10 
mL) was added and the resulting solution was stirred for 5 hrs at room temperature. In 
vacuo drying of the reaction mixture after the addition of toluene (3 x 3 mL) afforded 
64 (1.60, 100%) as a yellowish oily compound; 
1H NMR (300 MHz, DMSO-d6): ʴ 
(ppm) =  10.14 (1 H, s, NH), 8.63 (1 H, d, J = 5.0 Ηz, CHNHCO), 8.30 (2 H, s(b), 
NH2), 7.96 (2 Η, d, J = 5.0 Ηz, 2 x CH), 7.53-7.57 (4 Η, m, 4 x CH), 7.19 (2 H, d, J = 
5.0 Ηz, 2 x CH), 4.63-4.69 (1 H, m, CH2CHNH),   4.11 (2 H, s, CH2COOMe), 3.60-
3.61 (5 H, s, CH2NH2 + CH3COO), 1.72-1.82 (2 H, m, (CH3)2CHCH2CH) ), 1.59-1.72 
(1 Η, m, (CH3)2CHCH2), 0.91-0.96 (6 Η, m, C(CH3)2); 
13C NMR (100 MHz, DMSO-
d6): ʴ (ppm) = 172.2 (Cq), 171.8 (Cq), 166.4 (Cq), 137.6 (Cq), 132.5 (Cq), 129.0 
(CH), 129.0 (CH), 128.3 (CH), 119.8 (CH), 53.2 (CH), 52.1 (CH), 42.4 (CH2), 40.6 
(CH2), 39.3 (CH2), 23.8 (CH3), 23.5(CH3), 21.1 (CH); MSES: m/z = 412.5 [M+H]
+; 
HRMS  (ES):  Calcd  for  C23H30N3O4  412.2238  ([M+H]
+),  found  412.2226;  FT-IR 
(solid): ν max cm
-1 =  3041 (w), 1779 (w), 1658 (m), 1144 (s). 
 
(S)-Methyl 2-(4-(2-(4-((6-((3-(3-(benzylamino)-3-oxopropyl)-2-
((benzyloxy)carbonyl)guanidino)methyl)picolinamido)methyl)benzamido)-4-
methylpentanamido)phenyl)acetate  
(65) 
 
 Experimental  
   
 
 
 
Compound 59 (0.52 g, 1.06 mmol) was dissolved in DCM (50 mL). iPr2NEt (0.6 mL, 
3.71 mmol), EDC.HCl (0.48 g, 2.65 mmol), HOBt (0.43 g, 3.18 mmol) and 64 (0.48 g, 
1.20 mmol) were added successively and the resulting solution was stirred at room 
temperature for 48 hrs. DCM (30 mL) and aq. 1M KHSO4 (20 mL) were added to the 
reaction mixture. The organic layer was separated, washed with sat. aq. Na2CO3 (20 
mL) and brine (20 mL), and dried over MgSO4. In vacuo removal of the solvent and 
purification of the resulting crude product by column chromatography (SiO2, 1:50 
MeOH/DCM) afforded 65 (0.80 g, 75%) as a white solid. MP =128-130 ˚C;
1H NMR 
(300 MHz, DMSO-d6): ʴ (ppm) = 10.08 (1 H, s, NH), 9.37 (1 H, apparent triplet, NH), 
8.49 (2 H,d, J = 5.0 Hz, CH), 7.97 (2 Η, s, 2 x NH), 7.86 (2 H, d, J = 7.5 Hz, CH), 
7.55-7.57 (3 H, m, 3 x CH), 7.40 (2 H, d, J = 7.5 Hz, CH), 7.29-7.17 (12 H, m, CH), 
4.89 (2 H, s, CH2), 4.64-4.67 (1 H, m, (CH3)2CHCH2CH)), 4.58 (4 H, m, 2 x CH2), 
4.26 (2 H, d, J = 2.5 Hz, CH2), 3.61 (2 H, s, CH2), 3.60 (3 H, s, COOCH3), 3.51 (2 H, 
m, CH2), 2.12 (2 H, s, CH2), 1.70-1.81 (2 H, m, (CH3)2CHCH2CH),  1.55-1.60 (1 H, 
m, (CH3)2CHCH2CH), 0.90-0.94 (6 Η, m, (CH3)2CH);
13C NMR (100 MHz, DMSO-
d6): ʴ (ppm) = 171.9 (Cq), 171.5 (Cq), 170.7 (Cq), 166.4 (Cq), 143.0 (Cq), 138.0 (Cq), 
132.8 (Cq), 129.8 (CH), 128.4 (CH), 127.9 (CH), 127.4 (CH), 127.1 (CH), 126.9 
(CH), 119.5 (CH), 65.6 (CH2), 52.9 (CH), 51.8 (CH), 42.4 (CH2), 42.3 (CH2, 40.6 
(CH2), 37.4 (CH2), 35.7 (CH2), 24.7 (CH3), 23.2 (CH3), 21.7 (CH3); MSES: m/z = 
884.30 [M+H]
+; HRMS (ES): Calcd for C49H54N8NaO8 905.3963  ([M+Na]
+), found 
905.3941; FT-IR (solid): ν max cm
-1 = 3289 (w), 1734 (w), 1632 (s), 1558 (m), 1312 
(s). 
 Experimental  
   
(S)-2-(4-(2-(4-((6-((3-(3-(Benzylamino)-3-oxopropyl)-2-
((benzyloxy)carbonyl)guanidino)methyl)picolinamido)methyl)benzamido)-4-
methylpentanamido)phenyl)acetic acid 
(66) 
 
 
 
 
 
 
Compound  65  (0.6  g,  0.7  mmol)  was  dissolved  in  THF  (25  mL)  and  added  to 
Me3SiOK (0.35 g, 2.7 mmol) suspended in THF (25 mL) under an inert atmosphere. 
The reaction mixture was stirred overnight at room temperature. DCM (50 mL) and 
H2O (50 mL) were added and the reaction mixture was cooled to 0 ˚C. Citric acid (0.1 
M aqeous) was added dropwise until the pH is 6-7 and further stirred for 1hr. In vacuo 
drying  of  the  organic  phase  and  purification  of  the  resulting  crude  by  column 
chromatography (SiO2, 1:50 - 1:20  MeOH/DCM) afforded 66 (0.31 g, 60%) as a 
white solid. MP = 158 -160 ˚C;  
1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 10.06 (1 
H, s, NH), 9.37 (1 H, t, J = 2.5 Hz, NH), 8.49 (2 H, d, J = 5.0 Hz, CH), 7.96 (2 Η, s, 
NH), 7.85 (2 H, d,  J = 5.0 Hz, CH), 7.53-7.56 (3 H, m, CH), 7.39 (2 H, d, J = 5.0 Hz, 
CH), 7.17-7.31 (12 H, m, CH), 4.88 (2 H, s, CH2), 4.68-4.58 (5 H, m, 2 x CH2 + CH), 
4.25 (2 H, d, J = 5.0 Hz, CH2), 3.49 (4 H, m, 2 x CH2), 3.20 (2 H, overlap with water 
peak,CH2), 1.74 (2 H, m, (CH3)2CHCH2CH), 1.57 (1 H, m, (CH3)2CH), 0.90-0.94 (6 
Η, m, (CH3)2CH); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 172.8 (Cq), 171.4 (Cq), 
170.6 (Cq), 166.3 (Cq), 163.1 (Cq), 142.8 (Cq), 137.8 (Cq), 137.6 (Cq), 132.7 (Cq), 
129.9 (CH), 129.6 (CH), 128.2 (CH), 127.7 (CH), 127.2 (CH), 127.0 (CH), 126.7 
(CH), 119.3 (CH), 74.5 (CH), 65.9 (CH2), 53.5 (CH), 45.6 (CH2), 42.2 (CH2 ), 42.1 
(CH2), 40.9 (CH2), 40.6 (CH2), 37.3 (CH2), 24.6 (CH3), 23.0 (CH3), 21.5 (CH); MSES: Experimental  
   
m/z = 870.8 [M+H]
+, 891.5 [M+Na]
+; HRMS (ES): Calcd for C48H53N8O8   869.3986  
([M+H]
+), found 869.3959; FT-IR (solid): ν max cm
-1 = 3273 (w), 1630 (w), 1508 (m).  
 
(S)-2-(4-(2-(4-((6-((3-(3-(Benzylamino)-3- 
oxopropyl)guanidino)methyl)picolinamido)methyl)benzamido)-4-
methylpentanamido)phenyl)acetic acid  
(57) 
 
 
 
 
 
Compound 66 (100 mg, 0.12 mmol) was dissolved in MeOH (30 mL). Pd/C (30 mg, 
0.12 mmol) was added and the reaction mixture was stirred for 4 hrs under hydrogen 
(1 atm) at room temperature. The reaction mixture was filtered through celite and 
dried in vacuo. Purification of the resulting solid by precipitation from Et2O/MeOH 
afforded 57 (70 mg, 90%) as a white solid. MP > 250 ˚C; [ʱ]D 
25 =-5.4 
o (c 0.2, MeOH);
 
1H NMR (300 MHz, DMSO-d6): ʴ (ppm) = 10.09 (1 H, s, NH), 9.89 (1 H, broad, NH), 
8.86 (1 H, broad, NH), 8.57 (2 Η, s, NH), 7.96-8.03 (3 H, m, CH), 7.87 (2 H, d, J = 
5.0 Hz, CH), 7.51 (3 H, t, J = 5.0 Hz, CH), 7.42 (2 H, d, J = 5.0 Hz, CH), 7.17-7.29 (4 
H, m, CH), 7.14 (2 H, d, J = 5.0 Hz, CH), 4.56-4.68 (5 H, m, 2 x CH2 + CH), 4.26 (2 
H, d, J = 5.0 Hz, CH2), 3.42 (4 H,overlap with water peak, 2 x CH2), 2.46 (2 H, t, J = 
5.0 Ηz, CH2), 1.68-1.74 (2 H, m, (CH3)2CHCH2CH), 1.58 (1 H, m, CH3)2CHCH2), 
0.95-0.99 (6 Η, m, (CH3)2CH);
 13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 171.2 
(Cq), 170.1 (Cq), 166.2 (Cq), 163.7 (Cq), 156.3 (Cq), 154.5 (Cq), 149.2 (Cq), 143.0 
(Cq), 139.2 (Cq), 139.1 (Cq), 138.6 (CH), 132.5 (Cq), 129.4 (CH), 128.2 (CH), 127.2 
(CH), 127.1 (CH), 126.7 (CH), 124.2 (CH), 120.8 (CH), 119.1 (CH), 52.8 (CH), 45.3 
(CH2), 42.1 (CH2), 41.5 (CH2),  40.8 (CH2), 37.6 (CH2), 34.7 (CH2), 24.6 (CH3), 23.0 
(CH3), 21.5 (CH); (CH and Cq missing)  MSES: m/z = 735.8 [M+H]
+, 757.6 [M+Na]
+; Experimental  
   
HRMS  (ES):  Calcd  for  C40H47N8O6 735.3618    ([M+H]
+),  found  735.3603;  FT-IR 
(solid): ν max cm
-1 = 3274 (m) (broad), 1636 (s), 1539 (s).  
 
2-(2-(2-(2-Hydroxyethoxy)ethoxy)ethoxy)ethyl methanesulfonate  
(69) 
 
 
 
 
68 (15.50 g, 80.00 mmol) was dissolved in THF (125 mL) under nitrogen. Et3N (11.2 
mL, 80.00 mmol) was added and the reaction mixture was cooled down to 0 °C. 
Mesyl chloride (6.2 mL, 80.00 mmol) was added dropwise to the reaction mixture 
over a period of 10 mins. The reaction mixture was stirred at 0 °C for 2 hrs and then 
warmed to room temperature and left overnight. The resulting precipitate was filtered 
and washed with ethyl acetate. In vacuo concentration of the filtrate  and purification 
of the resulting crude product  by column chromatography (SiO2, 4:1 EA:Hexane - 
EA) afforded 69 (7.0 g, 50%) as a clear oil. 
1H NMR (300 MHz, CDCl3): ʴ (ppm) = 
4.39 - 4.36 (2 Η, m, CΗ2), 3.78-3.58 (14 Η, m, CΗ2), 3.07 (3 Η, s, CΗ3), 2.50 (2 Η, s, 
OH); 
13C NMR (100 MHz, CDCl3): ʴ (ppm) = 72.3 (CH2), 71.1 (CH2), 71.1 (CH2), 
71.0 (CH2), 71.0 (CH2), 70.9 (CH2), 70.4 (CH2), 59.4 (CH3), 51.1 (CH2); MSES: m/z 
= 295.1 [M+Na]
+; FT-IR (liquid): ν  max cm
-1 = 3440 (w) (br), 2872 (m), 1346 (s), 
1171 (s), 1103 (s). 
 
2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethanol 
(70) 
 
 
 
Compound 69 (7.0 g, 25.74) was dissolved in acetonitrile (50 mL) and stirred under 
nitrogen. NaN3 (2.5 g, 38.17 mmol) was added and the reaction mixture was further 
stirred  under  reflux  for  48  hrs.  Water  (60  mL)  was  added  and  the  solution  was 
extracted with DCM (3 x 100 mL) after the reaction mixture was cooled to room 
temperature. The organic extracts were combined and dried over MgSO4.  In vacuo 
concentration of the organic extracts and purification of the resulting crude product by 
column chromatography (SiO2, EA) afforded 70 (5.50 g, 82%) as a clear oil. 
1H NMR 
(300 MHz, CDCl3): ʴ (ppm) = 3.70-3.67 (2 Η, m, CΗ2), 3.65-3.62 (8 Η, m, 4 x CΗ2), 
3.58-3.56 (2 Η, m, CΗ2), 3.64-3.66 (2 Η, m, CΗ2), 3.69-3.72 (2 Η, m, CΗ2), 2.47 (1 Η, Experimental  
   
s, OH); 
13C NMR (100 MHz, CDCl3): ʴ (ppm) =  72.9 (CH2), 71.1 (CH2), 71.1 (CH2), 
71.0 (CH2), 70.7 (CH2), 70.4 (CH2), 62.1 (CH2), 51.1 (CH2); MSES: m/z = 242.2 
[M+Na]
+; FT-IR (liquid): ν max cm
-1 = 3436 (w) (br), 2868 (m), 2098 (s), 1101 (s). 
 
13-Azido-2,5,8,11-tetraoxatridecane  
(71) 
 
 
 
Sodium hydride (1.98 g, 49.6 mmol) was suspended in DMF (20 mL) and stirred for 
15 mins under nitrogen. Compound 70 (5.5 g, 25.11 mmol) dissolved in DMF (10 mL) 
was added to the solution of sodium hydride. Methyl iodide (3.1 mL, 49.60 mmol) 
was added dropwise to the reaction mixture over a period of 5 mins. The reaction 
vessel was wrapped in aluminium foil and was stirred at room temperature overnight. 
Water (150 mL) was added, extracted with DCM (4 x 200 mL) and the organic phase 
was washed with brine (100 mL). The organic extract was combined and dried over 
MgSO4.  In vacuo concentration and purification of the resulting crude product by 
column chromatography (SiO2, EA) afforded 71 (4.53 g, 85%) as clear oil, 
1H NMR 
(300 MHz, CDCl3): ʴ (ppm) = 3.72-3.66 (10 Η, m, CΗ2), 3.59-3.57 (2 Η, m, CΗ2), 
3.58-3.56  (2  Η,  m,  CΗ2),  3.43-3.41  (5  Η,  m,  CH3 +  CΗ2);
  13C  NMR  (100  MHz, 
CDCl3): ʴ (ppm) = 72.3 (CH2), 71.1 (CH2), 71.1 (CH2), 71.0 (CH2), 71.0 (CH2), 70.9 
(CH2), 70.4 (CH2), 59.4 (CH3), 51.1 (CH2); MSES: m/z = 256.2 [M+Na]
+; FT-IR 
(liquid): ν max cm
-1 =  2869  (m), 2098 (s), 1100 (s), 1103 (s).  
 
2,5,8,11-Tetraoxatridecan-13-amine  
(72) 
 
 
 
 
To a stirred solution of 71 (1.0 g, 4.29 mmol) in MeOH, was added Et3N (3 mL, 21.50 
mmol). This was followed by 1, 3 - propane dithiol (2.15 mL, 21.50 mmol). The 
mixture was stirred at room temperature for three days. The residue was concentrated 
in vacuo and diluted with water (50 mL). The mixture was washed with diethyl ether 
(50 mL) to remove excess reducing agent. In vacuo concentration of the organic layer 
afforded 72 (1.0 g, 100%) as a yellowish liquid, 
1H NMR (300 MHz, CDCl3): ʴ (ppm) 
= 6.06 (2 Η, s(broad), NΗ2), 3.69-3.63 (12 Η, m, CΗ2), 3.57-3.55 (2 Η, m, CΗ2), 3.38 Experimental  
   
(3 Η, s, CH3), 3.06-3.03 (2 Η, m, CΗ2); 
13C NMR (100 MHz, CDCl3): ʴ (ppm) = 73.0 
(CH2), 71.5 (CH2), 71.5 (CH2), 71.3 (CH2), 70.1 (CH2), 60.1 (CH3), 54.6 (CH2), 41.0 
(CH2), 24.8 (CH2); MSES: m/z = 208.20 [M+H]
+; HRMS (ES): Calcd for C9H22NO4 
208.1551 ([M+H]
+), found 208.1544; FT-IR (liquid): ν max cm
-1 = 3368 (w), 2872 (m), 
2868 (m), 1097 (s).  
 
3-(1,3-Dioxoisoindolin-2-yl)-N-(2,5,8,11-tetraoxatridecan-13-yl)propanamide  
(73) 
 
 
Compound  40  (1.10  g,  4.6  mmol)  was  dissolved  in  DCM  (30  mL)  and  added 
dropwise to a solution of 72 (0.95 g, 4.61 mmol) and Et3N (1.3 mL) in DCM (20 mL) 
at 0 °C. The reaction mixture was stirred overnight at room temperature and poured 
into ice cold 2M HCl (30 mL) and extracted with DCM (3 x 50 mL). The organic 
phases were combined, washed with brine and dried over MgSO4. In vacuo removal 
of the solvents afforded compound 73 (1.0 g, 52%) as a white solid. MP = 68-70 °C; 
1H NMR (300 MHz, CDCl3) ʴ (ppm): 7.82-7.84 (2 H, m, CH), 7.69-7.72 (2 H, m, 
CH), 6.65 (1 Η, s(broad), NΗ), 4.01 (2 H, t, J = 2.5 Hz, CH2), 3.61-3.64 (8 Η, m, 4 x 
CΗ2), 3.57-3.59 (4 Η, m, 2 x CΗ2), 3.51-3.54 (4 Η, m, 2 x CΗ2), 3.40-3.44 (2 Η, m, 
CΗ2) 3.34 (3 Η, s, CH3); 
13C NMR (100 MHz, CDCl3): ʴ (ppm) = 171.7 (Cq), 169.9 
(Cq), 135.7 (CH), 134.0 (Cq), 125.1 (CH ), 73.7 (CH2), 72.3 (CH2), 72.2 (CH2), 72.0 
(CH2), 71.6 (CH2), 60.8 (CH3), 41.7 (CH2), 36.5 (CH2), 36.3 (CH2); HRMS (ES): 
Calcd  for  C20H29N2O7    409.1975  ([M+H]
+),  C20H28N2NaO7    431.1795  ([M+Na]
+), 
found 409.1963, 431.1779; FT-IR (solid): ν max cm
-1 = 3349 (m), 1759 (m), 1682 (m), 
1518 (m), 1365 (m), 1155 (s). 
 
Compound 74 
 
 
 Experimental  
   
Compound 76 (0.60 g, 2.20 mmol) was suspended in EtOH (20 mL) and hydrazine 
hydrate (120 μL) was added and the reaction mixture was refluxed for 8 hours. The 
solution was cooled to 0 
oC and stirred overnight. The reaction mixture was filtered 
off and the filtrate was dried in vacuo to give a yellowish solid residue. The resulting 
crude was dissolved in DCM and cooled to 0 
oC. Et3N (0.73 mL) and CbzNCS (0.40 g, 
2.20 mmol) were added slowly and the reaction mixture was stirred for 30 mins at 
0 °C and then overnight at room temperature. In vacuo drying of the reaction mixture 
and purification of the resulting crude product by column chromatography (SiO2, 1:50  
MeOH/DCM) afforded 74 (0.5 g, 50%) as a white gummy  solid. 
1H NMR (400 MHz, 
CDCl3) ʴ (ppm): 11.30 (1H, s, NH), 10.10 (1H, t, J = 2.5 Hz,  NH), 7.40-7.46 (5 H, m, 
CH), 5.23 (2 Η, s, CΗ2), 3.79-3.84 (2 Η, m, CΗ2), 3.55-3.58 (10 Η, m, 5 x CΗ2), 3.45-
3.47 (4 Η, m, 2 x CΗ2), 3.25-3.28 (5 Η, m, CΗ2 + CΗ3) 2.50 (2 Η, t, J = 5 Hz, 
CH2);
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 179.6 (Cq), 170.9 (Cq), 153.6 (Cq), 
136.1 (Cq), 128.9 (CH), 128.7 (CH), 128.3 (CH), 71.7 (CH2), 70.3 (CH2), 70.2 (CH2), 
70.0 (CH2), 69.5 (CH2), 67.1 (CH2), 58.5 (CH2), 55.4 (CH3), 39.0 (CH2), 33.8 (CH2); 
HRMS (ES): Calcd for C21H33N3NaO7S  494.1937 ([M+Na]
+), found 494.1928; FT-IR 
(solid): ν max cm
-1 = 3271 (m), 1713 (s), 1628 (m), 1378 (m), 1088 (m), 718 (s).  
 
Compound 75 
 
 
 
 
 
Compound 35 (0.50 g, 1.42 mmol) was dissolved in DCM (30 mL). iPr2EtN (0.86 mL, 
5.00 mmol), EDC.HCl (0.65 g, 3.39 mmol), HOBt (0.58 g, 4.29 mmol) and 4-amino 
methyl benzoic acid benzyl ester (0.40 g, 1.70 mmol) were added successively and the 
resulting solution was stirred at room temperature for 48 hours. DCM (20 mL) and aq. 
1M  KHSO4  (15  mL)  were  added  to  the  reaction  mixture.  The  organic  layer  was 
separated,  washed  with  sat.  Na2CO3  (15  mL)  and  brine  (15  mL),  and  dried  over 
MgSO4.  In  vacuo  removal  of  the  solvent  and  purification  of  the  resulting  crude Experimental  
   
product  by column chromatography (SiO2, 1:50 MeOH/DCM) afforded 75 (0.51g, 
65%) as a white gummy solid;  
1H NMR (400 MHz, CDCl3): ʴ (ppm) = 8.41 (2 H, 
apparent triplet, NH), 8.13 (1 H, d, J = 5.0 Hz, CH), 8.05-8.07 (2 H, m, CH), 7.85 (1 
H, t, J = 5.0 Hz, CH), 7.37-7.45 (8 H, m, CH),  5.37 (2 Η, s, COOCΗ2Ar), 4.74 (2Η, d, 
J = 2.5 Hz, NHCΗ2), 1.67 (2 Η, s, CΗ2NBoc2), 1.43-1.46 (18 Η, m, C(CΗ3)3); 
13C 
NMR (100 MHz, CDCl3): ʴ (ppm) = 166.6 (Cq), 164.6 (Cq), 157.5 (Cq), 156.4 (Cq), 
149.4 (Cq), 144.1 (Cq), 138.8 (CH), 136.5 (Cq), 130.5 (CH), 129.7 (CH), 129.0 (CH), 
128.5 (CH), 128.0 (CH), 124.8 (CH), 121.6 (CH), 80.3 (Cq), 67.1 (CH2), 46.1 (CH2), 
43.5 (CH2), 28.8 (CH3), 28.6 (CH3); MSES: m/z = 498.3 [M+Na]
+; FT-IR (solid): ν 
max cm
-1 = 3379 (w), 2978 (w), 1716 (s), 1630 (s), 1094 (s). 
 
Compound 76 
 
 
 
Compound  75  (0.6  g,  1  mmol)  was  dissolved  in  DCM  (20  mL).  20  %(  V/V) 
TFA/DCM (10 mL) was added and the resulting solution was stirred for 5 hrs at room 
temperature. In vacuo drying of the reaction mixture after the addition of toluene (3 x 
2 mL) afforded 76 (0.6 g, quantitative yield) as a yellowish oily compound and was 
used for the next step with no further purification. 
 
Benzyl 4-((6-(3-(((benzyloxy)carbonyl)imino)-7-oxo-11,14,17,20-tetraoxa-2,4,8-
triazahenicosyl)picolinamido)methyl)benzoate  
(77) 
 Experimental  
   
 
 
Compound 76 (0.40 g, 0.85 mmol) was dissolved in DCM (30 mL) and cooled to 0 
oC. 
Et3N (0.40 mL), EDC.HCl (0.40 g, 2.25 mmol) and 74 (0.40 g, 0.85 mmol) were 
added successively and the reaction mixture was stirred for 30 mins at 0 
oC and then 
overnight at room temperature. In vacuo removal of the solvent and purification of the 
resulting  crude  product  by  column  chromatography  (SiO2,  3:100    MeOH/DCM) 
afforded 77 (0.40 g, 60%) as a white solid. MP = 74-76 
oC; 
1H NMR (300 MHz, 
CDCl3): ʴ (ppm) = 10.39 (1 Η, s, ΝΗ), 9.75 (1 Η, s, ΝΗ), 9.75 (1 Η, s, ΝΗ), 9.07 (1 Η, 
s, ΝΗ), 8.06 (1 Η, d, J = 6.8 Ηz, CΗ), 7.90 (1 Η, d, J = 6.8 Ηz, CΗ), 7.76 (1 Η, s, CΗ), 
7.35-7.16 (14 Η, m, CΗ2), 5.01-4.87 (2 Η, m, CΗ2), 4.63-4.44 (4 Η, m, CΗ2), 3.52-
3.12 (23 Η, m, 10 x CΗ2 + CΗ3), 2.33-2.23 (2 Η, m, CΗ2); 
13C NMR (100 MHz, 
CDCl3): ʴ (ppm) = 165.2 (Cq), 137.6 (CH), 135.1 (CH), 128.9 (CH), 127.9 (CH), 
127.6 (CH), 127.3 (CH), 127.1 (CH), 126.6 (CH), 126.4 (CH), 70.8 (CH2), 69.5 (CH2), 
69.3 (CH2), 69.2 (CH2), 68.7 (CH2), 68.4 (CH2),  65.6 (CH2), 65.5 (CH2),  57.9 (CH3), 
44.6  (CH2),  42.06  (CH2),  38.3  (CH2),  36.3  (CH2);  MSES:  m/z  =  813.5  [M+H]
+; 
HRMS (ES): Calcd for C43H52N6NaO10  813.3823, ([M+Na]
+), found 813.3806; FT-IR 
(solid): ν max cm
-1 =   2914m, 1714s, 1611s, 1523s, 1405s, 1119s. 
 
4-((6-(3-Imino-7-oxo-11,14,17,20-tetraoxa-2,4,8-
triazahenicosyl)picolinamido)methyl)benzoic acid  
(67) 
 
 
 Experimental  
   
Compound 77 (0.3g, 0.37 mmol) was dissolved in MeOH (30 mL). Pd/C (40 mg, 0.40 
mmol) was added and the reaction mixture was stirred for 4 hrs at room temperature 
under hydrogen (1 atm). The reaction mixture was filtered through celite and dried in 
vacuo. Purification of the resulting solid by precipitation from MeOH using Et2O 
afforded 67 (0.20 g, 90%) as a white solid. MP = 102-105 
oC; 
1H NMR (400 MHz, 
DMSO-d6): ʴ (ppm) = 9.69 (1 Η, s, ΝΗ), 8.19 (1 Η, s, ΝΗ), 8.01-7.94 (2 Η, m, CΗ), 
7.53-7.48 (3 Η, m, CΗ),  6.78 (2 Η, m, CΗ), 4.61 (2 Η, s, CΗ2), 4.37 (2 Η, d, J = 3.2 
Hz, CΗ2), 3.48-3.21 (21 Η, overlapped with water peak, 9 x CΗ2 + CH3), 2.40 ( 2 Η, t, 
J = 4.4 Hz, CΗ2); 
13C NMR (100 MHz, CDCl3): ʴ (ppm) = 171.7 (Cq), 170.2 (Cq),  
164.0 (Cq), 156.7 (Cq), 155.0 (Cq), 149.1 (Cq), 139.7 (CH), 138.2 (CH), 128.5 (CH), 
125.0 (CH),  124.2 (Cq), 120.3 (CH), 70.9 (CH2), 69.4 (CH2), 69.3 (CH2), 69.2 (CH2), 
68.6 (CH2), 57.6 (CH3), 44.9 (CH2), 41.9 (CH2), 38.2 (CH2), 37.3 (CH2), 34.5 (CH2) 
(2 x CH2 peaks are overlapped with  DMSO peak);  MSES: m/z = 589.4 [M+H]
+; 
HRMS (ES): Calcd for C28H40N6NaO8 589.2986 ([M+Na]
+), found  589.2970; FT-IR 
(solid): ν max cm
-1 = 3290 (w)(b), 2874 (m), 1644 (s), 1591 (s), 1527 (s), 1375 (s), 
1089 (s). 
 
(S)-Methyl 2-(4-(2-(4-((6-(((tert-
butoxycarbonyl)amino)methyl)picolinamido)methyl)benzamido)-4-
methylpentanamido)phenyl)acetate  
(79) 
 
 
 
Compound 36 (1.10 g, 2.67 mmol) was dissolved in DCM (40 mL). iPr2EtN (1.64 mL, 
9.45  mmol),  EDC.HCl  (1.24  g,  6.80  mmol),  HOBt  (1.10  g,  8.10  mmol)  and 
compound 66 (0.68 g, 2.70 mmol) were added successively and the resulting solution Experimental  
   
was stirred at room temperature for 48 hrs. DCM (30 mL) and aq. 1M KHSO4 (20 mL) 
were added to the reaction mixture. The organic layer was separated, washed with sat. 
Na2CO3 (20 mL) and brine (20 mL), and dried over MgSO4. In vacuo removal of the 
solvent and purification of the resulting crude product by column chromatography 
(SiO2, 1:50 MeOH/DCM) afforded 79 (1.00 g, 57%) as a white solid. MP = 108 -110 
˚C;  
1H NMR (400 MHz, CDCl3): ʴ (ppm) = 9.13 (1 H, s, NH), 8.46 (1 H, t, J = 2.5 
Hz, NH), 8.11 (1 H, t, J = 2.5 Hz, NH), 7.82 (1 Η, t, J = 5.0 Hz, CH), 7.12 (1 H, d,  J 
= 5.0 Hz, CH), 7.43-7.52 (4 H, m, CH), 7.27-7.30 (3 H, m, CH), 7.14 (2 H, d,  J = 5.0 
Hz, CH), 4.86-4.90 (1 H, m,  (CH3)2CHCH2CH), 4.64 (2 H, apparent doublet, CH2), 
4.45 (2 H, d, J = 2.5 Hz, CH2), 3.67 (3 H, s,COOCH3), 3.56 (2 H, s, CH2),  1.84-1.94 
(3 H, m, (CH3)2CHCH2CH) + (CH3)2CHCH2CH)), 1.42 (11 H, m, C(CH3)3 + CH2), 
0.95-0.99 (6 Η, m, (CH3)2CH); 
13C NMR (100 MHz, CDCl3): ʴ (ppm) = 170.8 (Cq), 
169.6 (Cq), 166.3 (Cq), 163.0 (Cq), 165.0 (Cq), 156.0 (Cq)154.8 (Cq), 147.8 (Cq), 
141.1 (Cq), 137.0 (CH), 135.8 (Cq), 131.2 (CH), 128.4 (CH), 126.4 (CH), 125.2 (CH), 
123.1 (CH), 119.8 (CH), 118.9 (CH), 78.6 (Cq), 52.0 (CH), 50.8 (CH3), 48.0 (CH2), 
44.5 (CH2 ), 41.8 (CH2), 32.6 (CH2), 27.1 (CH3), 23.8 (CH3), 21.7 (CH3) 21.0 (CH); 
MSES:  m/z  =668.2[M+Na]
+;  HRMS  (ES):  Calcd  for  C35H43N5NaO7    668.3060  
([M+Na]
+), found 668.3043; FT-IR (solid): ν max cm
-1 = 3308 (w), 2929 (w), 1716 (s), 
1456 (s), 1164 (m).  
 
(S)-(6-((4-((1-((4-(2-Methoxy-2-oxoethyl)phenyl)amino)-4-methyl- 
1-oxopentan-2-yl)carbamoyl)benzyl)carbamoyl)pyridin-2-yl)methanaminium 
triflouro acetate 
(80a) 
 
 
 Experimental  
   
Compound  79  (0.70  g,  1.09  mmol)  was  dissolved  in  DCM  (20  mL).  20%  (v/v) 
TFA/DCM (10 mL) was added to the reaction mixture which was stirred for 5 hrs at 
room  temperature.  In  vacuo  drying  of  the  reaction  mixture  after  the  addition  of 
toluene (3 x 2 mL) afforded 80a (1.0 g, 100%) as a white solid. MP = 60 - 62 ˚C;  
1H 
NMR (400 MHz, DMSO-d6): ʴ (ppm) = 10.11 (1 H, s, NH), 9.69(1 H, t, J = 2.5 Hz, 
NH), 8.53 (1 H, t, J = 5.0 Hz, CH), 8.38 (2 H, s(b), NH2), 8.04-8.10 (2 Η, m, CH), 
7.90 (1 H, d,  J = 5.0 Hz, CH), 7.68 (1 H, d,  J = 2.5 Hz, CH), 7.56 (2 H, d,  J = 5.0 Hz, 
CH), 7.42 (2 H, d,  J = 5.0 Hz, CH), 7.19 (2 H, d,  J = 5.0 Hz, CH), 4.61-4.64 (3 H, m,  
(CH3)2CHCH2CH  +  CH2),  4.34-4.36  (3  H,  app  doublet,  CH2),  3.60  (3  H,  m, 
COOCH3),  1.71-1.79  (2  H,  m,  (CH3)2CHCH2CH)),  1.58-1.61  (1  H,  m, 
(CH3)2CHCH2CH), 1.09-1.12 (2 H, m, CH2),  0.91-0.95 (6 Η, m, (CH3)2CH); 
13C 
NMR (100 MHz, DMSO-d6): ʴ (ppm) = 170.9 (Cq), 170.6 (Cq), 165.4 (Cq), 162.8 
(Cq), 151.6 (Cq), 148.0 (Cq), 142.0 (Cq), 138.2 (CH), 137.0 (Cq), 132.0 (CH), 128.8 
(CH), 127.0 (CH), 126.1 (CH), 124.2 (Cq), 120.5 (CH), 118.5 (CH), 52.0 (CH), 50.9 
(CH3), 48.0 (CH2), 41.3 (CH2), 41.0 (CH2),  40.9 (CH2), 23.8 (CH3), 22.2 (CH3), 20.8 
(CH); MSES: m/z =546.3  [M+H]
+; HRMS (ES): Calcd for C30H36N5O5  546.2716 
([M+Na]
+), found 546.2707; FT-IR (solid): ν max cm
-1 = 3292 (w), 2956 (w), 1666 (s), 
1537 (s), 1131 (m).  
 
(S)-Methyl 2-(4-(2-(4-((6-(3-(((benzyloxy)carbonyl)imino)-7-oxo-11,14,17-trioxa-
2,4,8-triazaicosyl)picolinamido)methyl)benzamido)-4-
methylpentanamido)phenyl)acetate  
(80) 
 
 
 Experimental  
   
Compound 80a (0.70 g, 1.28 mmol) was dissolved in DCM (25 mL) and cooled to 0 
oC.  Et3N  (0.6  mL)  and  EDC.HCl  (0.6  g,  3.28  mmol)  were  added  to  the  reaction 
mixture. A DCM (20 mL) solution of 74 (0.6 g, 1.28 mmol) was added slowly and the 
reaction  mixture  was  stirred  for  30  mins  at  0
  oC  and  then  overnight  at  room 
temperature. In vacuo removal of the solvent and purification of the resulting crude 
product by column chromatography (SiO2, 3:100 MeOH/DCM) afforded compound 
80 (0.70 g, 55 %) as a white solid. MP = 98-100 
 oC; 
1H NMR (400 MHz, CDCl3): ʴ 
(ppm) = 10.41 (1 Η, s(b), ΝΗ), 9.67 (1 Η, s(b), ΝΗ),  9.31 (1 Η, s(b), ΝΗ),  9.15 (1 Η, 
s(b), ΝΗ), 8.94 (1 Η, s, ΝΗ), 8.14 (1 Η, d, J = 5.0 Ηz, CΗ), 7.84 (1 Η, s(b), NΗ), 7.72 
(2 Η, d, J = 5.0 Ηz, 2 x CΗ),  7.49 (2 Η, d, J = 5.0 Ηz, CΗ), 7.38-7.24 (9 Η, m, 9 x 
CΗ), 7.16 (2 Η, d, J = 5.0 Ηz, CΗ), 5.08-4.99 (2 Η, s, CΗ2), 4.81-4.84 (1 Η, m, CΗ), 
4.68-4.59 (5 Η, m, CΗ2 + CΗ3),  3.66-3.33 (21 Η, overlap with water peak, 9 x CΗ2 + 
CΗ3), 2.45 (2 H, t,  J = 3.8 Ηz, CΗ2), 1.87 (1 Η, m, CΗ), (2 Η, m, CΗ2), 1.75 (2 Η, m, 
CΗ2), 1.32 (2 Η, t, J = 3.8 Ηz, CΗ2), 0.97 (6 Η, m, CH(CΗ3)2);
13C NMR (100 MHz, 
CDCl3): ʴ (ppm) = 172.6 (Cq), 171.0 (Cq), 168.3 (Cq), 143.9 (Cq), 139.3 (Cq), 137.6 
(Cq), 132.9 (Cq), 130.3 (CH), 129.2 (CH), 128.9 (CH), 128.2 (CH), 128.0 (CH), 
127.9 (CH), 120.7 (CH), 72.4 (CH2), 71.1 (CH2), 71.0 (CH2), 70.8 (CH2), 70.4 (CH2), 
69.9 (CH2), 67.2 (CH2), 59.5 (CH3), 53.7 (CH2), 52.6 (CH3), 46.2 (CH2), 43.6 (CH2), 
42.3  (CH2),  25.5  (CH),  23.5  (CH3),  22.8  (CH3),  9.08  (CH);  MSES:  m/z  =1005.7 
[M+Na]
+; HRMS (ES): Calcd for C52H70N8O12  983.4879 ([M+H]
+), found  983.4864; 
FT-IR (solid): ν max cm
-1 = 3287 (w), 2871 (m), 1646 (s), 1570 (s), 1540 (s), 310 (m), 
1162 (m), 1021 (s), 799 (m), 696 (m). 
 
 
(S)-2-(4-(2-(4-((6-(3-(((Benzyloxy)carbonyl)imino)-7-oxo-11,14,17,20-tetraoxa-
2,4,8-triazahenicosyl)picolinamido)methyl)benzamido)-4-
methylpentanamido)phenyl)acetic acid  
(81) 
 Experimental  
   
 
 
Compound  80  (0.25 g, 0.28 mmol) was  dissolved in  THF (30 mL) and added to 
Me3SiOK  (54  mg,  0.42  mmol)  suspended  in  THF  (20  mL)  under  nitrogen.  After 
overnight  stirring, DCM (40 mL)  and H2O (40 mL) were  added and the reaction 
mixture was cooled to 0 
°C. Citric acid (0.1 M) was added dropwise until the pH is 6-
7 and further stirred for 1hr. In vacuo drying of the organic phase and purification of 
the resulting crude product by column chromatography (SiO2, 3:100 MeOH/DCM → 
1:20 MeOH/DCM) afforded 81 (0.17 g, 62%) as a white solid. MP = 130-132
 oC; 
1H 
NMR (400 MHz, DMSO-d6): ʴ (ppm) = 12.24 (1 H, s, NH), 10.06 (1 H, s, NH), 8.49 
(2 H, d, J = 5.0 Hz, CH), 7.99 (2 Η, s(b), NH), 7.86 (2 H, d, J = 5.0 Hz, CH), 7.55 (3 
H, d, J = 5.0 Hz, 3 x CH), 7.40 (2 H, d, J = 5.0 Hz, CH), 7.22-7.32 (5 H, m, CH), 7.18 
(2 H, d, J = 5.0 Hz, CH), 4.88 (2 H, s, CH2), 4.68-4.59 (5 H, m, CH + 2 x CH2), 3.50-
3.39 (18 H, m, 9 x CH2), 3.22-3.16 (5 H, m, CH3 + CH2), 2.36 (2 H, s(b), CH2), 1.74 
(2 H, m, CH2), 1.57 (1 H, m, CH), 0.90-0.94 (6 Η, m, CH(CΗ3)2); 
13C NMR (100 
MHz, DMSO-d6): ʴ (ppm) = 173.2 (Cq), 171.8 (Cq), 171.1 (Cq), 166.7 (Cq), 143.2 
(Cq), 138.2 (Cq), 138.2 (Cq), 133.1 (Cq), 130.3 (CH), 130.0 (CH), 128.7 (CH), 128.1 
(CH), 127.9 (CH), 127.4 (CH), 119.7 (CH), 71.7 (CH2), 70.2 (CH2), 70.2 (CH2), 70.0 
(CH2), 69.5 (CH2), 65.9 (CH2), 58.5 (CH), 53.1 (CH3), 42.7 (CH2), 40.9 (CH2), 39.0 
(CH2), 37.7 (CH2), 25.0 (CH3), 23.5 (CH3), 22.0 (CH ); MSES: m/z =991.7 [M+H]
+; 
HRMS (ES): Calcd for C51H68N8O12 969.4723 ([M+H]
+), C51H67N8NaO12 991.4542 
([M+Na]
+), found 969.4714, 991.4530; FT-IR (solid): ν  max cm
-1 = 3295 (m), 2870 
(m), 1635 (s), 1307 (m), 1284 (m), 1149 (m), 1087 (m). 
 Experimental  
   
(S)-2-(4-(2-(4-((6-(3-Imino-7-oxo-11,14,17,20-tetraoxa-2,4,8-
triazahenicosyl)picolinamido)methyl)benzamido)-4-
methylpentanamido)phenyl)acetic acid  
(78) 
 
 
 
Compound 81 (100mg, 0.12 mmol) was dissolved in MeOH (25 mL). Pd/C (30 mg, 
0.12  mmol)  was  added  and  the  reaction  mixture  was  stirred  for  4  hrs  at  room 
temperature under hydrogen (1 atm). The reaction mixture was filtered through celite 
and dried in vacuo. Purification of the resulting solid by precipitation from MeOH 
using Et2O afforded 78 (70 mg, 69%) as a white solid. MP = 130-132
 oC; [ʱ]D 
25 =-17.1 
o  (c  0.2, MeOH); 
1H NMR  (400 MHz, DMSO):  ʴ (ppm) = 
1H NMR (400 MHz, 
DMSO-d6): ʴ (ppm) = 12.24 (1 H, s, NH), 10.00 (1 H, s, NH), 8.61 (1 H, d, J = 5.0 Hz, 
NH), 8.14 (1 H, s, NH), 8.01-7.94 (2 H, m, CH), 7.87 (2 H, d, J = 5.0 Hz, CH), 7.42-
7.36 (5 H, m, CH), 7.05 (2 H, d, J = 5.0 Hz, CH), 4.88 (2 H, s, CH2), 4.64-4.53 (5 H, 
m, CH+ 2 x CH2), 3.49-3.36 (16 H, m, 8 x CH2 (overlap with water peak)), 3.22-3.16 
(5 H, m, CH3 + CH2), 2.33 (2 H, s(b) CH2), 1.71-1.68 (2 H, m, CH2), 1.57-1.59 (1 H, 
m, CH), 0.88-0.93 (6 Η, m, 2 x CH(CΗ3)2); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) 
= 170.9 (Cq), 170.3 (Cq), 166.0 (Cq), 163. 9 (Cq), 156.5 (Cq), 155.1 (Cq), 149.1 (Cq), 
142.7 (Cq), 138.3 (CH), 136.2 (Cq), 133.8 (Cq), 132.4 (Cq), 128.9 (CH), 127.4 (CH), 
126.6 (CH), 123.8 (CH), 120.4 (CH), 118.8 (CH), 71.0 (CH2), 69.6 (CH2), 69.4 (CH2), 
68.8 (CH2), 57.8 (CH), 52.6 (CH3), 45.2 (CH2), 44.5 (CH2), 42.0 (CH2), 38.4 (CH2), 
37.4  (CH2), 34.6 (CH2), 24.4  (CH3), 22.8 (CH3), 21.4 (CH); MSES:  m/z  =  836.0 
[M+H]
+, 857.6 [M+Na]
+; HRMS (ES): Calcd for C43H62N8O10  835.4355 ([M+H]
+), 
C43H61N8NaO10  857.4174 ([M+Na]
+), found 835.4340, 857.4179; FT-IR (solid): ν max 
cm
-1 = 3300 (w) (broad)), 2900 (w), 2158 (m), 2035 (m), 1969 (w), 1652 (s).  Experimental  
   
(2R, 5S, 6R)-Methyl 5-((tert-butoxycarbonyl)amino)-2,6-dimethyl-4-oxooctanoate 
(85) 
 
 
 
Compound 84 (4.00 g, 16.67 mmol) was dissolved in DMF (50 mL). iPr2NEt (10.40 
mL,  59.82  mmol),  DCC  (7.00  g,  33.98  mmol),  HOBt  (7.00  g,  51.85  mmol)  and 
alanine methyl ester (2.30 g, 16.67 mmol) were added successively and the resulting 
solution  was  stirred  at  room  temperature  for  48  hrs.  The  solid  residue  from  the 
reaction mixture was filtered off and the DMF was removed in vacuo. The resulting 
crude  was  dissolved  with  DCM  (70  mL)  and  washed  successively  with  aq.  1M 
KHSO4 (40 mL), sat. Na2CO3 (40 mL) and brine (20 mL), and dried over MgSO4. In 
vacuo  removal  of  the  solvent  and  purification  of  the  resulting  crude  product  by 
column chromatography (SiO2, 1:100 MeOH/DCM) afforded 85 (1.60g, 65%) as a 
white solid. MP =  118-120
 oC;  
1H NMR (400 MHz, CDCl3): ʴ (ppm) = 6.51 (1 Η, d, 
J = 5.0 Hz, NHBoc),  5.08 (1 Η, d, J = 2.5 Hz, NH), 4.56-4.60 (1 H, m, CH), 3.96 (1 
H, t, J = 5.0 Ηz, CH), 3.74 (3 H, s, COOCH3), 1.66-1.68 (1 H, m, CH2CHCH3), 1.44 
(9 Η, s, C(CΗ3)3), 1.33 (3 Η, d, J = 5.0 Hz,  CH3CΗCOOMe(NH)), 1.08-1.18 (2 Η, m, 
CH3CΗ2CH), 0.89-0.95 (6 Η, m, CH3CΗ2 + CHCΗ3); 
13C NMR (100 MHz, CDCl3): ʴ 
(ppm) = 173.5 (Cq), 171.5 (Cq), 80.3 (CH3), 59.6 (CH3), 52.8 (CH3), 48.4 (CH), 37.8 
(CH3), 34.3 (CH2), 18.7 (CH3), 15.9 (CH), 11.8 (CH); MSES: m/z = 339.1 [M+Na]
+; 
FT-IR (solid): ν max cm
-1 = 3324 (s),  2928 (m), 1654 (m), 1521 (m), 1166 (m), 640 
(m).  
 
(S)-Methyl 2-((2S,3R)-2-amino-3-methylpentanamido)propanoate  
(86) 
 
 
 
Compound  85  (1.60  g,  7.41  mmol)  was  dissolved  in  DCM  (10  mL).  20%  (v/v) 
TFA/DCM (10 mL) was added and the resulting solution was stirred for 5 hrs at room Experimental  
   
temperature. In vacuo drying of the reaction mixture after the addition of toluene (3 x 
3 mL) followed by crystallisation from diethyl ether afforded compound 86 (1.60 g, 
quantitative yield) as a white solid. MP =  134-136
 oC;  
1H NMR (400 MHz, DMSO): 
ʴ (ppm) = 8.84 (1 Η, d, J = 2.5 Hz, NH), 8.16 (2 Η, s(b), NH2), 4.34-4.39 (1 H, m, 
CH), 3.63 (3 H, s, COOCH3), 3.55-3.41 (1 H, m, CH), 1.82-1.84 (1 Η, m, CH),  1.51-
1.53 (1 Η, m, CH3CΗ2CH)), 1.33 (3 Η, d, J = 2.5 Hz,  CH3CΗCOOMe(NH)),  1.15-
1.20 (1 Η, m, CH3CΗ2CH), 0.93 (3 Η, d, J = 5.0 Hz,  CH3CΗ), 0.87 (3 Η, t, J = 5 Hz,  
CH3CΗ2); 
13C NMR (100 MHz, DMSO): ʴ (ppm) = 172.8 (Cq), 168.2 (Cq), 56.8 
(CH3), 52.4 (CH3), 48.1 (CH), 36.7 (CH3), 24.3 (CH2), 17.2 (CH3), 14.7 (CH), 11.6 
(CH); MSES: m/z = 217.2 [M+H]
+; HRMS (ES): Calcd for C10H21N2O3  217.1552 
([M+H]
+), found 217.1545; FT-IR (solid): ν max cm
-1 = 3355 (s),  2962 (m), 1672 (s), 
1202 (s), 1134 (m), 720 (m).  
 
(9S,12S)-Methyl 9-((R)-sec-butyl)-2,2,12-trimethyl-4,7,10-trioxo-3-oxa-5,8,11-
triazatridecan-13-oate  
(87) 
 
 
 
Boc protected glycine (1.10 g, 8.76 mmol) was dissolved in DMF (50 mL). iPr2NEt 
(4.3 mL, 24.33 mmol), DCC (4.30 g, 20.87 mmol), HOBt (3.40 g, 25.18 mmol) and 
86 (1.80 g, 8.33 mmol) were added successively and the resulting solution was stirred 
at  room  temperature  for  48  hrs.  The  solid  residue  from  the  reaction  mixture  was 
filtered off and the DMF was removed in vacuo. The resulting crude was dissolved in 
DCM (70 mL) and washed successively with aq. 1M KHSO4 (20 mL),   sat. Na2CO3 
(20 mL) and brine (20 mL), and dried over MgSO4. In vacuo removal of the solvent 
and  purification  the  resulting  crude  product  by  column  chromatography  (1:100 
MeOH/DCM) afforded 87 (2.30 g, 73%) as a white solid. MP = 122 -124
 oC; 
1H NMR 
(300 MHz, CDCl3): ʴ (ppm) = 6.90 (1 Η, s, NH), 6.84 (1 Η, s, NH), 5.35 (1 Η, d, J = 
5.0 Hz, NH), 4.54 (1 H, m, CH), 4.37 (1 H, dd, J = 5.0 Hz, 2.5 Hz, CH), 3.82 (2 H, d, 
J  =  2.5  Hz,  CH2),  3.74  (3  Η,  s,  CΗ3OOC),  1.86  (1  H,  m,  CH),  1.51  (1  Η,  m, 
CH3CΗ2CH (Diastereotopic porton)), 1.44 (9 Η, s, C(CΗ3)3), 1.40 (3 Η, d, J = 5.0 Ηz, Experimental  
   
CHCΗ3), 1.13-1.16 (1 Η, m, CH3CΗ2CH (Diastereotopic porton)), 0.94 (3 Η, d, J = 
5.0 Ηz CHCΗ3), 0.89 (3 Η, t, J = 5.0 Ηz CH2CΗ3); 
13C NMR (100 MHz, CDCl3): ʴ 
(ppm) = 174.7 (Cq), 172.3 (Cq), 171.2 (Cq), 164.2 (Cq), 81.9 (Cq),  59.2 (CH3), 54.1 
(CH3), 49.7 (CH), 46.0 (CH2), 39.2 (CH), 29.9 (CH3), 26.5 (CH2), 19.6 (CH3), 16.9 
(CH), 12.9 (CH3);MSES: m/z = 396.2  [M+Na]
+; HRMS (ES): Calcd for  C18H33N2O6  
396.2111 ([M+H]
+), found  396.2104; FT-IR (solid): ν max cm
-1 =  3292 (w) (b), 2874 
(w), 1635 (s), 1521 (s). 
 
(S)-Methyl 2-((2S,3R)-2-(2-aminoacetamido)-3-methylpentanamido)propanoate 
(88) 
 
 
 
Compound  87  (1.00  g,  2.68  mmol)  was  dissolved  in  DCM  (10  mL).  20%  (v/v) 
TFA/DCM (10 mL) was added and the resulting solution was stirred for 5 hrs at room 
temperature. In vacuo drying of the reaction mixture after the addition of toluene (3 x 
3 mL) followed by crystallization from diethyl ether afforded 88 (1.00 g, 100%) as a 
white solid. MP = 192 -194
 oC. 
1H NMR (300 MHz, DMSO-d6): ʴ (ppm) =  8.57 (1 Η, 
d, J = 5.0 Hz, NH), 8.46 (1 Η, d, J = 7.5 Hz, NH), 8.01 (2 Η, s(b), NΗ2), 4.21-4.32 (2 
Η,  m,  2  x  CH),  1.68-1.72  (1  Η,  m,  CΗ),  1.45-1.47  (1  Η,  m,  CH3CΗ2CH  (a 
diasteriotopic  proton)),  1.28  (3  Η,  d,  J  =  5.0  Ηz,  CHCΗ3),  1.08-1.10  (1  Η,  m, 
CH3CΗ2CH (a diasteriotopic proton)), 0.88 (3 Η, d, J = 5.0 Ηz CHCΗ3), 0.83 (3 Η, t, 
J = 5.0 Ηz CH2CΗ3); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 171.6 (Cq), 169.3 
(Cq), 164.5 (Cq), 55.3 (CH3), 50.6 (CH), 46.4 (CH), 40.5 (CH2), 37.5 (CH3), 23.0 
(CH2), 15.6 (CH), 13.8 (CH3),  9.8 (CH3); MSES: m/z = 296.2 [M+Na]
+; HRMS (ES): 
Calcd for C13H25N2O4 274.1768 ([M+H]
+), C13H24N2NaO4 296.1587 ([M+Na]
+) found  
274.1764, 296.1584; FT-IR (solid): ν max cm
-1 = 3280 (w), 2962 (w), 1683 (m), 1669 
(s), 1558 (m), 1130 (m). 
(S)-Methyl 2-((2S,3R)-2-(2-(6-(((tert-
butoxycarbonyl)amino)methyl)picolinamido)acetamido)-3-
methylpentanamido)propanoate  
(89) 
 Experimental  
   
 
 
Compound 36 (0.70 g, 2.78 mmol) was dissolved in DCM (50 mL). iPr2NEt (1.76 mL, 
10.12 mmol), EDC.HCl (1.3 g, 7.10 mmol), HOBt (1.2 g, 8.89 mmol) and 88 (0.80 g, 
2.93 mmol) were added successively and the resulting solution was stirred at room 
temperature for 48 hrs. After addition of DCM (40 mL), the organic layer was washed 
with aq. 1M KHSO4 (20 mL), sat. Na2CO3 (20 mL) and brine (20 mL), and dried over 
MgSO4. In vacuo removal of the solvent and purification of the resulting crude by 
column chromatography (SiO2, 1:100 MeOH/DCM) afforded 89 (1.00 g, 70%) as a 
white solid. MP = 188-190
 oC; 
1H NMR (300 MHz, DMSO-d6): ʴ (ppm) = 8.89 (1 Η, 
t, J = 2.5 Ηz, NΗ), 8.47 (1 Η, d, J = 5.0 Ηz, NΗ),  8.02-7.95 (2 Η, m, CH), 7.89 (1 Η, 
d, J = 5.0 Ηz, CΗ), 7.55 (1Η, t, J = 2.5 Ηz, NΗ), 7.48 (1 Η, d, J = 5.0 Ηz, NΗ), 4.33-
4.22 (4 Η, m, 2 H x CΗ2), 4.01 (2 Η, d, J = 2.5 Ηz, CΗ2), 3.60 (3 Η, s, CΗ3), 1.68-
1.71 (1 Η, m, CΗ), 1.45-1.48 (1 Η, m, CH3CΗ2CH (a diastereotopic proton))1.41 (9 Η, 
s, 2 x CΗ3), 1.28 (3 Η, d, J = 5.0 Ηz, CHCΗ3), 1.05-1.12 (1 Η, m, CH3CΗ2CH (a 
diastereotopic proton)), 0.87 (3 Η, d, J = 5.0 Ηz CHCΗ3), 0.82 (3 Η, t, J = 5.0 Ηz 
CH2CΗ3); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 172.8 (Cq), 170.9 (Cq), 168.2 
(Cq), 163.8 (Cq), 158.3 (Cq), 155.9 (Cq), 148.8 (Cq), 138.4 (CH), 123.5 (CH), 120.0 
(CH), 78.2 (Cq), 56.3 (CH3), 51.7 (CH), 47.5 (CH), 45.3 (CH2), 42.0 (CH2), 40.2 
(CH2), 37.1 (CH3), 28.2 (CH3), 24.2 (CH3), 16.7 (CH), 15.1 (CH3), 11.0 (CH3); MSES: 
m/z = 530.3 [M+Na]
+; HRMS (ES): Calcd for  C24H37N5NaO7  530.2591 ([M+Na]
+), 
found  530.2589; FT-IR (solid): ν max cm
-1 =  3333 (w), 1685 (s), 1642 (s), 1527 (s), 
1164 (s).  
 
(6-((2-(((2S,3R)-1-(((S)-1-Methoxy-1-oxopropan-2- 
yl)amino)-3-methyl-1-oxopentan-2-yl)amino)-2-oxoethyl)carbamoyl)pyridin-2-
yl)methanaminium  
(90) 
 
 Experimental  
   
Compound  89  (0.30  g,  0.59  mmol)  was  dissolved  in  DCM  (10  mL).  20  %  (v/v) 
TFA/DCM (10 mL) was added and the reaction mixture was stirred for 5 hrs at room 
temperature. In vacuo drying of the reaction mixture after the addition of toluene (3 x 
3 mL) followed by crystallization from diethyl ether afforded 90 (0.29 g, 100%) as a 
white solid compound. MP = 160-162
 oC; 
1H NMR (300 MHz, DMSO-d6): ʴ (ppm) = 
9.31 (1 Η, t, J = 2.5 Hz, NH), 8.47 (1 Η, d, J = 5.0 Hz, CH), 8.40 (2 Η, s(broad), NΗ2), 
8.06 (1 Η,  J = 2.5 Hz, CH), 8.01 (1 Η,  s, NH), 7.99 (1 Η,  s(broad), NH), 7.67 (1 Η,  
J = 5.0 Hz, CH), 4.33 (2 Η, apparent quartet, CΗ2), 4.24-4.39 (2 Η, m, 2 x CΗ), 4.04 
(2 Η,  J = 5.0 Hz, NHCH2), 3.60 (3 Η, s, CΗ3), 1.71-1.73 (1 Η, m, CH3CΗ2CH), 1.49-
1.42 (1 Η, m, CH3CΗ2CH (a diastereotopic proton)), 1.28 (3 Η, d, J = 5.0 Ηz, CΗ3), 
1.05-1.12 (1 Η, m, CH3CΗ2CH (a diastereotopic proton)), 0.88 (3 Η, d, J = 2.5 Ηz 
CHCΗ3), 0.83 (3 Η, t, J = 2.5 Ηz CH2CΗ3);
 13C NMR (100 MHz, DMSO-d6): ʴ (ppm) 
= 173.3 (Cq), 171.3 (Cq), 168.7 (Cq), 164.1 (Cq), 152.8 (Cq), 149.2 (Cq), 139.4 (CH), 
125.4 (CH), 121.6 (CH), 56.8 (CH3), 52.2 (CH), 48.0 (CH), 42.6 (CH2), 42.3 (CH2), 
37.6  (CH3), 24.6 (CH2), 17.2  (CH), 15.5  (CH3), 11.5 (CH3);  MSES:  m/z  = 430.2  
[M+Na]
+; HRMS (ES): Calcd for C19H32N5O4 408.2247 ([M+H]
+), found  408.2239; 
FT-IR (solid): ν max cm
-1 = 3306w(b), 2957 (m), 1745 (m), 1654 (s), 1521 (s), 1366 
(m). 
 
(S)-Methyl 2-((2S,3R)-2-(2-(6-(3-(((benzyloxy)carbonyl)imino)-7-oxo-11,14,17,20-
tetraoxa-2,4,8-triazahenicosyl)picolinamido)acetamido)-3-
methylpentanamido)propanoate  
(91) 
 
 
 
Compound 90 (0.70 g, 1.49 mmol) was dissolved in DCM (50 mL) and cooled to 0 
oC. 
Et3N (0.60 mL) and EDC.HCl (0.70 g, 3.83 mmol) were added to the reaction mixture. 
A  DCM  solution  of  74  (0.70  g,  1.49  mmol)  was  slowly  added  and  the  resulting 
solution was stirred for 30 mins at 0 
oC and then overnight at room temperature. In 
vacuo drying of the reaction mixture and purification of the resulting crude by column 
chromatography (SiO2, 1:50 MeOH/DCM) afforded 91 (0.76 g, 60%) as a white solid. 
MP = 102-104
 oC;  H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 10.26 (1 H, s, NH), Experimental  
   
9.86 (1 H, s, NH), 9.25 (1 H, s, NH), 8.12 (1 H, d, J = 2.5 Ηz, NH), 7.42 (2 H, d, J = 
5.0 Hz, CH), 7.32-7.36 (3 H, m, 3 x CH), 7.27-7.30 (3 H, m, 3 x CH),  6.93 (1 H, s(b), 
NH), 6.58 (1 H, s, NH), 5.15 (2 H, s, CH2), 4.72 (2 H, s, CH2), 4.47-4.54 (1 H, m, 
CH), 4.31-4.35 (1 H, m , CH), 4.12 (2 H, s, CH2), 3.70 (3 H, s, CH3),  3.54-3.70 (21 H, 
m, CH3  + 9 x CH2), 3.36 (3 H, s, CH3), 2.46-2.52 (2 H, m, CΗ2), 1.92-1.95 (1 H, m, 
CH3CΗ2CH), 1.45-1.50 (1 Η, m, diastereotopic proton, CH3CΗ2CH), 1.06-1.15 (1 H, 
m, diastereotopic proton, CH3CΗ2CH), 0.91 (3 Η, d, J = 5.0 Ηz, CHCΗ3), 0.87 (3 Η, t, 
J = 5.0 Ηz CH2CΗ3); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 173.4 (Cq), 170.8 
(Cq), 129.1 (CH), 128.4 (CH), 128.0 (CH),  72.9 (CH2), 70.9 (CH2), 70.8 (CH2), 70.7 
(CH2), 70.3 (CH2), 69.8 (CH2), 59.4 (CH3), 58.1 (CH), 52.8 (CH), 48.5 (CH3), 46.4 
(CH3), 44.6 (CH2), 37.4 (CH3), 25.1 (CH2), 18.4 (CH), 15.8 (CH3), 11.8 (CH3); MSES: 
m/z  = 867.7 [M+Na]
+; HRMS (ES): Calcd for C40H61N8O12  845.4409 ([M+H]
+), 
found 845.4392; FT-IR (solid): ν max cm
-1 = 3276 (w), 2876 (w), 2364 (w), 1636 (s), 
1541 (m). 
 
(S)-2-((2S,3R)-2-(2-(6-(3-(((Benzyloxy)carbonyl)imino)-7-oxo-11,14,17,20-
tetraoxa-2,4,8-triazahenicosyl)picolinamido)acetamido)-3-
methylpentanamido)propanoic acid 
(92) 
 
 
 
Compound 91 (0.20 g, 0.24 mmol) was dissolved in THF (30 mL) and added to a 
suspension of Me3SiOK (0.47 g, 0.4 mmol) in THF (25 mL) under nitrogen. After 
overnight  stirring, DCM (50 mL)  and H2O (50 mL) were  added and the reaction 
mixture was cooled to 0 
oC. Citric acid (0.1 M) was added dropwise until the pH was 
6-7 and further stirred for 1hr. In vacuo drying of the organic phase and purification 
of the resulting crude by column chromatography (SiO2, 3:10 MeOH/DCM → 1:20 
MeOH/DCM) afforded 92 (0.13 g, 54%) as a white solid. MP = 118 - 120
 oC; 
 1H 
NMR (400 MHz, DMSO-d6): ʴ (ppm) = 12.40 (1 H, s(broad), COOH), 8.91 (1 H, s, 
NH), 8.32 (1 H, d, J = 5.0 Ηz, CH), 8.10 (1 H, s, NH), 7.99 (1 H, d, J = 5.0 Ηz, CH), 
7.93 (1 H, m, CH), 7.52 (borad, NH), 7.31 (5 H, m, CH), 4.94 (2 H, s, CH2), 4.60 (2 H, 
d, J = 5.0 Ηz, CH2), 4.23-4.31 (1 H, m, CH), 4.13-4.21 (1 H, m, CH), 4.01 (2 H, d, J = Experimental  
   
5.0 Ηz, CH2), 3.51-3.49 (2 H, m, 1 x CH2 (overlapped with water peak)), 3.38-3.42 (4 
H, m, 2 x CH2), 3.16-3.23 (6 H, m, 3 x CH2), 2.39 (2 H, s,  CΗ2), 2.09 (4 H, s, 2 x 
CΗ2),  1.70-171  (1  H,  m,  CH3CΗ2CH),  1.42-147  (1  H,  m,  diastereotopic  proton, 
CH3CΗ2CH), 1.26 (3 H, d, J = 5.0 Ηz, CH3), 1.02-1.10 (1 H, m, diastereotopic proton, 
CH3CΗ2CH), 0.86 (3 Η, d, J = 5.0 Ηz, CHCΗ3), 0.79 (3 Η, t, J = 5.0 Ηz CH2CΗ3); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 175.3 (Cq), 172.1 (Cq), 171.9 (Cq), 
169.5 (Cq), 165.1 (Cq), 129.6 (CH), 129.1 (CH), 128.8 (CH), 72.6 (CH2), 71.1 (CH2), 
70.9 (CH2), 70.4 (CH2), 66.9 (CH2), 59.4 (CH3), 57.7 (CH), 46.7 (CH), 43.4 (CH2), 
40.0(CH2), 38.5 (CH3), 32.0 (CH), 25.6 (CH2), 18.3 (CH3), 16.5 (CH3); MSES: m/z = 
831.5.60 [M+H]
+, 854.7 [M+Na]
+; HRMS (ES): Calcd for C39H58N8NaO12  853.4072 
([M+Na]
+), found 853.4080; FT-IR (solid): ν max cm
-1 = 3300 (w), 2989 (w), 1710 (w), 
1635 (s), 1101 (s).  
 
(S)-2-((2S,3R)-2-(2-(6-(3-Imino-7-oxo-11,14,17,20-tetraoxa-2,4,8-
triazahenicosyl)picolinamido)acetamido)-3-methylpentanamido)propanoic acid 
(82) 
 
 
 
Compound 92 (300 mg, 0.36 mmol) was dissolved in MeOH (50 mL). Pd/C (38 mg, 
0.36  mmol)  was  added  and  the  reaction  mixture  was  stirred  for  4  hrs  at  room 
temperature under hydrogen (1 atm). The reaction mixture was filtered through celite 
and dried in vacuo. Purification of the resulting solid by precipitation from MeOH 
using Et2O afforded 82 (170 mg, 85%) as a white solid. MP = 220-222
  oC; [ʱ]D 
25 =-
4.2 
o (c 0.2, MeOH);
 1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 9.76 (1 H, s, NH), 
8.90 (1 H, s, NH), 8.79 (1 H, s, NH), 8.25 (1 H, s, NH), 8.10 (1 H, s, NH), 8.03-7.96 
(3 H, m, 2 x CH + NH), 7.60 (1 H, d, J = 7.5 Hz, CH), 7.55 (1 H, s, NH),  4.52 (2 H, 
m, CH2), 4.12-4.18 (1 H, m, CH), 4.02-4.03 (2 H, m, CH2), 3.82 (1 H, m, CH), 3.33-
3.43 (16 H, m, 8 x CH2), 3.23-3.19 (5 H, m, CH2 + CH3), 2.36 (2 H, s, CH2), 1.84 (1 H, 
m, CH), 1.42 (1 H, m, CH3CH2 (a diastereotopic proton)), 1.16-1.18 (4 H, m, CH3 + 
CH3CH2 (a diastereotopic proton)), 0.81-0.87 (6 Η, m, CH3CH2 + CH2CH(CH)CΗ3); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 170.7 (Cq), 170.0 (Cq), 169.5 (Cq), 
164.1 (Cq), 157.0 (Cq), 155.8 (Cq), 139.2 (CH), 125.4 (CH), 121.2 (CH), 71.7 (CH2), Experimental  
   
70.0 (CH2), 70.2 (CH2), 70.0 (CH2), 69.4 (CH2), 58.5 (CH), 49.7 (CH), 45.9 (CH2), 
43.0 (CH3), 39.4 (CH2), 39.1 (CH2), 38.0 (CH2), 36.4 (CH3), 35.1 (CH2), 24.9 (CH2), 
19.5 (CH3), 16.1 (CH3), 11.8 (CH); MSES: m/z = 697.60 [M+H]
+, 719.6 [M+Na]
+; 
HRMS (ES): Calcd for C31H52N8NaO10  719.3704 ([M+Na]
+), found  719.3700; FT-IR 
(solid): ν max cm
-1 = 3300 (w), 1662 (s), 1082 (m).  
 
(R)-Methyl 2-((S)-2-amino-4-methylpentanamido)-4-methylpentanoate 
(97) 
 
 
Compound  96  (2.50  g,  6.98  mmol)  was  dissolved  in  DCM  (10  mL).  20%  (v/v) 
TFA/DCM (20 mL) was added and the reaction mixture was stirred for 5 hrs at room 
temperature. In vacuo drying of the reaction mixture after the addition of toluene (3 x 
3 mL) followed by crystallization from diethyl ether afforded 97 (2.50 g, 100%) as a 
white solid compound. MP = 172-174 ˚C;
 1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 
8.81  (1  Η,  d,  J  =  5.0  Ηz,  NH),  8.19  (2  Η,  s,  NH2),  4.31-4.37  (1  H,  m, 
CHCH2CH(CΗ3)2), 3.80 (1 H, m, CHCH2CH(CΗ3)2), 3.75 (3 H, s, COOCH3), 1.68-
1.69 (2 H, m, 2 x CHCH2CH(CΗ3)2), 1.49-1.59 (4 H, m, 2 x CHCH2CH(CΗ3)2), 0.86-
0.95 (12 Η, m, CH(CΗ3)2); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 172.3 (Cq), 
169.2 (Cq), 52.0 (CH), 50.6 (CH), 50.4 (CH3), 40.1 (CH2), 38.9 (CH2), 24.0 (CH3), 
23.4  (CH3),  22.7  (CH3),  22.6  (CH3),  21.9  (CH),  21.2  (CH);  MSES:  m/z  =  259.3 
[M+H]
+; HRMS (ES): Calcd for  C13H27N2O3 259.2023 ([M+H]
+), found  259.2017; 
FT-IR (solid): ν max cm
-1 = 3350 (w), 2957 (w), 1725 (m), 1664 (s), 1522 (s), 1183 (s), 
1136 (s). 
 
(R)-Methyl 2-((S)-2-(4-(((tertbutoxycarbonyl)amino)methyl)benzamido)-4-
methylpentanamido)-4-methylpentanoate  
(98) 
 Experimental  
   
 
 
Boc-protected-p-methylamino  benzoic  acid  (0.50  g,  1.99  mmol)  was  dissolved  in 
DMF (5 mL). A solution of HOBt (0.81 g, 6.00 mmol) and DCC (0.82 g, 3.98 mmol) 
in DMF (10 mL) was added dropwise to the reaction mixture at 0 
oC and was stirred 
for 1 hr at room temperature. Compound 97 (0.50 g, 1.99 mmol) and iPr2NEt (1.2 mL, 
6.90  mmol)  were  then  added  successively  and  the  resulting  solution  was  further 
stirred at room temperature for 12 hrs. The reaction mixture was added to EtOAc (20 
mL), the resulting white precipitate (dicyclohexyl urea) was filtered off and the filtrate 
was washed with aq. 10% NaHCO3 (10 mL), aq. 10% citric acid (10 mL) and water 
(10 mL). The organic layer was then dried over MgSO4 and concentrated in vacuo. 
Purification  of  the  resulting  crude  by  column  chromatography  (SiO2,  1:100 
MeOH/DCM) afforded 98 (0.5g, 51%) as white solid. MP = 98-103 ˚C; 
 1H NMR 
(400 MHz, CDCl3): ʴ (ppm) = 8.32 (1 Η, d, J = 5.0 Ηz, NH), 8.25 (1 Η, d, J = 5.0 Ηz, 
NH), 7.82 (2 Η, d, J = 5.0 Ηz, CH), 7.43 (1 Η, t, J = 2.5 Ηz, NHBoc), 7.30 (2 Η, d, J 
=  5.0  Ηz,  CH),  4.52-4.58  (1  H,  m,  CHCH2CH(CΗ3)2),  4.26-4.32  (1  H,  m, 
CHCH2CH(CΗ3)2), 4.16 (2 Η, d, J = 5.0 Ηz, CH2NH), 3.60 (3 Η, s, COOCH3), 1.49-
1.73 (6 H, m, 2 x CHCH2CH(CΗ3)2 + 2 x CHCH2CH(CΗ3)2), 1.39 (9 H, s, OC(CΗ3)3), 
0.82-0.92 (12 Η, m, CH(CΗ3)2); 
13C NMR (100 MHz, CDCl3): ʴ (ppm) = 173.1 (Cq), 
172.7 (Cq), 166.3 (Cq), 156.0 (Cq), 143.8 (Cq), 132.8 (Cq), 127.7 (CH), 126.7 (CH), 
78.1 (Cq), 52.0 (CH), 51.6 (CH), 50.4 (CH3), 43.4 (CH2), 40.5 (CH2), 40.1 (CH2), 
24.7 (CH3), 24.6 (CH3), 24.4 (CH3), 23.4 (CH3), 23.0 (CH3), 21.7 (CH), 21.2 (CH); 
MSES:  m/z  =  514.4  [M+Na]
+;  HRMS  (ES):  Calcd  for  C26H41N3NaO6  514.2893 
([M+Na]
+), found  514.2877; FT-IR (solid): ν max cm
-1 = 3290 (w), 2954 (w), 1633 
(s),1537 (s), 1503 (m), 1164 (s). Experimental  
   
Compound 99 
 
 
 
Compound 98  (0.20 g, 0.41 mmol) was  dissolved in  THF (15 mL) and added to 
Me3SiOK  (78  mg,  0.61  mmol)  suspended  in  THF  (25  mL)  under  nitrogen.  After 
overnight  stirring, DCM (20 mL)  and H2O (20 mL) were  added and the reaction 
mixture was cooled to 0 ˚C. Citric acid (0.1 M) was added dropwise until the pH was 
6-7 and further stirred for 1hr. In vacuo drying of the organic phase and purification 
of the resulting crude product by column chromatography (SiO2, 1:20 MeOH/DCM) 
afforded 99 (0.15 g, 77%) as a white solid. MP = 172-174 ˚C; 
 1H NMR (400 MHz, 
CDCl3): ʴ (ppm) = 8.33 (1 Η, d, J = 5.0 Ηz, NH), 8.08 (1 Η, d, J = 5.0 Ηz, NH), 7.83 
(2 Η, d, J = 5.0 Ηz, CH), 7.43 (1 Η, s(b), NHBoc), 7.31 (2 Η, d, J = 5.0 Ηz, CH), 
4.53-4.59 (1 H, m, CH), 4.20-4.26 (1 H, m, CH), 4.16 (2 Η, d, J = 5.0 Ηz, NHCH2), 
1.65-1.68  (3  H,  m,  CHCH2CH(CΗ3)2  +  CHCH2CH(CΗ3)2),  1.48-1.56  (3  H,  m, 
CHCH2CH(CΗ3)2 + CHCH2CH(CΗ3)2), 1.40 (9 H, s, OC(CΗ3)3), 0.82-0.92 (12 Η, m,  
2 x CH(CΗ3)2); 
13C NMR (100 MHz, CDCl3): ʴ (ppm) = 174.5 (Cq), 172.9 (Cq), 
166.6 (Cq), 156.4 (Cq), 144.2 (Cq), 132.2 (Cq), 128.1 (CH), 127.2 (CH), 78.5 (Cq), 
52.1 (CH), 50.8 (CH), 43.8 (CH2), 40.9 (CH2), 40.4 (CH2), 28.8 (CH3), 24.9 (CH3), 
24.9  (CH3),  23.7  (CH3),  23.5  (CH3),  22.1  (CH),  22.0  (CH);  MSES:  m/z  =  500.3 
[M+Na]
+;  HRMS  (ES):  Calcd  for  C25H39N3NaO6  500.2737  ([M+Na]
+),  found  
500.2733; FT-IR (solid): ν max cm
-1 = 3268 (w), 2960 (w), 2361 (m), 2017 (m), 1716 
(m),1698 (m), 1540 (s), 1508 (m).  
 
 Experimental  
   
Methyl 2-(4-((R)-2-((S)-2-(4-(((tert-butoxycarbonyl)amino)methyl)benzamido)-4-
methylpentanamido)-4-methylpentanamido)phenyl)acetate  
(100) 
 
 
 
 
Compound 99 (0.40 g, 0.84 mmol) was dissolved in DCM (20 mL). iPr2NEt (0.5 mL, 
2.94 mmol), EDC.HCl (0.4 g, 2.19 mmol), HOBt (0.34 g, 2.52 mmol) and p-amino 
benzylcarboxylic acid methyl ester (0.14 g, 0.84 mmol), previously dissolved in DMF 
(5  mL),  were  added  successively  and  the  resulting  solution  was  stirred  at  room 
temperature for 72 hrs. DCM (30 mL) and aq. 1M KHSO4 (20 mL) were added to the 
reaction mixture. The organic layer was separated, washed with sat. Na2CO3 (20 mL) 
and brine (20 mL) successively, and dried over MgSO4. In vacuo removal of the 
solvent and purification of the resulting crude by column chromatography (SiO2, 1:20 
MeOH/DCM) afforded 100 (0.5 g, 95%) as a white solid. MP = 102-104 ˚C;
 1H NMR 
(400 MHz, DMSO- d6): ʴ (ppm) = 8.51 (1 Η, t, J = 5.0 Ηz, NH), 8.05(1 Η, d, J = 5.0 
Ηz, NH), 8.05 (1 Η, d, J = 5.0 Ηz, NH), 7.85 (1 Η, d, J = 5.0 Ηz, CH), 7.65 (2 Η, d, J 
= 5.0 Ηz, CH), 7.55 (1 Η, d, J = 5.0 Ηz, CH), 7.43 (1 Η, t, J = 2.5 Ηz, NHBoc), 7.32 
(2  Η,  d,  J  =  5.0  Ηz,  CH),  7.18-7.21  (2  Η,  m,  CH),  4.40-4.52  (2  H,  m,  2  x 
CHCH2CH(CΗ3)2),  4.17  (2  Η,  d,  J  =  5.0  Ηz,  NHCH2),  3.60-3.62  (5  Η,  m, 
CH2COOMe  +  COOCH3),  1.51-1.72  (6  H,  m,  2  x  CHCH2CH(CΗ3)2  +  2  x 
CHCH2CH(CΗ3)2), 1.40 (9 H, s, OC(CΗ3)3), 0.85-0.95 (12 Η, m, 2 x CH(CΗ3)2); 
13C 
NMR (100 MHz, DMSO-d6): ʴ (ppm) = 172.4 (Cq), 171.5 (Cq), 170.8 (Cq), 166.5 
(Cq), 155.6 (Cq), 143.8 (Cq), 137.4 (Cq), 137.3 (Cq), 129.3 (CH), 127.3 (CH), 126.4 
(CH), 119.1 (CH), 77.7 (Cq), 52.5 (CH3),  52.0 (CH), 51.6 (CH3), 51.4 (CH3), 42.9 
(CH2), 40.5 (CH2), 40.2 (CH2), 39.8 (CH2), 28.0 (CH3), 24.2 (CH3), 22.9 (CH3), 22.6 Experimental  
   
(CH),  21.0  (CH);  MSES:  m/z  =  647.5  [M+Na]
+;  HRMS  (ES):  Calcd  for 
C34H48N4NaO7 647.3421 ([M+Na]
+), found  647.3418; FT-IR (solid): ν  max cm
-1 = 
3309 (w), 2956 (w), 2361 (m), 2333 (m), 1697 (s), 1671 (s), 1636 (s), 1522 (m),1509 
(m),1169 (m). 
 
Methyl 2-(4-((R)-2-((S)-2-(4-(aminomethyl)benzamido)-4- 
methylpentanamido)-4-methylpentanamido)phenyl)acetate  
(101) 
 
 
Compound 100 (0.40 g, 0.64 mmol) was stirred in 20% (v/v) TFA/DCM (20 mL) at 
room temperature for 3 hrs. In vacuo drying of the reaction mixture after the addition 
of toluene (3 x 3 mL) followed by precipitation from diethyl ether afforded 101 (0.40 
g, 100%) as a white solid compound. MP =134-136 ˚C; 
 1H NMR (400 MHz, DMSO-
d6): ʴ (ppm) = 9.76 (1 Η, s, NH), 8.60 (1 Η, d, J = 5.0 Ηz, NH), 8.52 (1 Η, t, J = 5.0 
Ηz, NH), 8.22 (2 Η, s(b), NH2), 7.93-7.96 (2 Η, m, CH), 7.63 (1 Η, d, J = 5.0 Ηz, CH), 
7.52 (2 Η, d, J = 5.0  Ηz, CH), 7.17-7.20 (2 Η, m, CH), 4.40-4.52 (2 H, m, 2 x 
CHCH2CH(CΗ3)2), 4.10 (2 Η, d, J = 5.0 Ηz, CH2), 3.60-3.62 (5 Η, m, CH2COOMe + 
COOCH3), 1.52-1.80 (6 H, m, 2 x CHCH2CH(CΗ3)2 + 2 x CHCH2CH(CΗ3)2), 0.85-
0.95 (12 Η, m, 2 x CH(CΗ3)2); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) =  171.4 
(Cq), 170.7 (Cq), 169.90 (Cq), 136.6 (Cq), 136.3 (Cq), 129.8 (CH), 128.7 (CH), 128.0 
(CH), 119.5 (CH), 119.5 (CH), 53.0 (CH3), 52.3 (CH),  52.1 (CH), 42.0 (CH2), 40.7 
(CH2), 40.3 (CH2),  39.7 (CH2), 24.9 (CH3), 23.3 (CH3), 22.3 (CH3), 22.1 (CH3), 21.9 
(CH), 21.6 (CH); MSES: m/z = 525.4 [M+H]
+; HRMS (ES): Calcd for C29H41N4O5 
525.3077 ([M+H]
+), found 525.3071; FT-IR (solid): ν max cm
-1 = 3275 (m), 2956 (m), 
2360 (m), 2026 (m), 1648 (s), 1540 (s), 1520 (s), 1199 (m), 1176 (m), 1137 (m). 
 
 
 Experimental  
   
Methyl 2-(4-((R)-2-((S)-2-(4-((6-(((tert- 
butoxycarbonyl)amino)methyl)picolinamido)methyl)benza 
mido)-4-methylpentanamido)-4-methylpentanamido)phenyl)acetate 
(102) 
 
 
Compound 36 (0.20 g, 0.80 mmol) was dissolved in DCM (20 mL). iPr2NEt (0.6 mL, 
2.80 mmol), EDC.HCl (0.37 g, 2.02 mmol), HOBt (0.32 g, 2.37 mmol) and 101 (0.40 
g, 0.76 mmol), previously dissolved in DMF (5 mL), were added successively to the 
reaction mixture which was stirred at room temperature for 48 hrs. DCM (20 mL) and 
aq. 1M KHSO4 (15 mL) were added to the reaction mixture. The organic layer was 
separated, washed with sat. Na2CO3 (15 mL) and brine (15 mL) successively, and 
dried over MgSO4. In vacuo removal of the solvent and purification of the resulting 
crude by column chromatography (SiO2, 1:25 MeOH/DCM) afforded 102 (0.40 g, 
66%) as a white solid. MP = 69-70 ˚C;
  1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 
9.89 (1 Η, s, NH), 9.76 (1 Η, s, NH), 9.35 (1 Η, s(b), NH), 8.51 (1 Η, t, J = 5.0Ηz, 
NHBoc), 7.85-7.97 (4 Η, m, CH), 7.63-7.65 (1 Η, d, J = 5.0 Ηz, CH), 7.53-7.55 (1 Η, 
m, CH), 7.47-7.49 (1 Η, m, CH), 7.40-7.42 (2 Η, m, CH), 7.17-7.20 (2 Η, m, CH), 
4.33-4.59 (6 H, m, 2 x CHCH2CH(CΗ3)2 + CH2NH + CH2NHBoc), 3.59-3.61 (5 Η, m, 
CH2COO  +  COOCH3),  1.48-1.69  (6  H,  m,  2  x  CHCH2CH(CΗ3)2  +  2  x 
CHCH2CH(CΗ3)2), 1.39 (9 H, s, OC(CΗ3)3), 0.85-0.94 (12 Η, m, 2 x CH(CΗ3)2); 
13C 
NMR (100 MHz, DMSO-d6): ʴ (ppm) = 172.7 (Cq), 171.9 (Cq), 171.1 (Cq), 166.8 
(Cq), 164.2 (Cq), 158.4 (Cq), 156.0 (Cq), 149.2 (Cq), 143.2 (Cq), 143.1 (Cq), 138.5 
(Cq), 137.7 (Cq), 132.6 (Cq), 129.8 (CH), 129.5 (CH), 127.8 (CH), 127.2 (CH), 123.7 
(CH), 120.3 (CH), 119.5 (CH), 119.4 (CH), 78.3 (Cq), 52.8 (CH3), 51.9 (CH), 51.8 
(CH), 45.3 (CH2), 42.3 (CH2), 41.0 (CH2), 39.5 (CH2), 39.3 (CH2), 28.4 (CH3), 24.6 
(CH3), 23.3 (CH3), 22.1 (CH3), 21.8 (CH3), 21.6 (CH), 21.4 (CH); MSES: m/z = Experimental  
   
781.7 [M+Na]
+; FT-IR (solid): ν max cm
-1 = 3301w, 2955w, 1716 (m), 1677 (m), 1633 
(m), 1598 (m), 1526 (s), 1409 (s), 1276 (s), 1250 (s), 1170 (s). 
 
(6-((4-(((S)-1-(((R)-1-((4-(2-Methoxy-2-oxoethyl)phenyl)amino)-4-methyl-1-
oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-
yl)carbamoyl)benzyl)carbamoyl)pyridin-2-yl)methanaminium  
(103) 
 
 
 
Compound 102 (0.44 g, 0.52 mmol) was stirred in 20% (v/v) TFA/DCM (20 mL) at 
room temperature for 3h. In vacuo drying of the reaction mixture after the addition of 
toluene (3 x 3 mL) followed by precipitation from diethyl ether afforded 103 (0.40 g, 
100%) as a white solid compound. MP = 128-130 ˚C; 
 1H NMR (400 MHz, DMSO-
d6): ʴ (ppm) = 9.91 (1 Η, s, NH), 9.79 (1 Η, s, NH), 9.68 (1 Η, t,  J = 5.0 Ηz, NH), 
8.50-8.53 (2 Η, m, CH + NH), 8.36 (s(b), NH), 8.03-8.10 (2 Η, m, CH + NH), 7.87-
7.89 (2 Η, m, CH), 7.61-7.68 (1 Η, m, CH), 7.52-7.55 (1 Η, m, CH), 7.41-7.43 (2 Η, 
m, CH), 7.17-7.20 (2 Η, m, CH), 4.64 (2 Η, d, J = 2.5 Ηz, CH2NH2), 4.43-4.52 (2 H, 
m, 2 x CHCH2CH(CΗ3)2), 4.34 (2 Η, d, J = 5.0 Ηz, NHCH2), 3.59-3.61 (5 Η, m, 
CH2COO  +  COOCH3),  1.55-1.69  (6  H,  m,  2  x  CHCH2CH(CΗ3)2  +  2  x 
CHCH2CH(CΗ3)2),  0.85-0.94  (12  Η,  m,  2  x  CH(CΗ3)2); 
13C  NMR  (100  MHz, 
DMSO-d6): ʴ (ppm) = 172.5 (Cq), 171.7 (Cq), 170.9 (Cq), 166.5 (Cq), 163.6 (Cq), 
152.3 (Cq), 148.8 (Cq), 142.8 (Cq), 139.0 (CH), 137.5 (Cq), 132.5 (Cq), 129.6 (CH), 
127.7  (CH),  126.9  (CH),  124.9  (CH),  121.2  (CH),  119.3  (CH),  119.2  (CH),  52.5 
(CH3), 51.8 (CH), 51.6 (CH), 42.1 (CH2), 42.0 (CH2), 40.8 (CH2), 40.4 (CH2), 24.4 
(CH3), 23.1  (CH3), 22.9 (CH3), 22.8(CH3), 21.8 (CH), 21.2 (CH) (One CH2 peak 
overlap with solvent peak); MSES: m/z = 659.5 [M+H]
+; HRMS (ES): Calcd for  Experimental  
   
C36H47N6O6  659.3557 ([M+H]
+), found 659.3565; FT-IR (solid): ν max cm
-1 = 3292 
(w), 2957 (w), 1658 (s), 1535 (s), 1200 (m), 1231 (m), 1175 (m), 1137 (m).  
 
Methyl 2-(4-((R)-2-((S)-2-(4-((6-(3-(((benzyloxy)carbonyl)imino)-7-oxo-
11,14,17,20-tetraoxa-2,4,8-triazahenicosyl)picolinamido)methyl)benzamido)-4-
methylpentanamido)-4-methylpentanamido)phenyl)acetate  
(104) 
 
 
 
Compound 103 (0.35 g, 0.53 mmol) was dissolved in DCM (40 mL). Et3N (0.22 mL, 
1.59 mmol) and EDC (0.24 g, 1.30 mmol) were added to the reaction mixture which 
was stirred until it formed a clear solution. Compound 74 (0.25 g, 0.53 mmol) was 
added and the resulting solution was further stirred for 48 hrs at room temperature. In 
vacuo  removal  of  the  solvent  and  purification  of  the  resulting  crude  product  by 
column chromatography (SiO2, 1:2 MeOH/DCM) afforded 104 (0.40 g, 86%) as a 
white solid. MP = 86-88 ˚C; 
1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 10.06 (1 Η, s, 
NH), 9.89 (1 Η, s, NH), 9.76 (1 Η, s, NH), 9.38 (1 Η, s, NH), 8.49-8.51 (1 Η, m, CH), 
7.91-8.05 (4 Η, m, 3 x CH + NH), 7.83-7.84 (2 Η, d,  J = 2.5 Ηz,  CH), 7.62-7.64 (1 Η, 
d,  J = 5.0 Ηz,  CH), 7.52-7.54 (2 Η, d,  J = 5.0 Ηz,  CH), 7.24-7.28 (5 Η, m, CH), 
7.17-7.19 (2 Η, d,  J = 5.0 Ηz, CH), 4.87 (2 Η, s, CH2), 4.59 (4 Η, m, 2 x CH2), 4.39-
4.50 (2H, m, 2 x CHCH2CH(CΗ3)2), 3.58-3.59 (5 Η, m, CH2 + CH3), 3.38-3.46 (15 Η, 
m, 6 x CH2 + CH3), 3.19-3.23 (6 Η, m, 3 x CH2), 2.36 (2 Η, s, CH2), 1.55-1.68 (6 H, 
m,  2  x  CHCH2CH(CΗ3)2  +  2  x  CHCH2CH(CΗ3)2),  0.85-0.95  (12  Η,  m,  2  x 
CH(CΗ3)2); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 172.5 (Cq), 172.2 (Cq), 
171.7 (Cq), 170.9 (Cq), 170.6 (Cq), 166.6 (Cq), 166.3 (Cq), 137.7 (Cq), 137.6 (Cq), 
129.5  (CH),  129.3  (CH),  129.3  (CH),  128.4  (CH),  127.9  (CH),  127.6  (CH),127.4 
(CH), 126.9 (CH), 119.3 (CH), 119.2 (CH), 71.2 (CH2), 69.7 (CH2), 69.7 (CH2), 69.5 Experimental  
   
(CH2), 69.0 (CH2), 65.4 (CH2), 58.0 (CH3), 51.7 (CH), 51.6 (CH), 42.2 (CH2), 42.2 
(CH2), 40.4 (CH2), 38.5 (CH2), 37.2 (CH2), 24.4 (CH3), 24.4 (CH3), 23.1 (CH3), 21.8 
(CH3),  21.6  (CH3),  21.4  (CH),  21.2  (CH);  MSES:  m/z  =1119.0  [M+Na]
+;  FT-IR 
(solid): ν max cm
-1 =  3282 (w), 2952 (w), 1736 (m), 1627 (s), 1571 (s), 1522 (s), 1310 
(m), 1231 (m), 1100 (m). 
 
2-(4-((R)-2-((S)-2-(4-((6-(3-(((Benzyloxy)carbonyl)imino)-7-oxo-11,14,17,20-
tetraoxa-2,4,8-triazahenicosyl)picolinamido)methyl)benzamido)-4- 
methylpentanamido)-4-methylpentanamido)phenyl)acetic acid  
(105) 
 
 
 
Compound 104 (0.31 g, 0.28 mmol) was dissolved in THF (30 mL) and added to 
Me3SiOK  (54  mg,  0.42  mmol)  suspended  in  THF  (30  mL)  under  nitrogen.  After 
overnight  stirring, DCM (20 mL)  and H2O (20 mL) were  added and the reaction 
mixture was cooled to 0 ˚C. Citric acid (0.1 M) was added dropwise until the pH was 
6-7. In vacuo removal of the organic phase and purification of the resulting crude 
product by column chromatography (SiO2, 3:50 MeOH/DCM) afforded 105 (0.25g, 
83%) as a white solid. MP = 101-102 ˚C;
 1H NMR (400 MHz, DMSO): ʴ (ppm) = 
10.25(1 Η, s(b), NH), 10.06 (1 Η, s, NH), 9.87 (1 Η, s, NH), 9.76 (1 Η, s, NH), 9.38 
(1 Η, s, NH), 8.96 (1 Η, s(b), NH), 8.49 (1 Η, m, CH), 7.97-8.05 (2 Η, m, CH + NH), 
7.83-7.85 (2 Η, d,  J = 2.5 Ηz,  CH), 7.61-7.63 (1 Η, d,  J = 5.0 Ηz,  CH), 7.52-7.54 (2 
Η, d,  J = 5.0 Ηz,  CH), 7.39-7.41 (2 Η, d,  J = 5.0 Ηz,  CH), 7.24-7.27 (5 Η, m, CH), 
7.16-7.18 (2 Η, d,  J = 5.0 Ηz, CH), 4.87 (2 Η, s, CH2), 4.59 (4 Η, s, 2 x CH2), 4.40-
4.50 (2 H, m, 2 x CHCH2CH(CΗ3)2), 3.46-3.49 (17 Η, overlapped with water peak, 7 
x CH2 + CH3), 3.18-3.21 (6 Η, m, 3 x CH2), 2.36 (2 Η, s, CH2), 1.55-1.68 (6 H, m, 2 x Experimental  
   
CHCH2CH(CΗ3)2 + 2 x CHCH2CH(CΗ3)2), 0.86-0.93 (12 Η, m, 2 x CH(CΗ3)2); 
13C 
NMR (100 MHz, DMSO-d6): ʴ (ppm) = 172.7 (Cq), 172.5 (Cq), 172.2 (Cq), 170.9 
(Cq), 170.6 (Cq), 166.6 (Cq), 142.9 (Cq), 137.7 (Cq), 137.3 (Cq), 132.4 (Cq), 130.0 
(Cq), 129.5 (CH), 128.2 (CH), 127.9 (CH), 127.6 (CH), 127.4 (CH), 126.9 (CH), 
119.3 (CH), 119.1 (CH), 71.2 (CH2), 69.7 (CH2), 69.6 (CH2), 69.5 (CH2), 69.0 (CH2), 
65.4 (CH2), 58.0 (CH3), 52.6 (CH), 51.7 (CH), 42.2 (CH2), 24.4 (CH3), 23.1 (CH3), 
22.7 (CH3), 21.8 (CH3), 21.6 (CH), 21.2 (CH), (3 x CH2 peaks overlap with solvent  
peak); MSES: m/z =1104.9 [M+Na]
+; Anal.Calcd for C56H75N9O13: C, 62.15; H, 6.98; 
N,11.64. Found: C, 61.19; H, 7.15; N,11.15.  FT-IR (solid): ν max cm
-1 = 3282 (m) (b), 
2951(w), 1736 (m), 1633 (s), 1532 (s), 1310 (m), 1234 (m), 1085 (m). 
 
2-(4-((R)-2-((S)-2-(4-((6-(3-Imino-7-oxo-11,14,17,20-tetraoxa-2,4,8- 
triazahenicosyl)picolinamido)methyl)benzamido)-4-methylpentanamido)-4- 
methylpentanamido)phenyl)acetic acid  
(93) 
 
 
Compound 105 (0.20 g, 0.18 mmol) was dissolved in MeOH (20 mL). Pd/C (20 mg, 
0.18  mmol)  was  added  and  the  reaction  mixture  was  stirred  for  8  hrs  at  room 
temperature under hydrogen (1 atm). The reaction mixture was filtered through celite 
and dried in vacuo. Purification of the resulting solid by precipitation from MeOH 
using Et2O afforded 93 (150 mg, 79%) as a white solid. MP = 121-123 ˚C; -4.2 
o (c 
0.2, MeOH);
 1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 9.50-9.61 (1 Η, s(b), NH), 
9.39 (1 Η,  s,  NH),
  8.72 (2 Η, s(b), 2 x NH), 8.15 (1 Η, m, CH), 7.97-8.05 (2 Η, m, 
CH), 7.83-7.85 (2 Η, d,  J = 2.5 Ηz,  CH), 7.54 (2 Η, s(b),  J = 5.0 Ηz,  CH), 7.34-7.36 
(2  Η,  m,  CH),  7.01-7.07  (2  Η,  d,    J  =  5.0  Ηz,  CH),  4.30-4.65  (6  H,  m,  2  x 
CHCH2CH(CΗ3)2 + 2 x CH2), 3.33-3.41 (17 Η, overlapped with water peak, CH2 + Experimental  
   
CH3),  3.18-3.22  (6  Η, m,  3  x  CH2),  2.36  (2 Η,  s,  CH2),  1.59-1.63  (6  H,  m,  2 x 
CHCH2CH(CΗ3)2 + 2 x CHCH2CH(CΗ3)2), 0.85-0.95 (12 Η, m, 2 x CH(CΗ3)2); 
 13C 
NMR (100 MHz, DMSO-d6): ʴ (ppm) = 176.3 (Cq), 172.2 (Cq), 170.5 (Cq), 170.3 
(Cq), 163.8 (Cq), 156.2 (Cq), 143.1 (Cq), 136.0 (Cq), 134.2 (Cq), 132.1 (CH), 129.2 
(CH), 129.1 (CH), 127.7 (CH), 127.6 (CH), 127.0 (CH), 126.8 (CH), 120.7 (CH), 
119.1 (CH), 119.0 (CH), 71.2 (CH2), 69.7 (CH2), 69.7 (CH2), 69.5 (CH2), 69.0 (CH2), 
58.0 (CH3), 54.9 (CH), 52.0 (CH), 44.6 (CH2), 41.5 (CH2), 40.1 (CH2), 38.6 (CH2), 
34.8 (CH2), 24.6 (CH3), 23.4 (CH3), 22.6 (CH3), 22.6 (CH3), 21.9 (CH), 21.1 (CH); 
MSES:  m/z  =  970.8[M+Na]
+;  HRMS  (ES):  Calcd  for  C48H70N9O11  948.5196 
([M+H]
+), found  948.5164; FT-IR (solid): ν max cm
-1 = 3270 (m) (b), 2952 (w), 1642 
(s), 1528 (s). 
 
(6R, 9R, 12R)-Methyl 6, 9, 12-triisobutyl-2,2-dimethyl-4,7,10-trioxo-3-oxa-5,8,11-
triazatridecan-13-oate  
(107) 
 
 
Boc-Leu-OH (0.54 mg, 2.15 mmol) was dissolved in DMF (5 mL). A solution of 
HOBt (395 mg, 2.58 mmol) and DCC (444 mg, 2.15 mmol) in DMF (10 mL) was 
added dropwise to the reaction mixture at 0 
oC which was stirred for 1 hr at room 
temperature. Compound 106 (523 mg, 2.15 mmol) and iPr2EtN (1.33 g, 10.3 mmol) 
were added successively at 0 
oC and the resulting solution was further stirred at room 
temperature  for  12  hrs.  The  reaction  mixture  was  added  to  EtOAc  (25  mL),  the 
resulting white precipitate (dicyclohexyl urea) was filtered off and the filtrate was 
washed with aq. 10% NaHCO3 (10 mL), aq. 10% citric acid (10 mL) and water (10 
mL) successively. The organic layer was dried over MgSO4 concentrated in vacuo. 
Purification of the resulting crude product by column chromatography (SiO2, 15:85 
EtOAc/PE) afforded 107 (0.66 mg, 65%) as a white solid. MP = 153 - 154 
oC. 
1H-
NMR (300 MHz, CDCl3): ʴ(ppm) = 6.69 (1 H, d, J = 6.6 Hz, NH), 6.61 (1 H, d, J = 
7.7 Hz, NH), 4.99 (1 H, m, NH), 4.58 - 4.51 (1 H, m, CHCH2CH(CH3)2), 4.48 - 4.41 
(1  H,  m,  CHCH2CH(CH3)2),  4.07  (1  H,  m,  CHCH2CH(CH3)2),  3.69  (3  H,  s, 
COOCH3), 1.69 - 1.51 (9 H, m, 3 x CHCH2CH(CH3)2 + 3 x CHCH2CH(CH3)2), 1.41 Experimental  
   
(9 H, s, OC(CH3)3), 0.91 - 0.87 (18 H, m, 3 x CH(CH3)2); 
13C-NMR (75 MHz, CDCl3): 
ʴ(ppm) = 173.1 (Cq), 172.7 (Cq), 171.5 (Cq), 155.7 (Cq), 80.1 (Cq), 53.0 (CH), 52.2 
(CH), 51.6 (CH), 50.7 (CH3), 41.3 (CH2), 41.0 (CH2), 40.6 (CH2), 28.3 (CH3), 24.7 
(CH), 24.6 (CH), 22.9 (CH), 22.8 (CH3), 22.1 (CH3), 21.8 (CH3); MSES: m/z = 494.4 
[M+Na]
+;  HRMS  (ES):  Calcd  for  C24H45N3NaO6  494.3206  ([M+Na]
+),  found  
494.3201; FT-IR (solid): ν max cm
-1 = 3292 (w)(b), 2956 (m),  1751 (m), 1643 (s), 
1539 (m),1367 (m). 
 
(S)-1-(((R)-1-(((R)-1-Methoxy-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-
oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-aminium 
(108) 
 
                                                
Compound 107 (0.5 g, 1.02 mmol) was stirred in 20% v/v TFA/DCM (20 mL) at 
room temperature for 3 hrs. In vacuo drying of the reaction mixture after the addition 
of toluene (3 x 3 mL) followed by crystallization from diethyl ether afforded 108 
(0.50 g, 100%) as a white solid compound. MP = 200-202˚C; 
 1H NMR (400 MHz, 
CDCl3): ʴ (ppm) = 8.61 (1 Η, d, J = 5.0 Ηz, NH), 8.44 (1 Η, d, J = 5.0 Ηz, NH), 8.13 
(2 Η, s(b), NH2), 4.27-4.33 (2 H, m, CH), 3.78 (1 H, m,  CH), 3.61 (3 H, s, COOCH3), 
1.40-1.70 (9 H, m, 3 x CH2CH(CΗ3)2 + 3 x CH2CH(CΗ3)2), 0.81-0.93 (18 Η, m, 3 x 
CH(CΗ3)2); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm)  =  173.9 (Cq),  172.7 (Cq), 
169.7 (Cq), 53.0 (CH), 52.1 (CH), 51.9 (CH), 51.2 (CH3), 41.4 (CH2), 40.8 (CH2), 
39.9 (CH2), 25.4 (CH3), 25.1 (CH3), 24.7 (CH3), 24.1 (CH3), 23.8 (CH3), 23.3 (CH), 
23.2  (CH),  22.2  (CH);  MSES:  m/z  =  372.4  [M+Η]
+;  HRMS  (ES):  Calcd  for  
C19H37N3NaO4 371.2862 ([M+Na]
+), found  371.2859; FT-IR (solid): ν  max cm
-1 = 
3287 (w), 2962 (w), 1697 (s), 1651 (s), 1518 (m), 1198 (m),1134 (s). 
 
 
 
 
 
 
 
 Experimental  
   
(R)-methyl 2-((R)-2-((S)-2-(4-(((Tert-butoxycarbonyl)amino)methyl)benzamido)-
4-methylpentanamido)-4-methylpentanamido)-4-methylpentanoate 
(109) 
 
 
 
Boc-Protected  p-methyl  aminobenzoic  acid  (1.00  g,  3.98  mmol)  was  dissolved  in 
DCM (30 mL). iPr2EtN (1.80 g, 13.7 mmol), EDC.HCl (1.84 g, 9.84 mmol), HOBt 
(1.6 g, 11.85 mmol) and compound 108 (1.50 g, 3.86 mmol), previously dissolved in 
DMF (5 mL), were added successively and the resulting solution was stirred at room 
temperature for 72 hrs. DCM (40 mL) and aq. 1M KHSO4 (30 mL) were added to the 
reaction mixture. The organic layer was separated, washed with sat. Na2CO3 (30 mL) 
and  brine  (30  mL),  and  dried  over  MgSO4.  In  vacuo  removal  of  the  solvent  and 
purification  of  the  resulting  crude  by  column  chromatography  (SiO2,  1:20 
MeOH/DCM) afforded 109 (1.30 g, 55%) as a white solid. MP = 102-104 ˚C;
 1H 
NMR (400 MHz, CDCl3): ʴ (ppm) = 8.37 (1 Η, d, J = 5.0 Ηz, NH), 8.13 (1 Η, d, J = 
5.0 Ηz, NH), 7.93(1 Η, d, J = 5.0 Ηz, NH), 7.83 (2 Η, d, J = 5.0 Ηz, CH), 7.43 (1 Η, t, 
J  =  2.5  Ηz,  NHBoc),  7.31  (2  Η,  d,  J  =  5.0  Ηz,  CH),  4.47-4.51  (1  H,  m, 
CHCH2CH(CH3)2),  4.33-4.37  (1  H,  m,  CHCH2CH(CH3)2),  4.26-4.27  (1  H,  m, 
CHCH2CH(CH3)2), 4.17 (2 Η, d, J = 5.0 Ηz, CH2NH), 3.60 (3 Η, s, COOCH3), 1.46-
1.70 (9 H, m, 3 x CHCH2CH(CH3)2) + 3 x CHCH2CH(CH3)2), 1.40 (9 H, s, 3 x 
OC(CH3)3), 0.82-0.91 (18 Η, m, 3 x CH(CH3)2); 
13C NMR (100 MHz, DMSO-d6): ʴ 
(ppm) = 172.5 (Cq), 172.0 (Cq), 171.9 (Cq), 166.2 (Cq), 155.8 (Cq), 143.6 (Cq), 
132.5 (Cq), 127.5 (CH), 126.5 (CH), 77.9 (Cq), 51.9 (CH), 51.7 (CH), 51.1 (CH), 
50.1 (CH3), 43.1 (CH2), 41.1 (CH2), 40.4 (CH2), 40.0 (CH2), 28.2 (CH3), 24.4 (CH3), 
24.1 (CH3), 23.0 (CH3), 22.9 (CH3), 22.7 (CH3), 21.8 (CH), 21.5 (CH), 21.2 (CH); Experimental  
   
MSES:  m/z  =  627.5  [M+Na]
+;  HRMS  (ES):  Calcd  for  C32H52N4NaO7  627.3734 
([M+Na]
+), found  627.3727; FT-IR (solid): ν max cm
-1 = 3269 (w), 2955 (w), 2361 
(m), 1633 (s), 1538 (s), 1161 (s). 
 
(R)-2-((R)-2-((S)-2-(4-(((Tert-butoxycarbonyl)amino)methyl)benzamido)-4-
methylpentanamido)-4-methylpentanamido)-4-methylpentanoic acid 
(110) 
 
 
Compound 109  (1.1 g, 1.80 mmol) was  dissolved in  THF (30 mL) and added to 
Me3SiOK  (0.35  g,  2.73  mmol)  suspended  in  THF  (30  mL)  under  nitrogen.  After 
overnight  stirring, DCM (20 mL)  and H2O (20 mL) were  added and the reaction 
mixture was cooled to 0 
°C. Citric acid (0.1 M) was added dropwise until the pH was 
6-7. The organic phase was separated and dried over MgSO4. In vacuo removal of the 
organic solvent afforded 110 (1.00 g, 94%) as a white solid. MP = 120-122 ˚C; 
1H 
NMR (400 MHz, DMSO-d6): ʴ (ppm) = 12.43 (1 Η, s(b), COOH), 8.37 (1 Η, d, J = 
5.0 Ηz, NH), 7.95 (1 Η, d, J = 5.0 Ηz, NH), 7.93 (1 Η, d, J = 5.0 Ηz, NH), 7.82 (2 Η, 
d, J = 5.0 Ηz, CH), 7.43 (1 Η, t, J = 2.5 Ηz, NHBoc), 7.31 (2 Η, d, J = 5.0 Ηz, CH), 
4.46-4.52 (1 H, m, CHCH2CH(CH3)2), 4.31-4.37 (1 H, m, CHCH2CH(CH3)2), 4.15-
4.22 (3 Η, m, CHCH2CH(CH3)2 + NHCH2), 1.42-1.68 (9 H, m, 3 x CHCH2CH(CH3)2 
+ 3 x CHCH2CH(CH3)2), 1.39 (9 H, s, C(CH3)3), 0.80-0.91 (18 Η, m, 3 x CH(CH3)2); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 173.8 (Cq), 171.9 (Cq), 171.8 (Cq), 
166.2 (Cq), 155.8 (Cq), 143.6 (Cq), 132.6 (Cq), 127.5 (CH), 126.5 (CH), 77.8 (Cq), 
51.9 (CH), 51.7 (CH), 50.1 (CH), 43.1 (CH2), 40.7 (CH2), 40.1 (CH2), 39.8 (CH2), 
28.2 (CH3), 24.4 (CH3), 24.2 (CH3), 24.0 (CH3), 23.0 (CH3), 22.8 (CH3), 21.7 (CH), 
21.4  (CH),  21.3  (CH);  MSES:  m/z  =  613.5  [M+Na]
+;  HRMS  (ES):  Calcd  for Experimental  
   
C31H51N4O7 591.3757 ([M+H]
+), found 591.3756; FT-IR (solid): ν  max cm
-1 = 3274 
(m), 2957 (m), 2360 (m), 2339 (m), 2019 (m), 1974 (m), 1635 (s), 1539 (s), 1164 (s). 
 
Methyl 2-(4-((R)-2-((R)-2-((S)-2-(4-(((tert-
butoxycarbonyl)amino)methyl)benzamido)-4-methylpentanamido)-4-
methylpentanamido)-4-methylpentanamido)phenyl)acetate  
(111) 
 
 
 
Compound 110 (1.00 g, 1.69 mmol) was dissolved in DCM (20 mL). iPr2EtN (1.1 mL, 
5.60 mmol), EDC.HCl (0.80 g, 4.37 mmol), HOBt (0.70 g, 5.19 mmol) and p-amino 
benzylcarboxylic acid methyl ester (0.30 g, 1.82 mmol), previously dissolved in DMF 
(5  mL),  were  added  successively  and  the  resulting  solution  was  stirred  at  room 
temperature for 72 hours. DCM (40 mL) and aq. 1M KHSO4 (20 mL) were added to 
the reaction mixture. The organic layer was separated, washed with sat. Na2CO3 (20 
mL) and brine (20 mL) successively, and dried over MgSO4. In vacuo removal of the 
solvent and purification of the resulting crude product by column chromatography 
(SiO2, 1:25 MeOH/DCM) afforded 111 (1.00 g, 80%) as a white solid. MP = 118-120 
˚C; 
 1H NMR (400 MHz, DMSO): ʴ (ppm) =  9.77 (1 Η, s, NH), 8.22 (1 Η, d, J = 5.0 
Ηz, NH), 8.13 (1 Η, d, J = 5.0 Ηz, NH), 7.89 (1 Η, d, J = 5.0 Ηz, NH), 7.81-7.84 (2 Η, 
m, 2 x CH), 7.53-7.59 (2 Η, m, 2 x CH), 7.43 (1 Η, t, J = 2.5 Ηz, NHBoc), 7.29-7.32 
(2  Η,  m,  2  x  CH),  7.13-7.19  (2  Η,  m,  2  x  CH),  4.23-4.49  (3  H,  m,  3  x 
CHCH2CH(CH3)2), 4.16 (2 Η, J = 2.5 Ηz, NHCH2), 3.60-3.61 (5 Η, m, CH2COOMe 
+ COOCH3), 1.46-1.70 (9 H, m, 3 x CHCH2CH(CH3)2 + 3 x CHCH2CH(CH3)2), 1.39 
(9 H, s, C(CH3)3), 0.82-0.92 (18 Η, m, 3 x CH(CΗ3)2); 
13C NMR (100 MHz, DMSO-
d6): ʴ (ppm) = 172.7 (Cq), 172.2 (Cq), 172.1 (Cq), 171.4 (Cq), 171.2 (Cq), 166.9 (Cq), Experimental  
   
156.3 (Cq), 144.1 (Cq), 138.0 (Cq), 130.0 (CH), 128.0 (CH), 119.9 (CH), 119.7 (CH), 
78.4 (Cq), 52.5 (CH), 52.3 (CH), 52.1 (CH), 51.5 (CH3), 43.6 (CH2), 41.3 (CH2), 40.9 
(CH2), 40.7 (CH2), 40.1 (CH2), 28.7 (CH3), 24.7 (CH3), 23.6 (CH3), 23.4 (CH3), 23.3 
(CH3), 22.0 (CH), 21.9 (CH), 21.7 (CH); MSES: m/z = 760.6 [M+Na]
+; HRMS (ES): 
Calcd for C39H59N5NaO7 760.4262 ([M+Na]
+), found 760.4243; FT-IR (solid): ν max 
cm
-1 = 3274 (m), 2956 (m), 2360 (m), 2019 (m), 1634 (s), 1538 (s), 1520 (s), 1164 
(w). 
 
(4-(((S)-1-(((R)-1-(((R)-1-((4-(2-Methoxy-2-oxoethyl)phenyl)amino)-4-methyl-1-
oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl- 
1-oxopentan-2-yl)carbamoyl)phenyl)methanaminium  
(112) 
 
 
 
Compound 111 (1.0 g, 1.40 mmol) was stirred in 20% (v/v) TFA/DCM (20 mL) at 
room temperature for 3 hrs. In vacuo drying of the reaction mixture after the addition 
of toluene (3 x 3 mL) followed by precipitation from diethyl ether afforded 112 (1.00 
g, 100%) as a white solid compound. MP = 128-130 ˚C;
  
1H NMR (400 MHz, DMSO-
d6):ʴ (ppm) = 9.92 (1 Η, s, NH), 9.80 (1 Η, s, NH), 8.50-8.53 (1 Η, m, NH), 8.24 (2 Η, 
s(b), NH2), 8.05 (1 Η, d, J = 5.0 Ηz, NH), 7.89-7.94 (2 Η, m, 2 x CH), 7.51-7.58 (4 Η, 
m, 4 x CH), 7.14-7.19 (2 Η, m, 2 x CH), 4.20-4.52 (3 H, m, 3 x CH2CH(CH3)2), 4.11 
(2  Η,  apparent  triplate,  J  =  2.5  Ηz,  CH2),  3.60-3.61  (5  Η,  m,  CH2COOCH3  + 
COOCH3), 1.46-1.70 (9 H, m, 3 x CHCH2CH(CH3)2 + 3 x CHCH2CH(CH3)2), 0.80-
0.92 (18 Η, m, 3 x CH(CH3)2);
 13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 174.6 
(Cq), 174.2 (Cq), 172.1 (Cq), 173.9 (Cq), 173.1 (Cq), 168.2 (Cq), 160.4 (Cq), 139.8 
(Cq), 136.2 (Cq), 131.4 (CH), 130.7 (CH), 120.0 (CH), 121.6 (CH), 121.4 (CH), 52.4 
(CH), 52.1 (CH), 51.5 (CH), 42.4 (CH2), 41.3 (CH2), 41.0 (CH2), 40.0 (CH2), 26.6 
(CH3), 26.4 (CH3), 25.3 (CH3), 25.2 (CH3), 25.0 (CH3), 24.0 (CH3), 23.8 (CH3), 23.7 Experimental  
   
(CH), 23.6 (CH), 23.4 (CH); MSES: m/z = 660.5 [M+Na]
+; HRMS (ES): Calcd for 
C35H52N5O6  638.3917 ([M+H]
+), found 638.3907; FT-IR (solid): ν max cm
-1 = 3271 
(w), 2956 (w), 2360 (m), 2340 (m),  1636 (s), 1536 (s), 1199 (s), 1139 (s). 
 
Compound 113a 
 
                                          
 
Compound 36 (0.42 g, 1.20 mmol) was dissolved in DCM (30 mL). iPr2EtN (0.73 mL, 
4.20 mmol), EDC.HCl (0.55 g, 3.00 mmol), HOBt (0.49 g, 3.60 mmol) and 112 (0.75 
g, 1.20 mmol) were successively added to the reaction mixture which was stirred for 
24 hours at room temperature. DCM (40 mL) and aq. 1M KHSO4 (20 mL) were added 
to the reaction mixture. The organic layer was separated, washed with sat. Na2CO3 
(20 mL) and brine (20 mL), and dried over MgSO4. In vacuo removal of the organic 
solvent and purification of the resulting crude by column chromatography (SiO2, 1:50 
MeOH/DCM) afforded 113a (0.70 g, 60%) as a white solid compound. MP = 92-94 
˚C; 
 1H NMR (400 MHz, CDCl3): ʴ (ppm) = 9.90 (1 H, s, NH), 9.77 (1 H, s, NH), 8.83 
(1 Η, t, J = 2.5 Ηz, NH), 8.43 (1 Η, d, J = 2.5 Ηz, NH), 7.94-8.03 (3 Η, m, 2 x CH + 
NH), 7.83-7.86 (2 Η, m, CH), 7.52-7.59 (2 Η, m, CH), 7.36-7.43 (3 Η, m, CH), 7.12-
7.19 (2 Η, m, CH), 4.87 (2 Η, s, CH2), 4.59 (2 Η, d, J = 2.5 Ηz, CH2), 4.47-4.52 (1 H, 
m, CHCH2CH(CH3)2), 4.22-4.39 (2 H, m, 2 x CHCH2CH(CH3)2), 3.61 (5 Η, m, CH2 + 
COOCH3), 1.46-1.70 (9 H, m, 3 x CHCH2CH(CH3)2 + 3 x CHCH2CH(CH3)2), 1.33 
(18 H, s, 2 x OC(CH3)3), 0.81-0.91 (18 Η, m, 3 x CH(CH3)2);
 13C NMR (100 MHz, 
CDCl3): ʴ (ppm) = 172.9 (Cq), 172.5 (Cq), 172.1 (Cq), 171.2 (Cq), 166.7 (Cq), 166.6 
(Cq), 164.1 (Cq), 157.3 (Cq), 152.6 (Cq), 149.2 (Cq), 142.9 (Cq), 139.2 (CH), 138.1 
(Cq),  133.3 (Cq), 130.0  (CH),  129.7 (CH), 128.1 (CH), 127.5 (CH), 123.4 (CH), Experimental  
   
120.7 (CH), 119.9 (CH), 119.7 (CH), 82.1 (Cq), 51.8 (CH), 51.6 (CH), 51.4 (CH), 
50.2 (CH2), 42.2 (CH2), 40.4 (CH2), 39.4 (CH2), 27.9 (CH3), 24.9 (CH3), 24.7 (CH3), 
23.6 (CH3), 23.5 (CH3), 23.2 (CH3), 22.3 (CH3), 22.1 (CH3), 22.0 (CH), 21.9 (CH), 
21.7  (CH);  MSES:  m/z  =  995  [M+Na]
+;  HRMS  (ES):  Calcd  for  C52H73N7NaO11  
994.5266 ([M+Na]
+), found 994.5246; FT-IR (solid): ν max cm
-1 = 3294 (w), 2955 (w), 
1739 (s), 1634 (s), 1518 (s), 1366 (s), 1227 (s), 1141 (m). 
 
(6-((4-(((S)-1-(((R)-1-(((R)-1-((4-(2-Methoxy-2-oxoethyl)phenyl)amino)-4-methyl-
1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4- 
methyl-1-oxopentan-2-yl)carbamoyl)benzyl)carbamoyl)pyridin-2- 
yl)methanaminium  
(113) 
 
 
 
Compound 113a (0.70 g, 0.72 mmol) was stirred in 20% (v/v) TFA/DCM (20 mL) at 
room temperature for 3 hrs. In vacuo drying of the reaction mixture after the addition 
of toluene (3 x 3 mL) followed by precipitation from diethyl ether afforded 113 (0.70 
g, 100%) as a white solid compound. MP = 122-127 ˚C; 
 1H NMR (400 MHz, DMSO-
d6): ʴ (ppm) = 9.92 (1 H, s, NH), 9.79 (1 H, s, NH), 9.68 (1 Η, t, J = 5.0 Ηz, NH), 
8.42 (1 Η, d, J = 5.0 Ηz, CH), 8.35 (1 Η, s, NH2), 8.03-8.10 (2 Η, m, CH + NH), 7.85-
7.85 (2 Η, m, CH), 7.66-7.68 (1 Η, m, CH), 7.52-7.58 (2 Η, m, CH), 7.39-7.42 (2 Η, 
m, CH), 7.13-7.19 (2 Η, m, CH), 4.63 (2 Η, d, J = 5.0 Ηz, NHCΗ2), 4.47-4.52 (1 H, m, 
CHCH2CH(CH3)2), 4.31-4.43 (4 H, m, 2 x CHCH2CH(CH3)2 + CH2),  3.59-3.63 (5 Η, 
m,  CH2COOMe  +  COOCH3),  1.46-1.69  (9  H,  m,  3  x  CHCH2CH(CH3)2  +  3  x 
CHCH2CH(CH3)2),  0.81-0.91  (18  Η,  m,  3  x  CH(CH3)2); 
13C  NMR  (100  MHz, 
DMSO-d6): ʴ (ppm) = 172.2 (Cq), 172.1 (Cq), 171.8 (Cq), 171.3 (Cq), 166.5 (Cq), 
164.0 (Cq), 152.7 (Cq), 149.1 (Cq), 143.1 (Cq), 139.4 (CH), 133.2 (Cq), 130.0 (CH), Experimental  
   
129.9 (CH), 128.1 (CH), 127.2 (CH), 125.3 (CH), 121.7 (CH), 119.6 (CH), 119.6 
(CH), 52.1 (CH), 51.8 (CH), 51.2 (CH), 42.3 (CH2), 42.2 (CH2), 40.2 (CH2), 39.8 
(CH2), 39.4 (CH2), 24.6 (CH3), 24.4 (CH3), 23.3 (CH3), 23.0 (CH3), 23.0 (CH3), 22.0 
(CH3), 21.8 (CH3), 21.7 (CH), 21.4 (CH), 21.4 (CH), (CH2 peak overlap with solvent 
peaks); MSES: m/z = 772.6 [M+H]
+; HRMS (ES): Calcd for C42H58N7O7 772.4396 
([M+H]
+), found 772.4408; FT-IR (solid): ν max cm
-1 = 3289 (w), 2958 (w), 1638 (m), 
1535 (s), 1170 (s). 
    
Methyl 2-(4-((R)-2-((R)-2-((S)-2-(4-((6-(3-(((benzyloxy)carbonyl)imino)-7-oxo-
11,14,17,20-tetraoxa-2,4,8-triazahenicosyl)picolinamido)methyl)benzamido)-4-
methylpentanamido)-4-methylpentanamido)-4-
methylpentanamido)phenyl)acetate  
(114) 
 
 
 
 
Compound 113 (0.60 g, 0.70 mmol) was dissolved in DCM (50 mL). Et3N (0.30 mL, 
2.1 mmol) and EDC.HCl (0.32 g, 1.75 mmol) were added and the reaction mixture 
was stirred until it formed a clear solution. Compound 74 (0.33 g, 0.70 mmol) was 
added and the resulting solution was further stirred for 48 hrs at room temperature. In 
vacuo  removal  of  the  solvent  and  purification  of  the  resulting  crude  product  by 
column chromatography (SiO2, 1:20 MeOH/DCM) afforded 114 (0.60 g, 71%) as a 
white solid. MP = 102-107 ˚C; 
 1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 9.94 (1 Η, 
s, NH), 9.90 (1 Η, s, NH), 9.80 (1 Η, s, NH), 9.38 (1 Η, s, NH), 8.42-8.44 (1 Η, m, 
CH), 8.16-8.19 (1 Η, m, CH), 7.92-8.04 (4 Η, m, 1 x CH + NH), 7.81-7.84 (2 Η, m,  
CH), 7.52-7.60 (3 Η, m,  CH), 7.37-7.40 (2 Η, m,  CH), 7.23-7.28 (5 Η, m, CH), 7.17-
7.19 (2 Η, d,  J = 5.0 Ηz, CH), 4.89 (2 Η, s, CH2), 4.60 (5 Η, m, CH2 + CH3), 4.24-Experimental  
   
4.49 (3 H, m, 3 x CHCH2CH(CH3)2), 3.58-3.61 (5 Η, m, CH2 + CH3), 3.38-3.49 (14 Η, 
overlapped with water peak, 7 x CH2), 3.17-3.23 (6 Η, m, 3 x CH2), 2.37 (2 Η, s, CH2), 
1.40-1.66 (9 H, m, 3 x CHCH2CH(CH3)2 + 3 x CHCH2CH(CH3)2), 0.81-0.91 (18 Η, 
m, 6 x CΗ3);
 13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 172.7 (Cq), 172.2 (Cq), 
170.8 (Cq), 166.5 (Cq), 166.4 (Cq), 137.5 (Cq), 129.5 (CH), 129.5 (CH), 129.2 (CH), 
128.2 (CH), 127.6 (CH), 127.6 (CH), 127.4 (CH), 126.9 (CH), 119.4 (CH), 119.2 
(CH), 71.2 (CH2), 69.7 (CH2), 69.7 (CH2), 69.5 (CH2), 69.0 (CH2), 58.0 (CH3), 51.9 
(CH), 51.6 (CH), 50.7 (CH), 42.2 (CH2), 40.4 (CH2), 38.5 (CH2), 24.4 (CH3), 24.2 
(CH3), 23.1 (CH3), 23.0 (CH3), 22.7 (CH3), 21.8 (CH3), 21.5 (CH), 21.5 (CH), 21.1 
(CH), CH2 peaks overlap with solvent peaks; FT-IR (solid): ν  max cm
-1 = 278 (w), 
2954 (w), 1627 (s), 1572 (s), 1529 (m), 1311 (m), 1164 (m). 
 
2-(4-((R)-2-((R)-2-((S)-2-(4-((6-(3-(((benzyloxy)carbonyl)imino)-7-oxo-
11,14,17,20-tetraoxa-2,4,8-triazahenicosyl)picolinamido)methyl)benzamido)-4-
methylpentanamido)-4-methylpentanamido)-4-
methylpentanamido)phenyl)acetic acid  
(115) 
 
 
 
 
Compound 114 (0.50 g, 0.40 mmol) was dissolved in THF (30 mL) and added to 
Me3SiOK  (77  mg,  0.66  mmol)  suspended  in  THF  (30  mL)  under  nitrogen.  After 
overnight  stirring, DCM (20 mL)  and H2O (20 mL) were  added and the reaction 
mixture was cooled to 0 
ºC. Citric acid (0.1 M) was added dropwise until the pH was 
6-7. The organic phase was separated and dried over MgSO4. In vacuo removal of the 
solvent and purification of the resulting crude by column chromatography (SiO2, 3:50 
MeOH/DCM) afforded 115 (0.35 g, 73%) the target compound as a white solid. MP = Experimental  
   
112-114˚C; 
1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 9.77 (1 Η, s, NH), 9.34 (1 Η, 
s, NH), 8.39-8.41 (1 Η, m, CH), 8.12-8.14 (1 Η, m, CH), 7.99-8.01 (2 Η, m(b), NH), 
7.81-7.84 (2 Η, m, CH), 7.51-7.57 (3 Η, m, CH), 7.38-7.41 (2 Η, m, CH), 7.28-7.31 (5 
Η, m, CH), 7.12-7.18 (2 Η, m, CH), 4.95 (2 H, s, CH2), 4.23-4.63 (6 H, m, 3 x 
CHCH2CH(CH3)2 + CH3), 3.36-3.49 (18 Η, overlapped with water peak, 9 x CH2), 
3.16-3.23  (6  Η,  m,  3  x  CH2),  2.39  (2  Η,  s,  CH2),  1.46-1.65  (9  H,  m,  3  x 
CHCH2CH(CH3)2 + 3 x CHCH2CH(CH3)2), 0.81-0.90 (18 Η, m, 3 x CH(CH3)2); 
13C 
NMR (100 MHz, DMSO-d6): ʴ (ppm) = 172.9 (Cq), 172.6 (Cq), 171.4 (Cq), 170.9 
(Cq),  137.6  (CH), 130.1  (Cq),  129.7  (CH), 128.5 (CH), 127.8 (CH),  127.1  (CH), 
126.9 (CH), 119.5 (CH), 71.4 (CH2), 70.1 (CH2), 69.9 (CH2), 69.7 (CH2), 69.2 (CH2), 
58.2 (CH3), 52.0 (CH), 42.8 (CH2), 40.3 (CH2), 38.8 (CH2), 24.4 (CH3), 23.3 (CH3), 
23.0 (CH3), 23.0 (CH), 22.0 (CH), 21.7 (CH) (CH2 peaks overlap with DMSO solvent 
peak); MSES: m/z = 1196.1 [M+H]
+; FT-IR (solid): ν max cm
-1 = 3268 (m) (b), 2950 
(w), 1736 (m),1632 (s), 1529 (s), 1367 (m), 1231 (s), 1091 (m). 
 
2-(4-((R)-2-((R)-2-((S)-2-(4-((6-(3-Imino-7-oxo-11,14,17,20-tetraoxa-2,4,8-
triazahenicosyl)picolinamido)methyl)benzamido)-4-methylpentanamido)-4- 
methylpentanamido)-4-methylpentanamido)phenyl)acetic acid (94) 
 
 
 
Compound 115 (0.3g, 0.25 mmol) was dissolved in MeOH (20 mL) under N2. Pd/C 
(26 mg, 0.2 mmol) was added and the reaction mixture was stirred for 10 hrs at room 
temperature under hydrogen.  The reaction mixture was  filtered through celite and 
dried in vacuo. Purification of the resulting solid by precipitation from MeOH using 
Et2O afforded 94 (200 mg, 75%) as a white solid. MP = 123-125 ˚C; -8.5 
o (c 0.2, 
MeOH); 
 1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 9.87 (1 Η, s, NH), 9.81 (1 Η,  Experimental  
   
s(b),  NH), 9.64 (1 Η, s, NH), 9.58 (1 Η,  s(b),  NH), 8.98 (1 H, s(b), NH), 8.41-8.43 
(1 Η, d, J = 5.0 Ηz, NH), 8.32-8.36 (1 Η, t, J = 5.0 Ηz, NH), 8.13-8.17 (2 Η, m, CH + 
NH), 7.98-8.02 (3 Η, m, 2 x CH + NH), 7.82-7.84 (2 Η, m,  CH), 7.51-7.53 (3 Η, m, 
CH), 7.36-7.40 (2 Η, m, CH), 7.14-7.16 (1 Η, d,  J = 5.0 Ηz, CH), 6.86 (1 Η, s(b), 
NH), 4.17-4.64 (7 H, m, 3 x CH + 2 x CH2), 3.22-3.42 (21 Η, overlapped with water 
peak, CH2 + CH3), 2.37 (2 Η, s, CH2), 1.50-1.68 (9 H, m, 3 x CH + 3 x CH2), 0.84-
0.90 (18 Η, m, 6 x CΗ3); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 172.7 (Cq), 
171.9 (Cq), 170.7 (Cq), 170.3 (Cq), 166.5 (Cq),   164.0 (Cq), 149.3 (Cq), 142.8 (Cq), 
138.6 (CH), 132.7 (Cq), 129.5 (Cq), 129.2 (CH), 127.6 (CH), 127.0(CH), 126.6 (CH), 
120.8 (CH), 119.1 (CH), 71.2 (CH2), 69.7 (CH2), 69.7 (CH2), 69.5 (CH2), 69.0 (CH2), 
58.0 (CH3), 54.9 (CH), 52.0 (CH), 45.4 (CH2), 42.1 (CH2), 40.2 (CH2), 39.8 (CH2), 
38.6 (CH2), 37.6 (CH2), 34.6 (CH3), 24.4 (CH3), 23.2 (CH3), 23.1 (CH3),  22.6 (CH3), 
22.1  (CH3),  21.6 (CH3), 21.5 (CH),  21.2 (CH),  21.0 (CH);  MSES: m/z =  1084.0 
[M+Na]
+; FT-IR (solid): ν max cm
-1 = 3291 (m) (b), 2953 (w), 1634 (s), 1532 (s), 1086 
(m). 
  
 
Methyl 6-((N-((Benzyloxy)carbonyl) carbamimidoyl)carbamoyl)picolinate (119) 
 
 
 
A solution of PyBOP (4.30 g, 8.25 mmol) and NMM (2 mL, 18.20 mmol) in dry 
DMF (15 mL) was added to a solution of 118 (1 g, 5.49 mmol), Cbz guanidine (1.60 g, 
8.25 mmol), and DMF (5 mL). The reaction mixture was stirred at room temperature 
overnight.  Water (100  mL) was  added to  the  reaction mixture and extracted with 
DCM (3 x 100 mL). The combined organic layer was washed with brine (50 mL) and 
dried over MgSO4. In vacuo removal of the organic solvent and purification of the 
resulting crude by column chromatography (SiO2, 3:7, EA/DCM) afforded 119 (1.80 
g, 92%) as a light yellow solid. MP = 144-146 ˚C; 
1H NMR (300 MHz, DMSO-d6): ʴ 
(ppm) = 8.30 (1 H, dd, J = 8.5 Hz, 1.2 Hz, CH), 8.26 (1 H, dd, J = 8.9 Hz, 1.2 Hz, 
CH), 8.00 (1 H, t, J = 8.5 Hz, CH), 7.40-7.20 (5 H, m, CH), 5.10 (2 H, s, CH2), 3.95 
(3 H, s, CH3); 
13C NMR (75 MHz, DMSO-d6): ʴ (ppm) = 165.1 (Cq), 164.7 (Cq), 
162.4 (Cq), 162.8 (Cq), 158.0 (Cq), 148.2 (Cq), 147.5 (Cq), 140.0 (CH), 139.7 (CH), 
128.5 (CH), 128.3 (CH), 127.7 (CH), 126.3 (CH), 66.0 (CH2), 52.8 (CH3); MSES: m/z Experimental  
   
= 379.2 [M+Na]
+, HRMS (ES): Calcd for C17H17N4O5 ([M+H]
+) 357.1199, found 
357.1198; FT-IR (solid): ν max cm
-1 = 3405 (w), 3367 (w), 3030 (w), 2945 (w), 1722 
(m), 1696 (m), 1655 (s), 1560 (m), 1434 (m), 1246 (m), 741 (s), 686 (s). 
 
6-((N-((benzyloxy)carbonyl)carbamimidoyl)carbamoyl)picolinic acid (120) 
 
 
 
Compound 119 (100 mg, 0.28 mmol) was dissolved in 2% H2O/CH3CN (15 mL). 
Et3N (0.12 mL, 0.84 mmol) and LiBr (0.24 g, 2.80 mmol) were added successively to 
the reaction mixture which was stirred for three days at room temperature. Water (20 
mL) and EA (20 mL) were added and the reaction mixture was directly acidified with 
2 M HCl. The organic phase was extracted with water and dried over MgSO4. In 
vacuo removal of the organic solvent then afforded 120 (81 mg, 85 %) as a white 
solid. MP = 241- 243 ˚C; 
1H NMR (300 MHz, DMSO-d6): ʴ (ppm) = 9.15 (1 H, s, 
NH), 8.28-8.40 (3 H, m, CH), 7.30-7.37 (5 H, m, CH), 5.09 (2 H, s, CH2); 
13C NMR 
(75 MHz, DMSO-d6): ʴ (ppm) = 165.2 (Cq), 155.5 (Cq), 153.0 (Cq), 147.7 (Cq), 
147.5 (Cq),  140.9 (CH), 129.3 (CH), 129.0 (CH), 128.9 (CH), 128.6 (CH), 127.0 
(CH), 68.9 (CH2); MSES: m/z = 343.2 [M+H]
+; HRMS (ES): Calcd for C16H15N4O5 
343.1042 ([M+H]
+), found 343.1042; FT-IR (solid): ν max cm
-1 = 3000w(b), 1698m, 
1655 (s), 1533 (m), 1529 (s), 1132 (m), 746 (s), 694 (s).  
 
Methyl 4-((6-((N-((benzyloxy)carbonyl)carbamimidoyl)carbamoyl)picolinamid 
o)methyl)benzoate (121) 
 
 
 
Compound 120 (0.30 g, 0.88 mmol) was dissolved in DCM (50 mL). iPr2NEt (0.35 
mL, 2.00 mmol), EDC.HCl (0.37 g, 1.93 mmol) and HOBt (0.32 g, 2.40 mmol) were 
successively added to  the reaction mixture. 4-(Aminomethyl) benzoic  acid  methyl 
ester (0.20 g, 1.00 mmol) dissolved in DCM:DMF  (1:1) (10 mL) was added and the 
resulting solution was stirred for 24 hrs at room temperature. After the addition of aq. Experimental  
   
1M KHSO4 (40 mL), the organic layer was separated and washed with sat. Na2CO3 
(40 mL) and brine (40 mL). The organic layer was dried over MgSO4 and the solvent 
was removed in vacuo. Purification of the resulting crude by column chromatogrpahy 
(SiO2, 1:2 PE/DCM → 1:50 MeOH/DCM) afforded 121 (0.30 g, 70%) as a white 
solid compound. MP = 226-228 ˚C; 
1H NMR (300 MHz, DMSO-d6): ʴ (ppm) = 12.50 
(1 H, s, NH), 9.93 (1 H, s, NH), 8.96 (2 H, s, NH), 8.30-8.33 (3 H, m, CH), 7.93 (2 H, 
d, J = 9.7 Hz , CH), 7.49 (2 H, d, J = 9.7 Hz , CH), 7.37-7.47 (5 H, m, CH), 5.00 (2 H, 
s, CH2), 4.72 (2 H, d, J = 6.9 Hz,  CH2), 3.83 (3 H, s, CH3); 
13C NMR (75 MHz, 
DMSO-d6): ʴ (ppm) = 166.5 (Cq), 163.6 (Cq), 158.6 (Cq), 149.3 (Cq), 145.2 (Cq), 
140.8 (CH), 137.4 (Cq), 129.8 (CH), 128.8 (CH), 128.1 (CH), 127.9 (CH), 127.7 
(CH), 126.6 (CH), 126.2 (CH), 66.2 (CH2), 52.5 (CH3), 42.6 (CH2); MSES: m/z = 
512.4  [M+Na]
+;  HRMS  (ES):  Calcd  for  C25H24N5O6  490.1726,  found  490.1723 
([M+H]
+); FT-IR (solid): ν max cm
-1 = 3318 (m), 1649 (s), 1535 (w), 1422 (m), 1381 
(m), 1353 (m), 1135 (m), 841 (m), 807 (m), 728 (s), 686 (s), 594 (s), 1384 (s), 1281 
(s), 759 (w), 629 (w). 
 
Benzyl 4-((6-((N'-((benzyloxy)carbonyl)carbamimidoyl)carbamoyl)picoli 
namido)methyl)benzoate (123) 
 
 
 
Compound 120 (0.20 g, 0.58 mmol) was dissolved in DCM (30 mL). iPr2NEt (0.23 
mL, 1.30 mmol), EDC.HCl (0.24 g, 1.30 mmol) and HOBt (0.21 g, 1.56 mmol) were 
successively  added  to  the  reaction  mixture.  4-(Aminomethyl)  benzoic  acid  benzyl 
ester (0.15 g, 0.62 mmol) was added to the reaction mixture which was stirred for 24 
hrs at room temperature. After the addition of 1M KHSO4 (20 mL); the organic layer 
was separated and washed with sat. Na2CO3 (20 mL) and brine (20 mL) successively. 
The organic layer was dried over MgSO4 and the solvent was removed in vacou. 
Purification of the resulting crude by column chromatogrpahy (SiO2, DCM → 1:50 
MeOH/DCM) afforded 123 (0.15 mg, 40%) as a white solid. MP = 238-240 ˚C.  
1H 
NMR (400 MHz, DMSO-d6): ʴ (ppm) = 12.50 (1 H, s, NH), 9.90 (1 H, s, NH), 8.94 (2 
H, s, NH), 8.37-8.34 (3 H, m, CH), 7.94 (2 H, d, J = 5.3 Hz , CH), 7.49 (2 H, d, J = Experimental  
   
5.3 Hz , CH), 7.46-7.25 (10 H, m, CH), 5.33 (2 H, s, CH2), 4.77 (2 H,s,  CH2), 4.71 (2 
H, d, J = 5.4 Hz, CH2NH);
 13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 165.5 (Cq), 
163.2 (Cq), 158.3 (Cq), 149.0 (Cq), 145.0 (Cq), 140.4 (CH), 137.0 (Cq), 136.3 (Cq), 
129.5 (CH), 128.6 (CH), 128.9 (CH), 128.4 (CH), 128.2 (CH), 128.0 (CH), 127.7 
(CH), 127.5 (CH), 127.4 (CH), 126.3 (CH), 125.8 (Cq), 66.1 (CH2), 65.8 (CH2), 42.3 
( CH2 ); MSES: m/z = 566.10 [M+H]
+; HRMS (ES): Calcd for C31H28N5O6 566.2039 
([M+H]
+), found 566.2039; FT-IR (solid): ν max cm
-1 =  3379w, 3032 (w), 1727 (m), 
1709 (m), 1676 (m), 1625 (m), 1300 (s), 1269 (m).  
  
4-((6-(Carbamimidoylcarbamoyl)picolinamido)methyl)benzoic acid (116) 
 
 
 
Compound 123 (80 mg, 0.14 mmol) was dissolved in DCM/ MeOH (1:1) (20 mL). 
Pd/C  (10  mg)  was  added  and  the  reaction  mixture  was  stirred  overnight  at  room 
temperature under hydrogen (1 atm). The reaction mixture was filtered through celite 
and  dried  in  vacuo.  Purification  of  the  resulting  solid  by  precipitation  from 
Et2O/MeOH afforded 116 (25 mg, 52%) as a pale yellow solid.  MP > 300 ˚C; 
1H 
NMR (400 MHz, DMSO-d6): ʴ (ppm) = 12.57 (1 H, s, NH), 10.71 (1 H, s, NH), 9.43 
(1 H, s, NH), 8.62 (2 H, s, NH), 8.40-8.30 (3 H, m, CH), 7.89 (2 H, d, J = 5.4 Hz , 
CH), 7.52 (2 H, d, J = 5.4 Hz , CH), 4.60 (2 H, d, J = 4.1 Hz, CH2NH);
 13C NMR (100 
MHz, DMSO-d6) ʴ (ppm) = 166.0 (Cq), 161.4 (Cq), 148.0 (Cq), 143.4 (Cq), 139.0 
(CH), 128.0 (CH), 126.3 (CH), 125.4 (CH), 124.7 (CH), 40.9 (CH2); HRMS (ES): 
Calcd for C16H16N5O4  342.1202 ([M+H]
+), found 342.1199; FT-IR (solid): ν max cm
-1 
= 3050 (m) broad, 2360 (m), 2157 (m), 1719 (s), 1670 (s), 1541 (s), 1319 (s), 1234 
(s),742 (s).  
 
6-((4-((Benzyloxy)carbonyl)benzyl)carbamoyl)picolinic acid (125) 
 
 Experimental  
   
 
Pyridine-2, 6-dicarboxylic acid (1.40 g, 8.30 mmol) was dissolved in DCM (30 mL) 
and dry DMF (10 mL). iPr2NEt (0.72 mL, 4.15 mmol), EDC.HCl (0.76 g, 4.15 mmol) 
and HOBt (0.56 g, 4.15 mmol) were successively added to the reaction mixture. 4-
(Aminomethyl) benzoic acid benzyl ester (1.00 g, 4.15 mmol) dissolved in DCM (10 
mL) was added and the resulting was stirred for 24 hours at room temperature. Aq. 
1M KHSO4 (30 mL) was added, the organic layer separated, and washed with sat. 
Na2CO3 (30 mL) and brine (30 mL). The organic layer was dried over MgSO4 and the 
solvent was removed in vacuo. Purification of the resulting crude product by column 
chromatography (SiO2, 1:20 MeOH/DCM) afforded 125 (80 mg, 40 %) as a white 
solid. MP = 250-252 ˚C; 
1H NMR (400 MHz, CDCl3): ʴ (ppm) = 9.26 (1 H, t, J = 3.8 
Hz, NH), 8.27 (1 H, d,  J = 4.7 Hz, CH), 8.17 (1 H, d, , J = 5.0 Hz, CH), 7.89 (1 H, t, J 
= 5.0 Hz, CH), 7.72 (2 H, d,  J = 6.7 Hz, CH), 7.32-7.14 (5 H, m, CH), 7.15 (2 H, d,  J 
= 6.7 Hz, CH), 5.21 (2 H, s, CH2Ph), 4.50 (2 H, d, J = 3.8 Hz, NHCH2);
 13C NMR 
(100 MHz, CDCl3): ʴ (ppm) = 165.2 (Cq), 164.0 (Cq), 163.7 (Cq), 162.9 (Cq), 162.5 
(Cq), 148.0 (Cq), 144.6 (CH), 142.3 (Cq), 138.5 (CH), 134.8 (Cq), 128.9 (CH), 128.0 
(CH), 127.0 (CH), 126.5 (CH), 126.0 (CH), 125.4 (CH), 65.8 (CH2), 42.2 (CH2); 
MSES: m/z = 414.0 [M+Na]
+;  FT-IR (solid): ν max cm
-1 = 2843 (b), 1694 (s), 1449 
(m), 1429 (m), 1138 (s). 
 
Compound 129 
 
 
 
The amine (41a) (22 mg, 0.12 mmol) was dissolved in DMF (2 mL). Compound 19 
(37 mg, 0.12 mmol) dissolved in THF (5 mL) was added to the reaction mixture and 
the resulting solution was stirred at room temperature for 3 days. In vacuo drying of  
the  reaction  mixture  and  purification  of  the  resulting  crude  by  column 
chromatography (1:100, MeOH/DCM) afforded 129 (35 mg, 70%) as a yellowish oily 
liquid. 
1H NMR (400 MHz, CDCl3): ʴ (ppm) = 11.27 (1 H, s, NH), 8.94 (1 H, s, NH), 
7.91 (1 H, s, NH), 7.23-7.12 (5 H, m, CH), 4.35 (2 H, d, J = 3.5 Hz , CH), 3.72-3.68 
(2 H, m, CH2), 2.51 (2 H, t, J = 3.8 Hz , CH2), 1.54 (9 H, s, C(CH3)3), 1.40 (9 H, s, 
C(CH3)3);
 13C NMR (100 MHz, CDCl3): ʴ (ppm) =  170.0 (Cq), 154.7 (Cq), 151.6 Experimental  
   
(Cq), 137.4 (Cq), 127.7 (CH), 126.7 (CH), 126.3 (CH), 83.0 (Cq), 82.4 (Cq), 42.5 
(CH2), 35.4 (CH2), 30.4 (CH2), 27.1 (CH3), 27.0 (CH3); MSES: m/z = 421.2 [M+H]
+; 
FT-IR (solid): ν max cm
-1 = 3322 (w), 2980 (w), 2360 (w), 1786 (m), 1723 (m), 1618 
(s), 1132 (s), 747 (s). 
 
N-Benzyl-3-guanidinopropanamide (130) 
 
 
 
Compound 129 (50 mg, 0.12 mmol) was dissolved in 20% TFA/DCM (5 mL). The 
resulting solution was left stirring overnight at room temperature. The solvent was 
removed in vacuo and the residual TFA was removed by the addition of toluene (1 
mL) and further evaporation in vacou. Triturating the resulting gummy material by the 
addition of diethylether afforded 130 (26 mg, 100%) as a white solid. MP = 120-123 
oC; 
1H NMR (400 MHz, CDCl3): ʴ (ppm) = 8.49 (1 H, t, J = 3.5 Hz, NH), 7.49 (1 H, t, 
J = 3.5 Hz, NH), 7.32-7.21 (5 H, m, CH), 4.28 (2 H, d, J = 3.8 Hz, CH2), 2.42 (2 H, t, 
J = 4.1 Hz, CH2), (one CH2 peak has overlapped with the water peak). 
13C NMR (100 
MHz, CDCl3): ʴ (ppm) = 170.5 (Cq), 157.3 (Cq), 139.7 (Cq), 128.8 (CH), 127.7 (CH), 
127.3 (CH), 42.6 (CH2), 37.6 (CH2), 34.8 (CH2); MSES: m/z = 221.2 [M+H]
 +;  FT-IR 
(solid): ν max cm
-1 =  3375 (w), 3271 (w), 1683 (s), 1638 (s), 1616 (s), 1171 (s), 1135 
(s).   
 
Methyl 4-((5-((N-((benzyloxy)carbonyl)carbamimidoyl)carbamoyl)- 
1H-pyrrole-2-carboxamido)methyl)benzoate (142) 
 
 
 
 
 
Compound 141 (0.18 g, 0.55 mmol) was dissolved in dry DCM (50 mL). iPr2NEt (0.6 
mL, 1.40 mmol), EDC.HCl (0.26 g, 1.38 mmol) and HOBt (0.22 g, 1.65 mmol) were 
successively added to  the reaction mixture. 4-(Aminomethyl) benzoic  acid  methyl 
ester (0.11 g, 0.55 mmol) dissolved in DCM : DMF (1:1) (10 mL) was added to the Experimental  
   
reaction mixture which was stirred for 24 hrs at room temperature.  Aq. 1M KHSO4 
(30 mL) was added, the organic layer separated, and washed with aq sat. Na2CO3 (30 
mL) and brine (30 mL) successively. The organic layer was dried over MgSO4 and the 
solvent  was  evaporated  in  vacuo.  Purification  of  the  resulting  crude  by  column 
chromatography (SiO2, 1:100-1:50 MeOH/DCM) afforded 142  (0.20 g, 76%) as a 
white solid. MP = 210-211˚C; 
1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 11.15 (1 H, 
s, NH), 9.39 (1 H, s, NH), 9.00 (1 H, t, J = 3.5 Hz, NH), 8.80 (1 H, s, NH), 7.94 (2 H, 
d, J = 5.0 Hz, CH), 7.45 (2 H, d, J = 5.0 Hz, CH), 7.31-7.40 (6 H, m, CH), 6.95 (1 H, 
m, CH), 5.15 (2 H, s, OCH2Ph), 4.55 (2 H, d, J = 3.8 Hz, NHCH2), 3.85 (3 H, s, 
CH3COO); 
13C NMR (100 MHz, DMSO- d6): ʴ (ppm) =180.6 (Cq), 166.3 (Cq), 159.9 
(Cq), 145.3 (Cq), 129.6 (CH), 128.7 (CH), 128.5 (CH), 128.1 (CH), 127.9 (CH), 
127.7 (CH), 112.4 (CH), 66.4 (CH3), 52.3 (CH2), 42.2 (CH2); MSES: m/z = 500.2 
[M+Na]
+; HRMS (ES): Calcd for C24H24N5O ([M+H]
+) 478.1726, found 478.1729; 
FT-IR (solid): ν max cm
-1 = 3395 (w), 3370 (m), 2970 (b), 1715 (m), 1673 (m), 1641 
(m), 1616 (w),1532 (m), 1263 (s), 752 (m). 
 
4-((5-((N-((Benzyloxy)carbonyl)carbamimidoyl)carbamoyl)-1H-pyrrole-2-
carboxamido)methyl)benzoic acid 
(143) 
 
 
 
 
Compound 142 (0.19 g, 0.40 mmol) was dissolved in THF (20 mL) and added to 
Me3SiOK (65 mg, 0.5 mmol) suspended in THF (10 mL) under N2. The reaction 
mixture was stirred for 72 hrs at room temperature. DCM (30 mL) and H2O (30 mL) 
were added and the reaction mixture was cooled to 0 ˚C. Citric acid (0.1 M aqeous) 
was added dropwise until the pH was 6-7 and further stirred for 1 hr. In vacuo drying 
of  the  organic  phase  and  purification  of  the  resulting  crude  by  column 
chromatography (SiO2, 1:20 MeOH/DCM) afforded 143 (0.16 g, 86%) as a white 
solid. MP = 294-296 ˚C; 
1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 11.83 (1 H, s, 
NH), 9.36 (1 H, s, NH), 8.97 (1 H, t, J = 3.8 Hz, NH), 8.76 (1 H, s, NH), 7.90 (2 H, d, 
J = 5.0 Hz, CH), 7.31-7.42 (7 H, m, CH), 6.97 (1 H, s, CH), 6.87 (1 H, s, CH), 5.12 (2 
H, s, CH2), 4.52 (2 H, d, J = 3.8 Hz, CH2);
 13C NMR (100 MHz, DMSO-d6): ʴ (ppm) Experimental  
   
= 180.6 (Cq), 171.7 (Cq), 167.6 (Cq), 160.1 (Cq), 159.4 (Cq), 145.0 (Cq), 129.9 (CH), 
128.9 (CH), 128.3 (CH), 128.1 (CH), 127.7 (CH), 112.4 (CH), 66.6 (CH2), 42.4 (CH2); 
MSES: m/z = 464.1 [M+H]
 +; FT-IR (solid): ν max cm
-1 = 3077m(b), 2949m(b), 1726s, 
1666s, 1283s, 1109m, 848m, 749m, 756m, 635m. 
 
Benzyl 4-((5-((N-((benzyloxy)carbonyl)carbamimidoyl)carbamoyl)-1H-pyrrole-2-
carboxamido)methyl)benzoate 
(144) 
 
 
 
 
 
Compound 141 (1.10 g, 3.33 mmol) was dissolved in dry DCM (50 mL). iPr2NEt 
(1.43 mL, 1.40 mmol), EDC.HCl (1.29 g, 8.33 mmol) and HOBt (1.1 g, 8.3 mmol) 
were  successively  added  to  the  reaction  mixture.  4-(Aminomethyl)  benzoic  acid 
benzyl ester (0.90 g, 4.00 mmol) dissolved in DCM (25 mL) was added to the reaction 
mixture which was stirred for 24 hrs at room temperature. Aq. 1 M KHSO4 (30 mL) 
was added and the organic layer separated and washed with sat. aq Na2CO3 (30 mL) 
and brine (30 mL). The organic layer was dried over MgSO4 and the solvent was 
evaporated in vacuo. Purification of the resulting crude by column chromatography 
(SiO2, 1:100-1:50 MeOH/DCM) afforded 144 (0.73 g, 40%) as a white solid. MP = 
215-216 ˚C;
 1H NMR (400 MHz, DMSO-d6): ʴ (ppm) = 11.16 (1 H, s, NH), 9.35 (1 H, 
s, NH), 9.00 (1 H, s, NH), 8.76 (1 H, s, NH), 7.96 (2 H, d, J = 5.35 Hz, CH), 7.46-
7.36 (12 H, m, CH), 6.97 (1 H, s, CH), 6.86 (1 H, s, CH), 5.33 (2 H, s, CH2), 5.12 (2 
H, s, CH2), 4.52 (2 H, s, CH2);  
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 165.5 
(Cq), 159.7 (Cq), 145.3 (Cq), 136.3 (Cq), 129.3 (CH), 128.6 (CH), 128.5 (CH), 128.3 
(CH), 128.2 (CH), 128.0 (CH), 127.6 (CH), 66.1 (CH2 ), 42.0 (CH2);  HRMS (ES): 
Calcd for C30H28N5O6 ([M+H]
+) 554.2039, found 554.2024; FT-IR (solid): ν max cm
-1 
= 3345 (w), 3222 (m), 2957 (w)(b), 1720 (m), 1674 (m), 1641 (m), 1324 (s), 1262 (s), 
1237 (s). 
 
 Experimental  
   
4-((5-(Carbamimidoylcarbamoyl)-1H-pyrrole-2-carboxamido)methyl)benzoic 
acid  
(133) 
 
 
 
 
Compound 144 (90 mg, 0.2 mmol) was dissolved in DCM/ MeOH (1:4) (10 mL). 
Pd/C (10 mg) was added to the reaction mixture which was stirred under hydrogen (1 
atm) overnight at room temperature. The reaction mixture was filtered through celite 
and  dried  in  vacuo.  Purification  of  the  resulting  solid  by  precipitation  from 
Et2O/MeOH afforded 133 (30 mg, 45%) as a pale yellow solid. MP > 250 ˚C; 
1H 
NMR (400 MHz, DMSO-d6): ʴ (ppm) = 12.35 (1 H, s, NH), 11.85 (1 H, s, NH), 9.05 
(1 H, t, J = 3.8 Hz, NHCH2), 8.44 (2 H, d, J = 5.0 Hz, NH), 7.92 (2 H, d, J = 5.0 Hz , 
CH), 7.43 (2 H, d, J = 5.0 Hz, CH), 7.37 (1 H, s(broad), CH), 6.91 (1 H, d, J = 2.2 Hz, 
CH), 4.54 (2 H, d, J = 2.5 Hz, NHCH2); 
13C NMR (100 MHz, DMSO-d6): ʴ (ppm) = 
167.6 (Cq), 159.9 (Cq), 144.8 (Cq), 129.9 (CH), 127.8 (CH), 113.0 (CH), 42.5 (CH2); 
MSES: m/z = 330.2 [M+H]
+; HRMS (ES): Calcd for C15H16N5O4 330.1202 ([M+H]
+), 
found 330.1198; FT-IR (solid): ν max cm
-1 = 2979 (w)(b), 2362 (w), 1590 (m), 1552 (s). 
 
N.B Compounds 31a 
128, 32 
129, 40 
130, 48 
131, 61 
132, 96 
134, 118 
70, 127 
125, 128 
125, 
135 
133, 136 
 96, 138
 96, 139 
 96, 140 
 96 and 141 
 96 were  prepared according to literature 
procedures and their spectroscopic data are consistent with the reported literature data. 
 
 
 
 
 
 
 
 
 Appendices 
   
Appendices 
Appendix A- ITC dilution data 
 
ITC data of guandinium carboxylate 29 
 
         [monomer] = 20 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 38 
         ∆Gdim
  [kJ mol
-1] = -9.0 
         ∆Hdim
  [kJ mol
-1] = -6.0 
         T∆Sdim
  [kJ mol
-1] = 3.0 
 
 
 
 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 29 
1  0.13639  582.8645 
2  0.27184  581.477 
3  0.40635  577.5922 
4  0.53993  543.001 
5  0.67257  529.6865 
6  0.80427  503.7762 
7  0.93504  484.5144 
8  1.06487  464.8826 
9  1.19377  468.9053 
10  1.32173  450.2652 
11  1.44875  446.5529 
12  1.57484  446.3665 
13  1.69998  428.9436 
14  1.8242  402.567 
15  1.94747  393.5152 
16  2.06981  388.3179 
17  2.19122  384.3716 
18  2.31168  376.9056 
19  2.43121  363.5502 
20  2.54981  358.2004 
21  2.66747  344.9901 
22  2.78419  336.5519 
23  2.89997  330.9379 
24  3.01482  323.6815 
25  3.12873  313.4672 
26  3.24171  298.826 
27  3.35375  299.794 
28  3.46485  287.4068 
29  0.13639  582.8645 
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Model: Dissociation
C = 20 mM
H (cal/mole) 1445 ±78.6
K (mM) 26.3 ±4.6
OFFSET (cal/mole) -89.7 ±8.1
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ITC data of guanidinium-carboxylate 30 
 
 
 
 
 
         [monomer] = 10 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 400 
         ∆Gdim
  [kJ mol
-1] = -14.9 
         ∆Hdim
  [kJ mol
-1] = -11.1 
         T∆Sdim
  [kJ mol
-1] = 3.7 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 30 
1  0.06819  1029.967 
2  0.13592  943.0357 
3  0.20318  862.9701 
4  0.26996  783.4125 
5  0.33628  728.5454 
6  0.40214  662.9338 
7  0.46752  600.3399 
8  0.53244  564.5805 
9  0.59688  523.2009 
10  0.66086  510.01 
11  0.72437  466.0615 
12  0.78742  441.7893 
13  0.84999  421.3278 
14  0.9121  409.2686 
15  0.97374  392.2766 
16  1.03491  360.3329 
17  1.09561  340.3065 
18  1.15584  330.0532 
19  1.21561  322.0468 
20  1.2749  308.9202 
21  1.33373  291.0364 
22  1.39209  286.0037 
23  1.44999  268.8602 
24  1.50741  254.5628 
25  1.56437  246.7858 
26  1.62085  239.9488 
27  1.67687  229.4327 
28  1.73242  226.5848 
29  0.06819  1029.967  ITC final figure
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Model: Dissociation
C = 10 mM
H (cal/mole) 2655 ±25.2
K (mM) 2.50 ±0.14
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ITC data of guandinium-carboxylate 45 
 
 
 
 
 
         [monomer] = 10 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 240 
         ∆Gdim
  [kJ mol
-1] = -13.6 
         ∆Hdim
  [kJ mol
-1] = -16.7 
         T∆Sdim
  [kJ mol
-1] = -3.1 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 45 
1  0.06819  1548.599 
2  0.13592  1454.206 
3  0.20318  1366.935 
4  0.26996  1270.348 
5  0.33628  1199.276 
6  0.40214  1120.013 
7  0.46752  1053.079 
8  0.53244  1000.365 
9  0.59688  920.3925 
10  0.66086  893.0963 
11  0.72437  845.3409 
12  0.78742  832.6059 
13  0.84999  758.2611 
14  0.9121  740.978 
15  0.97374  717.3456 
16  1.03491  690.3944 
17  1.09561  649.0963 
18  1.15584  621.6606 
19  1.21561  606.4449 
20  1.2749  580.0727 
21  1.33373  542.835 
22  1.39209  533.0577 
23  1.44999  519.4099 
24  1.50741  499.3891 
25  1.56437  482.8966 
26  1.62085  473.8048 
27  1.67687  459.4052 
28  1.73242  425.7022 
29  0.06819  1548.599 
ITC final figure
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Model: Dissociation
C = 10 mM
H (cal/mole) 3983 ±42.2
K (mM) 4.16 ±0.22
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ITC data of guandinium-carboxylate 45 
 
 
 
 
 
         [monomer] = 20 mM                                                                  
         Solvent = 10% H2O/DMSO                                                        
         Kdim[M
-1] = 54 
         ∆Gdim
  [kJ mol
-1] = -9.9 
         ∆Hdim
  [kJ mol
-1] = -6.2 
         T∆Sdim
  [kJ mol
-1] = 3.6 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 45 
1  0.13639  589.4092 
2  0.27184  568.0632 
3  0.40635  553.2367 
4  0.53993  530.2699 
5  0.67257  508.6899 
6  0.80427  486.0782 
7  0.93504  481.2641 
8  1.06487  459.8468 
9  1.19377  440.573 
10  1.32173  422.9418 
11  1.44875  408.7186 
12  1.57484  393.1313 
13  1.69998  382.9138 
14  1.8242  364.9136 
15  1.94747  358.2289 
16  2.06981  353.0942 
17  2.19122  342.6911 
18  2.31168  331.2941 
19  2.43121  324.8235 
20  2.54981  304.8985 
21  2.66747  295.6677 
22  2.78419  291.3028 
23  2.89997  286.7959 
24  3.01482  279.9466 
25  3.12873  270.0848 
26  3.24171  264.846 
27  3.35375  255.8926 
28  3.46485  251.892 
29  0.13639  589.4092 
ITC final figure
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Model: Dissociation
C = 20 mM
H (cal/mole) 1493 ±32.0
K (mM) 18.7 ±1.4
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ITC data of guandinium-carboxylate 46 
 
 
 
 
 
         [monomer] = 4 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 4608 
         ∆Gdim
  [kJ mol
-1] = -20.9 
         ∆Hdim
  [kJ mol
-1] = -21.7 
         T∆Sdim
  [kJ mol
-1] = -0.9 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 46 
1  0.02728  1481.307 
2  0.05437  1228.54 
3  0.08127  1039.061 
4  0.10799  918.9863 
5  0.13451  839.599 
6  0.16085  724.6821 
7  0.18701  643.8358 
8  0.21297  639.4556 
9  0.23875  555.7509 
10  0.26435  465.2519 
11  0.28975  465.1578 
12  0.31497  415.3962 
13  0.34  389.6998 
14  0.36484  372.077 
15  0.38949  361.4618 
16  0.41396  341.1894 
17  0.43824  338.6941 
18  0.46234  299.645 
19  0.48624  297.6352 
20  0.50996  267.0348 
21  0.53349  226.6123 
22  0.55684  229.9116 
23  0.57999  284.9057 
24  0.60296  237.2871 
25  0.62575  228.2035 
26  0.64834  173.537 
27  0.67075  189.493 
28  0.69297  211.6555 
29  0.02728  1481.307 
ITC final figure
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ITC data of guanidinium-carboxylate 46 
 
 
 
 
 
         [monomer] = 20 mM                                                                  
         Solvent = 10% H2O/DMSO                                                        
         Kdim[M
-1] = 54 
         ∆Gdim
  [kJ mol
-1] = -9.9 
         ∆Hdim
  [kJ mol
-1] = -5.6 
         T∆Sdim
  [kJ mol
-1] = 4.2 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 46 
1  0.13639  535.6104 
2  0.27184  516.776 
3  0.40635  492.168 
4  0.53993  473.7907 
5  0.67257  455.1108 
6  0.80427  445.283 
7  0.93504  423.4051 
8  1.06487  409.0048 
9  1.19377  400.5563 
10  1.32173  378.4534 
11  1.44875  368.1346 
12  1.57484  351.5004 
13  1.69998  342.9795 
14  1.8242  335.7038 
15  1.94747  334.5311 
16  2.06981  315.2711 
17  2.19122  310.8289 
18  2.31168  292.0199 
19  2.43121  291.0248 
20  2.54981  279.3251 
21  2.66747  270.0351 
22  2.78419  263.3474 
23  2.89997  261.6277 
24  3.01482  246.5664 
25  3.12873  242.7272 
26  3.24171  236.9132 
27  3.35375  227.9059 
28  3.46485  223.0008 
29  0.13639  535.6104 
ITC final figure
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Model: Dissociation
C = 20 mM
H (cal/mole) 1345 ±25.1
K (mM) 18.6 ±1.2
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ITC data of guanidinium-carboxylate 53 
 
 
 
 
 
         [monomer] = 10 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 952 
         ∆Gdim
  [kJ mol
-1] = -17.0 
         ∆Hdim
  [kJ mol
-1] = -16.7 
         T∆Sdim
  [kJ mol
-1] = 0.3 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 53 
1  0.06819  1535.011 
2  0.13592  1240.399 
3  0.20318  1063.472 
4  0.26996  948.9337 
5  0.33628  828.7126 
6  0.40214  751.2859 
7  0.46752  685.924 
8  0.53244  621.5231 
9  0.59688  558.6093 
10  0.66086  513.2643 
11  0.72437  486.0624 
12  0.78742  450.8132 
13  0.84999  438.1397 
14  0.9121  419.8108 
15  0.97374  373.6592 
16  1.03491  338.5508 
17  1.09561  369.954 
18  1.15584  353.4904 
19  1.21561  283.2167 
20  1.2749  267.9879 
21  1.33373  293.1073 
22  1.39209  245.786 
23  1.44999  261.0369 
24  1.50741  219.0222 
25  1.56437  231.5258 
26  1.62085  209.8938 
27  1.67687  215.0006 
28  1.73242  236.2752 
29  0.06819  1535.011 
ITC final figure
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Model: Dissociation
C = 10 mM
H (cal/mole) 3979 ±47.0
K (mM) 1.05 ±0.071
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ITC data of guanidinium-carboxylate 53 
 
 
 
 
 
         [monomer] = 20 mM                                                                  
         Solvent = 10% H2O/DMSO                                                        
         Kdim[M
-1] = 73 
         ∆Gdim
  [kJ mol
-1] = -10.6 
         ∆Hdim
  [kJ mol
-1] = -8.6 
         T∆Sdim
  [kJ mol
-1] = 2.0 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 53 
1  0.13639  814.7614 
2  0.27184  789.8495 
3  0.40635  743.4171 
4  0.53993  714.1899 
5  0.67257  682.7087 
6  0.80427  637.575 
7  0.93504  620.7341 
8  1.06487  588.3947 
9  1.19377  563.4242 
10  1.32173  557.417 
11  1.44875  536.7141 
12  1.57484  514.8635 
13  1.69998  494.3066 
14  1.8242  478.3506 
15  1.94747  460.8538 
16  2.06981  434.6123 
17  2.19122  431.3305 
18  2.31168  415.9101 
19  2.43121  400.2346 
20  2.54981  384.1484 
21  2.66747  371.9534 
22  2.78419  359.3785 
23  2.89997  350.9882 
24  3.01482  356.0036 
25  3.12873  333.9854 
26  3.24171  328.686 
27  3.35375  310.7691 
28  3.46485  304.0664 
29  0.13639  814.7614 
ITC final figure
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Model: Dissociation
C = 20 mM
H (cal/mole) 2045 ±33.2
K (mM) 13.8 ±0.87
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ITC data of guanidinium-carboxylate 53 
 
 
 
 
 
         [monomer] = 40 mM                                                                  
         Solvent = 50% H2O/DMSO                                                        
         Kdim[M
-1] = 13 
         ∆Gdim
  [kJ mol
-1] = -6.4 
         ∆Hdim
  [kJ mol
-1] = -1.8 
         T∆Sdim
  [kJ mol
-1] = 4.6 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 53 
1  0.27277  232.4499 
2  0.54367  222.4874 
3  0.8127  220.2105 
4  1.07986  222.4285 
5  1.34514  211.4203 
6  1.60855  215.0561 
7  1.87008  207.5 
8  2.12975  208.6904 
9  2.38754  203.4767 
10  2.64345  196.9539 
11  2.8975  195.1989 
12  3.14967  194.9533 
13  3.39997  186.0931 
14  3.64839  183.1811 
15  3.89495  181.4643 
16  4.13963  178.278 
17  4.38243  168.3892 
18  4.62337  176.4388 
19  4.86243  177.672 
20  5.09962  167.1739 
21  5.33493  159.8071 
22  5.56837  162.4328 
23  5.79994  160.5358 
24  6.02964  161.5837 
25  6.25746  162.5643 
26  6.48341  154.4675 
27  6.70749  154.5085 
28  6.92969  154.455 
29  0.27277  232.4499 
ITC final figure
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ITC data of guanidinium-carboxylate 53 
 
 
 
 
 
         [monomer] = 40 mM                                                                  
         Solvent = 75% H2O/DMSO                                                        
         Kdim[M
-1] = 5 
         ∆Gdim
  [kJ mol
-1] = -4.0 
         ∆Hdim
  [kJ mol
-1] = -2.3 
         T∆Sdim
  [kJ mol
-1] = 1.7 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 53 
1  0.34097  216.8087 
2  0.67959  208.2562 
3  1.01588  217.8864 
4  1.34982  204.9368 
5  1.68142  182.27 
6  2.01069  172.7955 
7  2.33761  173.9801 
8  2.66218  224.2853 
9  2.98442  225.3709 
10  3.30432  203.1723 
11  3.62187  173.2495 
12  3.93709  179.3489 
13  4.24996  152.1873 
14  4.56049  192.7629 
15  4.86868  155.2425 
16  5.17453  159.6459 
17  5.47804  142.3568 
18  5.77921  177.0456 
19  6.07804  136.8977 
20  6.37452  159.8666 
21  6.66866  164.1536 
22  6.96047  148.3184 
23  7.24993  140.9159 
24  7.53705  147.4637 
25  7.82183  137.8061 
26  8.10427  132.2024 
27  8.38436  132.6134 
28  8.66212  149.5444 
29  0.34097  216.8087 
ITC final figure
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ITC data of guanidinium-carboxylate 57 
 
 
 
 
 
         [monomer] = 3 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 4032 
         ∆Gdim
  [kJ mol
-1] = -20.6 
         ∆Hdim
  [kJ mol
-1] = -13.8 
         T∆Sdim
  [kJ mol
-1] = 6.8 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 57 
1  0.01025  1070.74 
2  0.02046  966.5833 
3  0.03063  963.6294 
4  0.04078  680.2051 
5  0.05088  607.1643 
6  0.06095  498.8218 
7  0.07099  609.2261 
8  0.08099  515.3998 
9  0.09095  533.7236 
10  0.10089  208.4286 
11  0.11078  420.8158 
12  0.12064  156.9195 
13  0.13047  115.0583 
14  0.14026  300.1156 
15  0.15001  381.3619 
16  0.15973  168.2936 
17  0.16942  219.2553 
18  0.17907  261.4352 
19  0.18868  304.3861 
20  0.19826  220.2145 
21  0.2078  1.96792 
22  0.21731  131.5099 
23  0.22679  206.0906 
24  0.23623  94.74537 
25  0.24563  -35.7505 
26  0.255  112.7255 
27  0.26433  32.87384 
28  0.27363  171.4396 
29  0.28289  215.9282 
ITC final figure
 
0.00 0.05 0.10 0.15 0.20 0.25 0.30
0
2 -0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
-10 0 10 20 30 40 50 60 70 80 90 100110120130
Time (min)
µ
c
a
l
/
s
e
c
Guanidinium-carboxylate 57 in DMSO
Model: Dissociation
C = 3 mM
H (cal/mole) 3669 ±277
K (mM)0.328±0.15
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ITC data of guanidinium-carboxylate 57 
 
 
 
 
 
         [monomer] = 20 mM                                                                  
         Solvent = 10% H2O/DMSO                                                        
         Kdim[M
-1] = 336 
         ∆Gdim
  [kJ mol
-1] = -14.4 
         ∆Hdim
  [kJ mol
-1] = -3.7 
         T∆Sdim
  [kJ mol
-1] = 10.8 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 57 
1  0.13639  317.9293 
2  0.27184  263.9745 
3  0.40635  234.2109 
4  0.53993  220.7908 
5  0.67257  169.3606 
6  0.80427  161.9809 
7  0.93504  132.3573 
8  1.06487  140.2771 
9  1.19377  125.5838 
10  1.32173  116.3109 
11  1.44875  113.3768 
12  1.57484  82.90507 
13  1.69998  77.52011 
14  1.8242  77.49117 
15  1.94747  87.57144 
16  2.06981  91.41337 
17  2.19122  66.71729 
18  2.31168  63.28454 
19  2.43121  43.81419 
20  2.54981  56.41177 
21  2.66747  47.52595 
22  2.78419  25.71653 
23  2.89997  45.02554 
24  3.01482  54.84943 
25  3.12873  36.8154 
26  3.24171  53.23039 
27  3.35375  31.56108 
28  3.46485  25.16868 
29  0.13639  317.9293 
ITC final figure
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2O/ DMSO
Model: Dissociation
C= 20 mM
H (cal/mole) 873.3 ±24.4
K (mM)2.98±0.52
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ITC data of guanidinium-carboxylate 57 
 
 
 
 
 
         [monomer] = 10 mM                                                                  
         Solvent = 50% H2O/DMSO                                                        
         Kdim[M
-1] = 334 
         ∆Gdim
  [kJ mol
-1] = -14.5 
         ∆Hdim
  [kJ mol
-1] = -0.6 
         T∆Sdim
  [kJ mol
-1] = 13.9 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 57 
1  0.06819  110.6255 
2  0.13592  154.8958 
3  0.20318  146.0179 
4  0.26996  136.2531 
5  0.33628  115.3443 
6  0.40214  107.2727 
7  0.46752  116.493 
8  0.53244  120.0475 
9  0.59688  117.0199 
10  0.66086  90.14614 
11  0.72437  134.5073 
12  0.78742  87.33339 
13  0.84999  82.37251 
14  0.9121  77.86754 
15  0.97374  89.95909 
16  1.03491  85.4027 
17  1.09561  94.55916 
18  1.15584  107.1945 
19  1.21561  107.5672 
20  1.2749  99.7082 
21  1.33373  113.7951 
22  1.39209  103.8491 
23  1.44999  109.8129 
24  1.50741  106.2173 
25  1.56437  87.70996 
26  1.62085  84.66482 
27  1.67687  94.81133 
28  1.73242  89.12951 
29  0.06819  110.6255 
ITC final figure
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2O/DMSO
Model: Dissociation
C = 10 mM
H (cal/mole) 149.6 ±40.1
K (mM)2.90±4.5
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ITC data of guanidinium-carboxylate 67 
 
 
 
 
 
         [monomer] = 3 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 7692 
         ∆Gdim
  [kJ mol
-1] = -22.2 
         ∆Hdim
  [kJ mol
-1] = -4.7 
         T∆Sdim
  [kJ mol
-1] = 17.5 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 67 
1  0.02046  270.7547 
2  0.04078  122.0604 
3  0.06095  133.2901 
4  0.08099  24.61232 
5  0.10089  -1.69407 
6  0.12064  -24.0811 
7  0.14026  29.24413 
8  0.15973  0.88459 
9  0.17907  -13.1276 
10  0.19826  -9.99776 
11  0.21731  -0.90787 
12  0.23623  -27.4382 
13  0.255  -16.1238 
14  0.27363  -80.437 
15  0.29212  -49.0432 
16  0.31047  -58.8897 
17  0.32868  -101.461 
18  0.34675  -121.283 
19  0.36468  -76.2555 
20  0.38247  -77.178 
21  0.40012  -58.8989 
22  0.41763  -76.5828 
23  0.435  -56.9363 
24  0.45222  -78.2048 
25  0.46931  -103.647 
26  0.48626  -165.308 
27  0.50306  -157.386 
28  0.51973  -120.05 
29  0.02046  270.7547 
ITC final figure
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Model: Dissociation
C = 3 mM
H (cal/mole) 1094 ±112
K (mM)0.165±0.078
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ITC data of guanidinium-carboxylate 67 
 
 
 
 
 
         [monomer] = 20 mM                                                                  
         Solvent = 10% H2O/DMSO                                                        
         Kdim[M
-1] = 495 
         ∆Gdim
  [kJ mol
-1] = -15.4 
         ∆Hdim
  [kJ mol
-1] = -9.8 
         T∆Sdim
  [kJ mol
-1] = 5.6 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 67 
1  0.13639  890.3695 
2  0.27184  733.2514 
3  0.40635  633.3786 
4  0.53993  553.0476 
5  0.67257  495.993 
6  0.80427  439.7383 
7  0.93504  390.357 
8  1.06487  342.4304 
9  1.19377  302.1241 
10  1.32173  301.2538 
11  1.44875  291.6009 
12  1.57484  252.1471 
13  1.69998  244.1995 
14  1.8242  230.7084 
15  1.94747  210.0998 
16  2.06981  191.2566 
17  2.19122  173.1413 
18  2.31168  175.6001 
19  2.43121  177.6385 
20  2.54981  173.4444 
21  2.66747  157.7729 
22  2.78419  156.7273 
23  2.89997  154.9719 
24  3.01482  154.4555 
25  3.12873  141.5913 
26  3.24171  134.3133 
27  3.35375  129.2073 
28  3.46485  111.4981 
29  0.13639  890.3695 
ITC final figure
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2O/ DMSO
Model: Dissociation
C = 20 mM
H (cal/mole) 2344 ±37.1
K (mM)2.02±0.18
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ITC data of guanidinium-carboxylate 67 
 
 
 
 
 
         [monomer] = 20 mM                                                                  
         Solvent = 20% H2O/DMSO                                                        
         Kdim[M
-1] = 57 
         ∆Gdim
  [kJ mol
-1] = -10.0 
         ∆Hdim
  [kJ mol
-1] = - 4.6 
         T∆Sdim
  [kJ mol
-1] = 5.4 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 67 
1  0.13639  400.5412 
2  0.27184  393.583 
3  0.40635  376.9221 
4  0.53993  367.4068 
5  0.67257  348.912 
6  0.80427  334.4894 
7  0.93504  321.0904 
8  1.06487  302.1076 
9  1.19377  302.4781 
10  1.32173  277.8551 
11  1.44875  273.5147 
12  1.57484  255.4022 
13  1.69998  242.163 
14  1.8242  240.9809 
15  1.94747  229.5505 
16  2.06981  229.1133 
17  2.19122  206.3608 
18  2.31168  207.7092 
19  2.43121  200.9869 
20  2.54981  205.7332 
21  2.66747  206.5932 
22  2.78419  188.2099 
23  2.89997  174.0106 
24  3.01482  169.3128 
25  3.12873  171.1624 
26  3.24171  172.5926 
27  3.35375  152.7597 
28  3.46485  150.1991 
29  0.13639  400.5412 
ITC final figure
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Model: Dissociation
C = 20 mM
H (cal/mole) 1095 ±47.5
K (mM)17.5±2.7
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ITC data of guanidinium-carboxylate 78 
 
 
 
 
 
         [monomer] = 3 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 5076 
         ∆Gdim
  [kJ mol
-1] = -21.1 
         ∆Hdim
  [kJ mol
-1] = - 11.7 
         T∆Sdim
  [kJ mol
-1] = 9.4 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 78 
1  0.02046  1015.751 
2  0.04078  813.6497 
3  0.06095  723.9875 
4  0.08099  500.2608 
5  0.10089  477.0202 
6  0.12064  363.3647 
7  0.14026  371.7165 
8  0.15973  364.2035 
9  0.17907  281.83 
10  0.19826  267.6187 
11  0.21731  270.9691 
12  0.23623  254.2144 
13  0.255  248.626 
14  0.27363  229.4177 
15  0.29212  183.9683 
16  0.31047  209.9109 
17  0.32868  228.8116 
18  0.34675  159.5333 
19  0.36468  154.7319 
20  0.38247  186.6366 
21  0.40012  116.6147 
22  0.41763  125.0727 
23  0.435  147.1851 
24  0.45222  123.9258 
25  0.46931  120.8954 
26  0.48626  90.46449 
27  0.50306  124.2907 
28  0.51973  69.66365 
29  0.02046  1015.751 
ITC final figure
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Model: Dissociation
C = 3 mM
H (cal/mole) 2800 ±99.8
K (mM)0.197±0.034
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ITC data of guanidinium-carboxylate 78 
 
 
 
 
 
         [monomer] = 10 mM                                                                  
         Solvent = 5% H2O/DMSO                                                        
         Kdim[M
-1] = 862 
         ∆Gdim
  [kJ mol
-1] = -16.7 
         ∆Hdim
  [kJ mol
-1] = -10.3 
         T∆Sdim
  [kJ mol
-1] = 6.4 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 78 
1  0.06819  1026.049 
2  0.13592  831.0022 
3  0.20318  751.5362 
4  0.26996  620.0662 
5  0.33628  616.0074 
6  0.40214  548.0316 
7  0.46752  484.3801 
8  0.53244  465.8637 
9  0.59688  421.5469 
10  0.66086  408.3777 
11  0.72437  374.6027 
12  0.78742  378.1343 
13  0.84999  358.3461 
14  0.9121  358.6175 
15  0.97374  306.2486 
16  1.03491  320.4483 
17  1.09561  300.6358 
18  1.15584  214.3444 
19  1.21561  248.4988 
20  1.2749  236.7443 
21  1.33373  241.8786 
22  1.39209  248.4592 
23  1.44999  222.1031 
24  1.50741  230.1554 
25  1.56437  251.1154 
26  1.62085  185.5107 
27  1.67687  190.1331 
28  1.73242  180.1535 
29  0.06819  1026.049 
ITC final figure
0.0 0.5 1.0 1.5 2.0
0.2
0.4
0.6
0.8
1.0
0
5
-10 0 10 20 30 40 50 60 70 80 90 100110120130
Time (min)
µ
c
a
l
/
s
e
c
Model: Dissociation
Chi^2 = 455.5
H (cal/mole) 2462 ±51.3
K (mM)1.16±0.14
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ITC data of guanidinium-carboxylate 78 
 
 
 
 
 
         [monomer] = 10 mM                                                                  
         Solvent = 10% H2O/DMSO                                                        
         Kdim[M
-1] = 156 
         ∆Gdim
  [kJ mol
-1] = -12.5 
         ∆Hdim
  [kJ mol
-1] = -7.4 
         T∆Sdim
  [kJ mol
-1] = 5.1 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 78 
1  0.13639  711.9548 
2  0.27184  650.3678 
3  0.40635  580.3131 
4  0.53993  558.9752 
5  0.67257  513.0282 
6  0.80427  485.0643 
7  0.93504  451.1931 
8  1.06487  423.1163 
9  1.19377  403.6405 
10  1.32173  376.7011 
11  1.44875  365.3502 
12  1.57484  341.0457 
13  1.69998  331.5105 
14  1.8242  311.5874 
15  1.94747  299.2547 
16  2.06981  286.4118 
17  2.19122  275.6302 
18  2.31168  266.4468 
19  2.43121  259.3672 
20  2.54981  244.1421 
21  2.66747  227.3492 
22  2.78419  218.781 
23  2.89997  217.3703 
24  3.01482  206.0993 
25  3.12873  201.3442 
26  3.24171  194.7789 
27  3.35375  187.6458 
28  3.46485  182.1243 
29  0.13639  711.9548 
ITC final figure
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Model: Dissociation
C = 20 mM
H (cal/mole) 1806 ±26.9
K (mM)8.62±0.62
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ITC data of guanidinium-carboxylate 82 
 
 
 
 
 
         [monomer] = 10 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 357 
         ∆Gdim
  [kJ mol
-1] = -14.6 
         ∆Hdim
  [kJ mol
-1] = -3.1 
         T∆Sdim
  [kJ mol
-1] = 11.5 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 82 
1  0.06819  445.2186 
2  0.13592  413.3985 
3  0.20318  414.7525 
4  0.26996  325.6465 
5  0.33628  345.946 
6  0.40214  324.4266 
7  0.46752  330.103 
8  0.53244  320.0542 
9  0.59688  320.623 
10  0.66086  294.4177 
11  0.72437  289.0147 
12  0.78742  281.1459 
13  0.84999  277.0877 
14  0.9121  281.1414 
15  0.97374  264.1301 
16  1.03491  257.748 
17  1.09561  259.0549 
18  1.15584  251.6177 
19  1.21561  246.6774 
20  1.2749  222.2816 
21  1.33373  246.6756 
22  1.39209  229.0389 
23  1.44999  237.3561 
24  1.50741  211.1446 
25  1.56437  223.3512 
26  1.62085  218.6038 
27  1.67687  202.6463 
28  0.06819  445.2186 
29  0.13592  413.3985 
ITC final figure
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Guanidinium-carboxylate 82 in DMSO
Model: Dissociation
Chi^2 = 174.8
H (cal/mole) 740.0 ±35.3
K (mM) 2.80 ±0.77
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ITC data of guanidinium-carboxylate 82 
 
 
 
 
 
         [monomer] = 20 mM                                                                  
         Solvent = 10% H2O/DMSO                                                        
         Kdim[M
-1] = 78 
         ∆Gdim
  [kJ mol
-1] = -10.8 
         ∆Hdim
  [kJ mol
-1] = -2.7 
         T∆Sdim
  [kJ mol
-1] = 8.1 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 82 
1  0.13639  360.1677 
2  0.27184  321.0363 
3  0.40635  361.4471 
4  0.53993  333.6741 
5  0.67257  317.1002 
6  0.80427  288.6113 
7  0.93504  294.2549 
8  1.06487  277.4665 
9  1.19377  291.4978 
10  1.32173  277.8912 
11  1.44875  282.6107 
12  1.57484  252.3568 
13  1.69998  250.2703 
14  1.8242  230.2727 
15  1.94747  255.72 
16  2.06981  227.8381 
17  2.19122  218.101 
18  2.31168  233.2753 
19  2.43121  221.0632 
20  2.54981  225.9528 
21  2.66747  210.2339 
22  2.78419  198.6501 
23  2.89997  214.1101 
24  3.01482  215.0317 
25  3.12873  192.4871 
26  3.24171  214.8893 
27  3.35375  200.3798 
28  3.46485  197.6202 
29  0.13639  360.1677 
ITC final figure
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Guanidinium-carboxylate 82 in 10% H2O/DMSO
Model: Dissociation
C = 20mM
H (cal/mole) 646.1 ±62.7
K (mM) 12.9 ±5.0
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ITC data of guanidinium-carboxylate 82 
 
 
 
 
 
         [monomer] = 40 mM                                                                  
         Solvent = 50% H2O/DMSO                                                        
         Kdim[M
-1] = 24 
         ∆Gdim
  [kJ mol
-1] = -7.8 
         ∆Hdim
  [kJ mol
-1] = -1.4 
         T∆Sdim
  [kJ mol
-1] = 6.5 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 82 
1  0.40916  239.6855 
2  0.81551  187.3761 
3  1.21905  183.1618 
4  1.61979  183.4541 
5  2.01771  203.8911 
6  2.41282  183.0415 
7  2.80513  180.3327 
8  3.19462  179.0225 
9  3.58131  170.2817 
10  3.96518  185.8982 
11  4.34625  159.9951 
12  4.72451  167.676 
13  5.09995  167.8052 
14  5.47259  168.6434 
15  5.84242  158.8081 
16  6.20944  153.4551 
17  6.57365  144.4317 
18  6.93505  147.5993 
19  7.29364  135.8326 
20  7.64942  137.9379 
21  8.0024  136.7784 
22  8.35256  146.7226 
23  8.69991  140.0552 
24  9.04446  130.714 
25  9.38619  128.815 
26  9.72512  137.7476 
27  10.06124  134.7008 
28  10.39454  132.0201 
29  0.40916  239.6855 
ITC final figure
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2O/DMSO
Model: Dissociation
C = 60 mM
H (cal/mole) 330.6 ±54.8
K (mM) 42.2 ±27
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ITC data of guanidinium-carboxylate 93 
 
 
 
 
 
         [monomer] = 20 mM                                                                  
         Solvent = 75% H2O/DMSO                                                        
         Kdim[M
-1] = 27 
         ∆Gdim
  [kJ mol
-1] = -8.1 
         ∆Hdim
  [kJ mol
-1] = -4.1 
         T∆Sdim
  [kJ mol
-1] = 4.0 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 93 
1  0.13639  467.2507 
2  0.27184  453.2614 
3  0.40635  443.86 
4  0.53993  442.8732 
5  0.67257  428.848 
6  0.80427  418.7716 
7  0.93504  401.7638 
8  1.06487  400.3926 
9  1.19377  388.655 
10  1.32173  376.5334 
11  1.44875  361.6381 
12  1.57484  371.9674 
13  1.69998  359.7162 
14  1.8242  361.1065 
15  1.94747  355.2 
16  2.06981  356.4061 
17  2.19122  343.7182 
18  2.31168  339.632 
19  2.43121  327.8597 
20  2.54981  324.959 
21  2.66747  312.7782 
22  2.78419  309.7764 
23  2.89997  303.4462 
24  3.01482  303.2519 
25  3.12873  291.3745 
26  3.24171  280.1756 
27  3.35375  283.6748 
28  3.46485  275.6988 
29  0.13639  467.2507 
ITC final figure
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Model: Dissociation
C = 20 mM
H (cal/mole) 996.7 ±83.6
K (mM) 37.7 ±9.8
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ITC data of guanidinium-carboxylate 94 
 
 
 
 
 
         [monomer] = 10 mM                                                                  
         Solvent = 75% H2O/DMSO                                                        
         Kdim[M
-1] = 127 
         ∆Gdim
  [kJ mol
-1] = -12.0 
         ∆Hdim
  [kJ mol
-1] = -33.4 
         T∆Sdim
  [kJ mol
-1] = -21.4 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 94 
1  0.06819  2454.375 
2  0.13592  2206.454 
3  0.20318  2360.827 
4  0.26996  2422.016 
5  0.33628  2400.899 
6  0.40214  2447.049 
7  0.46752  2040.727 
8  0.53244  1411.053 
9  0.59688  1399.769 
10  0.66086  1301.594 
11  0.72437  1355.388 
12  0.78742  1270.49 
13  0.84999  1405.375 
14  0.9121  1280.655 
15  0.97374  1305.084 
16  1.03491  1233.042 
17  1.09561  1125.997 
18  1.15584  687.4067 
19  1.21561  1437.231 
20  1.2749  494.0954 
21  1.33373  1055.312 
22  1.39209  1453.526 
23  1.44999  994.3124 
24  1.50741  922.6757 
25  1.56437  809.7317 
26  1.62085  751.0828 
27  1.67687  669.5469 
28  1.73242  239.3349 
29  0.06819  2454.375 
ITC final figure
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Model: Dissociation
C = 10 mM
H (cal/mole) 7981 ±1.69E3
K (mM) 7.87 ±6.2
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ITC data of guanidinium-carboxylate 116 
 
 
 
 
 
         [monomer] = 3 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 1002 
         ∆Gdim
  [kJ mol
-1] = -17.1 
         ∆Hdim
  [kJ mol
-1] = -8.5 
         T∆Sdim
  [kJ mol
-1] = 8.6 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 116 
1  0.02046  1251.285 
2  0.04078  1162.246 
3  0.06095  1045.685 
4  0.08099  1035.119 
5  0.10089  939.1429 
6  0.12064  936.9648 
7  0.14026  913.3319 
8  0.15973  898.8061 
9  0.17907  902.1655 
10  0.19826  861.3918 
11  0.21731  823.2552 
12  0.23623  819.6478 
13  0.255  801.8791 
14  0.27363  758.7807 
15  0.29212  725.4847 
16  0.31047  762.1949 
17  0.32868  742.3539 
18  0.34675  708.7523 
19  0.36468  742.9584 
20  0.38247  689.4308 
21  0.40012  700.6147 
22  0.41763  655.7673 
23  0.435  643.8494 
24  0.45222  647.8605 
25  0.46931  623.2526 
26  0.48626  624.2542 
27  0.50306  554.4971 
28  0.51973  592.6216 
29  0.02046  1251.285 
ITC final figure
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Model: Dissociation
C = 3 mM
H (cal/mole) 2036 ±75.6
K (mM) 0.998 ±0.20
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ITC data of guanidinium-carboxylate 116 
 
 
 
 
 
         [monomer] = 10 mM                                                                  
         Solvent = 10% H2O/DMSO                                                        
         Kdim[M
-1] = 2695 
         ∆Gdim
  [kJ mol
-1] = -19.6 
         ∆Hdim
  [kJ mol
-1] = -6.7 
         T∆Sdim
  [kJ mol
-1] = 12.9 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 116 
1  0.06819  549.7635 
2  0.13592  413.1658 
3  0.20318  300.4874 
4  0.26996  234.0588 
5  0.33628  198.4033 
6  0.40214  190.0672 
7  0.46752  187.0514 
8  0.53244  149.3284 
9  0.59688  148.7519 
10  0.66086  150.093 
11  0.72437  129.3041 
12  0.78742  101.3938 
13  0.84999  97.44372 
14  0.9121  114.1193 
15  0.97374  114.6592 
16  1.03491  58.02614 
17  1.09561  81.76825 
18  1.15584  78.34983 
19  1.21561  68.03227 
20  1.2749  43.60338 
21  1.33373  68.01357 
22  1.39209  76.55501 
23  1.44999  44.10678 
24  1.50741  70.33935 
25  1.56437  72.94642 
26  1.62085  37.99424 
27  1.67687  4.09021 
28  1.73242  82.68496 
29  0.06819  549.7635 
ITC final figure
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Model: Dissociation
C = 10 mM
H (cal/mole) 1594 ±89.3
K (mM) 0.371 ±0.085
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ITC data of guanidinium-carboxylate 133 
 
 
 
 
 
         [monomer] = 3 mM                                                                  
         Solvent = DMSO                                                        
         Kdim[M
-1] = 1767 
         ∆Gdim
  [kJ mol
-1] = -18.5 
         ∆Hdim
  [kJ mol
-1] = -19.5 
         T∆Sdim
  [kJ mol
-1] = -0.9 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 133 
1  0.01025  4544.97 
2  0.02046  4333.193 
3  0.03063  4150.022 
4  0.04078  4091.449 
5  0.05088  3970.88 
6  0.06095  4104.563 
7  0.07099  3800.997 
8  0.08099  3922.435 
9  0.09095  3648.704 
10  0.10089  3673.324 
11  0.11078  3641.177 
12  0.12064  3567.185 
13  0.13047  3562.207 
14  0.14026  3588.404 
15  0.15001  3560.526 
16  0.15973  3574.128 
17  0.16942  3519.308 
18  0.17907  3457.449 
19  0.18868  3414.729 
20  0.19826  3282.165 
21  0.2078  3459.297 
22  0.21731  3265.843 
23  0.22679  3263.845 
24  0.23623  3335.185 
25  0.24563  3201.162 
26  0.255  3201.374 
27  0.26433  3206.477 
28  0.27363  3170.465 
29  0.28289  3183.144 
ITC final figure
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ITC data of guanidinium-carboxylate 133 
 
 
 
 
 
         [monomer] = 10 mM                                                                  
         Solvent = 10% H2O/DMSO                                                        
         Kdim[M
-1] = 7634 
         ∆Gdim
  [kJ mol
-1] = -22.2 
         ∆Hdim
  [kJ mol
-1] = -2.8 
         T∆Sdim
  [kJ mol
-1] = 19.4 
 
 
 
 
Inj. 
No. 
Molar 
ratio  
Cal/mol of 
injected 133 
1  0.04092  71.34053 
2  0.08155  42.79089 
3  0.12191  41.54887 
4  0.16198  41.2283 
5  0.20177  14.95972 
6  0.24128  27.1825 
7  0.28051  16.92545 
8  0.31946  -20.834 
9  0.35813  11.32559 
10  0.39652  14.75362 
11  0.43462  -0.88948 
12  0.47245  2.49588 
13  0.51  23.66004 
14  0.54726  16.35735 
15  0.58424  12.72356 
16  0.62094  16.75129 
17  0.65737  -0.4407 
18  0.69351  3.74826 
19  0.72936  -13.8684 
20  0.76494  -0.63128 
21  0.80024  15.5098 
22  0.83526  11.06631 
23  0.86999  9.99491 
24  0.90445  -4.50713 
25  0.93862  -21.3629 
26  0.97251  -8.3646 
27  1.00612  26.97792 
28  1.03945  14.81587 
29  0.04092  71.34053 
ITC final figure
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K (mM) 0.0755 ±0.072
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Appendix B- NMR dilution data 
 
NMR dilution data of guanidinium-carboxylate 45 
 
 
Conc.(mM)  NH 
1 (ppm)  NH
 2 (ppm) 
56  10.00  10.00 
50  10.04  9.94 
44  10.09  9.90 
38  10.12  9.83 
32  10.17  9.75 
26  10.19  9.69 
20  10.24  9.63 
14  10.31  9.42 
8  10.46  9.19 
2  10.75  8.80 
                                
                                a) 
 
 
 
 
                                        b) 
 
 
 
 
                                            c) 
 
a)  1H NMR dilution data for  two NH protons (NH
1  and  NH
2)  in  compound  45 
recorded in DMSO at 298 K. 
 
b) c) The curve shows the fit to the dimerization isotherm. The data span 10%–70% 
bound  and  were  used  to  determine  the  bound  and  free  chemical  shifts  and  the 
dimerisation constant. 
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 NMR dilution data of guanidinium-carboxylate 53 
 
 
Con. (mM)  NH
1(ppm)  NH
2 (ppm) 
 40.60  8.80  - 
20.60  8.81  - 
12.10  8.90  - 
7.70  8.90  - 
5.14  8.95  - 
3.58  8.99  - 
2.55  9.09  7.80 
1.85  9.18  7.76 
1.35  9.17  7.75 
0.99  9.20  7.73 
0.72  9.27  7.70 
0.51  9.30  7.68 
0.35  9.42  7.65 
0.23  9.45  7.61 
0.13  9.51 
 
7.58 
                              a)  
 
                                                  
 
                                b)                                                                 c) 
 
 
a) 
1H  NMR  dilution  data  for  two  NH  protons  (NH
1  and  NH
2)  in  compound  53 
recorded in DMSO at 298 K. 
 
b) c) The curve shows the fit to the dimerization isotherm. The data span 10%–65% 
bound  and  were  used  to  determine  the  bound  and  free  chemical  shifts  and  the 
dimerisation constant. 
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NMR dilution data of guanidinium-carboxylate 78 
 
 
 
Conc. (mM)  NH
1 (ppm)  NH
2(ppm)  
23.3  9.69  - 
14.0  9.66  - 
9.10  9.61  - 
6.20  -  - 
4.40  9.56  - 
3.16  9.55  - 
 2.30  9.53  7.79 
1.73  9.49  7.76 
1.29  9.49  7.75 
0.96  9.47  7.74 
0.71  9.44  7.72 
0.52  9.42  7.70 
0.36  9.40  7.69 
0.24  9.38  7.67 
0.14  9.36  7.66 
                                 
                                 a) 
 
 
 
b)  c) 
 
a) 
1H  NMR  dilution  data  for  two  NH  protons  (NH
1  and  NH
2)  in  compound  78 
recorded in DMSO at 298 K. 
 
b) c) The curve shows the fit to the dimerization isotherm. The data span 5%–77% 
bound  and  were  used  to  determine  the  bound  and  free  chemical  shifts  and  the 
dimerisation constant. 
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NMR dilution data of guanidinium-carboxylate 82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            a)     
 
                                  
    
                              b) 
 
a) 
1H  NMR  dilution  data  for  two  NH  protons  (NH
1  and  NH
2)  in  compound  78 
recorded in DMSO at 298 K. 
 
b) The curve shows the fit to the dimerization isotherm. The data span 14%–76% 
bound  and  were  used  to  determine  the  bound  and  free  chemical  shifts  and  the 
dimerisation constant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conc. (mM)  NH (ppm) 
33.8  7.55 
18.4  7.52 
11  7.5 
6.9  7.48 
4.5  7.45 
2.9  7.44 
1.9  7.44 
1.2  7.43 
0.7  7.42 
0.4  7.40 
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Appendix C 
 
X-ray crystal data of guanidinium-carboxylate 45 
 
 
Table 15. Crystal data and structure refinement details. 
 
Identification code         2008sot0404 (BT/5029/37)     
Empirical formula         C18H21N5O3 
Formula weight             355.40 
Temperature                  120(2) K 
Wavelength                   0.71073 Å 
Crystal system              Monoclinic 
Space group                  P21/n  
Unit cell dimensions     a = 8.4729(3) Å   
                                     b = 19.3608(6) Å                            = 105.552(2)° 
                                     c = 11.2976(5) Å   
Volume  1785.43(12) Å
3 
Z  4 
Density (calculated)  1.322 Mg / m
3 
Absorption coefficient  0.093 mm
1 
F(000)  752 
Crystal  Lozenge; Colourless 
Crystal size  0.12  0.03  0.02 mm
3 
 range for data collection  3.26  25.03° 
Index ranges  9  h  10, 22  k  23, 13  l  13 
Reflections collected  16301 
Independent reflections  3131 [Rint = 0.1008] 
Completeness to  = 25.03°  99.7 %  
Absorption correction  Semiempirical from equivalents 
Max. and min. transmission  0.9981 and 0.9789 
Refinement method  Full-matrix least-squares on F
2 
Data / restraints / parameters  3131 / 1 / 254 
Goodness-of-fit on F
2  1.097 
Final R indices [F
2 > 2(F
2)]  R1 = 0.0880, wR2 = 0.1467 
R indices (all data)  R1 = 0.1430, wR2 = 0.1725 
Largest diff. peak and hole  0.400 and 0.390 e Å
3 
 
 
Diffractometer: Nonius KappaCCD area detector ( scans and  scans to fill asymmetric unit ). Cell 
determination: DirAx (Duisenberg, A.J.M.(1992). J. Appl. Cryst. 25, 92-96.) Data collection: Collect 
(Collect: Data collection software, R. Hooft, Nonius B.V., 1998). Data reduction and cell refinement: 
Denzo  (Z.  Otwinowski  &  W.  Minor,  Methods  in  Enzymology  (1997)  Vol.  276:  Macromolecular 
Crystallography,  part  A,  pp.  307326;  C.  W.  Carter,  Jr.  &  R.  M.  Sweet,  Eds.,  Academic  Press). 
Absorption  correction:  Sheldrick,  G.  M.  SADABS  -  Bruker  Nonius  area  detector  scaling  and 
absorption correction - V2.10 Structure solution: SHELXS97 (G. M. Sheldrick, Acta Cryst. (1990) 
A46 467473). Structure refinement: SHELXL97 (G. M. Sheldrick (1997), University of Göttingen, 
Germany). Graphics: Cameron - A Molecular Graphics Package. (D. M. Watkin, L. Pearce and C. K. 
Prout, Chemical Crystallography Laboratory, University of Oxford, 1993). 
 
Special details:  All hydrogen atoms were placed in idealised positions and refined using a riding 
model, those of the hetero atoms were located in the difference map and refined. 
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Table 16. Atomic coordinates [ 10
4], equivalent isotropic displacement parameters 
[Å
2  10
3] and site occupancy factors. Ueq is defined as one third of the trace of the 
orthogonalized U
ij tensor. 
 
Atom   x  y  z  Ueq  S.o.f.  
 
O1  7404(4)  1596(2)  8954(3)  32(1)  1 
O2  6704(4)  1061(2)  7161(3)  34(1)  1 
O3  11727(4)  410(2)  7551(3)  30(1)  1 
N1  9354(5)  209(2)  7061(3)  26(1)  1 
N2  10385(4)  977(2)  5455(3)  24(1)  1 
N3  10155(5)  2350(2)  3158(3)  26(1)  1 
N4  9055(5)  1661(2)  1432(4)  29(1)  1 
N5  10304(5)  2700(2)  1257(3)  27(1)  1 
C1  7415(5)  1082(2)  8279(4)  25(1)  1 
C2  8369(6)  450(2)  8866(4)  27(1)  1 
C3  8557(6)  88(2)  7935(4)  28(1)  1 
C4  10839(5)  51(2)  6966(4)  24(1)  1 
C5  11423(5)  489(2)  6064(4)  23(1)  1 
C6  12968(5)  382(2)  5899(4)  26(1)  1 
C7  13459(5)  796(2)  5065(4)  29(1)  1 
C8  12394(5)  1295(2)  4430(4)  28(1)  1 
C9  10880(5)  1371(2)  4647(4)  23(1)  1 
C10  9644(5)  1918(2)  4036(4)  27(1)  1 
C11  9823(5)  2225(2)  1959(4)  24(1)  1 
C12  10721(5)  2520(2)  131(4)  29(1)  1 
C13  12100(5)  1997(2)  302(4)  28(1)  1 
C14  13348(6)  1966(3)  1386(4)  36(1)  1 
C15  14617(6)  1498(3)  1534(5)  46(1)  1 
C16  14683(6)  1064(3)  579(5)  46(1)  1 
C17  13462(6)  1095(3)  511(5)  42(1)  1 
C18  12179(6)  1557(2)  650(5)  35(1)  1 
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Table 17 
 
Bond Length’s (Ǻ) and Angles(°) 
 
 
O1C1  1.256(5)                     
O2C1  1.246(5) 
O3C4  1.239(5) 
N1C4  1.327(6) 
N1C3  1.456(5) 
N2C9  1.340(5) 
N2C5  1.348(5) 
N3C11  1.329(6) 
N3C10  1.449(5) 
N4C11  1.327(6) 
N5C11  1.347(5) 
N5C12  1.451(6) 
C1C2  1.517(6) 
C2C3  1.520(6) 
C4C5  1.507(6) 
C5C6  1.386(6) 
C6C7  1.383(6) 
C7C8  1.384(6) 
C8C9  1.377(6) 
C9C10  1.519(6) 
C12C13  1.519(6) 
C13C18  1.387(6) 
C13C14  1.388(6) 
C14C15  1.383(7) 
C15C16  1.380(8) 
C16C17  1.381(7) 
 
C17C18                          1.385(7) 
C4N1C3    125.9(4) 
C9N2C5  117.8(4) 
C11N3C10  124.9(4) 
C11N5C12  122.4(4) 
O2C1O1  124.2(4) 
O2C1C2  118.2(4) 
O1C1C2  117.6(4) 
C1C2C3  113.2(4) 
N1C3C2  110.6(3) 
O3C4N1  125.2(4) 
O3C4C5  120.2(4) 
N1C4C5  114.6(4) 
N2C5C6  123.1(4) 
N2C5C4  116.9(4) 
C6C5C4  120.0(4) 
C7C6C5  118.2(4) 
C6C7C8  119.0(4) 
C9C8C7  119.4(4) 
N2C9C8  122.5(4) 
N2C9C10  113.8(4) 
C8C9C10  123.7(4) 
N3C10C9  114.6(4) 
N4C11N3  123.4(4) 
N4C11N5  119.1(4) 
N3C11N5  117.5(4) 
N5C12C13  114.1(4) 
C18C13C14  118.4(4) 
C18C13C12  120.4(4) 
C14C13C12  121.2(4) 
C15C14C13  121.2(5) 
C16C15C14  119.9(5) 
C15C16C17  119.5(5) 
C16C17C18  120.5(5) 
C17C18C13  120.5(5) 
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Table 18 Hydrogen coordinates [ 10
4] and isotropic displacement parameters [Å
2  
10
3]. 
 
Atom   x  y  z  Ueq  S.o.f.
 
 
H2A  7804  238  9437  32  1 
H2B  9471  597  9354  32  1 
H3A  9217  480  8367  33  1 
H3B  7464  267  7489  33  1 
H6  13670  34  6347  32  1 
H7  14511  739  4931  35  1 
H8  12704  1583  3849  33  1 
H10A  8606  1686  3610  32  1 
H10B  9418  2218  4682  32  1 
H12A  11042  2945  232  35  1 
H12B  9735  2331  462  35  1 
H14  13330  2273  2039  43  1 
H15  15442  1474  2292  56  1 
H16  15562  746  671  55  1 
H17  13503  796  1170  51  1 
H18  11346  1574  1405  42  1 
H91  8870(60)  560(20)  6720(40)  30(14)  1 
H93  10890(60)  2730(30)  3460(50)  44(14)  1 
H94  8830(60)  1390(20)  1800(40)  27(15)  1 
H95  10760(60)  3110(30)  1620(40)  38(14)  1 
H99  7940(50)  1600(20)  9710(20)  36  1 
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Table 19 Hydrogen bonds [Å and °]. 
 
 DH···A  d(DH)  d(H···A)  d(D···A)  (DHA) 
 
 N1H91...O2  0.83(5)  2.25(5)  2.813(5)  125(4) 
 N3H93...O1
i  0.97(5)  1.80(5)  2.772(5)  174(4) 
 N4H94...O3
ii  0.73(5)  2.13(5)  2.834(5)  163(5) 
 N5H95...O2
i  0.94(5)  1.81(5)  2.749(5)  173(4) 
 O1H99...N4
iii  0.853(19)  1.93(2)  2.776(5)  175(5)  
  Symmetry transformations used to generate equivalent atoms:  
(i) x+1/2,y+1/2,z1/2    (ii) x+2,y,z+1    (iii) x,y,z+1   
   
 
 
Thermal ellipsoids drawn at the 45% probability level 
 
 
 
                            Part of the 3D hydrogen bonding network References 
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